{"18c14b5b5ac05623665e859e005b26b17c7a0598": [["Infection control in childrenInfection control following a biologic agent attack is complex, with some added considerations for the pediatric population.", [["Infection control", "TREATMENT", 0, 17], ["childrenInfection control", "TREATMENT", 21, 46], ["the pediatric population", "TREATMENT", 128, 152]]], ["First, early attribution of a cluster of febrile, respiratory illnesses to an intentional biologic agent attack in children might be difficult because children experience respiratory symptoms with common colds more often than adults, and they cannot easily report the subtleties of their own symptoms [7] .", [["respiratory", "ANATOMY", 171, 182], ["febrile", "DISEASE", 41, 48], ["respiratory illnesses", "DISEASE", 50, 71], ["colds", "DISEASE", 204, 209], ["children", "ORGANISM", 115, 123], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 115, 123], ["children", "SPECIES", 151, 159], ["febrile", "PROBLEM", 41, 48], ["respiratory illnesses", "PROBLEM", 50, 71], ["respiratory symptoms", "PROBLEM", 171, 191], ["common colds", "PROBLEM", 197, 209], ["cluster", "OBSERVATION_MODIFIER", 30, 37], ["febrile", "OBSERVATION_MODIFIER", 41, 48]]], ["Furthermore, strict isolation is complicated in children.", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56]]], ["Young patients might need to be sedated, especially if isolated in negative pressure tents or rooms.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["sedated", "TREATMENT", 32, 39]]], ["Parents might need to remain with their children in isolation, which can expose them to the infectious agents.", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48]]], ["In addition, pediatric hospitals need to prepare to care not only for the sick children but also for their Water safety threats (eg, Vibrio cholerae, Cryptosporidium parvum) a Category A: The US public health system and primary healthcare providers must be prepared to address various biologic agents, including pathogens that are rarely seen in the United States.", [["Cryptosporidium parvum", "DISEASE", 150, 172], ["children", "ORGANISM", 79, 87], ["Vibrio cholerae", "ORGANISM", 133, 148], ["Cryptosporidium parvum", "ORGANISM", 150, 172], ["children", "SPECIES", 79, 87], ["Vibrio cholerae", "SPECIES", 133, 148], ["Cryptosporidium parvum", "SPECIES", 150, 172], ["Vibrio cholerae", "SPECIES", 133, 148], ["Cryptosporidium parvum", "SPECIES", 150, 172], ["various biologic agents", "TREATMENT", 277, 300], ["pathogens", "PROBLEM", 312, 321]]], ["Highpriority agents include organisms that pose a risk to national security because they can be easily disseminated or transmitted from person to person; result in high mortality rates and have the potential for major public health impact; might cause public panic and social disruption; and require special action for public health preparedness. b Category B Diseases/Agents: second highest priority agents include those that are moderately easy to disseminate; result in moderate morbidity rates and low mortality rates; and require specific enhancements of CDC's diagnostic capacity and enhanced disease surveillance. c Category C Diseases/Agents: third highest priority agents include emerging pathogens that could be engineered for mass dissemination in the future because of availability; ease of production and dissemination; and potential for high morbidity and mortality rates and major health impact. parents if separation is to be avoided.", [["panic", "DISEASE", 259, 264], ["person", "SPECIES", 136, 142], ["person", "SPECIES", 146, 152], ["Highpriority agents", "TREATMENT", 0, 19], ["organisms", "PROBLEM", 28, 37], ["public panic and social disruption", "PROBLEM", 252, 286], ["public health preparedness", "TREATMENT", 319, 345], ["second highest priority agents", "TREATMENT", 377, 407], ["moderate morbidity rates", "PROBLEM", 473, 497], ["low mortality rates", "PROBLEM", 502, 521], ["CDC's diagnostic capacity", "TEST", 560, 585], ["enhanced disease surveillance", "PROBLEM", 590, 619], ["Category C Diseases", "PROBLEM", 623, 642], ["Agents", "TREATMENT", 643, 649], ["third highest priority agents", "TREATMENT", 651, 680], ["emerging pathogens", "TREATMENT", 689, 707], ["mass dissemination", "PROBLEM", 737, 755], ["high morbidity", "PROBLEM", 851, 865], ["social disruption", "OBSERVATION", 269, 286], ["moderate", "OBSERVATION_MODIFIER", 473, 481], ["morbidity", "OBSERVATION", 482, 491]]], ["Prolonged isolation can dramatically affect children's and parent's well being and their social relations [8] .", [["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["Prolonged isolation", "TREATMENT", 0, 19]]], ["Pediatric infection control after a bioterrorist event is even further complicated by the fact that there is little consistency in design, structure, organization, and implementation of infection control throughout pediatric facilities in the United States [9] .", [["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 186, 195], ["Pediatric infection control", "TREATMENT", 0, 27], ["infection control", "TREATMENT", 186, 203], ["infection", "OBSERVATION", 10, 19], ["little", "OBSERVATION_MODIFIER", 109, 115], ["consistency", "OBSERVATION_MODIFIER", 116, 127], ["infection", "OBSERVATION", 186, 195]]], ["Unresolved current controversies in pediatric isolation and infection control include the correct application of standard precautions and best precautions to prevent transmission of disease [10] .", [["infection", "DISEASE", 60, 69], ["pediatric isolation", "TREATMENT", 36, 55], ["infection control", "TREATMENT", 60, 77], ["standard precautions", "TREATMENT", 113, 133], ["best precautions", "TREATMENT", 138, 154], ["disease", "PROBLEM", 182, 189], ["infection", "OBSERVATION", 60, 69]]], ["Four general issues of infection control in pediatrics apply regardless of whether bioterrorism is involved:Infection control in children1.", [["infection", "DISEASE", 23, 32], ["infection control", "TREATMENT", 23, 40], ["Infection control in children1", "PROBLEM", 108, 138], ["infection", "OBSERVATION", 23, 32]]], ["Early recognition and identification of agent 2.", [["agent", "TREATMENT", 40, 45]]], ["Decontamination, infection control safety measures, isolation, and quarantine 4.", [["infection", "DISEASE", 17, 26], ["Decontamination", "TREATMENT", 0, 15], ["infection control safety measures", "TREATMENT", 17, 50], ["isolation", "TREATMENT", 52, 61], ["quarantine", "TREATMENT", 67, 77], ["infection", "OBSERVATION", 17, 26]]], ["Treatment, prophylaxis, and vaccinationInfection control in childrenEarly recognition and identification of agent ''Chance favors the prepared mind'' said Pasteur, and preparedness requires that clinicians and public health institutions remain aware of the possibility of bioterrorism at all times.", [["Treatment", "TREATMENT", 0, 9], ["prophylaxis", "TREATMENT", 11, 22], ["vaccinationInfection control", "TREATMENT", 28, 56], ["bioterrorism", "PROBLEM", 272, 284]]], ["Moreover, medical schools and postgraduate medical education curricula must include cognitive and training aspects of ''bioterrorism medicine'' and take a leadership role in instructing physicians and other members of the health care team about bioterrorism crisis management [11 -13] .", [["postgraduate medical education curricula", "TREATMENT", 30, 70], ["bioterrorism crisis management", "TREATMENT", 245, 275]]], ["Clues that suggest the possible release of a biologic agent include:Infection control in children1.", [["a biologic agent", "TREATMENT", 43, 59], ["Infection control in children1", "PROBLEM", 68, 98], ["suggest the possible", "UNCERTAINTY", 11, 31], ["Infection", "OBSERVATION", 68, 77]]], ["Multiple patients with unexplained, similar serious illnesses, especially acute severe pneumonia 2.", [["pneumonia", "DISEASE", 87, 96], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["similar serious illnesses", "PROBLEM", 36, 61], ["acute severe pneumonia", "PROBLEM", 74, 96], ["serious", "OBSERVATION_MODIFIER", 44, 51], ["illnesses", "OBSERVATION", 52, 61], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["pneumonia", "OBSERVATION", 87, 96]]], ["A cluster of diseases that are caused by agents known to be possible biologic weapons, as defined by the CDC [6] 3.", [["A cluster of diseases", "PROBLEM", 0, 21], ["biologic weapons", "PROBLEM", 69, 85], ["cluster", "OBSERVATION_MODIFIER", 2, 9], ["diseases", "OBSERVATION", 13, 21]]], ["An outbreak of infectious disease without natural explanation or outside its natural location 4.", [["infectious disease", "DISEASE", 15, 33], ["infectious disease", "PROBLEM", 15, 33], ["outbreak", "OBSERVATION_MODIFIER", 3, 11], ["infectious", "OBSERVATION", 15, 25]]], ["Serious illnesses with unusual clinical manifestation, unusual organisms, or unusual antibiotic resistance patterns 5.", [["Serious illnesses", "PROBLEM", 0, 17], ["unusual clinical manifestation", "PROBLEM", 23, 53], ["unusual organisms", "PROBLEM", 55, 72], ["unusual antibiotic resistance patterns", "PROBLEM", 77, 115], ["antibiotic resistance", "OBSERVATION", 85, 106]]], ["Unexplained illness or death in animals 6.", [["illness", "DISEASE", 12, 19], ["death", "DISEASE", 23, 28], ["Unexplained illness", "PROBLEM", 0, 19], ["death", "PROBLEM", 23, 28], ["illness", "OBSERVATION", 12, 19]]], ["Public claim of release of a biologic weapon or intelligence information [12, 14] Early detection surveillance systems have been developed [15, 16] and most often are based on automated medical records.", [["Early detection surveillance systems", "TEST", 82, 118]]], ["Several automated surveillance systems and their value in detecting disease clusters have been described [17, 18] .", [["Several automated surveillance systems", "TEST", 0, 38], ["their value", "TEST", 43, 54], ["disease clusters", "PROBLEM", 68, 84]]], ["The principal focus is generally on identifying unusual patterns of apparently common respiratory, gastrointestinal, or other illnesses in a population, although identification of a specific biologic agent can be difficult for laboratories.", [["respiratory", "ANATOMY", 86, 97], ["gastrointestinal", "ANATOMY", 99, 115], ["respiratory, gastrointestinal, or other illnesses", "DISEASE", 86, 135], ["gastrointestinal", "ANATOMICAL_SYSTEM", 99, 115], ["common respiratory, gastrointestinal", "PROBLEM", 79, 115], ["other illnesses", "PROBLEM", 120, 135], ["a specific biologic agent", "TREATMENT", 180, 205], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["focus", "OBSERVATION", 14, 19], ["gastrointestinal", "ANATOMY", 99, 115]]], ["The CDC or US Army Medical Research Institute of Infectious Diseases should be consulted before analysis of samples, and the examining laboratory must be warned that a biological agent is suspected.Notification of public health agenciesEarly notification of public health authorities and law enforcement agencies is essential if a biologic attack is suspected, even if the pathogens have not yet been positively identified.", [["samples", "ANATOMY", 108, 115], ["Infectious Diseases", "DISEASE", 49, 68], ["a biological agent", "TREATMENT", 166, 184], ["a biologic attack", "PROBLEM", 329, 346], ["the pathogens", "PROBLEM", 369, 382], ["Infectious", "OBSERVATION", 49, 59]]], ["The CDC has a telephone hotline number, 770-488-7100, and the telephone hotline number for the US Army Medical Research Institute of Infectious Diseases is 888-872-7443.Decontamination, infection control safety measures, isolation, and quarantinePlanning for a biologic agent incident must include the protection of health care providers, patients, families, the hospital or other facility and its environment.", [["Infectious Diseases", "DISEASE", 133, 152], ["infection", "DISEASE", 186, 195], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 339, 347], ["Decontamination", "TREATMENT", 169, 184], ["infection control safety measures", "TREATMENT", 186, 219], ["isolation", "TREATMENT", 221, 230], ["quarantine", "TREATMENT", 236, 246], ["a biologic agent", "TREATMENT", 259, 275], ["Infectious", "OBSERVATION", 133, 143], ["infection", "OBSERVATION", 186, 195]]], ["Decontamination of victims after the release of a biologic agent is less important than during a chemical or radiologic attack because most patients would seek medical care after the incubation period, having decontaminated themselves during this period with showers and clothing changes.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["a biologic agent", "TREATMENT", 48, 64]]], ["In contrast, an announced attack with aerosolized biologic agents would require decontamination.", [["an announced attack", "PROBLEM", 13, 32], ["aerosolized biologic agents", "TREATMENT", 38, 65], ["decontamination", "TREATMENT", 80, 95]]], ["Decontamination with water can cause significant heat loss in children because of their larger surface to body area.", [["surface", "ANATOMY", 95, 102], ["body area", "ANATOMY", 106, 115], ["heat loss", "DISEASE", 49, 58], ["children", "ORGANISM", 62, 70], ["surface", "CELLULAR_COMPONENT", 95, 102], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["children", "SPECIES", 62, 70], ["Decontamination", "TREATMENT", 0, 15], ["significant heat loss", "PROBLEM", 37, 58], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["heat loss", "OBSERVATION", 49, 58], ["larger", "OBSERVATION_MODIFIER", 88, 94], ["surface", "OBSERVATION_MODIFIER", 95, 102], ["body", "ANATOMY", 106, 110]]], ["Hypothermia can occur without precautions such as the use of warming lights or blankets [4] .", [["Hypothermia", "DISEASE", 0, 11], ["Hypothermia", "PROBLEM", 0, 11], ["precautions", "TREATMENT", 30, 41], ["warming lights", "TREATMENT", 61, 75], ["blankets", "TREATMENT", 79, 87]]], ["Decontamination similar to that recommended after a chemical attack might be necessary [19] Health care professionals who help to decontaminate patients or handle contaminated clothing must wear a gown, gloves, head and shoe covers, and an N95 (disposable) respirator.", [["head", "ANATOMY", 211, 215], ["patients", "ORGANISM", 144, 152], ["head", "ORGANISM_SUBDIVISION", 211, 215], ["patients", "SPECIES", 144, 152], ["Decontamination", "TREATMENT", 0, 15], ["a gown, gloves, head and shoe covers", "TREATMENT", 195, 231], ["an N95 (disposable) respirator", "TREATMENT", 237, 267], ["head", "ANATOMY", 211, 215]]], ["N-95 respirators are often used in tuberculosis (TB) isolation rooms, in transport of TB cases, or in other areas of the health care facility.", [["N-95", "CHEMICAL", 0, 4], ["tuberculosis", "DISEASE", 35, 47], ["TB", "DISEASE", 49, 51], ["TB", "DISEASE", 86, 88], ["tuberculosis", "OBSERVATION", 35, 47]]], ["When high-risk procedures such as bronchoscopy or necroscopy are conducted, respiratory protection exceeding the CDC standard performance criteria may be needed, such as full face piece negative-pressure respirators, powered airpurifying respirators (PAPRs), or positive-pressure airline-type respirators equipped with a half-mask or full face piece.", [["respiratory", "ANATOMY", 76, 87], ["high-risk procedures", "TREATMENT", 5, 25], ["bronchoscopy", "TEST", 34, 46], ["necroscopy", "TREATMENT", 50, 60], ["respiratory protection", "TREATMENT", 76, 98], ["pressure respirators", "TREATMENT", 195, 215], ["powered airpurifying respirators", "TREATMENT", 217, 249], ["type respirators", "TREATMENT", 288, 304], ["a half-mask", "TREATMENT", 319, 330], ["full face piece", "TREATMENT", 334, 349]]], ["Contaminated clothing must be placed in biohazard bags to avoid reaerosolization.", [["Contaminated clothing", "TREATMENT", 0, 21], ["biohazard bags", "TREATMENT", 40, 54], ["reaerosolization", "TREATMENT", 64, 80]]], ["If necessary, environmental surfaces should be cleaned with a solution of 10% hypochlorite.", [["hypochlorite", "CHEMICAL", 78, 90], ["hypochlorite", "CHEMICAL", 78, 90], ["hypochlorite", "SIMPLE_CHEMICAL", 78, 90], ["environmental surfaces", "TREATMENT", 14, 36], ["a solution of 10% hypochlorite", "TREATMENT", 60, 90]]], ["A 70% alcohol solution can be used after 10 minutes to continue the decontamination.Standard precautionsSmallpox, viral hemorrhagic fevers, and plague are transmitted from person to person and pose the greatest challenge to infection control (Table 2) .", [["alcohol", "CHEMICAL", 6, 13], ["viral hemorrhagic fevers", "DISEASE", 114, 138], ["plague", "DISEASE", 144, 150], ["infection", "DISEASE", 224, 233], ["alcohol", "CHEMICAL", 6, 13], ["alcohol", "SIMPLE_CHEMICAL", 6, 13], ["person", "SPECIES", 172, 178], ["person", "SPECIES", 182, 188], ["A 70% alcohol solution", "TREATMENT", 0, 22], ["the decontamination", "TREATMENT", 64, 83], ["Standard precautions", "TREATMENT", 84, 104], ["Smallpox", "TREATMENT", 104, 112], ["viral hemorrhagic fevers", "PROBLEM", 114, 138], ["plague", "PROBLEM", 144, 150], ["infection control", "TREATMENT", 224, 241], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["hemorrhagic", "OBSERVATION_MODIFIER", 120, 131], ["fevers", "OBSERVATION", 132, 138], ["infection", "OBSERVATION", 224, 233]]], ["Tularemia, anthrax, and botulism are not transmitted from person to person in their naturally occurring forms.", [["Tularemia", "DISEASE", 0, 9], ["anthrax", "DISEASE", 11, 18], ["botulism", "DISEASE", 24, 32], ["person", "SPECIES", 58, 64], ["person", "SPECIES", 68, 74], ["Tularemia", "PROBLEM", 0, 9], ["anthrax", "PROBLEM", 11, 18], ["botulism", "PROBLEM", 24, 32], ["botulism", "OBSERVATION", 24, 32]]], ["Standard precautions are sufficient for patients infected with these organisms.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Standard precautions", "TREATMENT", 0, 20], ["patients infected with these organisms", "PROBLEM", 40, 78]]], ["These precautions are designed to reduce the risk of transmission of blood-borne pathogens and pathogens from moist body substances and apply to all patients receiving care in hospitals, regardless of their diagnosis or presumed infection status.", [["blood", "ANATOMY", 69, 74], ["body", "ANATOMY", 116, 120], ["infection", "DISEASE", 229, 238], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["These precautions", "TREATMENT", 0, 17], ["blood-borne pathogens", "PROBLEM", 69, 90], ["pathogens", "PROBLEM", 95, 104], ["moist body substances", "TREATMENT", 110, 131], ["infection status", "PROBLEM", 229, 245], ["infection", "OBSERVATION", 229, 238]]], ["Standard precautions apply to blood, all body fluids, secretions, and excretions except sweat, regardless of whether or not they contain visible blood, non-intact skin, and mucous membranes [20] .Droplet transmission precautionsPlague and viral hemorrhagic fevers are believed to be spread by droplet nuclei.", [["blood", "ANATOMY", 30, 35], ["body fluids", "ANATOMY", 41, 52], ["secretions", "ANATOMY", 54, 64], ["sweat", "ANATOMY", 88, 93], ["blood", "ANATOMY", 145, 150], ["skin", "ANATOMY", 163, 167], ["mucous membranes", "ANATOMY", 173, 189], ["droplet nuclei", "ANATOMY", 293, 307], ["Plague", "DISEASE", 228, 234], ["viral hemorrhagic fevers", "DISEASE", 239, 263], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["fluids", "ORGANISM_SUBSTANCE", 46, 52], ["secretions", "ORGANISM_SUBSTANCE", 54, 64], ["sweat", "ORGANISM_SUBDIVISION", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["skin", "ORGAN", 163, 167], ["mucous membranes", "CELLULAR_COMPONENT", 173, 189], ["nuclei", "CELLULAR_COMPONENT", 301, 307], ["Standard precautions", "TREATMENT", 0, 20], ["blood", "TEST", 30, 35], ["all body fluids, secretions, and excretions", "TEST", 37, 80], ["sweat", "PROBLEM", 88, 93], ["visible blood", "PROBLEM", 137, 150], ["Droplet transmission precautions", "TREATMENT", 196, 228], ["Plague", "PROBLEM", 228, 234], ["viral hemorrhagic fevers", "PROBLEM", 239, 263], ["skin", "ANATOMY", 163, 167], ["mucous membranes", "ANATOMY", 173, 189], ["viral", "OBSERVATION_MODIFIER", 239, 244], ["hemorrhagic", "OBSERVATION_MODIFIER", 245, 256], ["fevers", "OBSERVATION", 257, 263], ["believed to be", "UNCERTAINTY", 268, 282], ["droplet nuclei", "OBSERVATION", 293, 307]]], ["Caregivers, including anesthesiologists, are particularly susceptible to sec- Table 2 The greatest challenges to infection controlDiseaseInfection control measures Smallpox All hospital employees as well as patients in hospital need to be vaccinated.", [["infection", "DISEASE", 113, 122], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["infection controlDiseaseInfection control measures", "TREATMENT", 113, 163], ["greatest", "OBSERVATION_MODIFIER", 90, 98], ["infection", "OBSERVATION", 113, 122]]], ["Individuals for whom vaccination is contraindicated; VIG should be provided.", [["whom vaccination", "TREATMENT", 16, 32], ["VIG", "TREATMENT", 53, 56]]], ["Patients should be isolated in rooms with negative airflow and equipped with HEPA filtration.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["HEPA filtration", "TREATMENT", 77, 92]]], ["Standard precautions such as gloves, gowns, and masks should be observed.", [["Standard precautions", "TREATMENT", 0, 20], ["gloves, gowns", "TREATMENT", 29, 42], ["masks", "TREATMENT", 48, 53]]], ["All laundry and waste shoud be placed in biohazard bags and autoclaved before being laundered or incinerated.", [["All laundry", "TREATMENT", 0, 11], ["waste shoud", "TREATMENT", 16, 27], ["biohazard bags", "TREATMENT", 41, 55], ["waste shoud", "OBSERVATION", 16, 27]]], ["Laboratory examination requires high-containment (BL-4) facilities.DiseaseMortuary workers need to be vaccinated, and cremation is recommended.", [["Laboratory examination", "TEST", 0, 22]]], ["PlagueDiseaseRespiratory droplet precautions (gown, gloves, and eye protection ondary infection by organisms spread by droplet nuclei.", [["eye", "ANATOMY", 64, 67], ["droplet nuclei", "ANATOMY", 119, 133], ["infection", "DISEASE", 86, 95], ["eye", "ORGANISM_SUBDIVISION", 64, 67], ["PlagueDiseaseRespiratory droplet precautions", "TREATMENT", 0, 44], ["gown, gloves", "TREATMENT", 46, 58], ["eye protection ondary infection", "TREATMENT", 64, 95], ["eye", "ANATOMY", 64, 67], ["infection", "OBSERVATION", 86, 95]]], ["In a case control study of 253 health care personnel exposed to 11 index cases of severe acute respiratory syndrome in five Hong Kong hospitals, 69 staff members who used complete droplet and contact precautions (surgical masks, gloves, gowns, and hand washing) were not infected, whereas all infected staff (13 of 253) had omitted at least one safety measure [21] .", [["hand", "ANATOMY", 248, 252], ["acute respiratory syndrome", "DISEASE", 89, 115], ["severe acute respiratory syndrome", "PROBLEM", 82, 115], ["complete droplet", "TREATMENT", 171, 187], ["contact precautions", "TREATMENT", 192, 211], ["surgical masks", "TREATMENT", 213, 227], ["gloves", "TREATMENT", 229, 235], ["gowns", "TREATMENT", 237, 242], ["hand washing", "TREATMENT", 248, 260], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115]]], ["Two of the infected staff were physicians.", [["infected", "OBSERVATION_MODIFIER", 11, 19]]], ["Droplet transmission involves contact of the conjunctivae or the mucous membranes of the nose or mouth of a susceptible person with large-particle droplets (larger than 5 mm in size) containing microorganisms generated from a person who has a clinical disease or who is a carrier of the microorganism [20] .", [["conjunctivae", "ANATOMY", 45, 57], ["mucous membranes", "ANATOMY", 65, 81], ["nose", "ANATOMY", 89, 93], ["mouth", "ANATOMY", 97, 102], ["conjunctivae", "CANCER", 45, 57], ["mucous membranes", "CELLULAR_COMPONENT", 65, 81], ["nose", "ORGAN", 89, 93], ["person", "SPECIES", 120, 126], ["person", "SPECIES", 226, 232], ["Droplet transmission", "PROBLEM", 0, 20], ["large-particle droplets", "PROBLEM", 132, 155], ["microorganisms", "PROBLEM", 194, 208], ["a clinical disease", "PROBLEM", 241, 259], ["conjunctivae", "ANATOMY", 45, 57], ["mucous membranes", "ANATOMY", 65, 81], ["nose", "ANATOMY", 89, 93], ["mouth", "ANATOMY", 97, 102], ["large", "OBSERVATION_MODIFIER", 132, 137], ["particle droplets", "OBSERVATION", 138, 155]]], ["Droplets are generated from the source person primarily during coughing, sneezing, or talking, and during the performance of certain procedures such as suctioning and bronchoscopy.", [["coughing", "DISEASE", 63, 71], ["person", "SPECIES", 39, 45], ["coughing", "PROBLEM", 63, 71], ["sneezing", "PROBLEM", 73, 81], ["certain procedures", "TREATMENT", 125, 143], ["suctioning", "TREATMENT", 152, 162], ["bronchoscopy", "TREATMENT", 167, 179]]], ["Transmission by large-particle droplets requires close contact between the source and the recipient because the droplets do not remain suspended in the air and generally travel only short distances (3 feet or less).", [["large-particle droplets", "PROBLEM", 16, 39], ["large", "OBSERVATION_MODIFIER", 16, 21], ["particle droplets", "OBSERVATION", 22, 39]]], ["Special air handling and ventilation are not required because the droplets do not remain suspended in the air.Airborne transmission precautionsAlthough most infectious disease specialists believe that viral hemorrhagic fever is transmitted by droplet nuclei, there are some reports that suggest airborne transmission [22] .", [["droplet nuclei", "ANATOMY", 243, 257], ["infectious disease", "DISEASE", 157, 175], ["viral hemorrhagic fever", "DISEASE", 201, 224], ["Special air handling", "TREATMENT", 0, 20], ["ventilation", "TREATMENT", 25, 36], ["the droplets", "PROBLEM", 62, 74], ["Airborne transmission precautions", "TREATMENT", 110, 143], ["viral hemorrhagic fever", "PROBLEM", 201, 224], ["air handling", "OBSERVATION", 8, 20], ["air", "OBSERVATION", 106, 109], ["viral", "OBSERVATION_MODIFIER", 201, 206], ["hemorrhagic", "OBSERVATION_MODIFIER", 207, 218], ["fever", "OBSERVATION", 219, 224]]], ["Indeed, most institutions would use airborne, droplet, and contact precautions for any patient suspected of being infected by viral hemorrhagic fever or smallpox.", [["viral hemorrhagic fever", "DISEASE", 126, 149], ["smallpox", "DISEASE", 153, 161], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["airborne", "TREATMENT", 36, 44], ["droplet", "TREATMENT", 46, 53], ["contact precautions", "TREATMENT", 59, 78], ["viral hemorrhagic fever", "PROBLEM", 126, 149], ["smallpox", "PROBLEM", 153, 161], ["viral", "OBSERVATION_MODIFIER", 126, 131], ["hemorrhagic", "OBSERVATION_MODIFIER", 132, 143], ["fever", "OBSERVATION", 144, 149]]], ["Hands should be cleaned before patient contact and should be double gloved.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["cleaned", "OBSERVATION", 16, 23]]], ["Watches, jewelry, and artificial fingernails should be removed from hands [23] .", [["fingernails", "ANATOMY", 33, 44], ["fingernails", "ORGANISM_SUBDIVISION", 33, 44], ["artificial fingernails", "TREATMENT", 22, 44]]], ["Beepers and cellular phones should also be removed.", [["cellular", "ANATOMY", 12, 20], ["cellular", "CELL", 12, 20], ["cellular phones", "TREATMENT", 12, 27], ["cellular phones", "OBSERVATION", 12, 27]]], ["Impermeable gowns, face shields, goggles, and hair covers must be worn.", [["hair", "ANATOMY", 46, 50], ["hair", "TISSUE", 46, 50], ["Impermeable gowns", "TREATMENT", 0, 17], ["face shields", "TREATMENT", 19, 31], ["goggles", "TREATMENT", 33, 40], ["gowns", "OBSERVATION", 12, 17], ["face shields", "OBSERVATION", 19, 31], ["goggles", "OBSERVATION", 33, 40]]], ["N-95 masks or PAPRs are recommended.", [["PAPRs", "SIMPLE_CHEMICAL", 14, 19], ["PAPRs", "TREATMENT", 14, 19]]], ["Experts have suggested the use of PAPRs for endotracheal intubation [23] .", [["endotracheal", "ANATOMY", 44, 56], ["PAPRs", "SIMPLE_CHEMICAL", 34, 39], ["PAPRs", "TREATMENT", 34, 39], ["endotracheal intubation", "TREATMENT", 44, 67]]], ["Waterproof leg and shoe covers are also advisable.", [["leg", "ANATOMY", 11, 14], ["leg", "ORGANISM_SUBDIVISION", 11, 14], ["Waterproof leg and shoe covers", "TREATMENT", 0, 30], ["leg", "ANATOMY", 11, 14], ["shoe", "OBSERVATION", 19, 23]]], ["After patient contact, gowns, leg and shoe covers need to be removed, and hands should be washed with disinfectant solutions.", [["leg", "ANATOMY", 30, 33], ["patient", "ORGANISM", 6, 13], ["leg", "ORGANISM_SUBDIVISION", 30, 33], ["patient", "SPECIES", 6, 13], ["gowns, leg and shoe", "TREATMENT", 23, 42], ["disinfectant solutions", "TREATMENT", 102, 124], ["leg", "ANATOMY", 30, 33], ["hands", "ANATOMY", 74, 79]]], ["After hand cleaning, facemasks, respirators, shields, goggles, and hair protection should be removed to decrease exposure to mucous membranes and eyes from potentially contaminated hands [22] .", [["hand", "ANATOMY", 6, 10], ["hair", "ANATOMY", 67, 71], ["mucous membranes", "ANATOMY", 125, 141], ["eyes", "ANATOMY", 146, 150], ["hair", "TISSUE", 67, 71], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 125, 141], ["eyes", "ORGAN", 146, 150], ["hand cleaning", "TREATMENT", 6, 19], ["facemasks", "TREATMENT", 21, 30], ["respirators", "TREATMENT", 32, 43], ["shields", "TREATMENT", 45, 52], ["goggles", "TREATMENT", 54, 61], ["hair protection", "TREATMENT", 67, 82], ["mucous membranes", "PROBLEM", 125, 141], ["mucous membranes", "ANATOMY", 125, 141], ["eyes", "ANATOMY", 146, 150]]], ["If decontamination is necessary, appropriate personal protective attire is to be used.Airborne transmission precautionsPatients should be placed in private rooms with negative-pressure systems.", [["Patients", "ORGANISM", 119, 127], ["Patients", "SPECIES", 119, 127], ["decontamination", "TREATMENT", 3, 18], ["appropriate personal protective attire", "TREATMENT", 33, 71], ["Airborne transmission precautions", "TREATMENT", 86, 119]]], ["In an outbreak in Germany in 1970, one isolated victim infected patients on three different floors [24] .", [["victim infected", "DISEASE", 48, 63], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["outbreak", "OBSERVATION_MODIFIER", 6, 14]]], ["In larger outbreaks, administrative decisions may need to be made about grouping patients in separate hospital wings or in separate hospitals for smallpox victims, or isolating patients at home.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 177, 185], ["larger", "OBSERVATION_MODIFIER", 3, 9], ["outbreaks", "OBSERVATION", 10, 19]]], ["Air should pass through highefficiency particulate air (HEPA) filters before being exhausted outdoors [25, 26] .", [["highefficiency particulate air (HEPA) filters", "TREATMENT", 24, 69], ["particulate", "OBSERVATION_MODIFIER", 39, 50], ["air", "OBSERVATION", 51, 54]]], ["In mass casualty situations, patients should be placed in the same part of the hospital.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["mass", "OBSERVATION", 3, 7]]], ["Access to patients should be restricted to only essential health care professionals and visitors, lest the rest of the institution and its personnel and visitors be contaminated.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Patients should only be transported when absolutely indicated, and immediate cleaning and disinfection should follow the patient's path.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 121, 128], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 121, 128], ["disinfection", "TREATMENT", 90, 102]]], ["It is helpful to transport patients in commercially available negativepressure tents.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["negativepressure tents", "TREATMENT", 62, 84]]], ["Pediatric patients might need to be sedated for such transport, for example, from the emergency department to the isolation room, potentially involving anesthesiologists directly.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["sedated", "TREATMENT", 36, 43]]], ["Health care workers, visitors, laboratory workers, and other potentially exposed persons should be under medical surveillance for at least 21 days.Airborne transmission precautionsLinen should be placed in two waterproof bags and washed in hot water with bleach, autoclaved, or incinerated.", [["persons", "ORGANISM", 81, 88], ["Linen", "SIMPLE_CHEMICAL", 180, 185], ["persons", "SPECIES", 81, 88], ["Airborne transmission precautions", "TREATMENT", 147, 180], ["Linen", "TREATMENT", 180, 185], ["two waterproof bags", "TREATMENT", 206, 225]]], ["Terminal room cleaning and equipment disinfection should be carried out with a solution of household bleach diluted 1:100.", [["Terminal room cleaning", "TREATMENT", 0, 22], ["equipment disinfection", "TREATMENT", 27, 49]]], ["Medical waste should be handled with extreme precautions.", [["Medical waste", "TREATMENT", 0, 13], ["extreme precautions", "TREATMENT", 37, 56]]], ["Laboratory personnel must be alerted if the disease is suspected.", [["the disease", "PROBLEM", 40, 51], ["disease", "OBSERVATION", 44, 51]]], ["From a safety and public health perspective, surgery or post-mortem care should be avoided [25] .Treatment and vaccinationOnce a bioterrorist attack has been confirmed and symptomatic patients identified, the next step in infection control is to limit the spread of the biologic agents.", [["infection", "DISEASE", 222, 231], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["surgery", "TREATMENT", 45, 52], ["Treatment", "TREATMENT", 97, 106], ["infection control", "TREATMENT", 222, 239], ["the biologic agents", "TREATMENT", 266, 285], ["infection", "OBSERVATION", 222, 231]]], ["Currently, there is a vaccine available for anthrax, although it is recommended for people over the age of 18; and there is a vaccine for Ebola virus [27, 28] , a devastating type of viral hemorrhagic fever that is just entering clinical trials.", [["anthrax", "DISEASE", 44, 51], ["Ebola virus", "DISEASE", 138, 149], ["viral hemorrhagic fever", "DISEASE", 183, 206], ["anthrax", "ORGANISM", 44, 51], ["people", "ORGANISM", 84, 90], ["Ebola virus", "ORGANISM", 138, 149], ["people", "SPECIES", 84, 90], ["Ebola virus", "SPECIES", 138, 149], ["Ebola virus", "SPECIES", 138, 149], ["a vaccine", "TREATMENT", 20, 29], ["anthrax", "PROBLEM", 44, 51], ["a vaccine", "TREATMENT", 124, 133], ["Ebola virus", "PROBLEM", 138, 149], ["viral hemorrhagic fever", "PROBLEM", 183, 206], ["devastating", "OBSERVATION_MODIFIER", 163, 174], ["viral", "OBSERVATION_MODIFIER", 183, 188], ["hemorrhagic", "OBSERVATION_MODIFIER", 189, 200], ["fever", "OBSERVATION", 201, 206]]], ["Routine smallpox vaccination of children in the United States at the age of 1 year was stopped in 1972, and the disease was considered eradicated in 1980.", [["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40], ["Routine smallpox vaccination", "TREATMENT", 0, 28]]], ["The strain of vaccinia used for the smallpox vaccine in the United States is the New York Board of Health strain, which is considered one of the strains of vaccinia least likely to cause complications; however, the complications of smallpox vaccination, although rare, can be devastating (Table 3) .Treatment and vaccinationVaccinating susceptible populations against bioterrorism agents before exposure is one strategy to limit the effects of a bioterrorism attack.", [["vaccinia", "DISEASE", 14, 22], ["smallpox", "DISEASE", 36, 44], ["smallpox", "DISEASE", 232, 240], ["vaccinia", "ORGANISM", 14, 22], ["vaccinia", "ORGANISM", 156, 164], ["vaccinia", "SPECIES", 14, 22], ["The strain of vaccinia", "TREATMENT", 0, 22], ["the smallpox vaccine", "TREATMENT", 32, 52], ["vaccinia", "TREATMENT", 156, 164], ["complications", "PROBLEM", 187, 200], ["smallpox vaccination", "TREATMENT", 232, 252], ["Treatment", "TREATMENT", 299, 308], ["vaccinationVaccinating susceptible populations", "TREATMENT", 313, 359], ["bioterrorism agents", "TREATMENT", 368, 387], ["a bioterrorism attack", "PROBLEM", 444, 465]]], ["In 2003, the United States government initiated a pre-event vaccination program for selected health care providers, to provide direct medical care for victims of a bioterrorism attack with suspected smallpox for the first 48 hours, until additional health care workers could be vaccinated [29] .", [["smallpox", "DISEASE", 199, 207], ["direct medical care", "TREATMENT", 127, 146], ["smallpox", "TREATMENT", 199, 207]]], ["As of January 2004, the CDC released approximately 200,000 doses of vaccine but only 39,000 doses have been administered for this voluntary program, amid concerns about liability and adverse reactions (Table 3 ) [30] .Treatment and vaccinationThe second strategy to control and limit the extent of a smallpox outbreak is to interrupt disease transmission by isolation and vaccination of primary contacts of the affected individuals and then vaccination of close contacts of the primary contacts (secondary contacts), thereby creating a ring of immune individuals around the affected individual.", [["primary contacts", "ANATOMY", 478, 494], ["contacts", "ANATOMY", 506, 514], ["smallpox", "DISEASE", 300, 308], ["vaccine", "TREATMENT", 68, 75], ["adverse reactions", "PROBLEM", 183, 200], ["Treatment", "TREATMENT", 218, 227], ["vaccination", "TREATMENT", 232, 243], ["The second strategy", "TREATMENT", 243, 262], ["a smallpox outbreak", "PROBLEM", 298, 317], ["isolation", "TREATMENT", 358, 367], ["vaccination", "TREATMENT", 372, 383], ["the affected individuals", "PROBLEM", 407, 431], ["immune individuals", "PROBLEM", 544, 562], ["smallpox", "OBSERVATION", 300, 308]]], ["It is conservatively estimated that these rings of people who would need to be emergently vaccinated during a smallpox outbreak could number in the thousands [29] .", [["smallpox", "DISEASE", 110, 118], ["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["a smallpox outbreak", "PROBLEM", 108, 127]]], ["There is some evidence that vaccinating contacts up to 4 days after exposure to a smallpox patient will either prevent or ameliorate the disease [26, 31] .", [["smallpox", "DISEASE", 82, 90], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["a smallpox", "TREATMENT", 80, 90], ["the disease", "PROBLEM", 133, 144]]], ["Although voluntary vaccination is not recommended under the age of 18 as part of the pre-event vaccination program, it is very likely that children would be included in any vaccination program of close contacts of smallpox victims [32] .Treatment and vaccinationApproximately one half of the US population has not been vaccinated because routine vaccination for smallpox in the United States ended [33] , and it is unclear what the immunization status is of the other half of the population [34] .", [["smallpox", "DISEASE", 214, 222], ["smallpox", "DISEASE", 362, 370], ["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["the pre-event vaccination program", "TREATMENT", 81, 114], ["Treatment", "TREATMENT", 237, 246], ["vaccination", "TREATMENT", 251, 262], ["routine vaccination", "TREATMENT", 338, 357], ["smallpox", "TREATMENT", 362, 370], ["very likely", "UNCERTAINTY", 122, 133]]], ["In the era of routine vaccination, the rate and severity of complications were greatest in children under the age of 5 [35] , and the overall mortality rate was 1 per million primary vaccinations [36] .", [["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["routine vaccination", "TREATMENT", 14, 33], ["complications", "PROBLEM", 60, 73], ["complications", "OBSERVATION", 60, 73]]], ["There are reliable data from the 1960s about the incidence and nature of adverse reactions to vaccination, but it may be that the incidence of adverse reactions to a national vaccination program would be higher now because more of the population is immunocompromised, and the incidence of childhood atopy has risen [37, 38] .", [["atopy", "DISEASE", 299, 304], ["adverse reactions", "PROBLEM", 73, 90], ["vaccination", "TREATMENT", 94, 105], ["adverse reactions", "PROBLEM", 143, 160], ["a national vaccination program", "TREATMENT", 164, 194], ["immunocompromised", "PROBLEM", 249, 266], ["childhood atopy", "PROBLEM", 289, 304], ["immunocompromised", "OBSERVATION", 249, 266]]], ["Elective vaccination is not recommended for certain population groups, although, in the event of an exposure to smallpox, the risks of the vaccination need to be weighed against the risks of clinical disease.", [["smallpox", "DISEASE", 112, 120], ["Elective vaccination", "TREATMENT", 0, 20], ["smallpox", "TREATMENT", 112, 120], ["the vaccination", "TREATMENT", 135, 150], ["clinical disease", "PROBLEM", 191, 207]]], ["In most cases, the patients that are most vulnerable to developing a complication from vaccination are also the patients that would be most at risk for developing smallpox.", [["smallpox", "DISEASE", 163, 171], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 112, 120], ["a complication", "PROBLEM", 67, 81], ["vaccination", "TREATMENT", 87, 98], ["smallpox", "OBSERVATION", 163, 171]]], ["Thus, there are relative but no absolute vaccination contraindications.", [["absolute vaccination contraindications", "PROBLEM", 32, 70], ["no", "UNCERTAINTY", 29, 31], ["absolute", "OBSERVATION_MODIFIER", 32, 40], ["vaccination", "OBSERVATION", 41, 52]]], ["The CDC has defined 11 relative contraindications to vaccination (Box 1).Treatment and vaccinationAfter primary vaccination, live vaccinia virus can be recovered at the vaccination site from the development of the papule at 2 to 5 days after vaccination, until the scab is shed at 14 to 21 days.", [["papule", "ANATOMY", 214, 220], ["vaccinia virus", "ORGANISM", 130, 144], ["papule", "PATHOLOGICAL_FORMATION", 214, 220], ["scab", "PATHOLOGICAL_FORMATION", 265, 269], ["vaccinia virus", "SPECIES", 130, 144], ["vaccination (Box", "TREATMENT", 53, 69], ["Treatment", "TREATMENT", 73, 82], ["vaccinationAfter primary vaccination", "TREATMENT", 87, 123], ["live vaccinia virus", "TREATMENT", 125, 144], ["the papule", "PROBLEM", 210, 220], ["vaccination", "TREATMENT", 242, 253], ["the scab", "PROBLEM", 261, 269], ["papule", "OBSERVATION", 214, 220], ["scab", "OBSERVATION", 265, 269]]], ["During this time, accidental inoculation may occur to other parts of the body or to other susceptible individuals.", [["body", "ANATOMY", 73, 77], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["accidental inoculation", "PROBLEM", 18, 40]]], ["The Advisory Committee on Immunization Practices of the Department of Health and Human Services has recommended that recently vaccinated health care workers be allowed to maintain patient care duties using rigid infection control procedures.", [["infection", "DISEASE", 212, 221], ["Human", "ORGANISM", 81, 86], ["patient", "ORGANISM", 180, 187], ["Human", "SPECIES", 81, 86], ["patient", "SPECIES", 180, 187], ["Immunization", "TREATMENT", 26, 38], ["rigid infection control procedures", "TREATMENT", 206, 240]]], ["These procedures include dressing the vaccination site with gauze and a semipermeable dressing and covering the area with a layer of clothing.", [["These procedures", "TREATMENT", 0, 16], ["dressing the vaccination site", "TREATMENT", 25, 54], ["gauze", "TREATMENT", 60, 65], ["a semipermeable dressing", "TREATMENT", 70, 94], ["a layer of clothing", "TREATMENT", 122, 141], ["gauze", "OBSERVATION", 60, 65], ["semipermeable", "OBSERVATION_MODIFIER", 72, 85], ["dressing", "OBSERVATION", 86, 94]]], ["In addition, scrupulous hand hygiene needs to be maintained after any contact with the vaccination site or the dressings [29] .Adverse reactions and complicationsThe most common adverse reaction is fever, with 70% of children having a fever of up to 100\u00b0for 1 day and up to 20% having a fever of greater than 102\u00b0.Adverse reactions and complicationsBox 1.", [["hand", "ANATOMY", 24, 28], ["fever", "DISEASE", 198, 203], ["fever", "DISEASE", 235, 240], ["fever", "DISEASE", 287, 292], ["hand", "ORGANISM_SUBDIVISION", 24, 28], ["children", "ORGANISM", 217, 225], ["Box 1", "GENE_OR_GENE_PRODUCT", 349, 354], ["children", "SPECIES", 217, 225], ["scrupulous hand hygiene", "TREATMENT", 13, 36], ["the vaccination site", "TREATMENT", 83, 103], ["the dressings", "TREATMENT", 107, 120], ["Adverse reactions", "PROBLEM", 127, 144], ["complications", "PROBLEM", 149, 162], ["The most common adverse reaction", "PROBLEM", 162, 194], ["fever", "PROBLEM", 198, 203], ["a fever", "PROBLEM", 233, 240], ["a fever of greater than 102\u00b0", "PROBLEM", 285, 313], ["Adverse reactions", "PROBLEM", 314, 331], ["complicationsBox", "PROBLEM", 336, 352], ["most common", "OBSERVATION_MODIFIER", 166, 177], ["fever", "OBSERVATION", 198, 203]]], ["Patients who should not get the smallpox vaccine unless they are exposed to smallpox aAdverse reactions and complicationsThe following individuals who should not receive smallpox vaccine have or are: 1.", [["Patients", "ORGANISM", 0, 8], ["individuals", "ORGANISM", 135, 146], ["Patients", "SPECIES", 0, 8], ["the smallpox vaccine", "TREATMENT", 28, 48], ["smallpox aAdverse reactions", "TREATMENT", 76, 103], ["complications", "PROBLEM", 108, 121], ["smallpox vaccine", "TREATMENT", 170, 186]]], ["Eczema, or atopic dermatitis 2.", [["Eczema", "DISEASE", 0, 6], ["atopic dermatitis", "DISEASE", 11, 28], ["Eczema", "PROBLEM", 0, 6], ["atopic dermatitis", "PROBLEM", 11, 28], ["atopic dermatitis", "OBSERVATION", 11, 28]]], ["Skin conditions such as burns, chicken pox, shingles, impetigo, herpes, severe acne, or psoriasis 3.", [["Skin", "ANATOMY", 0, 4], ["burns", "DISEASE", 24, 29], ["chicken pox", "DISEASE", 31, 42], ["shingles", "DISEASE", 44, 52], ["impetigo", "DISEASE", 54, 62], ["herpes", "DISEASE", 64, 70], ["acne", "DISEASE", 79, 83], ["psoriasis", "DISEASE", 88, 97], ["Skin", "ORGAN", 0, 4], ["chicken", "ORGANISM", 31, 38], ["herpes", "ORGANISM", 64, 70], ["chicken pox", "SPECIES", 31, 42], ["chicken pox", "SPECIES", 31, 42], ["Skin conditions", "PROBLEM", 0, 15], ["burns", "PROBLEM", 24, 29], ["chicken pox", "PROBLEM", 31, 42], ["shingles", "PROBLEM", 44, 52], ["impetigo", "PROBLEM", 54, 62], ["herpes", "PROBLEM", 64, 70], ["severe acne", "PROBLEM", 72, 83], ["psoriasis", "PROBLEM", 88, 97], ["burns", "OBSERVATION", 24, 29], ["herpes", "OBSERVATION", 64, 70], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acne", "OBSERVATION", 79, 83], ["psoriasis", "OBSERVATION", 88, 97]]], ["Weakened immune system 4.", [["Weakened immune system", "PROBLEM", 0, 22]]], ["Allergies to vaccine or its ingredients (polymyxin B, streptomycin, chlortetracycline, neomycin) 6.", [["Allergies", "DISEASE", 0, 9], ["polymyxin B", "CHEMICAL", 41, 52], ["streptomycin", "CHEMICAL", 54, 66], ["chlortetracycline", "CHEMICAL", 68, 85], ["neomycin", "CHEMICAL", 87, 95], ["polymyxin B", "CHEMICAL", 41, 52], ["streptomycin", "CHEMICAL", 54, 66], ["chlortetracycline", "CHEMICAL", 68, 85], ["neomycin", "CHEMICAL", 87, 95], ["polymyxin B", "SIMPLE_CHEMICAL", 41, 52], ["streptomycin", "SIMPLE_CHEMICAL", 54, 66], ["chlortetracycline", "SIMPLE_CHEMICAL", 68, 85], ["neomycin", "SIMPLE_CHEMICAL", 87, 95], ["Allergies", "PROBLEM", 0, 9], ["vaccine", "TREATMENT", 13, 20], ["its ingredients", "TREATMENT", 24, 39], ["polymyxin B", "TREATMENT", 41, 52], ["streptomycin", "TREATMENT", 54, 66], ["chlortetracycline", "TREATMENT", 68, 85], ["neomycin)", "TREATMENT", 87, 96]]], ["Moderate or severe short-term illness 8.", [["illness", "DISEASE", 30, 37], ["Moderate or severe short-term illness", "PROBLEM", 0, 37], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["short-term", "OBSERVATION_MODIFIER", 19, 29]]], ["Breast feeding 9.", [["Breast", "ANATOMY", 0, 6], ["Breast feeding", "TREATMENT", 0, 14]]], ["Using steroid drops in their eyes 10.", [["eyes", "ANATOMY", 29, 33], ["steroid", "CHEMICAL", 6, 13], ["steroid", "CHEMICAL", 6, 13], ["steroid", "SIMPLE_CHEMICAL", 6, 13], ["eyes", "ORGAN", 29, 33], ["steroid drops", "TREATMENT", 6, 19]]], ["A heart condition 11.", [["heart", "ANATOMY", 2, 7], ["heart", "ORGAN", 2, 7], ["heart", "ANATOMY", 2, 7]]], ["Three or more risk factors: high blood pressure, high blood cholesterol, diabetes, a first-degree relative who had a heart condition before the age of 50 and who smoke cigarettes a Data from CDC smallpox fact sheet [CDC web site].", [["blood", "ANATOMY", 33, 38], ["blood", "ANATOMY", 54, 59], ["heart", "ANATOMY", 117, 122], ["cholesterol", "CHEMICAL", 60, 71], ["diabetes", "DISEASE", 73, 81], ["heart condition", "DISEASE", 117, 132], ["cholesterol", "CHEMICAL", 60, 71], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["heart", "ORGAN", 117, 122], ["high blood pressure", "PROBLEM", 28, 47], ["high blood cholesterol", "PROBLEM", 49, 71], ["diabetes", "PROBLEM", 73, 81], ["a heart condition", "PROBLEM", 115, 132], ["heart", "ANATOMY", 117, 122]]], ["People who should not get the smallpox vaccine (unless they are exposed to smallpox).", [["smallpox", "DISEASE", 75, 83], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["the smallpox vaccine", "TREATMENT", 26, 46]]], ["Accessed November 5, 2003.Adverse reactions and complicationsThe incidence of fever in adults is much less, with only 5% to 9% reporting mild fevers and only 3% reporting a fever higher than 102\u00b0 [39] .", [["fever", "DISEASE", 78, 83], ["fevers", "DISEASE", 142, 148], ["fever", "DISEASE", 173, 178], ["Adverse reactions", "PROBLEM", 26, 43], ["complications", "PROBLEM", 48, 61], ["fever", "PROBLEM", 78, 83], ["mild fevers", "PROBLEM", 137, 148], ["a fever", "PROBLEM", 171, 178], ["fever", "OBSERVATION", 78, 83], ["mild", "OBSERVATION_MODIFIER", 137, 141], ["fevers", "OBSERVATION", 142, 148]]], ["In addition, approximately one half of recipients report mild pain at the site, and one third develop mild lymphadenopathy.", [["pain", "DISEASE", 62, 66], ["lymphadenopathy", "DISEASE", 107, 122], ["recipients", "ORGANISM", 39, 49], ["mild pain at the site", "PROBLEM", 57, 78], ["mild lymphadenopathy", "PROBLEM", 102, 122], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["pain", "OBSERVATION", 62, 66], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["lymphadenopathy", "OBSERVATION", 107, 122]]], ["Some patients exhibit hypersensitivity reactions to the vaccinations such as erythema multiforme and Stevens -Johnson syndrome.", [["erythema multiforme", "ANATOMY", 77, 96], ["hypersensitivity", "DISEASE", 22, 38], ["erythema multiforme", "DISEASE", 77, 96], ["Stevens -Johnson syndrome", "DISEASE", 101, 126], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["hypersensitivity reactions", "PROBLEM", 22, 48], ["the vaccinations", "TREATMENT", 52, 68], ["erythema multiforme", "PROBLEM", 77, 96], ["Johnson syndrome", "PROBLEM", 110, 126], ["hypersensitivity reactions", "OBSERVATION", 22, 48], ["erythema", "OBSERVATION", 77, 85], ["Johnson syndrome", "OBSERVATION", 110, 126]]], ["Treatment is supportive and may include steroids.Adverse reactions and complicationsThe most common vaccinia-specific complication is autoinoculation, which occurs when vaccinia from the vaccination site is spread to another site on the body such as the eye, mouth, genitals, or anus.", [["body", "ANATOMY", 237, 241], ["eye", "ANATOMY", 254, 257], ["mouth", "ANATOMY", 259, 264], ["genitals", "ANATOMY", 266, 274], ["anus", "ANATOMY", 279, 283], ["steroids", "CHEMICAL", 40, 48], ["steroids", "CHEMICAL", 40, 48], ["steroids", "SIMPLE_CHEMICAL", 40, 48], ["vaccinia", "ORGANISM", 100, 108], ["vaccinia", "ORGANISM", 169, 177], ["body", "ORGANISM_SUBDIVISION", 237, 241], ["eye", "ORGAN", 254, 257], ["mouth", "ORGANISM_SUBDIVISION", 259, 264], ["genitals", "ORGANISM_SUBDIVISION", 266, 274], ["anus", "ORGAN", 279, 283], ["vaccinia", "SPECIES", 169, 177], ["steroids", "TREATMENT", 40, 48], ["Adverse reactions", "PROBLEM", 49, 66], ["complications", "PROBLEM", 71, 84], ["autoinoculation", "PROBLEM", 134, 149], ["vaccinia", "PROBLEM", 169, 177], ["the vaccination site", "PROBLEM", 183, 203], ["most common", "OBSERVATION_MODIFIER", 88, 99], ["vaccinia", "OBSERVATION", 100, 108], ["specific", "OBSERVATION_MODIFIER", 109, 117], ["complication", "OBSERVATION", 118, 130], ["body", "ANATOMY_MODIFIER", 237, 241], ["eye", "ANATOMY", 254, 257], ["mouth", "ANATOMY", 259, 264], ["genitals", "ANATOMY", 266, 274], ["anus", "ANATOMY", 279, 283]]], ["This complication occurred at a rate of 529 per million primary vaccinations in the United States [35] and was most common in children 1 to 4 years of age.", [["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["This complication", "PROBLEM", 0, 17]]], ["It is usually self-limited unless it occurs in the eye.", [["eye", "ANATOMY", 51, 54], ["eye", "ORGAN", 51, 54], ["eye", "ANATOMY", 51, 54]]], ["Vaccinia can cause a keratitis leading to corneal scarring, which may be exacerbated if vaccinia immune globulin (VIG) is used for treatment.Adverse reactions and complicationsGeneralized vaccinia occurs at a rate of 241 cases per million primary vaccinations.", [["corneal", "ANATOMY", 42, 49], ["Vaccinia", "DISEASE", 0, 8], ["keratitis", "DISEASE", 21, 30], ["corneal scarring", "DISEASE", 42, 58], ["VIG", "CHEMICAL", 114, 117], ["vaccinia", "DISEASE", 188, 196], ["Vaccinia", "ORGANISM", 0, 8], ["corneal", "TISSUE", 42, 49], ["vaccinia", "ORGANISM", 88, 96], ["immune globulin", "GENE_OR_GENE_PRODUCT", 97, 112], ["VIG", "CANCER", 114, 117], ["vaccinia", "ORGANISM", 188, 196], ["vaccinia immune globulin", "PROTEIN", 88, 112], ["Vaccinia", "TREATMENT", 0, 8], ["a keratitis", "PROBLEM", 19, 30], ["corneal scarring", "PROBLEM", 42, 58], ["vaccinia immune globulin (VIG)", "TREATMENT", 88, 118], ["treatment", "TREATMENT", 131, 140], ["Adverse reactions", "PROBLEM", 141, 158], ["complications", "PROBLEM", 163, 176], ["Generalized vaccinia", "PROBLEM", 176, 196], ["keratitis", "OBSERVATION", 21, 30], ["corneal", "ANATOMY", 42, 49], ["scarring", "OBSERVATION", 50, 58], ["may be", "UNCERTAINTY", 66, 72], ["vaccinia", "OBSERVATION", 188, 196]]], ["It is characterized by a disseminated maculopapular or vesicular rash that can be distinguished from variola because the rash does not follow the centrifugal pattern of smallpox [38] .", [["maculopapular", "ANATOMY", 38, 51], ["vesicular", "ANATOMY", 55, 64], ["vesicular rash", "DISEASE", 55, 69], ["variola", "DISEASE", 101, 108], ["rash", "DISEASE", 121, 125], ["smallpox", "DISEASE", 169, 177], ["a disseminated maculopapular or vesicular rash", "PROBLEM", 23, 69], ["variola", "PROBLEM", 101, 108], ["the rash", "PROBLEM", 117, 125], ["disseminated", "OBSERVATION_MODIFIER", 25, 37], ["maculopapular", "OBSERVATION_MODIFIER", 38, 51], ["vesicular rash", "OBSERVATION", 55, 69], ["variola", "OBSERVATION", 101, 108]]], ["Because the lesions of generalized vaccinia are believed to contain live vaccinia virus, patients need to be treated with contact precautions and isolated if possible.", [["lesions", "ANATOMY", 12, 19], ["vaccinia", "DISEASE", 35, 43], ["vaccinia virus", "DISEASE", 73, 87], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["vaccinia", "ORGANISM", 35, 43], ["vaccinia virus", "ORGANISM", 73, 87], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["vaccinia virus", "SPECIES", 73, 87], ["the lesions", "PROBLEM", 8, 19], ["generalized vaccinia", "PROBLEM", 23, 43], ["live vaccinia virus", "PROBLEM", 68, 87], ["contact precautions", "TREATMENT", 122, 141], ["lesions", "OBSERVATION", 12, 19], ["generalized", "OBSERVATION_MODIFIER", 23, 34], ["vaccinia", "OBSERVATION", 35, 43], ["vaccinia virus", "OBSERVATION", 73, 87]]], ["Treatment with VIG is usually not necessary unless the patient is immunocompromised.Adverse reactions and complicationsEczema vaccinatum can be a life-threatening complication that occurs at a rate of 38 cases per million primary vaccinations [38] .", [["VIG", "CHEMICAL", 15, 18], ["Eczema vaccinatum", "DISEASE", 119, 136], ["VIG", "SIMPLE_CHEMICAL", 15, 18], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["Eczema vaccinatum", "SPECIES", 119, 136], ["VIG", "TREATMENT", 15, 18], ["immunocompromised", "PROBLEM", 66, 83], ["Adverse reactions", "PROBLEM", 84, 101], ["complications", "PROBLEM", 106, 119], ["Eczema vaccinatum", "PROBLEM", 119, 136], ["threatening complication", "PROBLEM", 151, 175], ["immunocompromised", "OBSERVATION", 66, 83]]], ["It occurs in patients with atopic dermatitis or eczema and is most severe in individuals who are undergoing their primary vaccination or are in close contact with recently vaccinated individuals.", [["atopic dermatitis", "DISEASE", 27, 44], ["eczema", "DISEASE", 48, 54], ["patients", "ORGANISM", 13, 21], ["individuals", "ORGANISM", 77, 88], ["patients", "SPECIES", 13, 21], ["atopic dermatitis", "PROBLEM", 27, 44], ["eczema", "PROBLEM", 48, 54], ["atopic dermatitis", "OBSERVATION", 27, 44], ["eczema", "OBSERVATION", 48, 54], ["most severe", "OBSERVATION_MODIFIER", 62, 73]]], ["The lesions are characterized by a localized or generalized papular, vesicular, or pustular rash that occurs anywhere in the body, with a predilection for areas of previous atopic dermatitis [38] .", [["lesions", "ANATOMY", 4, 11], ["papular", "ANATOMY", 60, 67], ["vesicular", "ANATOMY", 69, 78], ["body", "ANATOMY", 125, 129], ["pustular rash", "DISEASE", 83, 96], ["atopic dermatitis", "DISEASE", 173, 190], ["lesions", "CANCER", 4, 11], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["The lesions", "PROBLEM", 0, 11], ["a localized or generalized papular, vesicular", "PROBLEM", 33, 78], ["pustular rash", "PROBLEM", 83, 96], ["previous atopic dermatitis", "PROBLEM", 164, 190], ["lesions", "OBSERVATION", 4, 11], ["localized", "OBSERVATION_MODIFIER", 35, 44], ["generalized", "OBSERVATION_MODIFIER", 48, 59], ["papular", "OBSERVATION_MODIFIER", 60, 67], ["vesicular", "OBSERVATION_MODIFIER", 69, 78], ["pustular", "OBSERVATION_MODIFIER", 83, 91], ["rash", "OBSERVATION", 92, 96], ["body", "ANATOMY", 125, 129], ["atopic dermatitis", "OBSERVATION", 173, 190]]], ["The lesions occur at the same time as the initial vaccination lesion.", [["lesions", "ANATOMY", 4, 11], ["lesion", "ANATOMY", 62, 68], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["the initial vaccination lesion", "PROBLEM", 38, 68], ["lesions", "OBSERVATION", 4, 11], ["lesion", "OBSERVATION", 62, 68]]], ["The mortality from this complication has been reported to be as high as 30% and can be significantly reduced by the early use of VIG.", [["VIG", "CHEMICAL", 129, 132], ["VIG", "SIMPLE_CHEMICAL", 129, 132], ["this complication", "PROBLEM", 19, 36], ["VIG", "TREATMENT", 129, 132], ["significantly", "OBSERVATION_MODIFIER", 87, 100], ["reduced", "OBSERVATION_MODIFIER", 101, 108]]], ["Because these patients are capable of transmitting vaccinia to unvaccinated individuals, these patients need to be isolated and contact precautions observed.Adverse reactions and complicationsProgressive vaccinia rarely occurs during routine vaccinations, with an incidence of 1.5 cases per million vaccinations reported [35] .", [["vaccinia", "DISEASE", 204, 212], ["patients", "ORGANISM", 14, 22], ["vaccinia", "ORGANISM", 51, 59], ["patients", "ORGANISM", 95, 103], ["vaccinia", "ORGANISM", 204, 212], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 95, 103], ["vaccinia", "SPECIES", 51, 59], ["transmitting vaccinia", "TREATMENT", 38, 59], ["contact precautions", "TREATMENT", 128, 147], ["Adverse reactions", "PROBLEM", 157, 174], ["complications", "PROBLEM", 179, 192], ["Progressive vaccinia", "PROBLEM", 192, 212], ["routine vaccinations", "TREATMENT", 234, 254], ["vaccinia", "OBSERVATION", 204, 212]]], ["This disorder occurs in patients with an immunodeficiency and may be more severe in patients with cell-mediated rather than those with humoral deficiencies [40] .", [["cell", "ANATOMY", 98, 102], ["immunodeficiency", "DISEASE", 41, 57], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 84, 92], ["cell", "CELL", 98, 102], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 84, 92], ["This disorder", "PROBLEM", 0, 13], ["an immunodeficiency", "PROBLEM", 38, 57], ["humoral deficiencies", "PROBLEM", 135, 155], ["immunodeficiency", "OBSERVATION", 41, 57], ["may be", "UNCERTAINTY", 62, 68], ["more severe", "OBSERVATION_MODIFIER", 69, 80]]], ["This complication is characterized by unchecked growth of the vaccinia virus at the site of inoculation leading to necrosis and nonhealing of the initial vaccination lesion.", [["lesion", "ANATOMY", 166, 172], ["necrosis", "DISEASE", 115, 123], ["vaccinia virus", "ORGANISM", 62, 76], ["vaccinia virus", "SPECIES", 62, 76], ["This complication", "PROBLEM", 0, 17], ["unchecked growth", "PROBLEM", 38, 54], ["the vaccinia virus", "PROBLEM", 58, 76], ["inoculation", "PROBLEM", 92, 103], ["necrosis", "PROBLEM", 115, 123], ["nonhealing of the initial vaccination lesion", "PROBLEM", 128, 172], ["unchecked", "OBSERVATION_MODIFIER", 38, 47], ["growth", "OBSERVATION_MODIFIER", 48, 54], ["vaccinia virus", "OBSERVATION", 62, 76], ["inoculation", "OBSERVATION", 92, 103], ["necrosis", "OBSERVATION", 115, 123], ["nonhealing", "OBSERVATION_MODIFIER", 128, 138], ["lesion", "OBSERVATION", 166, 172]]], ["This complication was universally lethal before VIG was introduced but still has a high mortality rate.", [["This complication", "PROBLEM", 0, 17], ["VIG", "TREATMENT", 48, 51], ["a high mortality rate", "PROBLEM", 81, 102]]], ["Patients with this are infectious, so contact and isolation precautions need to be taken.Adverse reactions and complicationsInfants less than 12 months of age are at an especially high risk for postvaccinial central nervous system disease.", [["central nervous system", "ANATOMY", 208, 230], ["postvaccinial central nervous system disease", "DISEASE", 194, 238], ["Patients", "ORGANISM", 0, 8], ["Infants", "ORGANISM", 124, 131], ["central nervous system", "ANATOMICAL_SYSTEM", 208, 230], ["Patients", "SPECIES", 0, 8], ["Infants", "SPECIES", 124, 131], ["infectious", "PROBLEM", 23, 33], ["isolation precautions", "TREATMENT", 50, 71], ["Adverse reactions", "PROBLEM", 89, 106], ["complications", "PROBLEM", 111, 124], ["postvaccinial central nervous system disease", "PROBLEM", 194, 238], ["infectious", "OBSERVATION", 23, 33], ["central nervous system disease", "OBSERVATION", 208, 238]]], ["Postvaccinial encephalitis (encephalomyelitis) occurs at a rate of 12 cases per million primary vaccinations, but the rate for children less than 12 months of age is 42 cases per million primary vaccinations [32] .", [["Postvaccinial encephalitis", "DISEASE", 0, 26], ["encephalomyelitis", "DISEASE", 28, 45], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["Postvaccinial encephalitis", "PROBLEM", 0, 26], ["encephalomyelitis", "PROBLEM", 28, 45], ["encephalitis", "OBSERVATION", 14, 26], ["encephalomyelitis", "OBSERVATION", 28, 45]]], ["The cause of this disorder is unknown, although it appears to be similar to other postinfectious encephalitides with symptoms developing 6 to 10 days after vaccination.", [["encephalitides", "DISEASE", 97, 111], ["this disorder", "PROBLEM", 13, 26], ["other postinfectious encephalitides", "PROBLEM", 76, 111], ["symptoms", "PROBLEM", 117, 125], ["vaccination", "TREATMENT", 156, 167], ["postinfectious", "OBSERVATION", 82, 96]]], ["In the past, approximately 25% of patients were left with significant neurologic deficits, and 25% of patients died.", [["neurologic", "ANATOMY", 70, 80], ["neurologic deficits", "DISEASE", 70, 89], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 102, 110], ["significant neurologic deficits", "PROBLEM", 58, 89], ["left", "ANATOMY_MODIFIER", 48, 52], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["neurologic deficits", "OBSERVATION", 70, 89]]], ["This complication was more commonly found in patients who were vaccinated with a strain of vaccinia not used in Canada, and the US VIG administered prophylactically has resulted in a decreased incidence of postvaccinial encephalitis in military recruits in Europe; thus, VIG is administered with all first-time vaccinations in the Netherlands, a practice not recommended in the United States [41, 42] .Adverse reactions and complicationsFetal vaccinia has been reported less than 50 times and has occurred in all three trimesters of pregnancy.", [["VIG", "CHEMICAL", 131, 134], ["encephalitis", "DISEASE", 220, 232], ["VIG", "CHEMICAL", 271, 274], ["Fetal vaccinia", "DISEASE", 437, 451], ["patients", "ORGANISM", 45, 53], ["vaccinia", "ORGANISM", 91, 99], ["Fetal vaccinia", "ORGANISM", 437, 451], ["patients", "SPECIES", 45, 53], ["vaccinia", "SPECIES", 91, 99], ["This complication", "PROBLEM", 0, 17], ["a strain of vaccinia", "PROBLEM", 79, 99], ["the US VIG", "TEST", 124, 134], ["postvaccinial encephalitis", "PROBLEM", 206, 232], ["VIG", "TREATMENT", 271, 274], ["Adverse reactions", "PROBLEM", 402, 419], ["complications", "PROBLEM", 424, 437], ["Fetal vaccinia", "PROBLEM", 437, 451], ["decreased", "OBSERVATION_MODIFIER", 183, 192], ["postvaccinial", "OBSERVATION_MODIFIER", 206, 219], ["encephalitis", "OBSERVATION", 220, 232], ["vaccinia", "OBSERVATION", 443, 451]]], ["It is associated with a high incidence of fetal demise but not with prematurity or congenital anomalies.", [["fetal", "ANATOMY", 42, 47], ["fetal demise", "DISEASE", 42, 54], ["prematurity", "DISEASE", 68, 79], ["congenital anomalies", "DISEASE", 83, 103], ["fetal", "ANATOMICAL_SYSTEM", 42, 47], ["fetal demise", "PROBLEM", 42, 54], ["prematurity", "PROBLEM", 68, 79], ["congenital anomalies", "PROBLEM", 83, 103], ["high", "OBSERVATION_MODIFIER", 24, 28], ["fetal demise", "OBSERVATION", 42, 54], ["not with", "UNCERTAINTY", 59, 67], ["congenital", "OBSERVATION_MODIFIER", 83, 93], ["anomalies", "OBSERVATION", 94, 103]]], ["Babies demonstrate the lesions of generalized vaccinia and need to be treated with contact and isolation precautions.", [["lesions", "ANATOMY", 23, 30], ["vaccinia", "DISEASE", 46, 54], ["Babies", "ORGANISM", 0, 6], ["lesions", "PATHOLOGICAL_FORMATION", 23, 30], ["vaccinia", "ORGANISM", 46, 54], ["the lesions", "PROBLEM", 19, 30], ["generalized vaccinia", "PROBLEM", 34, 54], ["contact and isolation precautions", "TREATMENT", 83, 116], ["lesions", "OBSERVATION", 23, 30], ["generalized", "OBSERVATION_MODIFIER", 34, 45], ["vaccinia", "OBSERVATION", 46, 54]]], ["There are no data on the efficacy of VIG in treating these infants.Adverse reactions and complicationsMyopericarditis has never been reported as a complication of smallpox vaccination in young children, although it has been reported in military recruits and civilians taking part in the recent pre-event vaccination program.", [["VIG", "CHEMICAL", 37, 40], ["Myopericarditis", "DISEASE", 102, 117], ["smallpox", "DISEASE", 163, 171], ["VIG", "SIMPLE_CHEMICAL", 37, 40], ["infants", "ORGANISM", 59, 66], ["children", "ORGANISM", 193, 201], ["infants", "SPECIES", 59, 66], ["children", "SPECIES", 193, 201], ["VIG", "TREATMENT", 37, 40], ["Adverse reactions", "PROBLEM", 67, 84], ["complicationsMyopericarditis", "PROBLEM", 89, 117], ["smallpox vaccination", "TREATMENT", 163, 183], ["no", "UNCERTAINTY", 10, 12]]], ["In addition, there have been five civilian patients with cardiac ischemic events following vaccination.", [["cardiac", "ANATOMY", 57, 64], ["cardiac ischemic events", "DISEASE", 57, 80], ["patients", "ORGANISM", 43, 51], ["cardiac", "ORGAN", 57, 64], ["patients", "SPECIES", 43, 51], ["cardiac ischemic events", "PROBLEM", 57, 80], ["vaccination", "TREATMENT", 91, 102], ["cardiac", "ANATOMY", 57, 64], ["ischemic", "OBSERVATION", 65, 73]]], ["The causal relationship between the cardiac ischemic events and the smallpox vaccination is unclear, but there does appear to be a causal relationship between vaccination and myocarditis.", [["cardiac", "ANATOMY", 36, 43], ["cardiac ischemic events", "DISEASE", 36, 59], ["smallpox", "DISEASE", 68, 76], ["myocarditis", "DISEASE", 175, 186], ["cardiac", "ANATOMICAL_SYSTEM", 36, 43], ["the cardiac ischemic events", "PROBLEM", 32, 59], ["the smallpox vaccination", "TREATMENT", 64, 88], ["myocarditis", "PROBLEM", 175, 186], ["cardiac", "ANATOMY", 36, 43], ["ischemic", "OBSERVATION", 44, 52], ["myocarditis", "OBSERVATION", 175, 186]]], ["These recent reports of cardiac complications have led the Advisory Committee on Immunization Practices to revise their recommendations to exclude individuals with known heart disease or three or more cardiac risk factors [44] .Adverse reactions and complicationsGovernmental planning for a bioterror attack from smallpox presupposes that the smallpox released would be ''natural'' and not genetically modified.", [["cardiac", "ANATOMY", 24, 31], ["heart", "ANATOMY", 170, 175], ["cardiac", "ANATOMY", 201, 208], ["cardiac complications", "DISEASE", 24, 45], ["heart disease", "DISEASE", 170, 183], ["smallpox", "DISEASE", 313, 321], ["smallpox", "DISEASE", 343, 351], ["cardiac", "ORGAN", 24, 31], ["heart", "ORGAN", 170, 175], ["cardiac complications", "PROBLEM", 24, 45], ["Immunization Practices", "TREATMENT", 81, 103], ["known heart disease", "PROBLEM", 164, 183], ["more cardiac risk factors", "PROBLEM", 196, 221], ["Adverse reactions", "PROBLEM", 228, 245], ["a bioterror attack", "PROBLEM", 289, 307], ["cardiac", "ANATOMY", 24, 31], ["complications", "OBSERVATION", 32, 45], ["heart", "ANATOMY", 170, 175], ["disease", "OBSERVATION", 176, 183]]], ["Recently, mousepox has been genetically engineered, creating a strain with 100% mortality for the mice [45] .", [["mousepox", "CHEMICAL", 10, 18], ["mice", "ORGANISM", 98, 102], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102]]], ["Even vaccinated mice were not fully protected.", [["mice", "ORGANISM", 16, 20], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20]]], ["Subsequent work on this genetically modified virus has revealed that vaccinated mice that were also treated with cidovir fared much better than mice that received just the vaccine or just cidovir.", [["cidovir", "CHEMICAL", 113, 120], ["cidovir", "CHEMICAL", 188, 195], ["cidovir", "CHEMICAL", 113, 120], ["mice", "ORGANISM", 80, 84], ["cidovir", "SIMPLE_CHEMICAL", 113, 120], ["mice", "ORGANISM", 144, 148], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 144, 148], ["this genetically modified virus", "PROBLEM", 19, 50], ["cidovir", "TREATMENT", 113, 120], ["the vaccine", "TREATMENT", 168, 179], ["cidovir", "TREATMENT", 188, 195]]], ["Although there are no studies on the efficacy of cidovir on treating smallpox, this drug has been used to treat vaccinia, monkeypox, and mousepox [46] .", [["cidovir", "CHEMICAL", 49, 56], ["smallpox", "DISEASE", 69, 77], ["vaccinia", "DISEASE", 112, 120], ["monkeypox", "DISEASE", 122, 131], ["cidovir", "CHEMICAL", 49, 56], ["cidovir", "SIMPLE_CHEMICAL", 49, 56], ["vaccinia", "ORGANISM", 112, 120], ["monkeypox", "ORGANISM", 122, 131], ["cidovir", "TREATMENT", 49, 56], ["smallpox", "TREATMENT", 69, 77], ["this drug", "TREATMENT", 79, 88], ["vaccinia", "PROBLEM", 112, 120]]], ["Suggested treatment for the other class A bioterror agents is reviewed in Table 4 .SummaryChildren may be especially vulnerable to bioterrorism attacks because of their higher metabolic and respiratory rates, their frequent hand-to-mouth contacts, and their proximity to the ground.", [["respiratory", "ANATOMY", 190, 201], ["hand", "ANATOMY", 224, 228], ["mouth", "ANATOMY", 232, 237], ["Children", "ORGANISM", 90, 98], ["Children", "SPECIES", 90, 98], ["treatment", "TREATMENT", 10, 19], ["A bioterror agents", "TREATMENT", 40, 58], ["their higher metabolic and respiratory rates", "PROBLEM", 163, 207]]], ["The treatments available against biologic agents that may be used in a bioterror incident have all been designed for and tested in adults and are often relatively contraindicated in children.", [["adults", "ORGANISM", 131, 137], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190], ["The treatments", "TREATMENT", 0, 14], ["biologic agents", "TREATMENT", 33, 48]]], ["Moreover, the usual methods needed to contain a bioterrorism attack are more difficult to implement in a pediatric setting.", [["a bioterrorism attack", "PROBLEM", 46, 67]]], ["The vaccines available either have not been recommended or used extensively in children (eg, anthrax) or have been proven to have more adverse effects in very young children (eg, smallpox).", [["anthrax", "DISEASE", 93, 100], ["smallpox", "DISEASE", 179, 187], ["children", "ORGANISM", 79, 87], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 165, 173], ["The vaccines", "TREATMENT", 0, 12]]], ["Effective infection control measures are more difficult to maintain in a population that psychologically and physically resists isolation measures.", [["infection", "DISEASE", 10, 19], ["Effective infection control measures", "PROBLEM", 0, 36], ["isolation measures", "TREATMENT", 128, 146], ["infection", "OBSERVATION", 10, 19]]], ["In fact, it is very possible that young children will need to be sedated if isolation from parents is necessary, which would require the active role of pediatric intensivists and anesthesiologists.SummaryUntil the introduction of effective antibiotics and vaccines for common pediatric infections, pediatric hospitals limited the spread of disease by placing young patients in quarantine in specific wards while they were infectious.", [["infections", "DISEASE", 286, 296], ["children", "ORGANISM", 40, 48], ["patients", "ORGANISM", 365, 373], ["children", "SPECIES", 40, 48], ["patients", "SPECIES", 365, 373], ["effective antibiotics", "TREATMENT", 230, 251], ["vaccines", "TREATMENT", 256, 264], ["common pediatric infections", "PROBLEM", 269, 296], ["disease", "PROBLEM", 340, 347], ["infectious", "PROBLEM", 422, 432], ["very possible", "UNCERTAINTY", 15, 28], ["infectious", "OBSERVATION", 422, 432]]], ["Ironically, the success in eliminating infection as the most common cause of pediatric mortality over the last 50 years is that pediatric hospitals are no longer designed for quarantine, which would be required following a bioterrorism attack.", [["infection", "DISEASE", 39, 48], ["eliminating infection", "PROBLEM", 27, 48], ["infection", "OBSERVATION", 39, 48]]], ["Indeed, the difficulties in vaccinating a cadre of health care workers against smallpox were highlighted by the sparse participation of health care workers in the voluntary program initiated by the US government.", [["smallpox", "DISEASE", 79, 87], ["smallpox", "TREATMENT", 79, 87]]], ["Presently, it is prudent to assume that children are extremely vulnerable to bioterrorism attacks and that the pediatric health care system is not fully prepared to deal with bioterrorism.", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["bioterrorism", "PROBLEM", 175, 187]]]], "16a28a8a87866ad16d935338c02a95251cb0e85c": [["IntroductionSequence analysis of SARS coronavirus genome reveals that it contains five major open reading frame (ORFs) that encode a polymerase, and S, M, E and N proteins like those of other coronavirus.", [["SARS coronavirus", "ORGANISM", 33, 49], ["E", "GENE_OR_GENE_PRODUCT", 155, 156], ["SARS coronavirus genome", "DNA", 33, 56], ["open reading frame", "DNA", 93, 111], ["ORFs", "DNA", 113, 117], ["polymerase, and S, M, E and N proteins", "PROTEIN", 133, 171], ["SARS coronavirus", "SPECIES", 33, 49], ["IntroductionSequence analysis", "TEST", 0, 29], ["SARS coronavirus genome", "PROBLEM", 33, 56], ["a polymerase", "TEST", 131, 143], ["other coronavirus", "PROBLEM", 186, 203]]], ["However, the nine potential ORFs are not found in other coronaviruses [1] .", [["ORFs", "DNA", 28, 32], ["the nine potential ORFs", "PROBLEM", 9, 32]]], ["Theoretically all these proteins can be used as targets in drug and vaccine design.", [["drug and vaccine design", "TREATMENT", 59, 82]]], ["However, there are some difficulties in understanding the functions of these unknown proteins due to very poor sequence homology with proteins available in the Protein Data Bank.", [["these unknown proteins", "PROBLEM", 71, 93], ["very poor sequence homology", "PROBLEM", 101, 128], ["some", "OBSERVATION_MODIFIER", 19, 23], ["difficulties", "OBSERVATION", 24, 36]]], ["The 3D jury system [2] utilizes a global network of independent structure prediction servers to detect patterns of structural similarity between diverse models and select the correct fold from a set of borderline predictions.", [["structural similarity between diverse models", "PROBLEM", 115, 159]]], ["An exciting finding based on such a method [3] is that the mRNA cap-1 methyltransferase function has been assigned to the nsp13 protein of the SARS coronavirus (3D jury scoreO100).", [["SARS coronavirus", "DISEASE", 143, 159], ["cap-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["nsp13", "GENE_OR_GENE_PRODUCT", 122, 127], ["SARS coronavirus", "ORGANISM", 143, 159], ["nsp13 protein", "PROTEIN", 122, 135], ["SARS coronavirus", "SPECIES", 143, 159], ["the mRNA cap", "TEST", 55, 67], ["the SARS coronavirus", "PROBLEM", 139, 159]]], ["In this study, we started with metaserver 3D jury system for fold recognition study of ORF3, constructed rational molecular model, hence to understand the potential function of ORF3 in terms of tertiary structure.Materials and methodsThe sequence of ORF3 protein in SARS-CoV was downloaded from GenBank (NP_828851) and used for fold prediction by 3D Jury system [2] , it is a comprehensive protein structure prediction servers including more than 10 novel fold recognition methods, which made a dramatic impact on the critical assessment of protein structure prediction (CASP-5) in 2002.", [["ORF3", "GENE_OR_GENE_PRODUCT", 177, 181], ["ORF3", "GENE_OR_GENE_PRODUCT", 250, 254], ["SARS-CoV", "ORGANISM", 266, 274], ["ORF3", "DNA", 87, 91], ["ORF3", "DNA", 177, 181], ["ORF3 protein", "PROTEIN", 250, 262], ["SARS-CoV", "DNA", 266, 274], ["SARS-CoV", "SPECIES", 266, 274], ["this study", "TEST", 3, 13], ["fold recognition study", "TEST", 61, 83], ["ORF3", "TREATMENT", 87, 91], ["ORF3 protein", "TEST", 250, 262], ["SARS", "PROBLEM", 266, 270], ["CoV", "PROBLEM", 271, 274], ["CASP", "TEST", 571, 575]]], ["The proteins with a sufficiently high 3D score were used as templates to construct 3D models of ORF3 using the MODELLER program [4] .", [["ORF3", "GENE_OR_GENE_PRODUCT", 96, 100], ["ORF3", "DNA", 96, 100], ["the MODELLER program", "TREATMENT", 107, 127]]], ["The quality of 3D models was evaluated by ProQ program [5] and the best model was used for further analyses.", [["further analyses", "TEST", 91, 107]]], ["Specifically, in order to get possible information about the function of ORF3, VAST (http://www.ncbi.nlm.nih.gov/Structure/VAST/vastsearch. html), DALI (http://www.ebi.ac.uk/dali/) and CE [6] programs were employed to search the structure neighbors of ORF3 protein.", [["ORF3", "GENE_OR_GENE_PRODUCT", 73, 77], ["ORF3", "GENE_OR_GENE_PRODUCT", 252, 256], ["ORF3", "DNA", 73, 77], ["VAST", "DNA", 79, 83], ["html", "PROTEIN", 140, 144], ["ORF3 protein", "PROTEIN", 252, 264], ["DALI (http://www.ebi.ac.uk/dali/) and CE [6] programs", "TREATMENT", 147, 200], ["ORF3 protein", "TEST", 252, 264]]], ["Finally, NCI program [8] was used to identify noncanonical interactions in protein structures.", [["noncanonical interactions in protein structures", "PROBLEM", 46, 93]]], ["The visualization of 3D structure was generated by PROTEINEXPLORER (http://www.proteinexplorer.org).Results and discussionThe 3D Jury system found three significant hits (3D scoreO90) which have a similar fold to ORF3 (threading Naturally, a question arises: what information about ORF3's function we can get from its 3D structure?", [["ORF3", "GENE_OR_GENE_PRODUCT", 282, 286], ["ORF3", "DNA", 213, 217], ["ORF3", "DNA", 282, 286], ["The visualization of 3D structure", "TEST", 0, 33], ["ORF3's function", "TREATMENT", 282, 297], ["significant", "OBSERVATION_MODIFIER", 153, 164], ["hits", "OBSERVATION", 165, 169]]], ["The above three templates (1LVL, 3GRS and 1GES), which belong a FAD/NAD-linked reductase family, lead us to the speculation that ORF3 may be a protein related to FAD/NAD-binding.", [["NAD", "CHEMICAL", 68, 71], ["NAD", "CHEMICAL", 166, 169], ["FAD", "CHEMICAL", 64, 67], ["NAD", "CHEMICAL", 68, 71], ["FAD", "CHEMICAL", 162, 165], ["NAD", "CHEMICAL", 166, 169], ["3GRS", "GENE_OR_GENE_PRODUCT", 33, 37], ["1GES", "GENE_OR_GENE_PRODUCT", 42, 46], ["NAD-linked reductase", "GENE_OR_GENE_PRODUCT", 68, 88], ["ORF3", "GENE_OR_GENE_PRODUCT", 129, 133], ["FAD", "SIMPLE_CHEMICAL", 162, 165], ["NAD", "SIMPLE_CHEMICAL", 166, 169], ["1GES", "PROTEIN", 42, 46], ["FAD/NAD-linked reductase family", "PROTEIN", 64, 95], ["ORF3", "DNA", 129, 133], ["FAD", "PROTEIN", 162, 165], ["NAD", "PROTEIN", 166, 169], ["NAD", "PROBLEM", 68, 71], ["NAD", "PROBLEM", 166, 169]]], ["This seems consistent with the speculation that ORF3 may encode a protein related to Table 1 The sequence alignment between ORF3 and 1LVL and the secondary structure ATP-binding [1] , because FAD/NAD is generally used as an oxidant to yield ATP [9] .Results and discussionIn order to collect as many evidence as possible for such a speculation, we employed VAST, DALI and CE to search the structure neighbors of ORF3.", [["ATP", "CHEMICAL", 166, 169], ["FAD", "CHEMICAL", 192, 195], ["NAD", "CHEMICAL", 196, 199], ["ATP", "CHEMICAL", 241, 244], ["ATP", "CHEMICAL", 166, 169], ["FAD", "CHEMICAL", 192, 195], ["NAD", "CHEMICAL", 196, 199], ["ATP", "CHEMICAL", 241, 244], ["ORF3", "GENE_OR_GENE_PRODUCT", 48, 52], ["Table 1", "GENE_OR_GENE_PRODUCT", 85, 92], ["ORF3", "GENE_OR_GENE_PRODUCT", 124, 128], ["1LVL", "GENE_OR_GENE_PRODUCT", 133, 137], ["ATP", "SIMPLE_CHEMICAL", 166, 169], ["FAD", "SIMPLE_CHEMICAL", 192, 195], ["NAD", "SIMPLE_CHEMICAL", 196, 199], ["ATP", "SIMPLE_CHEMICAL", 241, 244], ["ORF3", "GENE_OR_GENE_PRODUCT", 412, 416], ["ORF3", "DNA", 48, 52], ["ORF3", "DNA", 124, 128], ["1LVL", "DNA", 133, 137], ["ORF3", "DNA", 412, 416], ["a protein", "PROBLEM", 64, 73], ["The sequence alignment", "TEST", 93, 115], ["ORF3", "TEST", 124, 128], ["1LVL", "TEST", 133, 137], ["the secondary structure ATP", "PROBLEM", 142, 169], ["FAD/NAD", "PROBLEM", 192, 199], ["consistent with", "UNCERTAINTY", 11, 26]]], ["We found that the top hits, except the above templates, focus on the following dehydrogenases (also belong to the FAD/NAD-linked reductase family): 1OJT (lipoamide dehydrogenase from bacterium Neisseria meningitides), 1JEH (lipoamide dehydrogenase from yeast Saccharomyces cerevisiae), 1LPF (lipoamide dehydrogenase from bacterium Pseudomonas fluorescens), 1EBD (dehydrolipoamide dehydrogenase from bacterium Bacillus stearothermophilus), and 1DXL (lipoamide dehydrogenase from pea Pisum sativum).", [["NAD", "CHEMICAL", 118, 121], ["lipoamide", "CHEMICAL", 154, 163], ["lipoamide", "CHEMICAL", 224, 233], ["lipoamide", "CHEMICAL", 292, 301], ["dehydrolipoamide", "CHEMICAL", 363, 379], ["lipoamide", "CHEMICAL", 449, 458], ["FAD", "CHEMICAL", 114, 117], ["NAD", "CHEMICAL", 118, 121], ["1OJT", "CHEMICAL", 148, 152], ["lipoamide", "CHEMICAL", 154, 163], ["lipoamide", "CHEMICAL", 224, 233], ["lipoamide", "CHEMICAL", 292, 301], ["dehydrolipoamide", "CHEMICAL", 363, 379], ["lipoamide", "CHEMICAL", 449, 458], ["FAD", "SIMPLE_CHEMICAL", 114, 117], ["NAD-linked reductase", "GENE_OR_GENE_PRODUCT", 118, 138], ["1OJT", "SIMPLE_CHEMICAL", 148, 152], ["lipoamide dehydrogenase", "GENE_OR_GENE_PRODUCT", 154, 177], ["bacterium", "ORGANISM", 183, 192], ["Neisseria meningitides", "ORGANISM", 193, 215], ["1JEH", "GENE_OR_GENE_PRODUCT", 218, 222], ["lipoamide dehydrogenase", "GENE_OR_GENE_PRODUCT", 224, 247], ["yeast Saccharomyces cerevisiae", "ORGANISM", 253, 283], ["1LPF", "GENE_OR_GENE_PRODUCT", 286, 290], ["lipoamide dehydrogenase", "GENE_OR_GENE_PRODUCT", 292, 315], ["bacterium Pseudomonas fluorescens", "ORGANISM", 321, 354], ["1EBD", "GENE_OR_GENE_PRODUCT", 357, 361], ["dehydrolipoamide dehydrogenase", "GENE_OR_GENE_PRODUCT", 363, 393], ["bacterium Bacillus stearothermophilus", "ORGANISM", 399, 436], ["1DXL", "GENE_OR_GENE_PRODUCT", 443, 447], ["lipoamide dehydrogenase", "GENE_OR_GENE_PRODUCT", 449, 472], ["pea Pisum sativum", "ORGANISM", 478, 495], ["FAD/NAD-linked reductase family", "PROTEIN", 114, 145], ["1OJT", "PROTEIN", 148, 152], ["lipoamide dehydrogenase", "PROTEIN", 154, 177], ["1JEH", "PROTEIN", 218, 222], ["lipoamide dehydrogenase", "PROTEIN", 224, 247], ["yeast Saccharomyces cerevisiae), 1LPF (lipoamide dehydrogenase", "PROTEIN", 253, 315], ["1EBD", "PROTEIN", 357, 361], ["dehydrolipoamide dehydrogenase", "PROTEIN", 363, 393], ["bacterium Bacillus stearothermophilus", "PROTEIN", 399, 436], ["1DXL", "PROTEIN", 443, 447], ["lipoamide dehydrogenase", "PROTEIN", 449, 472], ["Neisseria meningitides", "SPECIES", 193, 215], ["yeast", "SPECIES", 253, 258], ["Saccharomyces cerevisiae", "SPECIES", 259, 283], ["Pseudomonas fluorescens", "SPECIES", 331, 354], ["Bacillus stearothermophilus", "SPECIES", 409, 436], ["pea", "SPECIES", 478, 481], ["Pisum sativum", "SPECIES", 482, 495], ["Neisseria meningitides", "SPECIES", 193, 215], ["yeast", "SPECIES", 253, 258], ["Saccharomyces cerevisiae", "SPECIES", 259, 283], ["Pseudomonas fluorescens", "SPECIES", 331, 354], ["Bacillus stearothermophilus", "SPECIES", 409, 436], ["Pisum sativum", "SPECIES", 482, 495], ["the top hits", "PROBLEM", 14, 26], ["the above templates", "PROBLEM", 35, 54], ["NAD", "PROBLEM", 118, 121], ["1OJT (lipoamide dehydrogenase", "TREATMENT", 148, 177], ["bacterium Neisseria meningitides", "TREATMENT", 183, 215], ["1JEH (lipoamide dehydrogenase", "TREATMENT", 218, 247], ["yeast Saccharomyces cerevisiae", "TREATMENT", 253, 283], ["1LPF (lipoamide dehydrogenase", "TREATMENT", 286, 315], ["bacterium Pseudomonas fluorescens", "PROBLEM", 321, 354], ["1EBD (dehydrolipoamide dehydrogenase", "TREATMENT", 357, 393], ["bacterium Bacillus stearothermophilus", "TREATMENT", 399, 436], ["1DXL (lipoamide dehydrogenase", "TREATMENT", 443, 472], ["pea Pisum sativum", "TEST", 478, 495], ["top", "OBSERVATION_MODIFIER", 18, 21], ["hits", "OBSERVATION", 22, 26]]], ["The superpositions between these enzymes and ORF3 are shown in Fig. 2 .", [["ORF3", "GENE_OR_GENE_PRODUCT", 45, 49], ["enzymes", "PROTEIN", 33, 40], ["ORF3", "DNA", 45, 49], ["these enzymes", "TEST", 27, 40], ["ORF3", "TEST", 45, 49]]], ["It can be seen from the revised structure alignment (Fig. 3 ) that there are a number of similar structural patterns showing conservative residues (bold representation).", [["conservative residues", "PROBLEM", 125, 146], ["structure", "OBSERVATION_MODIFIER", 32, 41], ["alignment", "OBSERVATION_MODIFIER", 42, 51], ["conservative residues", "OBSERVATION", 125, 146]]], ["In particular, among them are partially conserved FAD-bind motif (marked as '#') and NAD-binding motif (marked as '$') [10] [11] [12] [13] [14] .", [["NAD", "CHEMICAL", 85, 88], ["FAD", "CHEMICAL", 50, 53], ["NAD", "CHEMICAL", 85, 88], ["FAD", "SIMPLE_CHEMICAL", 50, 53], ["NAD", "SIMPLE_CHEMICAL", 85, 88], ["FAD-bind motif", "PROTEIN", 50, 64], ["NAD-binding motif", "PROTEIN", 85, 102], ["NAD", "PROBLEM", 85, 88]]], ["This suggests that there could be a link between ORF3 and FAD/NAD-binding protein indeed.", [["NAD", "CHEMICAL", 62, 65], ["FAD", "CHEMICAL", 58, 61], ["NAD", "CHEMICAL", 62, 65], ["ORF3", "GENE_OR_GENE_PRODUCT", 49, 53], ["FAD", "GENE_OR_GENE_PRODUCT", 58, 61], ["NAD-binding protein", "GENE_OR_GENE_PRODUCT", 62, 81], ["ORF3", "PROTEIN", 49, 53], ["FAD", "PROTEIN", 58, 61], ["NAD-binding protein", "PROTEIN", 62, 81], ["a link between ORF3", "PROBLEM", 34, 53], ["NAD", "PROBLEM", 62, 65]]], ["Finally, the non-canonical interactions in ORF3 protein structure were identified by NCI program and the results showed that there are three pairs of main chain-side chain interactions: Tyr160 (donor) and Phe43 (acceptor), Phe43 (donor) and Tyr206 (acceptor), and Ile232 (donor) and Phe231 (acceptor).", [["Tyr160", "CHEMICAL", 186, 192], ["Phe43", "CHEMICAL", 205, 210], ["Phe43", "CHEMICAL", 223, 228], ["Tyr206", "CHEMICAL", 241, 247], ["Ile232", "CHEMICAL", 264, 270], ["Phe231", "CHEMICAL", 283, 289], ["ORF3", "GENE_OR_GENE_PRODUCT", 43, 47], ["Tyr160", "GENE_OR_GENE_PRODUCT", 186, 192], ["Phe43", "SIMPLE_CHEMICAL", 205, 210], ["Phe43", "SIMPLE_CHEMICAL", 223, 228], ["Tyr206", "AMINO_ACID", 241, 247], ["Ile232", "SIMPLE_CHEMICAL", 264, 270], ["Phe231", "SIMPLE_CHEMICAL", 283, 289], ["ORF3 protein structure", "PROTEIN", 43, 65], ["Tyr206", "PROTEIN", 241, 247], ["ORF3 protein structure", "TEST", 43, 65], ["Phe43 (acceptor", "TREATMENT", 205, 220], ["Phe231 (acceptor", "TREATMENT", 283, 299], ["main", "OBSERVATION_MODIFIER", 150, 154], ["chain", "OBSERVATION_MODIFIER", 155, 160]]], ["Among these interactions, Phe43 forms two N-H/p bonds in a sandwich fashion: one donates to Tyr206, and one donated by Tyr160, as existed in human rac1 [15] and SARS-CoV main protease [16] .", [["Phe43", "CHEMICAL", 26, 31], ["N-H", "CHEMICAL", 42, 45], ["Phe43", "CHEMICAL", 26, 31], ["N-H", "CHEMICAL", 42, 45], ["p", "CHEMICAL", 46, 47], ["Tyr206", "CHEMICAL", 92, 98], ["Tyr160", "CHEMICAL", 119, 125], ["Phe43", "SIMPLE_CHEMICAL", 26, 31], ["Tyr206", "GENE_OR_GENE_PRODUCT", 92, 98], ["Tyr160", "GENE_OR_GENE_PRODUCT", 119, 125], ["human", "ORGANISM", 141, 146], ["rac1 [15]", "GENE_OR_GENE_PRODUCT", 147, 156], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["Tyr206", "PROTEIN", 92, 98], ["Tyr160", "PROTEIN", 119, 125], ["human rac1 [15] and SARS-CoV main protease", "PROTEIN", 141, 183], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["SARS-CoV", "SPECIES", 161, 169], ["SARS", "TEST", 161, 165], ["CoV main protease", "TREATMENT", 166, 183]]], ["These noncanonical bindings fix the big helix Phe43 locate to the two loops Tyr160 and Tyr206 locate, hence stabilizes the structure of ORF3 protein (Fig. 4) .", [["Tyr160", "CHEMICAL", 76, 82], ["Tyr206", "CHEMICAL", 87, 93], ["Tyr160", "GENE_OR_GENE_PRODUCT", 76, 82], ["Tyr206", "AMINO_ACID", 87, 93], ["ORF3", "GENE_OR_GENE_PRODUCT", 136, 140], ["big helix Phe43", "PROTEIN", 36, 51], ["Tyr206", "PROTEIN", 87, 93], ["ORF3 protein", "PROTEIN", 136, 148], ["the big helix Phe43", "TREATMENT", 32, 51], ["ORF3 protein", "TEST", 136, 148], ["bindings fix", "OBSERVATION", 19, 31]]], ["These results can be used for rational design of mutagenesis experiments and analysis of conservation of interactions at functional sites.", [["mutagenesis experiments", "TREATMENT", 49, 72], ["interactions at functional sites", "PROBLEM", 105, 137]]], ["In recent years, the non-canonical interactions have been shown to be important for the stability of protein structure [17] [18] [19] and ligand recognition [20] .", [["[17] [18] [19]", "SIMPLE_CHEMICAL", 119, 133]]]], "PMC7367781": [["IntroductionThe recent outbreak of the respiratory illness caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)1 has raised clinical and organizational concerns that culminated in the declaration of a pandemic on March 11th, 20202.", [["respiratory", "ANATOMY", 39, 50], ["respiratory illness", "DISEASE", 39, 58], ["acute respiratory syndrome coronavirus", "DISEASE", 86, 124], ["SARS-CoV-2)1", "CHEMICAL", 128, 140], ["SARS-CoV-2)1", "ORGANISM", 128, 140], ["severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)1", "SPECIES", 79, 140], ["the respiratory illness", "PROBLEM", 35, 58], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 69, 124], ["CoV", "TEST", 133, 136], ["outbreak", "OBSERVATION_MODIFIER", 23, 31], ["respiratory illness", "OBSERVATION", 39, 58], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory syndrome coronavirus", "OBSERVATION", 92, 124]]], ["The World Health Organization has named the disease caused by the SARS-CoV-2 as COVID-19, short for coronavirus disease 20193.Pathophysiology of Covid-19 relevant for anesthesiologistsCovid-19 is a new disease and only a part of the mechanisms that subtend its clinical course have been elucidated.", [["coronavirus disease", "DISEASE", 100, 119], ["SARS-CoV-2", "ORGANISM", 66, 76], ["COVID-19", "DNA", 80, 88], ["SARS-CoV", "SPECIES", 66, 74], ["the disease", "PROBLEM", 40, 51], ["the SARS", "TEST", 62, 70], ["CoV", "TEST", 71, 74], ["COVID", "TEST", 80, 85], ["coronavirus disease", "PROBLEM", 100, 119], ["Covid", "TEST", 145, 150], ["Covid", "TEST", 184, 189], ["a new disease", "PROBLEM", 196, 209], ["new", "OBSERVATION_MODIFIER", 198, 201], ["disease", "OBSERVATION", 202, 209]]], ["The progression from the nasopharyngeal cavity to the lung alveoli is suspected to be at the base of the onset of the most severe form of the disease; however, quantification of the minimum viral load that allows the onset of the disease is not known.Pathophysiology of Covid-19 relevant for anesthesiologistsThe mechanisms of viral infection are better characterized4 and replication also because the scientists have profited from previous knowledge on similar viruses.", [["nasopharyngeal cavity", "ANATOMY", 25, 46], ["lung alveoli", "ANATOMY", 54, 66], ["viral infection", "DISEASE", 327, 342], ["nasopharyngeal cavity", "MULTI-TISSUE_STRUCTURE", 25, 46], ["lung alveoli", "MULTI-TISSUE_STRUCTURE", 54, 66], ["The progression from the nasopharyngeal cavity", "PROBLEM", 0, 46], ["the disease", "PROBLEM", 138, 149], ["the minimum viral load", "PROBLEM", 178, 200], ["the disease", "PROBLEM", 226, 237], ["Covid", "TEST", 270, 275], ["viral infection", "PROBLEM", 327, 342], ["progression", "OBSERVATION_MODIFIER", 4, 15], ["nasopharyngeal", "ANATOMY", 25, 39], ["cavity", "OBSERVATION", 40, 46], ["lung", "ANATOMY", 54, 58], ["alveoli", "ANATOMY_MODIFIER", 59, 66], ["base", "ANATOMY_MODIFIER", 93, 97], ["most severe", "OBSERVATION_MODIFIER", 118, 129], ["disease", "OBSERVATION", 142, 149], ["viral load", "OBSERVATION", 190, 200], ["disease", "OBSERVATION", 230, 237], ["not known", "UNCERTAINTY", 241, 250], ["viral", "OBSERVATION_MODIFIER", 327, 332], ["infection", "OBSERVATION", 333, 342]]], ["The passage from the cytopatic level to the alteration of tissue structure is again less understood, although is widely acknowledged that a key role is played by local and general immunologic mechanisms5.", [["tissue", "ANATOMY", 58, 64], ["tissue", "TISSUE", 58, 64], ["passage", "OBSERVATION_MODIFIER", 4, 11], ["tissue structure", "OBSERVATION", 58, 74]]], ["However, also here the balance between innate and adaptive immune system during the course of the disease is a subject of discussion6.Pathophysiology of Covid-19 relevant for anesthesiologistsFor the reasons previously listed, in absence of certainties about several important steps of the pathophysiology, research has proceeded by gathering information about patterns of presentation by the observation of affected patients and then started ordering them in a possible time sequence of events.", [["immune system", "ANATOMY", 59, 72], ["immune system", "ANATOMICAL_SYSTEM", 59, 72], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 417, 425], ["innate and adaptive immune system", "TREATMENT", 39, 72], ["Covid", "TEST", 153, 158]]], ["Using this method, a recent systematic review7 on 42 published articles revealed that three clinical stages can be identified: viral infection, pulmonary involvement with inflammation, and fibrosis.", [["pulmonary", "ANATOMY", 144, 153], ["viral infection", "DISEASE", 127, 142], ["inflammation", "DISEASE", 171, 183], ["fibrosis", "DISEASE", 189, 197], ["pulmonary", "ORGAN", 144, 153], ["this method", "TREATMENT", 6, 17], ["a recent systematic review7", "TEST", 19, 46], ["viral infection", "PROBLEM", 127, 142], ["pulmonary involvement", "PROBLEM", 144, 165], ["inflammation", "PROBLEM", 171, 183], ["fibrosis", "PROBLEM", 189, 197], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infection", "OBSERVATION", 133, 142], ["pulmonary", "ANATOMY", 144, 153], ["inflammation", "OBSERVATION", 171, 183], ["fibrosis", "OBSERVATION", 189, 197]]], ["In all the stages co-existed epithelial damage (inflammation and diffuse alveolar damage), microvascular damage (including thrombosis) and fibrinous pneumonia; the presence of fibrotic patterns appeared after 3 weeks from the onset of the disease.", [["epithelial", "ANATOMY", 29, 39], ["alveolar", "ANATOMY", 73, 81], ["microvascular", "ANATOMY", 91, 104], ["inflammation", "DISEASE", 48, 60], ["alveolar damage", "DISEASE", 73, 88], ["microvascular damage", "DISEASE", 91, 111], ["thrombosis", "DISEASE", 123, 133], ["pneumonia", "DISEASE", 149, 158], ["epithelial", "TISSUE", 29, 39], ["alveolar", "TISSUE", 73, 81], ["microvascular", "TISSUE", 91, 104], ["epithelial damage (inflammation", "PROBLEM", 29, 60], ["diffuse alveolar damage)", "PROBLEM", 65, 89], ["microvascular damage", "PROBLEM", 91, 111], ["thrombosis", "PROBLEM", 123, 133], ["fibrinous pneumonia", "PROBLEM", 139, 158], ["fibrotic patterns", "PROBLEM", 176, 193], ["the disease", "PROBLEM", 235, 246], ["epithelial damage", "OBSERVATION", 29, 46], ["inflammation", "OBSERVATION_MODIFIER", 48, 60], ["diffuse", "OBSERVATION_MODIFIER", 65, 72], ["alveolar damage", "OBSERVATION", 73, 88], ["microvascular", "OBSERVATION_MODIFIER", 91, 104], ["damage", "OBSERVATION", 105, 111], ["thrombosis", "OBSERVATION", 123, 133], ["fibrinous", "OBSERVATION_MODIFIER", 139, 148], ["pneumonia", "OBSERVATION", 149, 158], ["fibrotic", "OBSERVATION", 176, 184], ["disease", "OBSERVATION", 239, 246]]], ["An important message from the mentioned paper by Polak and coworkers7 is that \u201cthe patients can present with more than one pattern, either simultaneously or consecutively\u201d.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["As we can note later, this pathologic finding has important implications on the way we ventilate these patients.Pathophysiology of Covid-19 relevant for anesthesiologistsParallel to this histopathological investigation, since the beginning of the COVID-19 outbreak, intensivists have tried to associate lung morphology (studied by computed tomography) with the measurements of lung mechanics on these patients.", [["lung", "ANATOMY", 303, 307], ["lung", "ANATOMY", 377, 381], ["patients", "ORGANISM", 103, 111], ["lung", "ORGAN", 303, 307], ["lung", "ORGAN", 377, 381], ["patients", "ORGANISM", 401, 409], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 401, 409], ["Covid", "TEST", 131, 136], ["this histopathological investigation", "TEST", 182, 218], ["computed tomography", "TEST", 331, 350], ["lung", "ANATOMY", 303, 307], ["lung", "ANATOMY", 377, 381], ["mechanics", "OBSERVATION", 382, 391]]], ["In a widely diffused editorial8, Gattinoni and coworkers on the base of the first evidences, outlined the presence of two different paradigmatic patterns, labeled as \u201cphenotypes\u201d by the authors.Pathophysiology of Covid-19 relevant for anesthesiologistsAmong the first they reported that the disease was characterized by a severe hypoxemia often associated with a near normal respiratory system compliance, whose clinical expression was very inhomogeneous, ranging from normal breathing (\u201csilent\u201d hypoxemia) or to remarkable dyspnea8.Pathophysiology of Covid-19 relevant for anesthesiologistsThe observation of many cases of the disease made them able to sketch two different patterns labeled as phenotype L and phenotype H. The characteristics of Type L were Low values of: Elastance, Low ventilation/perfusion ratio, Low lung weight and Low recruitability.", [["respiratory system", "ANATOMY", 375, 393], ["lung", "ANATOMY", 822, 826], ["hypoxemia", "DISEASE", 329, 338], ["hypoxemia", "DISEASE", 496, 505], ["dyspnea8", "DISEASE", 524, 532], ["lung", "ORGAN", 822, 826], ["Covid", "TEST", 213, 218], ["the disease", "PROBLEM", 287, 298], ["a severe hypoxemia", "PROBLEM", 320, 338], ["very inhomogeneous", "PROBLEM", 436, 454], ["silent\u201d hypoxemia", "PROBLEM", 488, 505], ["remarkable dyspnea8", "PROBLEM", 513, 532], ["Covid", "TEST", 552, 557], ["the disease", "PROBLEM", 624, 635], ["Elastance", "TEST", 774, 783], ["Low ventilation", "TREATMENT", 785, 800], ["perfusion ratio", "TEST", 801, 816], ["Low lung weight", "PROBLEM", 818, 833], ["Low recruitability", "PROBLEM", 838, 856], ["widely", "OBSERVATION_MODIFIER", 5, 11], ["diffused", "OBSERVATION_MODIFIER", 12, 20], ["editorial8", "OBSERVATION", 21, 31], ["base", "ANATOMY_MODIFIER", 64, 68], ["disease", "OBSERVATION", 291, 298], ["severe", "OBSERVATION_MODIFIER", 322, 328], ["hypoxemia", "OBSERVATION", 329, 338], ["respiratory system compliance", "OBSERVATION", 375, 404], ["inhomogeneous", "OBSERVATION_MODIFIER", 441, 454], ["remarkable", "OBSERVATION_MODIFIER", 513, 523], ["dyspnea8", "OBSERVATION", 524, 532], ["Low ventilation", "OBSERVATION", 785, 800], ["lung", "ANATOMY", 822, 826], ["Low recruitability", "OBSERVATION", 838, 856]]], ["Radiological expression of type L is a pattern based on multiple ground-glass/crazy paving opacities mainly in the subpleural region.Pathophysiology of Covid-19 relevant for anesthesiologistsInstead, the characteristics of Type H were High levels of: Elastance, Right-to-left shunt, lung weight and recruitability8.", [["subpleural region", "ANATOMY", 115, 132], ["lung", "ANATOMY", 283, 287], ["opacities", "DISEASE", 91, 100], ["type L", "GENE_OR_GENE_PRODUCT", 27, 33], ["subpleural region", "MULTI-TISSUE_STRUCTURE", 115, 132], ["lung", "ORGAN", 283, 287], ["multiple ground-glass/crazy paving opacities", "PROBLEM", 56, 100], ["Covid", "TEST", 152, 157], ["Elastance", "TEST", 251, 260], ["Right-to-left shunt", "TREATMENT", 262, 281], ["recruitability8", "PROBLEM", 299, 314], ["type L", "OBSERVATION_MODIFIER", 27, 33], ["multiple", "OBSERVATION_MODIFIER", 56, 64], ["ground", "OBSERVATION_MODIFIER", 65, 71], ["-glass", "OBSERVATION_MODIFIER", 71, 77], ["crazy", "OBSERVATION_MODIFIER", 78, 83], ["paving opacities", "OBSERVATION", 84, 100], ["subpleural", "ANATOMY_MODIFIER", 115, 125], ["region", "ANATOMY_MODIFIER", 126, 132], ["Right", "ANATOMY_MODIFIER", 262, 267], ["left", "ANATOMY_MODIFIER", 271, 275], ["shunt", "OBSERVATION", 276, 281], ["lung", "ANATOMY", 283, 287], ["weight", "OBSERVATION", 288, 294]]], ["Radiologically, this last phenotype resembles a classical patchy ARDS pattern.Pathophysiology of Covid-19 relevant for anesthesiologistsThe authors speculated that the clinical presentation of phase L was determined by an important hypoxemia deriving from a vasoplegic mechanism.", [["ARDS", "DISEASE", 65, 69], ["hypoxemia", "DISEASE", 232, 241], ["a classical patchy ARDS pattern", "PROBLEM", 46, 77], ["Covid", "TEST", 97, 102], ["an important hypoxemia", "PROBLEM", 219, 241], ["a vasoplegic mechanism", "TREATMENT", 256, 278], ["patchy", "OBSERVATION_MODIFIER", 58, 64], ["ARDS", "OBSERVATION", 65, 69], ["hypoxemia", "OBSERVATION", 232, 241]]], ["In fact a preliminary hypothesis made them ascribe this phenomenon to the loss of the hypoxic pulmonary vasoconstriction reflex, which is physiologically able to divert the blood flow away from the poorly ventilated areas; the absence of this reflex would cause a remarkable hyperperfusion of gasless tissue9.", [["pulmonary", "ANATOMY", 94, 103], ["blood", "ANATOMY", 173, 178], ["hyperperfusion", "DISEASE", 275, 289], ["pulmonary", "ORGAN", 94, 103], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["this phenomenon", "PROBLEM", 51, 66], ["the hypoxic pulmonary vasoconstriction reflex", "PROBLEM", 82, 127], ["the blood flow", "TEST", 169, 183], ["this reflex", "PROBLEM", 238, 249], ["a remarkable hyperperfusion of gasless tissue9", "PROBLEM", 262, 308], ["hypoxic", "OBSERVATION_MODIFIER", 86, 93], ["pulmonary", "ANATOMY", 94, 103], ["vasoconstriction reflex", "OBSERVATION", 104, 127], ["blood flow", "OBSERVATION", 173, 183], ["poorly", "OBSERVATION_MODIFIER", 198, 204], ["ventilated", "OBSERVATION", 205, 215], ["remarkable", "OBSERVATION_MODIFIER", 264, 274], ["hyperperfusion", "OBSERVATION", 275, 289], ["gasless", "OBSERVATION", 293, 300]]], ["The mechanism beyond hypoxia during L-phase could be the virus blockade of the ACE-2 vascular receptors10 or a more complex epithelial\u2013endothelial crosstalk, responsible of the endothelial disfunction and of a \u2018proinflammatory\u2019/\u2018procoagulant\u2019 phenotype change in the endothelial cells11.", [["vascular", "ANATOMY", 85, 93], ["epithelial\u2013endothelial", "ANATOMY", 124, 146], ["endothelial", "ANATOMY", 177, 188], ["endothelial cells", "ANATOMY", 267, 284], ["hypoxia", "DISEASE", 21, 28], ["ACE-2", "GENE_OR_GENE_PRODUCT", 79, 84], ["vascular receptors10", "GENE_OR_GENE_PRODUCT", 85, 105], ["epithelial\u2013endothelial", "CANCER", 124, 146], ["endothelial", "CELL", 177, 188], ["endothelial cells", "CELL", 267, 284], ["ACE-2 vascular receptors10", "PROTEIN", 79, 105], ["endothelial cells", "CELL_TYPE", 267, 284], ["hypoxia", "PROBLEM", 21, 28], ["the virus blockade", "TREATMENT", 53, 71], ["the ACE", "TEST", 75, 82], ["a more complex epithelial\u2013endothelial crosstalk", "PROBLEM", 109, 156], ["the endothelial disfunction", "PROBLEM", 173, 200], ["a \u2018proinflammatory\u2019/\u2018procoagulant", "PROBLEM", 208, 241], ["phenotype change in the endothelial cells", "PROBLEM", 243, 284], ["hypoxia", "OBSERVATION", 21, 28], ["virus", "OBSERVATION", 57, 62], ["vascular", "ANATOMY", 85, 93], ["epithelial\u2013endothelial crosstalk", "OBSERVATION", 124, 156], ["endothelial disfunction", "OBSERVATION", 177, 200], ["endothelial cells", "ANATOMY", 267, 284]]], ["In the attempt of compensating for the hypoxemia, the patient progressively begins hyperventilate up to 15-20 ml/kg8, although in many cases, for the almost normal compliance, these patients do not complain about the presence of dyspnea.", [["hypoxemia", "DISEASE", 39, 48], ["dyspnea", "DISEASE", 229, 236], ["patient", "ORGANISM", 54, 61], ["patients", "ORGANISM", 182, 190], ["patient", "SPECIES", 54, 61], ["patients", "SPECIES", 182, 190], ["the hypoxemia", "PROBLEM", 35, 48], ["dyspnea", "PROBLEM", 229, 236], ["hypoxemia", "OBSERVATION", 39, 48], ["dyspnea", "OBSERVATION", 229, 236]]], ["The tachypnea could be also caused by the viral neurotropism12, direct affecting the respiratory centers.Pathophysiology of Covid-19 relevant for anesthesiologistsIn this model proposed by Gattinoni8 in March, the transition to phase H can be caused by two possible mechanisms.", [["tachypnea", "DISEASE", 4, 13], ["Gattinoni8", "SIMPLE_CHEMICAL", 189, 199], ["The tachypnea", "PROBLEM", 0, 13], ["the viral neurotropism12", "PROBLEM", 38, 62], ["Covid", "TEST", 124, 129], ["tachypnea", "OBSERVATION", 4, 13], ["viral", "OBSERVATION", 42, 47], ["respiratory centers", "OBSERVATION", 85, 104]]], ["If the patient is still breathing spontaneously, a combination of deep negative intrathoracic pressure and increased lung permeability (due to inflammation) brings to a P-SILI (=Patient-Self Induced Lung Injury)13.", [["intrathoracic", "ANATOMY", 80, 93], ["lung", "ANATOMY", 117, 121], ["Lung", "ANATOMY", 199, 203], ["inflammation", "DISEASE", 143, 155], ["SILI", "DISEASE", 171, 175], ["Lung Injury", "DISEASE", 199, 210], ["patient", "ORGANISM", 7, 14], ["lung", "ORGAN", 117, 121], ["Lung", "ORGAN", 199, 203], ["patient", "SPECIES", 7, 14], ["Patient", "SPECIES", 178, 185], ["still breathing", "PROBLEM", 18, 33], ["deep negative intrathoracic pressure", "PROBLEM", 66, 102], ["increased lung permeability", "PROBLEM", 107, 134], ["inflammation", "PROBLEM", 143, 155], ["Self Induced Lung Injury", "PROBLEM", 186, 210], ["intrathoracic pressure", "OBSERVATION", 80, 102], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["lung", "ANATOMY", 117, 121], ["permeability", "OBSERVATION", 122, 134], ["Lung", "ANATOMY", 199, 203], ["Injury", "OBSERVATION", 204, 210]]], ["If the patients is already mechanically ventilated the reason of worsening can be a Ventilator-induced lung injury (VILI)14 determined by a pattern of ventilation that is no more appropriate for the by now edematous lungs, characterized by a higher lung weight than normal, which through a high superimposed pressure creates dependent atelectasis and reduction of the space available for ventilation (\u201cbaby lung\u201d)15.", [["lung", "ANATOMY", 103, 107], ["edematous lungs", "ANATOMY", 206, 221], ["lung", "ANATOMY", 249, 253], ["lung", "ANATOMY", 407, 411], ["Ventilator", "DISEASE", 84, 94], ["lung injury", "DISEASE", 103, 114], ["VILI", "DISEASE", 116, 120], ["atelectasis", "DISEASE", 335, 346], ["patients", "ORGANISM", 7, 15], ["lung", "ORGAN", 103, 107], ["lungs", "ORGAN", 216, 221], ["lung", "ORGAN", 249, 253], ["lung", "ORGAN", 407, 411], ["patients", "SPECIES", 7, 15], ["mechanically ventilated", "PROBLEM", 27, 50], ["a Ventilator", "TREATMENT", 82, 94], ["lung injury", "PROBLEM", 103, 114], ["ventilation", "TREATMENT", 151, 162], ["edematous lungs", "PROBLEM", 206, 221], ["a higher lung weight", "PROBLEM", 240, 260], ["a high superimposed pressure creates dependent atelectasis", "PROBLEM", 288, 346], ["the space", "TREATMENT", 364, 373], ["ventilation", "TREATMENT", 388, 399], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["no more", "UNCERTAINTY", 171, 178], ["edematous", "OBSERVATION", 206, 215], ["lungs", "ANATOMY", 216, 221], ["higher", "OBSERVATION_MODIFIER", 242, 248], ["lung", "ANATOMY", 249, 253], ["pressure", "OBSERVATION_MODIFIER", 308, 316], ["dependent", "OBSERVATION_MODIFIER", 325, 334], ["atelectasis", "OBSERVATION", 335, 346], ["reduction", "OBSERVATION_MODIFIER", 351, 360], ["lung", "ANATOMY", 407, 411]]], ["The H-phase shares similar features with ARDS; for this reason, as in ARDS, the further stage in the evolution of COVID-19 can be characterized by a fibrotic evolution16.Two recurring component of the disease are trombofilia17, 18, 19 and altered immune response20.", [["ARDS", "DISEASE", 41, 45], ["ARDS", "DISEASE", 70, 74], ["COVID-19", "CHEMICAL", 114, 122], ["COVID-19", "CHEMICAL", 114, 122], ["COVID-19", "GENE_OR_GENE_PRODUCT", 114, 122], ["COVID-19", "DNA", 114, 122], ["ARDS", "PROBLEM", 41, 45], ["ARDS", "PROBLEM", 70, 74], ["COVID", "TEST", 114, 119], ["a fibrotic evolution", "PROBLEM", 147, 167], ["the disease", "PROBLEM", 197, 208], ["altered immune response20", "PROBLEM", 239, 264], ["ARDS", "OBSERVATION", 41, 45], ["ARDS", "OBSERVATION", 70, 74], ["fibrotic", "OBSERVATION", 149, 157], ["recurring", "OBSERVATION_MODIFIER", 174, 183], ["component", "OBSERVATION_MODIFIER", 184, 193], ["disease", "OBSERVATION", 201, 208]]], ["The tendency to thrombophilia is associated to poor prognosis21.Pathophysiology of Covid-19 relevant for anesthesiologistsThe progressive accumulation of clinical and radiological evidence, although maintaining intact the value of the difference between the L and the H phenotypes, has brought to observation also the presence of intermediate patterns between the two.", [["thrombophilia", "DISEASE", 16, 29], ["The tendency to thrombophilia", "PROBLEM", 0, 29], ["poor prognosis21", "PROBLEM", 47, 63], ["Covid", "TEST", 83, 88], ["The progressive accumulation of clinical and radiological evidence", "PROBLEM", 122, 188], ["thrombophilia", "OBSERVATION", 16, 29], ["poor", "OBSERVATION_MODIFIER", 47, 51], ["progressive", "OBSERVATION_MODIFIER", 126, 137], ["accumulation", "OBSERVATION_MODIFIER", 138, 150], ["intact", "OBSERVATION_MODIFIER", 211, 217], ["L", "ANATOMY_MODIFIER", 258, 259], ["intermediate patterns", "OBSERVATION", 330, 351]]], ["Robba and co-authors22 reported the presence of transitional phenotypes characterized by the appearance of inhomogeneously distributed atelectasis and peri-bronchial opacities.Pathophysiology of Covid-19 relevant for anesthesiologistsThe association of these morphological aspects with the time sequence of the disease has even reawakened the debate on the correctness of the usage of term \u201cphenotype\u201d (as univocal external expression of a disease) in favor of the term \u201cstage\u201d of the disease11.", [["atelectasis", "DISEASE", 135, 146], ["opacities", "DISEASE", 166, 175], ["disease11", "CANCER", 485, 494], ["transitional phenotypes", "PROBLEM", 48, 71], ["inhomogeneously distributed atelectasis", "PROBLEM", 107, 146], ["peri-bronchial opacities", "PROBLEM", 151, 175], ["Covid", "TEST", 195, 200], ["the disease", "PROBLEM", 307, 318], ["a disease)", "PROBLEM", 438, 448], ["the disease11", "PROBLEM", 481, 494], ["transitional phenotypes", "OBSERVATION", 48, 71], ["inhomogeneously", "OBSERVATION_MODIFIER", 107, 122], ["distributed", "OBSERVATION_MODIFIER", 123, 134], ["atelectasis", "OBSERVATION", 135, 146], ["peri-bronchial", "ANATOMY_MODIFIER", 151, 165], ["opacities", "OBSERVATION", 166, 175], ["disease", "OBSERVATION", 311, 318]]], ["The debate will continue but the presence in the same patient of morphological elements of different phases of inflammation, in the same time or in temporal sequence speak in favor of stating that the Covid has one phenotype constituted by different stages23 (by definition a \u201cfull disease phenotype incorporates the abnormal phenotypes realized at each stage of the disease course\u201d)23.Aspect of PEEP physiology that are relevant for the management of Covid-19Nowadays the application of PEEP is finalized both to contribute to the maintenance of acceptable gas exchange (specifically blood oxygenation) and to position the pressure volume loop during ventilation in a range that minimizes tidal excursions (in order to reduce atelectotrauma and volu-/baro-trauma24).", [["blood", "ANATOMY", 585, 590], ["inflammation", "DISEASE", 111, 123], ["patient", "ORGANISM", 54, 61], ["blood", "ORGANISM_SUBSTANCE", 585, 590], ["patient", "SPECIES", 54, 61], ["inflammation", "PROBLEM", 111, 123], ["a \u201cfull disease phenotype", "PROBLEM", 274, 299], ["the abnormal phenotypes", "PROBLEM", 313, 336], ["PEEP physiology", "TEST", 396, 411], ["Covid", "TEST", 452, 457], ["PEEP", "TREATMENT", 488, 492], ["blood oxygenation", "TEST", 585, 602], ["the pressure volume loop", "TREATMENT", 620, 644], ["ventilation", "TREATMENT", 652, 663], ["tidal excursions", "PROBLEM", 690, 706], ["atelectotrauma", "TEST", 727, 741], ["volu-", "TEST", 746, 751], ["different phases", "OBSERVATION_MODIFIER", 91, 107], ["inflammation", "OBSERVATION", 111, 123], ["PEEP physiology", "OBSERVATION", 396, 411], ["acceptable", "OBSERVATION_MODIFIER", 547, 557], ["gas", "OBSERVATION", 558, 561], ["pressure", "OBSERVATION_MODIFIER", 624, 632], ["volume loop", "OBSERVATION", 633, 644]]], ["In fact, the direct effect of PEEP is to keep a definite amount of gas inside alveoli throughout expiration, thus maintaining them open, constituting a buffer for gas exchange, avoiding cyclic opening and closing25.Aspect of PEEP physiology that are relevant for the management of Covid-19The search for the \u201cbest PEEP\u201d has been at the center of a debate that have inflamed scientific literature over the past forty years.", [["alveoli", "ANATOMY", 78, 85], ["alveoli", "MULTI-TISSUE_STRUCTURE", 78, 85], ["PEEP", "TREATMENT", 30, 34], ["a buffer for gas exchange", "TREATMENT", 150, 175], ["cyclic opening", "TREATMENT", 186, 200], ["PEEP physiology", "TEST", 225, 240], ["Covid", "TEST", 281, 286], ["PEEP", "TREATMENT", 314, 318], ["definite", "UNCERTAINTY", 48, 56], ["amount", "OBSERVATION_MODIFIER", 57, 63], ["gas", "OBSERVATION", 67, 70], ["alveoli", "ANATOMY_MODIFIER", 78, 85], ["PEEP physiology", "OBSERVATION", 225, 240], ["inflamed", "OBSERVATION", 365, 373]]], ["It is now accepted that in order to achieve the best combination between respiratory mechanics, oxygenation, hemodynamics and lung protection it is necessary to accept a compromise26.Aspect of PEEP physiology that are relevant for the management of Covid-19Therefore, the ways to titrate and to monitor the effects of PEEP are different and highly dependent on the goals that the healthcare provider wishes to pursue.", [["respiratory", "ANATOMY", 73, 84], ["lung", "ANATOMY", 126, 130], ["lung", "ORGAN", 126, 130], ["respiratory mechanics", "TREATMENT", 73, 94], ["lung protection", "TREATMENT", 126, 141], ["PEEP physiology", "TEST", 193, 208], ["Covid", "TEST", 249, 254], ["PEEP", "TREATMENT", 318, 322], ["lung", "ANATOMY", 126, 130], ["PEEP physiology", "OBSERVATION", 193, 208]]], ["Physiological methods make use of different portions of the lung pressure volume curve27, compliance of the respiratory system28, gas exchange parameters29,30 or transpulmonary pressure31.", [["lung", "ANATOMY", 60, 64], ["respiratory", "ANATOMY", 108, 119], ["lung", "ORGAN", 60, 64], ["Physiological methods", "TREATMENT", 0, 21], ["the lung pressure volume", "TEST", 56, 80], ["the respiratory system28", "TEST", 104, 128], ["gas exchange parameters", "TEST", 130, 153], ["transpulmonary pressure31", "TEST", 162, 187], ["lung", "ANATOMY", 60, 64], ["pressure volume", "OBSERVATION", 65, 80]]], ["Morphometric methods are based on imaging technology as computed tomography32 and electrical impedance tomography33.Aspect of PEEP physiology that are relevant for the management of Covid-19The idea that the lung is inherently inhomogeneous even in healthy conditions34 has as logical consequence the fact that, instead of having only one critical opening (or closing) pressure, it presents a continuous distribution of them along the pressure/volume curve: the mechanical implication is that recruitment (and de-recruitment) phenomena must be considered distributed stochastically all over the curve35.Aspect of PEEP physiology that are relevant for the management of Covid-19For the hysteretic characteristics of the pressure volume curves, the opening pressures do not correspond to the closing pressures.", [["lung", "ANATOMY", 208, 212], ["Covid-19", "CHEMICAL", 182, 190], ["lung", "ORGAN", 208, 212], ["Morphometric methods", "TREATMENT", 0, 20], ["imaging technology", "TEST", 34, 52], ["computed tomography32", "TEST", 56, 77], ["electrical impedance tomography", "TEST", 82, 113], ["PEEP physiology", "TEST", 126, 141], ["Covid", "TEST", 182, 187], ["the pressure/volume curve", "TEST", 431, 456], ["recruitment (and de-recruitment) phenomena", "PROBLEM", 493, 535], ["PEEP physiology", "TEST", 613, 628], ["Covid", "TEST", 669, 674], ["the pressure volume curves", "TEST", 715, 741], ["the opening pressures", "TEST", 743, 764], ["the closing pressures", "TEST", 786, 807], ["PEEP physiology", "OBSERVATION", 126, 141], ["lung", "ANATOMY", 208, 212], ["inherently", "OBSERVATION_MODIFIER", 216, 226], ["inhomogeneous", "OBSERVATION", 227, 240], ["recruitment", "OBSERVATION_MODIFIER", 493, 504], ["PEEP physiology", "OBSERVATION", 613, 628], ["pressure volume", "OBSERVATION", 719, 734], ["closing pressures", "OBSERVATION", 790, 807]]], ["This implies that the maneuvers for opening the lung, the so called \u201crecruitment\u201d maneuvers36 should reach higher pressures than the ones successively maintained with PEEP.", [["lung", "ANATOMY", 48, 52], ["lung", "ORGAN", 48, 52], ["the maneuvers", "TREATMENT", 18, 31], ["recruitment\u201d maneuvers", "TREATMENT", 69, 91], ["PEEP", "TREATMENT", 167, 171], ["lung", "ANATOMY", 48, 52]]], ["Moreover PEEP as a procedure to prevent lung collapse, should be considered an aid to an expiratory event and inefficient per se to recruit the lung thoroughly26.", [["lung", "ANATOMY", 40, 44], ["lung", "ANATOMY", 144, 148], ["lung collapse", "DISEASE", 40, 53], ["lung", "ORGAN", 40, 44], ["lung", "ORGAN", 144, 148], ["PEEP", "TREATMENT", 9, 13], ["a procedure", "TREATMENT", 17, 28], ["lung collapse", "PROBLEM", 40, 53], ["lung", "ANATOMY", 40, 44], ["collapse", "OBSERVATION", 45, 53], ["lung", "ANATOMY", 144, 148]]], ["For this reason, the application of PEEP should be anticipated by a recruitment maneuver.Aspect of PEEP physiology that are relevant for the management of Covid-19Recruitment can be quantified as the amount of nonaerated lung tissue that becomes aerated after a recruitment maneuver and can be measured as an absolute quantity (grams, milliliters) or as incremental proportion.", [["lung tissue", "ANATOMY", 221, 232], ["Covid-19Recruitment", "SIMPLE_CHEMICAL", 155, 174], ["lung tissue", "TISSUE", 221, 232], ["PEEP", "TREATMENT", 36, 40], ["a recruitment maneuver", "TREATMENT", 66, 88], ["PEEP physiology", "TEST", 99, 114], ["Covid-19Recruitment", "TREATMENT", 155, 174], ["nonaerated lung tissue", "PROBLEM", 210, 232], ["a recruitment maneuver", "TREATMENT", 260, 282], ["PEEP physiology", "OBSERVATION", 99, 114], ["amount", "OBSERVATION_MODIFIER", 200, 206], ["lung", "ANATOMY", 221, 225], ["tissue", "OBSERVATION", 226, 232], ["aerated", "OBSERVATION", 246, 253]]], ["In fact, a key concept that progressively has funneled through different studies is that the effectiveness of PEEP application depends on the type and distribution of lung injury.", [["lung", "ANATOMY", 167, 171], ["lung injury", "DISEASE", 167, 178], ["lung", "ORGAN", 167, 171], ["PEEP application", "TREATMENT", 110, 126], ["lung injury", "PROBLEM", 167, 178], ["lung", "ANATOMY", 167, 171], ["injury", "OBSERVATION", 172, 178]]], ["If the lung presents a diffuse loss of aeration, it behaves almost as a single compartment and the risk of lung over-inflation from PEEP application is low37; on the contrary if the loss of aeration is focally distributed the system becomes multi-compartmental and can exhibit opposite response to the increment of intrathoracic pressure, resulting in a significant risk of over-inflation if high PEEP levels are used37.", [["lung", "ANATOMY", 7, 11], ["lung", "ANATOMY", 107, 111], ["intrathoracic", "ANATOMY", 315, 328], ["lung", "ORGAN", 7, 11], ["lung", "ORGAN", 107, 111], ["intrathoracic", "ORGAN", 315, 328], ["a diffuse loss of aeration", "PROBLEM", 21, 47], ["PEEP application", "TREATMENT", 132, 148], ["the loss of aeration", "PROBLEM", 178, 198], ["intrathoracic pressure", "TEST", 315, 337], ["high PEEP levels", "TEST", 392, 408], ["lung", "ANATOMY", 7, 11], ["diffuse", "OBSERVATION_MODIFIER", 23, 30], ["loss", "OBSERVATION_MODIFIER", 31, 35], ["aeration", "OBSERVATION_MODIFIER", 39, 47], ["lung", "ANATOMY", 107, 111], ["aeration", "OBSERVATION", 190, 198], ["focally", "OBSERVATION_MODIFIER", 202, 209], ["intrathoracic", "ANATOMY", 315, 328], ["pressure", "OBSERVATION", 329, 337], ["significant", "OBSERVATION_MODIFIER", 354, 365]]], ["These effects of PEEP on lung parenchyma are mirrored by the significant hyperinflation that focal ARDS pattern can exhibit after lung recruitment, while lungs with diffuse and patchy aeration loss respond with a significant recruitment without relevant hyperinflation38.Aspect of PEEP physiology that are relevant for the management of Covid-19Between the lines we understand that knowing the morphology of lung injury or applying a recruitment maneuver it is possible to predict the response by lung parenchyma to the application of PEEP.Clinical implications for Covid managementAs with many other researchers, we believe that COVID-19 is a specific disease39 composed of different phases that require specific treatments and aware that treating COVID-19 as a \u201cstandard\u201d ARDS may lead to adverse outcomes.Clinical implications for Covid managementAs previously discussed, the patients affected by COVID-19 might arrive to the observation of intensivists with a composite lung pattern.", [["lung parenchyma", "ANATOMY", 25, 40], ["lung", "ANATOMY", 130, 134], ["lungs", "ANATOMY", 154, 159], ["lung", "ANATOMY", 408, 412], ["lung parenchyma", "ANATOMY", 497, 512], ["lung", "ANATOMY", 974, 978], ["ARDS", "DISEASE", 99, 103], ["lung injury", "DISEASE", 408, 419], ["ARDS", "DISEASE", 774, 778], ["COVID-19", "CHEMICAL", 749, 757], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 25, 40], ["lung", "ORGAN", 130, 134], ["lungs", "ORGAN", 154, 159], ["Covid-19Between", "CELL", 337, 352], ["lung", "ORGAN", 408, 412], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 497, 512], ["patients", "ORGANISM", 879, 887], ["lung", "ORGAN", 974, 978], ["patients", "SPECIES", 879, 887], ["PEEP on lung parenchyma", "PROBLEM", 17, 40], ["the significant hyperinflation", "PROBLEM", 57, 87], ["focal ARDS pattern", "PROBLEM", 93, 111], ["lung recruitment", "TREATMENT", 130, 146], ["diffuse and patchy aeration loss", "PROBLEM", 165, 197], ["relevant hyperinflation", "PROBLEM", 245, 268], ["PEEP physiology", "TEST", 281, 296], ["Covid", "TEST", 337, 342], ["the lines", "TREATMENT", 353, 362], ["lung injury", "PROBLEM", 408, 419], ["a recruitment maneuver", "TREATMENT", 432, 454], ["PEEP", "TREATMENT", 535, 539], ["Covid management", "TREATMENT", 566, 582], ["COVID", "TEST", 630, 635], ["specific treatments", "TREATMENT", 705, 724], ["COVID", "TEST", 749, 754], ["ARDS", "PROBLEM", 774, 778], ["adverse outcomes", "PROBLEM", 791, 807], ["Covid management", "TREATMENT", 834, 850], ["a composite lung pattern", "PROBLEM", 962, 986], ["PEEP", "OBSERVATION", 17, 21], ["lung", "ANATOMY", 25, 29], ["parenchyma", "ANATOMY_MODIFIER", 30, 40], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["hyperinflation", "OBSERVATION", 73, 87], ["focal", "OBSERVATION_MODIFIER", 93, 98], ["ARDS", "OBSERVATION", 99, 103], ["lung", "ANATOMY", 130, 134], ["recruitment", "OBSERVATION", 135, 146], ["lungs", "ANATOMY", 154, 159], ["diffuse", "OBSERVATION_MODIFIER", 165, 172], ["patchy", "OBSERVATION_MODIFIER", 177, 183], ["aeration loss", "OBSERVATION", 184, 197], ["significant", "OBSERVATION_MODIFIER", 213, 224], ["recruitment", "OBSERVATION_MODIFIER", 225, 236], ["without", "UNCERTAINTY", 237, 244], ["relevant", "OBSERVATION_MODIFIER", 245, 253], ["hyperinflation", "OBSERVATION", 254, 268], ["PEEP physiology", "OBSERVATION", 281, 296], ["lung", "ANATOMY", 408, 412], ["injury", "OBSERVATION", 413, 419], ["lung", "ANATOMY", 497, 501], ["parenchyma", "ANATOMY_MODIFIER", 502, 512], ["lung", "ANATOMY", 974, 978]]], ["In our experience it is very rare that a patient with a pure L-phenotype is admitted to intensive care if not for other reasons (decompensation of another organ system).", [["organ", "ANATOMY", 155, 160], ["decompensation", "DISEASE", 129, 143], ["patient", "ORGANISM", 41, 48], ["organ", "ORGAN", 155, 160], ["patient", "SPECIES", 41, 48]]], ["As described by Robba et al.22 very often they present a transitional pattern or a frank ARDS-like phenotype H. These last can become more frequent if the hospital organization has a systematic delay in admitting the patient from the ward to the intensive care unit.", [["ARDS", "DISEASE", 89, 93], ["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224], ["a transitional pattern", "PROBLEM", 55, 77], ["a frank ARDS", "PROBLEM", 81, 93], ["phenotype H.", "PROBLEM", 99, 111], ["a systematic delay", "PROBLEM", 181, 199], ["ARDS", "OBSERVATION", 89, 93]]], ["The problem of deciding the level of PEEP follows the decision to start a positive pressure ventilation, often after hours already spent ventilating with high-flow oxygen.Clinical implications for Covid managementThe most advantageous level of PEEP for a COVID-19 patient is related to the extension and typology of lung injury.", [["lung", "ANATOMY", 316, 320], ["oxygen", "CHEMICAL", 164, 170], ["lung injury", "DISEASE", 316, 327], ["oxygen", "CHEMICAL", 164, 170], ["oxygen", "SIMPLE_CHEMICAL", 164, 170], ["patient", "ORGANISM", 264, 271], ["lung", "ORGAN", 316, 320], ["patient", "SPECIES", 264, 271], ["PEEP", "TREATMENT", 37, 41], ["a positive pressure ventilation", "TREATMENT", 72, 103], ["spent ventilating", "TREATMENT", 131, 148], ["high-flow oxygen", "TREATMENT", 154, 170], ["Covid management", "TREATMENT", 197, 213], ["PEEP", "TREATMENT", 244, 248], ["a COVID", "TEST", 253, 260], ["lung injury", "PROBLEM", 316, 327], ["flow oxygen", "OBSERVATION", 159, 170], ["lung", "ANATOMY", 316, 320], ["injury", "OBSERVATION", 321, 327]]], ["Different research letters have warned against the use of unneeded high PEEP40,41 and advocate the use of a personalized approach, tailored to the effective phase of COVID-1916,42.Clinical implications for Covid managementWhen the possibilities of executing a lung CT are limited, an alternative way to assess the potential for recruitment is the computation of recruitment-to-inflation (R/I) ratio43.", [["lung", "ANATOMY", 260, 264], ["COVID-1916,42", "CHEMICAL", 166, 179], ["COVID-1916,42", "CHEMICAL", 166, 179], ["lung", "ORGAN", 260, 264], ["a personalized approach", "TREATMENT", 106, 129], ["Covid management", "TREATMENT", 206, 222], ["a lung CT", "TEST", 258, 267], ["lung", "ANATOMY", 260, 264]]], ["Using this method, Beloncle et al.44 studied a series of 25 patients with COVID-19 and observed 64% highly recruitable and 36% poorly recruitable.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["a series", "TEST", 45, 53], ["COVID", "TEST", 74, 79]]], ["The authors concluded that the use of R/I ratio was useful in PEEP titration procedure and could help in the prevention of the harmful effect of unnecessary high PEEP.", [["R/I", "GENE_OR_GENE_PRODUCT", 38, 41], ["R/I ratio", "TREATMENT", 38, 47], ["PEEP titration procedure", "TREATMENT", 62, 86], ["unnecessary high PEEP", "TREATMENT", 145, 166], ["high PEEP", "OBSERVATION", 157, 166]]], ["In a small series of 12 patients, Pan et al.45 were able to assess that the 83% of their patients were poorly recruitable and that recruitability changed when modifying body position.Summarizing the recommendation of literatureIn Gattinoni\u2019s phenotype L8, corresponding to Robba\u2019s phenotype 122: lung compliance is nearly normal; lung CT shows subpleural ground glass patterns together with other high-perfusion areas.", [["body", "ANATOMY", 169, 173], ["lung", "ANATOMY", 296, 300], ["lung", "ANATOMY", 330, 334], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 89, 97], ["body", "ORGANISM_SUBDIVISION", 169, 173], ["lung", "ORGAN", 296, 300], ["lung", "ORGAN", 330, 334], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 89, 97], ["phenotype", "TEST", 281, 290], ["lung compliance", "TEST", 296, 311], ["lung CT", "TEST", 330, 337], ["subpleural ground glass patterns", "PROBLEM", 344, 376], ["other high-perfusion areas", "PROBLEM", 391, 417], ["small", "OBSERVATION_MODIFIER", 5, 10], ["lung", "ANATOMY", 296, 300], ["normal", "OBSERVATION", 322, 328], ["lung", "ANATOMY", 330, 334], ["subpleural", "ANATOMY", 344, 354], ["ground glass patterns", "OBSERVATION", 355, 376], ["high", "OBSERVATION_MODIFIER", 397, 401], ["perfusion areas", "OBSERVATION", 402, 417]]], ["Mechanism of hypoxia is the altered distribution of lung perfusion.", [["lung", "ANATOMY", 52, 56], ["hypoxia", "DISEASE", 13, 20], ["lung", "ORGAN", 52, 56], ["hypoxia", "PROBLEM", 13, 20], ["lung perfusion", "PROBLEM", 52, 66], ["hypoxia", "OBSERVATION", 13, 20], ["altered", "OBSERVATION_MODIFIER", 28, 35], ["distribution", "OBSERVATION_MODIFIER", 36, 48], ["lung", "ANATOMY", 52, 56], ["perfusion", "OBSERVATION_MODIFIER", 57, 66]]], ["Low to moderate levels of PEEP should be applied.", [["PEEP", "TREATMENT", 26, 30], ["moderate", "OBSERVATION_MODIFIER", 7, 15]]], ["The rationale behind moderate PEEP levels is the possibility (to be tested case by case) to divert pulmonary blood flow from impaired to non-damaged lung areas.", [["pulmonary blood", "ANATOMY", 99, 114], ["lung", "ANATOMY", 149, 153], ["pulmonary", "ORGAN", 99, 108], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["lung", "ORGAN", 149, 153], ["moderate PEEP levels", "PROBLEM", 21, 41], ["pulmonary blood flow", "TEST", 99, 119], ["impaired to non-damaged lung areas", "PROBLEM", 125, 159], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["PEEP levels", "OBSERVATION", 30, 41], ["pulmonary blood", "ANATOMY", 99, 114], ["impaired", "OBSERVATION", 125, 133], ["lung", "ANATOMY", 149, 153], ["areas", "ANATOMY_MODIFIER", 154, 159]]], ["If high PEEP is used in this phase, the recruiting effect will be minimal and the impairment of hemodynamics will be substantial, requiring additional fluid and vasopressors.Summarizing the recommendation of literatureIn Robba\u2019s transitional phenotype 2, atelectasis appears and it is inhomogenously distributed.22 The authors advocate the use of moderate to high PEEP in relation to the likely higher potential for recruitment in comparison to phenotype L/1.", [["atelectasis", "DISEASE", 255, 266], ["high PEEP", "TREATMENT", 3, 12], ["the impairment of hemodynamics", "PROBLEM", 78, 108], ["additional fluid", "TREATMENT", 140, 156], ["vasopressors", "TREATMENT", 161, 173], ["transitional phenotype 2", "PROBLEM", 229, 253], ["atelectasis", "PROBLEM", 255, 266], ["high PEEP", "TREATMENT", 359, 368], ["high PEEP", "OBSERVATION", 3, 12], ["transitional phenotype", "OBSERVATION", 229, 251], ["atelectasis", "OBSERVATION", 255, 266], ["inhomogenously", "OBSERVATION_MODIFIER", 285, 299], ["distributed", "OBSERVATION_MODIFIER", 300, 311]]], ["Of potential help is the measure of the potential for recruitment by computing the R/I ratio or by the method that is more suitable in the single units.Summarizing the recommendation of literatureIn Gattinoni\u2019s phenotype H8, corresponding to Robba\u2019s phenotype 3, in this condition, the strategies developed for the management ARDS should be used: protective ventilation using low tidal volumes and choice of PEEP according to accepted international guidelines22,46.", [["ARDS", "DISEASE", 326, 330], ["the R/I ratio", "TEST", 79, 92], ["the method", "TEST", 99, 109], ["phenotype H8", "PROBLEM", 211, 223], ["the management ARDS", "TREATMENT", 311, 330], ["protective ventilation", "TREATMENT", 347, 369], ["low tidal volumes", "TREATMENT", 376, 393], ["PEEP", "TREATMENT", 408, 412]]], ["In the late COVID phase H/3, when a fibrotic pattern is established, the response to recruitment and to PEEP are thought to be lower than at the beginning of the course of the disease.ConclusionIn summary COVID-19 is a new disease with different phases that can be catastrophic for subpopulations of patients with cardiovascular and pulmonary disease states at baseline.", [["cardiovascular", "ANATOMY", 314, 328], ["pulmonary", "ANATOMY", 333, 342], ["cardiovascular and pulmonary disease", "DISEASE", 314, 350], ["patients", "ORGANISM", 300, 308], ["cardiovascular", "ANATOMICAL_SYSTEM", 314, 328], ["pulmonary", "ORGAN", 333, 342], ["patients", "SPECIES", 300, 308], ["a fibrotic pattern", "PROBLEM", 34, 52], ["PEEP", "TREATMENT", 104, 108], ["the disease", "PROBLEM", 172, 183], ["COVID", "TEST", 205, 210], ["a new disease", "PROBLEM", 217, 230], ["cardiovascular and pulmonary disease states", "PROBLEM", 314, 357], ["fibrotic", "OBSERVATION", 36, 44], ["disease", "OBSERVATION", 176, 183], ["new", "OBSERVATION_MODIFIER", 219, 222], ["disease", "OBSERVATION", 223, 230], ["catastrophic", "OBSERVATION_MODIFIER", 265, 277], ["pulmonary", "ANATOMY", 333, 342], ["disease", "OBSERVATION", 343, 350]]], ["Appreciation for these different phases and treatment modalities including manipulation of ventilatory settings and therapeutics has made if a less lethal disease than when it emerged earlier this year.", [["treatment modalities", "TREATMENT", 44, 64], ["manipulation of ventilatory settings", "TREATMENT", 75, 111], ["therapeutics", "TREATMENT", 116, 128], ["a less lethal disease", "PROBLEM", 141, 162]]], ["Different aspects of the disease are still largely unknown.", [["the disease", "PROBLEM", 21, 32], ["disease", "OBSERVATION", 25, 32]]], ["However, laboratory investigation and clinical course of the COVID-19 show that this new disease is not a typical ARDS process, especially during the first phase.", [["ARDS", "DISEASE", 114, 118], ["laboratory investigation", "TEST", 9, 33], ["the COVID", "TEST", 57, 66], ["this new disease", "PROBLEM", 80, 96], ["a typical ARDS process", "PROBLEM", 104, 126], ["new", "OBSERVATION_MODIFIER", 85, 88], ["disease", "OBSERVATION", 89, 96], ["typical", "OBSERVATION_MODIFIER", 106, 113], ["ARDS", "OBSERVATION", 114, 118]]], ["For this reason, the best strategy to be applied is to treat differently the single phases and to support the single functions of the failing organs as they appear.FundingNone.AuthorshipAll named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.Declaration of Competing InterestDr.", [["organs", "ANATOMY", 142, 148], ["organs", "ORGAN", 142, 148], ["this version", "TREATMENT", 410, 422]]], ["Kaye serves on the Speakers Bureau for Merck, Inc.Practice Points-COVID-19 is a new disease with different phases that can be catastrophic for subpopulations of patients with cardiovascular and pulmonary disease states at baseline.-Appreciation for these different phases and treatment modalities including manipulation of ventilatory settings and therapeutics has made if a less lethal disease than when it emerged earlier this year.", [["cardiovascular", "ANATOMY", 175, 189], ["pulmonary", "ANATOMY", 194, 203], ["cardiovascular and pulmonary disease", "DISEASE", 175, 211], ["patients", "ORGANISM", 161, 169], ["cardiovascular", "ANATOMICAL_SYSTEM", 175, 189], ["pulmonary", "ORGAN", 194, 203], ["patients", "SPECIES", 161, 169], ["COVID", "TEST", 66, 71], ["a new disease", "PROBLEM", 78, 91], ["cardiovascular and pulmonary disease states", "PROBLEM", 175, 218], ["treatment modalities", "TREATMENT", 276, 296], ["manipulation of ventilatory settings", "TREATMENT", 307, 343], ["therapeutics", "TREATMENT", 348, 360], ["a less lethal disease", "PROBLEM", 373, 394], ["new", "OBSERVATION_MODIFIER", 80, 83], ["disease", "OBSERVATION", 84, 91], ["pulmonary", "ANATOMY", 194, 203], ["disease", "OBSERVATION", 204, 211]]]], "54b66999c17b3b7ccfecdb43d5d996bf067a9832": [["For example, since phytoplankton drifts passively according to water flows, it is strongly influenced by the distribution of the flow of the bay (Lucas et al. 1999) .", [["phytoplankton drifts", "PROBLEM", 19, 39], ["phytoplankton drifts", "OBSERVATION", 19, 39], ["flow", "OBSERVATION", 129, 133]]], ["The degree of influence naturally increases with the strength of the currents.Introduction to Physical Numerical Modeling in Urban Coastal AreasIn contrast, even if the flow is very small, it has some spatial patterns in common with outer bay directions.", [["the flow", "TEST", 165, 173], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["influence", "OBSERVATION_MODIFIER", 14, 23], ["naturally", "OBSERVATION_MODIFIER", 24, 33], ["increases", "OBSERVATION_MODIFIER", 34, 43], ["flow", "OBSERVATION", 169, 173], ["very", "OBSERVATION_MODIFIER", 177, 181], ["small", "OBSERVATION", 182, 187]]], ["In this case, a nutrient load that is discharged at the head of the bay is transported to distant locations and, probably, the water exchange rate of the bay also increases.", [["head", "ANATOMY", 56, 60], ["head", "ORGANISM_SUBDIVISION", 56, 60], ["a nutrient load", "PROBLEM", 14, 29], ["the water exchange rate", "TREATMENT", 123, 146], ["nutrient load", "OBSERVATION", 16, 29]]], ["The nutrient loading that is permissible -i.e. which the bay can accept -will then increase due to the increase in the water exchange rate.", [["water", "SIMPLE_CHEMICAL", 119, 124], ["The nutrient loading", "TREATMENT", 0, 20], ["the water exchange rate", "TREATMENT", 115, 138], ["nutrient loading", "OBSERVATION", 4, 20], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["For water retention rates, the strength of currents is not as important as spatial patterns.", [["water retention rates", "TREATMENT", 4, 25], ["water retention", "OBSERVATION", 4, 19]]], ["For example, tidal currents are dominant in urban coastal areas.", [["tidal currents", "OBSERVATION", 13, 27], ["dominant", "OBSERVATION_MODIFIER", 32, 40], ["urban", "OBSERVATION_MODIFIER", 44, 49], ["coastal", "OBSERVATION_MODIFIER", 50, 57]]], ["However they are oscillatory.", [["oscillatory", "OBSERVATION_MODIFIER", 17, 28]]], ["Water particles in tidal currents move to the head of the bay during flood tides, but move back to the mouth of the bay during ebb tides.", [["head", "ANATOMY", 46, 50], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["Water particles", "TREATMENT", 0, 15], ["tidal currents", "OBSERVATION", 19, 33], ["head", "ANATOMY", 46, 50], ["mouth", "ANATOMY", 103, 108]]], ["In contrast, density currents are clearly weaker than tidal currents, but they flow in one direction continuously and transport water particles more efficiently.", [["transport water particles", "TREATMENT", 118, 143], ["density", "OBSERVATION", 13, 20], ["weaker", "OBSERVATION_MODIFIER", 42, 48], ["water particles", "OBSERVATION_MODIFIER", 128, 143]]], ["As a result, they substantially effect water retention times and ecosystem characteristics.Introduction to Physical Numerical Modeling in Urban Coastal AreasA water quality model for bays must therefore consist of a threedimensional circulation model and an ecosystem model that describes pelagic and benthic aspect of nutrients cycling.", [["a threedimensional circulation model", "TREATMENT", 214, 250], ["an ecosystem model", "TREATMENT", 255, 273], ["ecosystem model", "OBSERVATION", 258, 273], ["pelagic", "OBSERVATION_MODIFIER", 289, 296], ["nutrients cycling", "OBSERVATION", 319, 336]]], ["This section focuses on the physical modeling and the next section deals with water quality modeling.", [["the physical modeling", "TEST", 24, 45]]], ["These models solve the Navier-Stokes equation with the forcing (the wind stress, Coriolis force and buoyancy force) under adequate approximations that are called the hydrostatic and Boussinesq approximations.Three-Dimensional Hydrodynamic ModelHydrostatic approximation assumes that there is a perfect balance between pressure gradients and gravity: in other words, no acceleration occurs in a vertical direction.", [["Coriolis force and buoyancy force", "TREATMENT", 81, 114], ["the hydrostatic and Boussinesq approximations", "TREATMENT", 162, 207], ["acceleration", "PROBLEM", 369, 381], ["Hydrodynamic ModelHydrostatic", "OBSERVATION", 226, 255], ["pressure", "OBSERVATION_MODIFIER", 318, 326], ["gradients", "OBSERVATION_MODIFIER", 327, 336], ["no", "UNCERTAINTY", 366, 368], ["acceleration", "OBSERVATION", 369, 381]]], ["This is justified because the aspect ratio of urban coastal areas is extremely small, and hence the vertical motions are considered to be small and also to be further inhibited by gravitational forces under stable density stratification.", [["urban", "OBSERVATION_MODIFIER", 46, 51], ["extremely", "OBSERVATION_MODIFIER", 69, 78], ["small", "OBSERVATION_MODIFIER", 79, 84], ["vertical motions", "OBSERVATION", 100, 116], ["small", "OBSERVATION_MODIFIER", 138, 143], ["stable", "OBSERVATION_MODIFIER", 207, 213], ["density", "OBSERVATION", 214, 221]]], ["This means that vertical acceleration is negligible and the fluid behaves as though it were under static equilibrium as far as vertical motion is concerned (Prudman 1953) .Three-Dimensional Hydrodynamic ModelDensity variations in urban coastal areas are also small (less than 3% or so), and so density can be considered to be constant, except when body forces resulting from the motion of a density stratified fluid in a gravitational field are concerned.", [["body", "ANATOMY", 348, 352], ["body", "ORGANISM_SUBDIVISION", 348, 352], ["vertical acceleration", "PROBLEM", 16, 37], ["a density stratified fluid", "PROBLEM", 389, 415], ["vertical", "OBSERVATION_MODIFIER", 16, 24], ["acceleration", "OBSERVATION_MODIFIER", 25, 37], ["negligible", "OBSERVATION_MODIFIER", 41, 51], ["fluid", "OBSERVATION", 60, 65], ["-Dimensional", "OBSERVATION_MODIFIER", 177, 189], ["Hydrodynamic ModelDensity", "OBSERVATION", 190, 215], ["variations", "OBSERVATION_MODIFIER", 216, 226], ["urban", "OBSERVATION_MODIFIER", 230, 235], ["coastal", "OBSERVATION_MODIFIER", 236, 243], ["areas", "OBSERVATION_MODIFIER", 244, 249], ["small", "OBSERVATION_MODIFIER", 259, 264], ["less than 3", "OBSERVATION_MODIFIER", 266, 277], ["density", "OBSERVATION", 294, 301], ["can be considered to be", "UNCERTAINTY", 302, 325], ["constant", "OBSERVATION_MODIFIER", 326, 334], ["motion", "OBSERVATION_MODIFIER", 379, 385], ["density", "OBSERVATION_MODIFIER", 391, 398], ["stratified", "OBSERVATION_MODIFIER", 399, 409], ["fluid", "OBSERVATION", 410, 415], ["gravitational field", "OBSERVATION_MODIFIER", 421, 440]]], ["This approximation is called the Boussinesq approximation: in other words, changes in the mass or inertia of a fluid body due to the changes in its density are negligible, while the same changes in density are consequential when the gravitational field is present ( Kantha and Clayson 2000) .", [["fluid body", "ANATOMY", 111, 121], ["fluid body", "ORGANISM_SUBDIVISION", 111, 121], ["the mass", "PROBLEM", 86, 94], ["a fluid body", "TREATMENT", 109, 121], ["the changes in its density", "PROBLEM", 129, 155], ["mass", "OBSERVATION", 90, 94], ["inertia", "OBSERVATION_MODIFIER", 98, 105], ["fluid body", "OBSERVATION", 111, 121], ["density", "OBSERVATION", 148, 155], ["negligible", "OBSERVATION_MODIFIER", 160, 170], ["density", "OBSERVATION", 198, 205]]], ["Therefore, following Boussinesq (1903) , this approximation justifies replacing r by a constant reference density r 0 everywhere except in terms involving gravitational acceleration constant g.", [["gravitational acceleration constant g.", "PROBLEM", 155, 193], ["density", "OBSERVATION", 106, 113], ["gravitational acceleration", "OBSERVATION", 155, 181]]], ["Under such approximations, the governing equations are transformed as follows:Three-Dimensional Hydrodynamic ModelHere, t stands for time. u , v, and w are the velocity components in x , y , and z directions.", [["velocity", "OBSERVATION_MODIFIER", 160, 168], ["components", "OBSERVATION_MODIFIER", 169, 179]]], ["The symbol r\u2032 is the reference density and it is defined as r = r 0 + r\u2032 .", [["symbol r\u2032", "DNA", 4, 13], ["density", "OBSERVATION", 31, 38]]], ["The symbol g is the acceleration due to gravity.Grid Systems of Urban Costal ModelAll currents including tides, wind-driven currents, and density currents in urban coastal zones are strongly influenced by geometry and bathymetry, whereas these areas are rarely regular in shape.", [["density", "OBSERVATION", 138, 145], ["shape", "OBSERVATION_MODIFIER", 272, 277]]], ["In particular, a coastline near an urban coastal area is more complex, due to reclamations and the constructions of harbors, than a natural one.", [["coastline", "OBSERVATION_MODIFIER", 17, 26], ["more complex", "OBSERVATION_MODIFIER", 57, 69]]], ["In addition, the uniformity of the bathymetry further lessened as a result of dredging for vessel transport.", [["vessel", "ANATOMY", 91, 97], ["vessel", "MULTI-TISSUE_STRUCTURE", 91, 97], ["vessel transport", "TEST", 91, 107], ["uniformity", "OBSERVATION_MODIFIER", 17, 27], ["lessened", "OBSERVATION_MODIFIER", 54, 62], ["vessel", "ANATOMY", 91, 97]]], ["A computational grid is required to accurately represent such complex geometry and bathymetry.", [["A computational grid", "TREATMENT", 0, 20], ["such complex geometry", "PROBLEM", 57, 78], ["bathymetry", "PROBLEM", 83, 93], ["complex", "OBSERVATION_MODIFIER", 62, 69], ["geometry", "OBSERVATION", 70, 78]]], ["For this reason, the selection of which grid system to use has varied along with the progress of modeling, although the governing equations are not basically different.Grid Systems of Urban Costal ModelFor vertical coordinate systems (shown in Fig. 3 -1 ), Cartesian ( z -coordinate vertical grid) and sigma-coordinate grids have been widely used.", [["Cartesian ( z -coordinate vertical grid", "TREATMENT", 257, 296], ["sigma-coordinate grids", "TREATMENT", 302, 324]]], ["It is sometimes more accurate than sigmacoordinate grids, especially if the bathymetry of the bay is simple and mild.", [["mild", "OBSERVATION_MODIFIER", 112, 116]]], ["The sigma-coordinate system tends to have an error featuring the presence of steep-bottom topography.", [["error", "OBSERVATION", 45, 50], ["steep", "OBSERVATION_MODIFIER", 77, 82]]], ["However, unless an excessively large number of vertical levels are employed, the Cartesian grid fails to represent the bottom topography with satisfied accuracy.Grid Systems of Urban Costal ModelThe sigma-coordinate system is convenient in the sense that it can essentially introduce a \"flattening out\" mechanism for variable bottoms at z = \u2212h(x, y).", [["an excessively large number of vertical levels", "PROBLEM", 16, 62], ["a \"flattening out\" mechanism", "PROBLEM", 284, 312], ["excessively", "OBSERVATION_MODIFIER", 19, 30], ["large", "OBSERVATION_MODIFIER", 31, 36], ["number", "OBSERVATION_MODIFIER", 37, 43]]], ["The flow near the seabed is also calculated well.", [["flow", "OBSERVATION", 4, 8], ["seabed", "OBSERVATION_MODIFIER", 18, 24]]], ["Moreover, the sigmacoordinate system is easy to program since the number of vertical grids can be the same, and the setting of boundary conditions will be simple.", [["vertical grids", "TREATMENT", 76, 90], ["boundary conditions", "PROBLEM", 127, 146]]], ["The sigma-coordinate system has long been widely used in both meteorology and oceanography (Phillips 1957 ; Freeman et al. 1972) .Grid Systems of Urban Costal ModelAfter the incorporation of approximations, the governing equations in the sigma coordinate system are as follows:Grid Systems of Urban Costal Modelwhere, t stands for time. u , v, and s \u22c5 are the velocity components in x , y, and z directions in the s \u22c5 coordinate system. h is change in surface elevation, h is initial water depth, and H is the total water depth ( H=h + h ). f is the Coriolis coefficient and P stands for pressure. r and r\u2032 are the constant reference density and the deviation from it, and r = r 0 + r\u2032 .", [["surface", "ANATOMY", 452, 459], ["H", "CHEMICAL", 501, 502], ["H", "CHEMICAL", 501, 502], ["surface", "CELLULAR_COMPONENT", 452, 459], ["r\u2032", "GENE_OR_GENE_PRODUCT", 604, 606], ["r\u2032", "DNA", 604, 606], ["the velocity components", "PROBLEM", 356, 379], ["change in surface elevation", "PROBLEM", 442, 469], ["the Coriolis coefficient", "TREATMENT", 546, 570], ["pressure", "TREATMENT", 588, 596], ["the deviation", "PROBLEM", 646, 659], ["incorporation", "OBSERVATION_MODIFIER", 174, 187], ["Costal", "ANATOMY", 299, 305], ["velocity", "OBSERVATION_MODIFIER", 360, 368], ["change", "OBSERVATION_MODIFIER", 442, 448], ["surface", "OBSERVATION_MODIFIER", 452, 459], ["elevation", "OBSERVATION", 460, 469], ["water depth", "OBSERVATION_MODIFIER", 484, 495], ["density", "OBSERVATION", 634, 641]]], ["A H and A V are the horizontal and vertical eddy viscosity coefficients, respectively. g is acceleration due to gravity.", [["A V", "GENE_OR_GENE_PRODUCT", 8, 11], ["acceleration", "OBSERVATION", 92, 104]]], ["Recently, the stretched grid system (S-grid system) has also been popular.", [["popular", "OBSERVATION_MODIFIER", 66, 73]]], ["This grid system is an extension of sigma-coordinate system.", [["coordinate system", "OBSERVATION", 42, 59]]], ["Generally, a sigma-coordinate grid divides the vertical coordinate into an equal number of points.", [["vertical", "OBSERVATION_MODIFIER", 47, 55]]], ["The S-grid system has a higher resolution near the surface and bottom (Haidvogel et al. 2000) .Grid Systems of Urban Costal ModelWind-stress and bottom friction are considered at surface and bottom boundary conditions, respectively.", [["surface", "ANATOMY", 51, 58], ["surface", "ANATOMY", 179, 186], ["surface", "CELLULAR_COMPONENT", 51, 58], ["Urban Costal ModelWind", "TREATMENT", 111, 133], ["stress", "PROBLEM", 134, 140], ["bottom friction", "PROBLEM", 145, 160], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["resolution", "OBSERVATION_MODIFIER", 31, 41], ["surface", "OBSERVATION_MODIFIER", 51, 58], ["bottom", "OBSERVATION_MODIFIER", 63, 69], ["Costal", "ANATOMY", 117, 123], ["bottom friction", "OBSERVATION", 145, 160]]], ["Settings in boundary conditions are easy in sigma-coordinate systems since they use the same number of vertical grids.", [["vertical grids", "TREATMENT", 103, 117]]], ["At lateral boundaries, normal velocities are set at zero, and a free slip condition is applied to the friction terms.", [["a free slip condition", "PROBLEM", 62, 83], ["normal", "OBSERVATION", 23, 29], ["velocities", "OBSERVATION_MODIFIER", 30, 40], ["free slip", "OBSERVATION", 64, 73], ["friction terms", "OBSERVATION", 102, 116]]], ["At open boundary, the velocity gradient is set at zero.Grid Systems of Urban Costal ModelHorizontal computational grids are also modified to fit topography.", [["the velocity gradient", "TEST", 18, 39], ["Urban Costal ModelHorizontal computational grids", "TREATMENT", 71, 119], ["velocity", "OBSERVATION_MODIFIER", 22, 30], ["gradient", "OBSERVATION_MODIFIER", 31, 39]]], ["The simplest horizontal computational grid is the rectangular grid with fixed spacing.", [["fixed spacing", "PROBLEM", 72, 85], ["horizontal", "OBSERVATION_MODIFIER", 13, 23], ["rectangular", "OBSERVATION_MODIFIER", 50, 61], ["grid", "OBSERVATION_MODIFIER", 62, 66], ["fixed spacing", "OBSERVATION", 72, 85]]], ["The rectangular grid is equivalent to the Cartesian vertical grid.", [["The rectangular grid", "TREATMENT", 0, 20], ["rectangular", "OBSERVATION_MODIFIER", 4, 15], ["grid", "OBSERVATION_MODIFIER", 16, 20], ["equivalent", "OBSERVATION_MODIFIER", 24, 34]]], ["Recently, curvilinear coordinate systems have been widely used.", [["curvilinear coordinate systems", "PROBLEM", 10, 40]]], ["These systems allow greater flexibility than rectangular grid systems.", [["greater", "OBSERVATION_MODIFIER", 20, 27], ["flexibility", "OBSERVATION_MODIFIER", 28, 39]]], ["The Chesapeake Bay, like other bays, has a typical complex geometry, and thus a horizontal curvilinear coordinate system is advantageous (Li et al. 2005) .Grid Systems of Urban Costal ModelThis is extended to a nested grid system in which finer grids are used in regions to yield detailed information.Density Effect Modeling for Urban Coastal WatersIn urban coastal areas, density difference plays an essential role for water quality and currents.", [["a horizontal curvilinear coordinate system", "PROBLEM", 78, 120], ["Urban Costal ModelThis", "TREATMENT", 171, 193], ["a nested grid system", "TREATMENT", 209, 229], ["Density Effect", "PROBLEM", 301, 315], ["Urban Costal", "ANATOMY", 171, 183], ["urban", "OBSERVATION_MODIFIER", 352, 357], ["coastal", "OBSERVATION_MODIFIER", 358, 365], ["areas", "OBSERVATION_MODIFIER", 366, 371], ["density difference", "OBSERVATION", 373, 391]]], ["One of the most important phenomena induced by the density effect is stratification.", [["most important", "OBSERVATION_MODIFIER", 11, 25], ["phenomena", "OBSERVATION", 26, 35], ["density effect", "OBSERVATION", 51, 65]]], ["Once stratification occurs in a coastal zone, surface water and bottom water are isolated.", [["surface", "ANATOMY", 46, 53], ["a coastal zone", "TREATMENT", 30, 44], ["surface water and bottom water", "TREATMENT", 46, 76], ["coastal", "ANATOMY_MODIFIER", 32, 39], ["zone", "ANATOMY_MODIFIER", 40, 44]]], ["Stratification also enhances the increase of phytoplankton in the surface layer and oxygen depletion near the seabed.", [["surface layer", "ANATOMY", 66, 79], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["phytoplankton", "SIMPLE_CHEMICAL", 45, 58], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["oxygen depletion", "PROBLEM", 84, 100], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["phytoplankton", "OBSERVATION_MODIFIER", 45, 58], ["surface", "OBSERVATION_MODIFIER", 66, 73], ["layer", "OBSERVATION_MODIFIER", 74, 79], ["oxygen depletion", "OBSERVATION", 84, 100], ["seabed", "OBSERVATION_MODIFIER", 110, 116]]], ["Moreover, estuarine circulation is induced by density differences in the salty sea water and the river flow.", [["estuarine circulation", "OBSERVATION", 10, 31], ["density", "OBSERVATION", 46, 53], ["salty sea", "OBSERVATION", 73, 82], ["river flow", "OBSERVATION", 97, 107]]], ["Fig. 3-3 shows a schematic diagram of estuarine circulation.", [["estuarine circulation", "OBSERVATION", 38, 59]]], ["River water runs through the urban area and runs off from the river mouth, spreading over the sea surface like a veil since river water has low density compared with saline sea water.", [["mouth", "ANATOMY", 68, 73], ["surface", "ANATOMY", 98, 105], ["mouth", "ORGANISM_SUBDIVISION", 68, 73], ["low density", "PROBLEM", 140, 151], ["saline sea water", "TREATMENT", 166, 182], ["river", "ANATOMY_MODIFIER", 62, 67], ["mouth", "ANATOMY", 68, 73], ["veil", "OBSERVATION", 113, 117], ["low density", "OBSERVATION_MODIFIER", 140, 151]]], ["To cancel the density difference between the river water and the saline water, a great deal of sea water is entrained into the river water flow.", [["the saline water", "TREATMENT", 61, 77], ["sea water", "TREATMENT", 95, 104], ["density", "OBSERVATION", 14, 21], ["water flow", "OBSERVATION", 133, 143]]], ["Such a mixing process continues until the river water reaches the same density as the surrounding sea water, resulting in vertical circulation in the bays that is is several to ten times greater than the river flux (Unoki 1998) .", [["a mixing process", "PROBLEM", 5, 21], ["vertical circulation in the bays", "PROBLEM", 122, 154], ["density", "OBSERVATION", 71, 78], ["vertical circulation", "OBSERVATION", 122, 142], ["bays", "ANATOMY_MODIFIER", 150, 154], ["several", "OBSERVATION_MODIFIER", 166, 173]]], ["Thus, estuarine circulation induces seaward currents on the surface and landward currents near the bottom.", [["surface", "ANATOMY", 60, 67], ["surface", "CELLULAR_COMPONENT", 60, 67], ["estuarine circulation", "TREATMENT", 6, 27], ["bottom", "ANATOMY_MODIFIER", 99, 105]]], ["The speed of the currents is slow compared with the tidal currents, as explained previously.", [["speed", "OBSERVATION_MODIFIER", 4, 9], ["slow", "OBSERVATION_MODIFIER", 29, 33]]], ["Since estuarine circulations are in a fixed direction, its material transport is very effective over a long time scale in spite of the small magnitude of its velocity.", [["estuarine circulations", "MULTI-TISSUE_STRUCTURE", 6, 28], ["a long time scale", "TREATMENT", 101, 118], ["estuarine circulations", "OBSERVATION", 6, 28], ["very", "OBSERVATION_MODIFIER", 81, 85], ["effective", "OBSERVATION_MODIFIER", 86, 95], ["small magnitude", "OBSERVATION_MODIFIER", 135, 150], ["velocity", "OBSERVATION_MODIFIER", 158, 166]]], ["Estuarine circulation also plays an important role in the nutrient cycles of stratified bays.", [["Estuarine circulation", "TREATMENT", 0, 21]]], ["Organic matters are deposited on the seabed after phytoplankton blooms or river runoffs.", [["Organic matters", "PROBLEM", 0, 15], ["phytoplankton blooms", "PROBLEM", 50, 70], ["river runoffs", "PROBLEM", 74, 87], ["river runoffs", "OBSERVATION", 74, 87]]], ["They are decomposed by bacteria in the seabed.", [["bacteria", "PROBLEM", 23, 31], ["bacteria", "OBSERVATION_MODIFIER", 23, 31], ["seabed", "OBSERVATION_MODIFIER", 39, 45]]], ["These nutrients are supplied from the seabed under anoxic condition in summer.Density Effect Modeling for Urban Coastal WatersIn order to include density effects in the numerical model, conservation equations for temperature and salinity are also included.", [["Density Effect", "PROBLEM", 78, 92], ["conservation equations", "TEST", 186, 208], ["temperature and salinity", "TREATMENT", 213, 237], ["anoxic condition", "OBSERVATION", 51, 67], ["density", "OBSERVATION", 146, 153]]], ["Then, to obtain a realistic prediction for vertical stratification, a turbulent closure model is employed (Mellor and Yamada 1982) .", [["vertical stratification", "TREATMENT", 43, 66], ["a turbulent closure model", "TREATMENT", 68, 93], ["turbulent", "OBSERVATION_MODIFIER", 70, 79], ["closure", "OBSERVATION", 80, 87]]], ["Consequently, flows driven by various mechanisms -e.g. the gravitational, wind-driven, and topographically induced flows -can be reproduced within physical numerical models.Density Effect Modeling for Urban Coastal WatersDiffusion equations for temperature and salinity in the sigma coordinate system are as follows:Density Effect Modeling for Urban Coastal WatersHere, T and S stand for temperature and salinity, respectively.", [["Density Effect", "PROBLEM", 173, 187], ["Urban Coastal WatersDiffusion equations", "TEST", 201, 240], ["Density Effect", "PROBLEM", 316, 330]]], ["Heat balance and moisture balance at surface are considered as surface boundary condition for temperature and salinity, respectively.", [["surface", "ANATOMY", 37, 44], ["surface", "ANATOMY", 63, 70], ["Heat balance", "TEST", 0, 12], ["moisture balance at surface", "TREATMENT", 17, 44], ["balance", "OBSERVATION", 5, 12]]], ["C P and Q stands for specific heat coefficient and net surface heat flux at the surface, respectively.", [["surface", "ANATOMY", 55, 62], ["surface", "ANATOMY", 80, 87], ["surface", "CELLULAR_COMPONENT", 80, 87], ["C P and Q stands", "TEST", 0, 16], ["specific heat coefficient", "PROBLEM", 21, 46], ["net surface heat flux", "PROBLEM", 51, 72]]], ["R stands for river discharge. k H and k V are the horizontal and vertical eddy diffusion coefficients, respectively.Turbulence ClosureThe vertical mixing coefficients, V A and V K are obtained by appealing to the second order turbulent closure scheme of Mellor and Yamada (1982) , which characterizes turbulence by equations for the kinetic energy of turbulence, q 2 , and turbulence macro scale l , according to:Turbulence Closurer r (3.12) Wall proximity functions W is defined as follows: 3.14) Mixing coefficients are given as:Turbulence ClosureThe stability functions S M , S H , and S q are analytically derived from algebraic relations.", [["k V", "GENE_OR_GENE_PRODUCT", 38, 41], ["V K", "GENE_OR_GENE_PRODUCT", 176, 179], ["H", "TEST", 32, 33], ["Turbulence Closure", "TREATMENT", 116, 134], ["The vertical mixing coefficients", "TEST", 134, 166], ["V A and V K", "TEST", 168, 179], ["turbulence macro scale l", "TREATMENT", 373, 397], ["Wall proximity functions W", "TEST", 442, 468], ["Turbulence Closure", "TREATMENT", 531, 549], ["S H", "TEST", 579, 582], ["k V", "OBSERVATION_MODIFIER", 38, 41], ["horizontal", "OBSERVATION_MODIFIER", 50, 60], ["vertical", "OBSERVATION_MODIFIER", 65, 73], ["eddy", "OBSERVATION_MODIFIER", 74, 78], ["diffusion coefficients", "OBSERVATION", 79, 101], ["Closure", "OBSERVATION", 127, 134], ["vertical", "OBSERVATION_MODIFIER", 138, 146], ["turbulent", "OBSERVATION_MODIFIER", 226, 235], ["closure", "OBSERVATION", 236, 243]]], ["They are functionally dependent onTurbulence Closure, q and l .Turbulence ClosureThese relations are derived from closure hypotheses described by Mellor (1973) and later summarized by Mellor and Yamada (1982) .Numerical SchemeA semi-implicit finite difference scheme has been adopted where equations are discretized explicitly in the horizontal direction and implicitly in the vertical direction.", [["Numerical SchemeA semi-implicit finite difference scheme", "PROBLEM", 210, 266], ["dependent", "OBSERVATION_MODIFIER", 22, 31], ["onTurbulence", "OBSERVATION_MODIFIER", 32, 44], ["Closure", "OBSERVATION", 45, 52], ["vertical", "OBSERVATION_MODIFIER", 377, 385]]], ["The tri-diagonal formation of the momentum equation is utilized, and in combination with the mass conservation equation, an algebraic equation is obtained where the only unknown variable is the surface elevation h in implicit form.", [["surface", "ANATOMY", 194, 201], ["surface", "CELLULAR_COMPONENT", 194, 201], ["the mass conservation equation", "PROBLEM", 89, 119], ["an algebraic equation", "TEST", 121, 142], ["momentum", "OBSERVATION_MODIFIER", 34, 42], ["mass", "OBSERVATION", 93, 97], ["surface", "OBSERVATION_MODIFIER", 194, 201], ["elevation", "OBSERVATION", 202, 211]]], ["This algebraic equation is solved through the successive over relaxation (SOR) method.Ecosystem Modeling of Coastal RegionsThe phenomena in urban coastal zone are not only physical but also biological or chemical, each of which relates to the other.", [["relaxation (SOR) method", "TREATMENT", 62, 85], ["Ecosystem Modeling of Coastal Regions", "PROBLEM", 86, 123], ["Coastal", "ANATOMY_MODIFIER", 108, 115], ["Regions", "ANATOMY_MODIFIER", 116, 123], ["phenomena", "OBSERVATION", 127, 136], ["urban", "OBSERVATION_MODIFIER", 140, 145], ["coastal", "OBSERVATION_MODIFIER", 146, 153], ["zone", "OBSERVATION_MODIFIER", 154, 158]]], ["The ecosystems and water quality of urban coastal zones are highly complicated.", [["ecosystems", "OBSERVATION_MODIFIER", 4, 14], ["highly", "OBSERVATION_MODIFIER", 60, 66], ["complicated", "OBSERVATION", 67, 78]]], ["To deal with these complex systems, a water quality model is composed of a three-dimensional physical circulation model and an ecosystem model that describes pelagic and benthic aspect of nutrients cycling.", [["an ecosystem model", "TREATMENT", 124, 142], ["ecosystem model", "OBSERVATION", 127, 142], ["pelagic", "OBSERVATION_MODIFIER", 158, 165], ["nutrients cycling", "OBSERVATION", 188, 205]]], ["The pelagic and benthic systems also have interactions with each other.Ecosystem Modeling of Coastal RegionsIn ecosystem models, each water quality variable is often called a compartment.", [["Ecosystem Modeling of Coastal Regions", "PROBLEM", 71, 108], ["pelagic", "OBSERVATION_MODIFIER", 4, 11], ["Coastal", "ANATOMY_MODIFIER", 93, 100], ["Regions", "ANATOMY_MODIFIER", 101, 108], ["ecosystem models", "OBSERVATION", 111, 127]]], ["Various kinds of models are also proposed for ecosystem models (Kremer and Nixon 1978 ; Fasham et al. 1990 ; Chai et al. 2002 ; Kishi et al. 2007) .", [["ecosystem models", "TEST", 46, 62]]], ["Some models, such as CE-QUAL-ICM (Cerco and cole 1995) Each model is developed with basic aquatic compartments such as phytoplankton, zooplankton, and nutrients.", [["Some models", "PROBLEM", 0, 11], ["CE", "TEST", 21, 23]]], ["Some differences in the modeling of sediment, detritus, and the detailed modeling of phytoplankton exist, depending on the target ecosystems and the objectives of the study.", [["the study", "TEST", 163, 172], ["differences", "OBSERVATION_MODIFIER", 5, 16], ["sediment", "OBSERVATION", 36, 44], ["detritus", "OBSERVATION_MODIFIER", 46, 54]]], ["For example, ocean ecosystem models tend to focus only on pelagic systems.", [["ocean ecosystem models", "PROBLEM", 13, 35]]], ["They tend to ignore benthic modeling, since the open ocean is deep enough to prevent the return of detritus to the seabed.", [["detritus", "PROBLEM", 99, 107], ["detritus", "OBSERVATION", 99, 107]]], ["Meanwhile, ocean ecosystem models generally deal with some metals in order to represent the limiting factor of phytoplankton.", [["metals", "CHEMICAL", 59, 65]]], ["These metals are fully abundant in urban coastal zones.", [["metals", "CHEMICAL", 6, 12], ["metals", "OBSERVATION", 6, 12], ["abundant", "OBSERVATION_MODIFIER", 23, 31], ["coastal", "ANATOMY_MODIFIER", 41, 48], ["zones", "ANATOMY_MODIFIER", 49, 54]]], ["However, they are often depleted during phytoplankton growth in the open ocean.", [["depleted", "OBSERVATION", 24, 32], ["phytoplankton", "OBSERVATION_MODIFIER", 40, 53], ["growth", "OBSERVATION_MODIFIER", 54, 60]]], ["On the other hand, the concentration of phytoplankton in coastal areas is highly variable both spatially and temporally as compared to the open sea.", [["phytoplankton", "OBSERVATION", 40, 53], ["coastal", "ANATOMY_MODIFIER", 57, 64]]], ["Subsequent sedimentation of this bloom also constitutes a major input to benthic ecology (Waite et al. 1992 ; Matsukawa 1990 ; Yamaguchi et al. 1991) .", [["Subsequent sedimentation of this bloom", "PROBLEM", 0, 38], ["sedimentation", "OBSERVATION", 11, 24], ["bloom", "OBSERVATION", 33, 38]]], ["To represent these phenomena, ecosystem models of coastal zones usually cover benthic systems.Ecosystem Modeling of Coastal RegionsEcosystem models solve conservation equations for relevant components with appropriate source and sink terms.", [["these phenomena", "PROBLEM", 13, 28], ["coastal zones", "PROBLEM", 50, 63], ["conservation equations", "TREATMENT", 154, 176], ["relevant components", "PROBLEM", 181, 200], ["phenomena", "OBSERVATION", 19, 28], ["ecosystem models", "OBSERVATION", 30, 46], ["coastal", "OBSERVATION_MODIFIER", 50, 57], ["zones", "OBSERVATION_MODIFIER", 58, 63], ["benthic systems", "OBSERVATION", 78, 93], ["Coastal", "ANATOMY_MODIFIER", 116, 123]]], ["3.1.4 .Ecosystem Modeling of Coastal RegionsFor the sigma coordinate system, a mathematical formulation of the conservation of mass is written by:Ecosystem Modeling of Coastal Regionswhere C denotes concentration of the water quality variable and t is time.", [["a mathematical formulation", "TREATMENT", 77, 103], ["mass", "PROBLEM", 127, 131], ["Coastal", "ANATOMY_MODIFIER", 29, 36], ["mass", "OBSERVATION", 127, 131], ["Coastal", "ANATOMY_MODIFIER", 168, 175]]], ["Fluxes into and out of the target control volume are calculated by using physical model results.", [["Fluxes", "TREATMENT", 0, 6]]], ["S(x,y,s,t) represents sources or sinks of the water quality variable due to internal production and the removal of the biogeochemical effect.", [["the water quality", "PROBLEM", 42, 59], ["internal production", "PROBLEM", 76, 95], ["the removal", "TREATMENT", 100, 111], ["biogeochemical effect", "OBSERVATION", 119, 140]]], ["It also represents the kinetic interactions of each compartment.", [["kinetic interactions", "OBSERVATION", 23, 43]]], ["W(x,y,s,t) represents the external inputs of the variable c .Ecosystem Modeling of Coastal RegionsFor example, phytoplankton constitutes the first level in the food chain of the pelagic ecosystem of bays.", [["Coastal", "ANATOMY_MODIFIER", 83, 90], ["pelagic ecosystem", "OBSERVATION", 178, 195]]], ["Phytoplankton photosynthesizes by using sunlight and increases.", [["Phytoplankton photosynthesizes", "TREATMENT", 0, 30]]], ["At this time, the source term S of phytoplankton is increased depending on the amount of photosynthesis that takes place.", [["photosynthesis", "TREATMENT", 89, 103], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["Phytoplankton is then decreased by the grazing of zooplankton.", [["Phytoplankton", "TREATMENT", 0, 13], ["decreased", "OBSERVATION_MODIFIER", 22, 31]]], ["The source term S of zooplankton is increased along with this grazing, and the source term of phytoplankton is decreased.", [["increased", "OBSERVATION_MODIFIER", 36, 45], ["phytoplankton", "OBSERVATION", 94, 107], ["decreased", "OBSERVATION_MODIFIER", 111, 120]]], ["These models provide a quantitative description of the influences of physical circulation on the biological and chemical processes of urban coastal zones.Outline of an Ecosystem Model DescriptionThe ecosystem model introduced here was developed to simulate the nutrient budget of an urban coastal zone.", [["Ecosystem Model", "OBSERVATION", 168, 183], ["ecosystem model", "OBSERVATION", 199, 214], ["nutrient budget", "OBSERVATION", 261, 276]]], ["It includes the temporal and spatial variations of phytoplankton, nutrients, detritus, and dissolved oxygen (DO).", [["oxygen", "CHEMICAL", 101, 107], ["DO", "CHEMICAL", 109, 111], ["oxygen", "CHEMICAL", 101, 107], ["phytoplankton", "SIMPLE_CHEMICAL", 51, 64], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["DO", "SIMPLE_CHEMICAL", 109, 111], ["temporal", "OBSERVATION_MODIFIER", 16, 24], ["spatial", "OBSERVATION_MODIFIER", 29, 36], ["variations", "OBSERVATION_MODIFIER", 37, 47], ["phytoplankton", "OBSERVATION_MODIFIER", 51, 64], ["detritus", "OBSERVATION_MODIFIER", 77, 85]]], ["In urban coastal zones, nutrients emitted from urban areas are not a limiting factor for phytoplankton growth.", [["phytoplankton", "SIMPLE_CHEMICAL", 89, 102], ["phytoplankton growth", "PROBLEM", 89, 109], ["nutrients emitted", "OBSERVATION", 24, 41]]], ["However, quantifying the nutrient budget is essential for analyzing and restoring the ecosystems of urban coastal zones.", [["nutrient budget", "OBSERVATION", 25, 40], ["ecosystems", "OBSERVATION_MODIFIER", 86, 96]]], ["Fig. 3 .4 shows schematic interactions of a lower trophic ecosystem model which is used for Tokyo Bay (Koibuchi et al. 2001 ) This model has 18 state variables: phytoplankton (Phy), zooplankton (Zoo), nutrients (NH4, NO3, PO4 and Si), labile detritus (LDON, LDOP, LDOSi) and refractory detritus (RDON, RDOP, RDOSi) for each nutrient, labile detritus carbon (LDOC), refractory detritus carbon (RDOC), dissolved organic carbon (DOC), and dissolved oxygen (DO), as well as sedimentation processed from particulate organic material.Outline of an Ecosystem Model DescriptionSince the basic structure of the model follows the widely applied CE-QUAL-ICM Cole 1993, 1995) , this section mainly focuses on our modifications of the CE-QUAL-ICM model in the following description.Phytoplankton and Zooplankton ModelingThis model deals with four phytoplankton groups.", [["NH4", "CHEMICAL", 212, 215], ["NO3", "CHEMICAL", 217, 220], ["PO4", "CHEMICAL", 222, 225], ["LDOC", "CHEMICAL", 358, 362], ["dissolved organic carbon", "CHEMICAL", 400, 424], ["DOC", "CHEMICAL", 426, 429], ["oxygen", "CHEMICAL", 446, 452], ["DO", "CHEMICAL", 454, 456], ["NH4", "CHEMICAL", 212, 215], ["NO3", "CHEMICAL", 217, 220], ["PO4", "CHEMICAL", 222, 225], ["Si", "CHEMICAL", 230, 232], ["carbon", "CHEMICAL", 350, 356], ["carbon", "CHEMICAL", 385, 391], ["carbon", "CHEMICAL", 418, 424], ["DOC", "CHEMICAL", 426, 429], ["oxygen", "CHEMICAL", 446, 452], ["NH4", "SIMPLE_CHEMICAL", 212, 215], ["NO3", "SIMPLE_CHEMICAL", 217, 220], ["PO4", "SIMPLE_CHEMICAL", 222, 225], ["LDON", "SIMPLE_CHEMICAL", 252, 256], ["detritus carbon", "SIMPLE_CHEMICAL", 341, 356], ["LDOC", "SIMPLE_CHEMICAL", 358, 362], ["detritus carbon", "SIMPLE_CHEMICAL", 376, 391], ["RDOC", "SIMPLE_CHEMICAL", 393, 397], ["dissolved organic carbon", "SIMPLE_CHEMICAL", 400, 424], ["DOC", "SIMPLE_CHEMICAL", 426, 429], ["oxygen", "SIMPLE_CHEMICAL", 446, 452], ["DO", "SIMPLE_CHEMICAL", 454, 456], ["Fig.", "TEST", 0, 4], ["a lower trophic ecosystem model", "TREATMENT", 42, 73], ["PO4", "TEST", 222, 225], ["labile detritus", "PROBLEM", 235, 250], ["LDON", "TEST", 252, 256], ["LDOP", "TEST", 258, 262], ["LDOSi", "TEST", 264, 269], ["refractory detritus", "PROBLEM", 275, 294], ["each nutrient", "PROBLEM", 319, 332], ["labile detritus carbon (LDOC)", "PROBLEM", 334, 363], ["refractory detritus carbon (RDOC)", "PROBLEM", 365, 398], ["dissolved organic carbon (DOC)", "TREATMENT", 400, 430], ["dissolved oxygen (DO)", "TREATMENT", 436, 457], ["CE", "TEST", 635, 637], ["this section", "TEST", 666, 678], ["the CE", "TEST", 718, 724], ["Phytoplankton", "TREATMENT", 769, 782], ["Zooplankton Modeling", "TREATMENT", 787, 807], ["ecosystem model", "OBSERVATION", 58, 73], ["labile", "OBSERVATION_MODIFIER", 235, 241], ["detritus", "OBSERVATION", 242, 250], ["refractory", "OBSERVATION_MODIFIER", 275, 285], ["detritus", "OBSERVATION", 286, 294], ["Ecosystem Model", "OBSERVATION", 542, 557], ["Zooplankton Modeling", "OBSERVATION", 787, 807]]], ["Phyd1 is based on Skeletonema costatum, which is a dominant phytoplankton species in Tokyo Bay.", [["Phyd1", "CHEMICAL", 0, 5], ["Phyd1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Skeletonema costatum", "ORGANISM", 18, 38], ["Phyd1", "DNA", 0, 5], ["Skeletonema costatum", "SPECIES", 18, 38], ["Skeletonema costatum", "SPECIES", 18, 38], ["dominant", "OBSERVATION_MODIFIER", 51, 59], ["phytoplankton species", "OBSERVATION", 60, 81]]], ["Phyd2 represent a winter diatom group (such as Eucampia ).Phytoplankton and Zooplankton ModelingPhyr is a mixed summer assemblage consisting primarily of Heterosigma akashiwo and Thalassosira .", [["Phyr", "CHEMICAL", 96, 100], ["Thalassosira", "CHEMICAL", 179, 191], ["Phyd2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Heterosigma akashiwo", "ORGANISM", 154, 174], ["Phyd2", "PROTEIN", 0, 5], ["Heterosigma akashiwo", "SPECIES", 154, 174], ["Heterosigma akashiwo", "SPECIES", 154, 174], ["Phytoplankton", "TREATMENT", 58, 71], ["Zooplankton Modeling", "TREATMENT", 76, 96], ["Thalassosira", "TREATMENT", 179, 191], ["Zooplankton Modeling", "OBSERVATION", 76, 96]]], ["These four phytoplankton assemblages have different optimal levels of light for photosynthesis, maximum growth rates, optimal temperatures for growth, and half saturation constants for nutrient uptake.", [["photosynthesis", "TREATMENT", 80, 94], ["maximum growth rates", "TEST", 96, 116], ["half saturation constants", "TEST", 155, 180]]], ["Diatoms only use silica during growth.Phytoplankton and Zooplankton ModelingThe time rate of change of phytoplankton due to biological activity and sink is given by: (3.18) where x = d1, d2, r, z , denote each phytoplankton assemblage.", [["silica", "CHEMICAL", 17, 23], ["silica", "CHEMICAL", 17, 23], ["Diatoms", "SIMPLE_CHEMICAL", 0, 7], ["silica", "SIMPLE_CHEMICAL", 17, 23], ["silica during growth", "PROBLEM", 17, 37], ["Phytoplankton", "TREATMENT", 38, 51], ["Zooplankton Modeling", "TREATMENT", 56, 76], ["Zooplankton Modeling", "OBSERVATION", 56, 76], ["phytoplankton assemblage", "OBSERVATION", 210, 234]]], ["The phytoplankton growth rate m depends on temperature T , on photosynthetically available radiation I , and on the nutrient concentration of nitrogen, phosphorus, and silica :Fig.3-4.Idealized nutrient cycling in Tokyo Bay's ecosystem according to the model of Koibuchi et al. (2001) .", [["nitrogen", "CHEMICAL", 142, 150], ["phosphorus", "CHEMICAL", 152, 162], ["silica", "CHEMICAL", 168, 174], ["nitrogen", "CHEMICAL", 142, 150], ["phosphorus", "CHEMICAL", 152, 162], ["silica", "CHEMICAL", 168, 174], ["Fig.3-4", "CHEMICAL", 176, 183], ["nitrogen", "SIMPLE_CHEMICAL", 142, 150], ["phosphorus", "SIMPLE_CHEMICAL", 152, 162], ["silica", "SIMPLE_CHEMICAL", 168, 174], ["radiation I", "TREATMENT", 91, 102], ["nitrogen", "TREATMENT", 142, 150], ["phosphorus", "TEST", 152, 162], ["silica", "TEST", 168, 174], ["phytoplankton", "OBSERVATION_MODIFIER", 4, 17], ["growth", "OBSERVATION_MODIFIER", 18, 24]]], ["Cycling between the 18 state variables: phytoplankton, zooplankton, nutrients (nitrogen, phosphorus, and silicate), labile detritus and refractory detritus for each nutrient, and dissolved oxygen, as well as sedimentation processed from particulate organic materialsFig.3-4.where m max (T) is the growth rate at ambient temperature, which relates m max , the maximum growth rate m max = m 0 \u00b7 1.066 T (Eppey 1972) , T opt , the optimal temperature of each plankton assemblage, and b 1 and b 2 are shaping coefficients, k NO3 , k NH4 , k PO4 and k Si , which is the Michaelis of the halfsaturation constant for each nutrient.", [["nitrogen, phosphorus, and silicate", "CHEMICAL", 79, 113], ["oxygen", "CHEMICAL", 189, 195], ["NH4", "CHEMICAL", 529, 532], ["nitrogen", "CHEMICAL", 79, 87], ["phosphorus", "CHEMICAL", 89, 99], ["silicate", "CHEMICAL", 105, 113], ["oxygen", "CHEMICAL", 189, 195], ["NO3", "CHEMICAL", 521, 524], ["NH4", "CHEMICAL", 529, 532], ["PO4", "CHEMICAL", 537, 540], ["Si", "CHEMICAL", 547, 549], ["phytoplankton", "SIMPLE_CHEMICAL", 40, 53], ["zooplankton", "SIMPLE_CHEMICAL", 55, 66], ["nitrogen", "SIMPLE_CHEMICAL", 79, 87], ["phosphorus", "SIMPLE_CHEMICAL", 89, 99], ["silicate", "SIMPLE_CHEMICAL", 105, 113], ["oxygen", "SIMPLE_CHEMICAL", 189, 195], ["zooplankton", "TREATMENT", 55, 66], ["nutrients (nitrogen", "TREATMENT", 68, 87], ["phosphorus", "TREATMENT", 89, 99], ["silicate", "TREATMENT", 105, 113], ["labile detritus", "PROBLEM", 116, 131], ["refractory detritus", "PROBLEM", 136, 155], ["dissolved oxygen", "TREATMENT", 179, 195], ["the maximum growth rate", "TEST", 355, 378], ["k NO3", "TEST", 519, 524], ["k NH4", "TEST", 527, 532], ["k PO4", "TEST", 535, 540], ["k Si", "TEST", 545, 549], ["labile", "OBSERVATION_MODIFIER", 116, 122], ["detritus", "OBSERVATION", 123, 131], ["refractory", "OBSERVATION_MODIFIER", 136, 146], ["detritus", "OBSERVATION", 147, 155]]], ["I is exponentially decreasing with water depth z according to: 3.24) where I 0 is shortwave radiation, and par is the fraction of light that is available for photosynthesis.", [["shortwave radiation", "TREATMENT", 82, 101], ["exponentially", "OBSERVATION_MODIFIER", 5, 18], ["decreasing", "OBSERVATION_MODIFIER", 19, 29]]], ["K w , K Chl , and K Sal are the light attenuation coefficients for water, chlorophyll, and depth average salinity, respectively.Fig.3-4.Suspended sediment reduces underwater light intensity and affects the growth of phytoplankton.", [["K", "CHEMICAL", 0, 1], ["K", "CHEMICAL", 18, 19], ["Chl", "CHEMICAL", 8, 11], ["Sal", "CHEMICAL", 20, 23], ["chlorophyll", "CHEMICAL", 74, 85], ["K w", "GENE_OR_GENE_PRODUCT", 0, 3], ["K Chl", "GENE_OR_GENE_PRODUCT", 6, 11], ["K Sal", "GENE_OR_GENE_PRODUCT", 18, 23], ["water", "SIMPLE_CHEMICAL", 67, 72], ["chlorophyll", "SIMPLE_CHEMICAL", 74, 85], ["K w", "TEST", 0, 3], ["K Chl", "TEST", 6, 11], ["K Sal", "TREATMENT", 18, 23], ["chlorophyll", "TREATMENT", 74, 85], ["Fig", "TEST", 128, 131], ["Suspended sediment", "PROBLEM", 136, 154], ["underwater light intensity", "PROBLEM", 163, 189], ["sediment", "OBSERVATION", 146, 154], ["reduces", "OBSERVATION_MODIFIER", 155, 162], ["underwater light intensity", "OBSERVATION_MODIFIER", 163, 189], ["growth", "OBSERVATION_MODIFIER", 206, 212]]], ["The effect of suspended sediment concentration on light intensity should be simulated as its own compartment.", [["suspended sediment concentration", "PROBLEM", 14, 46], ["suspended", "OBSERVATION_MODIFIER", 14, 23], ["sediment", "OBSERVATION", 24, 32], ["concentration", "OBSERVATION_MODIFIER", 33, 46], ["light intensity", "OBSERVATION_MODIFIER", 50, 65]]], ["However, the re-suspension rate of mixed mud and the available data on the concentration of sediment suspended in river water and on the seabed are very limited.", [["mixed mud", "TREATMENT", 35, 44], ["mixed mud", "OBSERVATION", 35, 44], ["sediment", "OBSERVATION", 92, 100]]], ["Therefore, we used observation results of salinity based on field observation data from 1999 and 2000, as shown in Fig. 3 -5 .Fig.3-4.The function L(I ) represents the photosynthesis-light relationship (Evans and Parslow 1985) , The rate of phytoplankton grazing, g, which is a function of an ambient temperature:Fig.3-4.where k grz is the predation rate at 20\u00b0C. Other phytoplankton loss terms are mortality, represented by the linear rate m p , where W px is the constant vertical sinking velocity for each phytoplankton.Fig.3-4.The growth rates of zooplankton are expressed as follows: Here b is the assimilation efficiency of phytoplankton by zooplankton, and l BM and l E denote excretion due to basal metabolism and ingestion, while the remaining fraction is transferred to the detritus. m Z is the loss coefficient of zooplankton mortality.Nutrients and Detritus ModelingThe nutrient compartments have four principal forms for each nutrient (nitrogen, phosphorus, and silica): dissolved organic nutrients, labile and refractory particulate organic nutrients (LPON and RPON, respectively) , and dissolved inorganic nutrients.", [["nitrogen, phosphorus", "CHEMICAL", 949, 969], ["silica", "CHEMICAL", 975, 981], ["LPON", "CHEMICAL", 1066, 1070], ["RPON", "CHEMICAL", 1075, 1079], ["nitrogen", "CHEMICAL", 949, 957], ["phosphorus", "CHEMICAL", 959, 969], ["silica", "CHEMICAL", 975, 981], ["k grz", "GENE_OR_GENE_PRODUCT", 327, 332], ["W px", "GENE_OR_GENE_PRODUCT", 453, 457], ["phytoplankton", "SIMPLE_CHEMICAL", 630, 643], ["l E", "SIMPLE_CHEMICAL", 673, 676], ["nitrogen", "SIMPLE_CHEMICAL", 949, 957], ["phosphorus", "SIMPLE_CHEMICAL", 959, 969], ["silica", "SIMPLE_CHEMICAL", 975, 981], ["LPON", "SIMPLE_CHEMICAL", 1066, 1070], ["RPON", "SIMPLE_CHEMICAL", 1075, 1079], ["W px", "DNA", 453, 457], ["salinity", "TREATMENT", 42, 50], ["field observation data", "TEST", 60, 82], ["Fig", "TEST", 126, 129], ["an ambient temperature", "TEST", 290, 312], ["the predation rate", "TEST", 336, 354], ["Fig", "TEST", 523, 526], ["basal metabolism", "PROBLEM", 701, 717], ["Nutrients", "TREATMENT", 847, 856], ["nitrogen, phosphorus", "TREATMENT", 949, 969], ["refractory particulate organic nutrients", "PROBLEM", 1024, 1064], ["L", "OBSERVATION_MODIFIER", 147, 148], ["phytoplankton grazing", "OBSERVATION", 241, 262], ["phytoplankton loss", "OBSERVATION", 370, 388], ["sinking velocity", "OBSERVATION", 483, 499], ["growth", "OBSERVATION_MODIFIER", 535, 541], ["l", "ANATOMY_MODIFIER", 664, 665], ["BM", "ANATOMY", 666, 668], ["basal", "ANATOMY_MODIFIER", 701, 706], ["metabolism", "OBSERVATION", 707, 717], ["detritus", "OBSERVATION", 784, 792], ["Detritus Modeling", "OBSERVATION", 861, 878], ["inorganic nutrients", "OBSERVATION", 1111, 1130]]], ["Only the dissolved inorganic nutrients are utilized by phytoplankton for growth.", [["the dissolved inorganic nutrients", "TREATMENT", 5, 38]]], ["Nutrients are changed to these various organic and inorganic forms via respiration and predation.", [["Nutrients", "TREATMENT", 0, 9]]], ["Fig. 3.6 shows an example of nutrient cycles using phosphorus.", [["phosphorus", "CHEMICAL", 51, 61], ["phosphorus", "CHEMICAL", 51, 61], ["phosphorus", "SIMPLE_CHEMICAL", 51, 61], ["Fig.", "TEST", 0, 4], ["nutrient cycles", "TREATMENT", 29, 44], ["phosphorus", "TREATMENT", 51, 61], ["nutrient cycles", "OBSERVATION", 29, 44]]], ["DOP, LPOP, and RPOP work as a pool of phosphorus.Nutrients and Detritus ModelingFor example, certain labile compounds that are rapidly degraded, such as the sugars and amino acids in the particulate organic matter deposited on the sediment surface, decompose readily; others, such as cellulose, are more refractory, or resistant to decomposition.", [["sediment surface", "ANATOMY", 231, 247], ["DOP", "CHEMICAL", 0, 3], ["phosphorus", "CHEMICAL", 38, 48], ["amino acids", "CHEMICAL", 168, 179], ["DOP", "CHEMICAL", 0, 3], ["LPOP", "CHEMICAL", 5, 9], ["phosphorus", "CHEMICAL", 38, 48], ["sugars", "CHEMICAL", 157, 163], ["amino acids", "CHEMICAL", 168, 179], ["DOP", "SIMPLE_CHEMICAL", 0, 3], ["LPOP", "SIMPLE_CHEMICAL", 5, 9], ["phosphorus", "SIMPLE_CHEMICAL", 38, 48], ["sugars", "SIMPLE_CHEMICAL", 157, 163], ["amino acids", "AMINO_ACID", 168, 179], ["cellulose", "SIMPLE_CHEMICAL", 284, 293], ["DOP", "TEST", 0, 3], ["phosphorus", "TREATMENT", 38, 48], ["Nutrients", "TREATMENT", 49, 58], ["certain labile compounds", "PROBLEM", 93, 117], ["the sugars", "TEST", 153, 163], ["amino acids", "TEST", 168, 179], ["the particulate organic matter", "PROBLEM", 183, 213], ["Detritus Modeling", "OBSERVATION", 63, 80], ["labile", "OBSERVATION_MODIFIER", 101, 107], ["compounds", "OBSERVATION_MODIFIER", 108, 117], ["particulate", "OBSERVATION_MODIFIER", 187, 198], ["organic matter", "OBSERVATION", 199, 213], ["sediment surface", "OBSERVATION_MODIFIER", 231, 247], ["more refractory", "OBSERVATION_MODIFIER", 299, 314]]], ["Table 3 .1 shows the distributions of each detritus form by each event, based on Pett (1989) .Nutrients and Detritus ModelingAmmonia and nitrate are utilized by phytoplankton for growth.", [["Ammonia", "CHEMICAL", 125, 132], ["nitrate", "CHEMICAL", 137, 144], ["Ammonia", "CHEMICAL", 125, 132], ["nitrate", "CHEMICAL", 137, 144], ["Ammonia", "SIMPLE_CHEMICAL", 125, 132], ["nitrate", "SIMPLE_CHEMICAL", 137, 144], ["Nutrients", "TREATMENT", 94, 103], ["Detritus ModelingAmmonia", "TREATMENT", 108, 132], ["nitrate", "TREATMENT", 137, 144], ["detritus", "OBSERVATION", 43, 51], ["Detritus", "OBSERVATION_MODIFIER", 108, 116]]], ["Ammonia is the preferred form of inorganic nitrogen for algal growth, but phytoplankton utilize nitrate when ammonia concentrations become depleted.", [["Ammonia", "CHEMICAL", 0, 7], ["inorganic nitrogen", "CHEMICAL", 33, 51], ["nitrate", "CHEMICAL", 96, 103], ["ammonia", "CHEMICAL", 109, 116], ["Ammonia", "CHEMICAL", 0, 7], ["nitrogen", "CHEMICAL", 43, 51], ["nitrate", "CHEMICAL", 96, 103], ["ammonia", "CHEMICAL", 109, 116], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["inorganic nitrogen", "SIMPLE_CHEMICAL", 33, 51], ["algal", "SIMPLE_CHEMICAL", 56, 61], ["phytoplankton", "SIMPLE_CHEMICAL", 74, 87], ["nitrate", "SIMPLE_CHEMICAL", 96, 103], ["ammonia", "SIMPLE_CHEMICAL", 109, 116], ["Ammonia", "TEST", 0, 7], ["inorganic nitrogen", "TREATMENT", 33, 51], ["algal growth", "PROBLEM", 56, 68], ["nitrate", "TREATMENT", 96, 103], ["ammonia concentrations", "PROBLEM", 109, 131]]], ["Nitrogen is returned from algal biomass to the various dissolved and particulate organic nitrogen pools through respiration and predatory grazing.", [["Nitrogen", "CHEMICAL", 0, 8], ["organic nitrogen", "CHEMICAL", 81, 97], ["Nitrogen", "CHEMICAL", 0, 8], ["nitrogen", "CHEMICAL", 89, 97], ["Nitrogen", "SIMPLE_CHEMICAL", 0, 8], ["Nitrogen", "TREATMENT", 0, 8], ["algal biomass", "TREATMENT", 26, 39], ["organic nitrogen pools", "TREATMENT", 81, 103], ["algal biomass", "OBSERVATION", 26, 39]]], ["The time rates for variations due to the biological processes of nitrate and ammonium are as follows.", [["nitrate", "CHEMICAL", 65, 72], ["ammonium", "CHEMICAL", 77, 85], ["nitrate", "CHEMICAL", 65, 72], ["ammonium", "CHEMICAL", 77, 85], ["nitrate", "SIMPLE_CHEMICAL", 65, 72], ["ammonium", "SIMPLE_CHEMICAL", 77, 85], ["The time rates", "TEST", 0, 14], ["nitrate and ammonium", "TREATMENT", 65, 85]]], ["Denitrification does not occur in the pelagic water systems in this model, but rather occurs in the anoxic sediment layer.", [["anoxic sediment", "OBSERVATION", 100, 115], ["layer", "OBSERVATION_MODIFIER", 116, 121]]], ["As a result, if denitrification occurs in the sediment, nitrate is transferred by diffusion effect into the sediment.Nutrients and Detritus ModelingPhosphorus kinetics is basically similar to nitrogen kinetics except for the denitrification and the alkaline phosphatase effects of the DOP degradation processes.", [["nitrate", "CHEMICAL", 56, 63], ["Phosphorus", "CHEMICAL", 148, 158], ["nitrogen", "CHEMICAL", 192, 200], ["DOP", "CHEMICAL", 285, 288], ["nitrate", "CHEMICAL", 56, 63], ["Phosphorus", "CHEMICAL", 148, 158], ["nitrogen", "CHEMICAL", 192, 200], ["DOP", "CHEMICAL", 285, 288], ["nitrate", "SIMPLE_CHEMICAL", 56, 63], ["Detritus", "SIMPLE_CHEMICAL", 131, 139], ["Phosphorus", "SIMPLE_CHEMICAL", 148, 158], ["nitrogen", "SIMPLE_CHEMICAL", 192, 200], ["DOP", "SIMPLE_CHEMICAL", 285, 288], ["alkaline phosphatase", "PROTEIN", 249, 269], ["denitrification", "PROBLEM", 16, 31], ["the sediment", "PROBLEM", 42, 54], ["nitrate", "TREATMENT", 56, 63], ["Nutrients", "TREATMENT", 117, 126], ["Detritus ModelingPhosphorus kinetics", "TEST", 131, 167], ["nitrogen kinetics", "TEST", 192, 209], ["the denitrification", "PROBLEM", 221, 240], ["the alkaline phosphatase", "TEST", 245, 269], ["the DOP degradation processes", "PROBLEM", 281, 310], ["sediment", "OBSERVATION", 108, 116], ["Detritus", "OBSERVATION_MODIFIER", 131, 139], ["alkaline phosphatase", "OBSERVATION", 249, 269]]], ["Many phytoplankton can enhance alkaline phosphatase activity.", [["phytoplankton", "SIMPLE_CHEMICAL", 5, 18], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 31, 51], ["alkaline phosphatase", "PROTEIN", 31, 51], ["alkaline phosphatase activity", "PROBLEM", 31, 60], ["phytoplankton", "OBSERVATION", 5, 18], ["alkaline phosphatase", "OBSERVATION", 31, 51]]], ["This effect makes it possible for them to use phosphate from DOP pools (Fitzgerald and Nelson 1966) .", [["phosphate", "CHEMICAL", 46, 55], ["DOP", "CHEMICAL", 61, 64], ["phosphate", "CHEMICAL", 46, 55], ["DOP", "CHEMICAL", 61, 64], ["phosphate", "SIMPLE_CHEMICAL", 46, 55], ["DOP", "SIMPLE_CHEMICAL", 61, 64], ["phosphate from DOP pools", "TREATMENT", 46, 70]]], ["This effect is formulated in the following model: (3.31) where, r DOP is the decomposition rate for DOP, r DOP-min is the minimum constant of DOP decomposition(day \u22121 ), k PO4 is a half saturation constant of phosphate uptake, and r DOP-di is the acceleration effect of DOP decomposition by diatoms.Nutrients and Detritus ModelingThe kinetics of the silica is fundamentally the same as the kinetics of the phosphorus.", [["DOP", "CHEMICAL", 66, 69], ["DOP", "CHEMICAL", 100, 103], ["DOP", "CHEMICAL", 107, 110], ["DOP", "CHEMICAL", 142, 145], ["PO4", "CHEMICAL", 172, 175], ["phosphate", "CHEMICAL", 209, 218], ["DOP", "CHEMICAL", 233, 236], ["DOP", "CHEMICAL", 270, 273], ["silica", "CHEMICAL", 350, 356], ["phosphorus", "CHEMICAL", 406, 416], ["DOP", "CHEMICAL", 66, 69], ["DOP", "CHEMICAL", 100, 103], ["DOP", "CHEMICAL", 107, 110], ["DOP", "CHEMICAL", 142, 145], ["PO4", "CHEMICAL", 172, 175], ["phosphate", "CHEMICAL", 209, 218], ["DOP", "CHEMICAL", 233, 236], ["DOP", "CHEMICAL", 270, 273], ["silica", "CHEMICAL", 350, 356], ["phosphorus", "CHEMICAL", 406, 416], ["DOP", "SIMPLE_CHEMICAL", 66, 69], ["DOP", "SIMPLE_CHEMICAL", 100, 103], ["DOP", "SIMPLE_CHEMICAL", 142, 145], ["PO4", "SIMPLE_CHEMICAL", 172, 175], ["phosphate", "SIMPLE_CHEMICAL", 209, 218], ["DOP", "SIMPLE_CHEMICAL", 270, 273], ["silica", "SIMPLE_CHEMICAL", 350, 356], ["phosphorus", "SIMPLE_CHEMICAL", 406, 416], ["the decomposition rate", "TEST", 73, 95], ["DOP", "TEST", 100, 103], ["r DOP", "TEST", 105, 110], ["DOP decomposition", "TEST", 142, 159], ["k PO4", "TEST", 170, 175], ["phosphate uptake", "PROBLEM", 209, 225], ["DOP decomposition", "TREATMENT", 270, 287], ["Nutrients", "TREATMENT", 299, 308], ["Detritus Modeling", "OBSERVATION", 313, 330], ["kinetics", "OBSERVATION_MODIFIER", 334, 342], ["silica", "OBSERVATION_MODIFIER", 350, 356]]], ["Only diatoms utilize silica during growth.", [["silica", "CHEMICAL", 21, 27], ["silica", "CHEMICAL", 21, 27], ["diatoms", "SIMPLE_CHEMICAL", 5, 12], ["silica", "SIMPLE_CHEMICAL", 21, 27], ["diatoms", "OBSERVATION", 5, 12]]], ["Silica is returned to the unavailable silica pool during respiration and predation.Sediment ProcessesThe sediment system is zoned in two layers (see Fig. 3 .6 ), an aerobic and an anoxic layer.", [["Silica", "CHEMICAL", 0, 6], ["silica", "CHEMICAL", 38, 44], ["Silica", "CHEMICAL", 0, 6], ["silica", "CHEMICAL", 38, 44], ["Silica", "SIMPLE_CHEMICAL", 0, 6], ["Sediment Processes", "PROBLEM", 83, 101], ["an aerobic and an anoxic layer", "PROBLEM", 162, 192], ["silica pool", "OBSERVATION", 38, 49], ["sediment system", "OBSERVATION", 105, 120], ["two", "OBSERVATION_MODIFIER", 133, 136], ["layers", "OBSERVATION_MODIFIER", 137, 143], ["anoxic layer", "OBSERVATION", 180, 192]]], ["Organic carbon concentrations in the sediment are controlled by detritus burial velocity, the speed of labile and refrigerate organic carbon decomposition, and the rate constant for the diagenesis of particulate organic carbon.", [["carbon", "CHEMICAL", 8, 14], ["organic carbon", "CHEMICAL", 212, 226], ["carbon", "CHEMICAL", 8, 14], ["carbon", "CHEMICAL", 134, 140], ["carbon", "CHEMICAL", 220, 226], ["Organic carbon", "SIMPLE_CHEMICAL", 0, 14], ["particulate organic carbon", "SIMPLE_CHEMICAL", 200, 226], ["Organic carbon concentrations", "PROBLEM", 0, 29], ["detritus burial velocity", "TEST", 64, 88], ["organic carbon decomposition", "TREATMENT", 126, 154], ["the rate", "TEST", 160, 168], ["carbon concentrations", "OBSERVATION", 8, 29], ["sediment", "OBSERVATION", 37, 45], ["detritus", "OBSERVATION_MODIFIER", 64, 72], ["burial velocity", "OBSERVATION", 73, 88], ["labile", "OBSERVATION_MODIFIER", 103, 109], ["carbon decomposition", "OBSERVATION", 134, 154], ["organic carbon", "OBSERVATION", 212, 226]]], ["The thickness of the aerobic layer is calculated by oxygen diffusion when the amount of oxygen at the bottom layer of the pelagic system isn't zero.", [["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 88, 94], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 88, 94], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["oxygen diffusion", "TEST", 52, 68], ["oxygen", "TREATMENT", 88, 94], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["aerobic", "OBSERVATION_MODIFIER", 21, 28], ["layer", "OBSERVATION_MODIFIER", 29, 34], ["oxygen diffusion", "OBSERVATION", 52, 68], ["amount", "OBSERVATION_MODIFIER", 78, 84], ["oxygen", "OBSERVATION_MODIFIER", 88, 94], ["bottom", "OBSERVATION_MODIFIER", 102, 108], ["layer", "OBSERVATION_MODIFIER", 109, 114], ["pelagic system", "OBSERVATION", 122, 136]]], ["The nutrient model, which is a simplified version of the model, treats the nutrients ammonium, nitrate, phosphate, and silica and their exchanges with the pelagic system.", [["ammonium", "CHEMICAL", 85, 93], ["nitrate", "CHEMICAL", 95, 102], ["phosphate", "CHEMICAL", 104, 113], ["silica", "CHEMICAL", 119, 125], ["ammonium", "CHEMICAL", 85, 93], ["nitrate", "CHEMICAL", 95, 102], ["phosphate", "CHEMICAL", 104, 113], ["silica", "CHEMICAL", 119, 125], ["ammonium", "SIMPLE_CHEMICAL", 85, 93], ["nitrate", "SIMPLE_CHEMICAL", 95, 102], ["phosphate", "SIMPLE_CHEMICAL", 104, 113], ["silica", "SIMPLE_CHEMICAL", 119, 125], ["the nutrients ammonium", "TREATMENT", 71, 93], ["nitrate", "TREATMENT", 95, 102], ["phosphate", "TREATMENT", 104, 113], ["silica", "TREATMENT", 119, 125], ["nutrient model", "OBSERVATION", 4, 18], ["silica", "ANATOMY", 119, 125], ["pelagic system", "OBSERVATION", 155, 169]]], ["Silicate-dependent diatoms and non-silicate-dependent algae are distinguished.Dissolved OxygenDissolved oxygen is an essential index for the water quality of an urban coastal zone.", [["Silicate", "CHEMICAL", 0, 8], ["non-silicate", "CHEMICAL", 31, 43], ["oxygen", "CHEMICAL", 104, 110], ["Silicate", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 104, 110], ["Silicate", "SIMPLE_CHEMICAL", 0, 8], ["diatoms", "SIMPLE_CHEMICAL", 19, 26], ["non-silicate", "SIMPLE_CHEMICAL", 31, 43], ["algae", "CELL", 54, 59], ["OxygenDissolved oxygen", "SIMPLE_CHEMICAL", 88, 110], ["Silicate-dependent diatoms", "TREATMENT", 0, 26], ["non-silicate-dependent algae", "TREATMENT", 31, 59], ["Dissolved OxygenDissolved oxygen", "TREATMENT", 78, 110], ["dependent", "OBSERVATION_MODIFIER", 9, 18], ["diatoms", "OBSERVATION", 19, 26], ["dependent", "OBSERVATION_MODIFIER", 44, 53], ["algae", "OBSERVATION", 54, 59], ["oxygen", "OBSERVATION_MODIFIER", 104, 110]]], ["Sources of DO included in the model are reaeration at the sea surface, photosynthesis of phytoplankton, and DO in inflows.", [["sea surface", "ANATOMY", 58, 69], ["DO", "CHEMICAL", 108, 110], ["DO", "SIMPLE_CHEMICAL", 108, 110], ["photosynthesis of phytoplankton", "TREATMENT", 71, 102]]], ["The sink of DO includes respiration of phytoplankton and zooplankton, oxidation of detritrial carbon (LDOC and RDOC), nitrification, and sediment oxygen demand.", [["DO", "CHEMICAL", 12, 14], ["detritrial carbon", "CHEMICAL", 83, 100], ["LDOC", "CHEMICAL", 102, 106], ["oxygen", "CHEMICAL", 146, 152], ["carbon", "CHEMICAL", 94, 100], ["LDOC", "CHEMICAL", 102, 106], ["RDOC", "CHEMICAL", 111, 115], ["oxygen", "CHEMICAL", 146, 152], ["detritrial carbon", "SIMPLE_CHEMICAL", 83, 100], ["LDOC", "SIMPLE_CHEMICAL", 102, 106], ["RDOC", "SIMPLE_CHEMICAL", 111, 115], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["respiration of phytoplankton", "TREATMENT", 24, 52], ["zooplankton", "TREATMENT", 57, 68], ["detritrial carbon (LDOC", "TREATMENT", 83, 106], ["RDOC)", "TREATMENT", 111, 116], ["nitrification", "TREATMENT", 118, 131], ["sediment oxygen demand", "TREATMENT", 137, 159], ["sediment", "OBSERVATION", 137, 145], ["oxygen demand", "OBSERVATION", 146, 159]]], ["The time variation of DO is formulated as follows:Dissolved Oxygen( ) where, K OC is the oxygen to carbon ratio.", [["Oxygen", "CHEMICAL", 60, 66], ["K", "CHEMICAL", 77, 78], ["OC", "CHEMICAL", 79, 81], ["oxygen", "CHEMICAL", 89, 95], ["Oxygen", "CHEMICAL", 60, 66], ["K", "CHEMICAL", 77, 78], ["oxygen", "CHEMICAL", 89, 95], ["carbon", "CHEMICAL", 99, 105], ["DO", "SIMPLE_CHEMICAL", 22, 24], ["Oxygen", "SIMPLE_CHEMICAL", 60, 66], ["K OC", "SIMPLE_CHEMICAL", 77, 81], ["oxygen", "SIMPLE_CHEMICAL", 89, 95], ["carbon", "SIMPLE_CHEMICAL", 99, 105], ["carbon ratio", "TEST", 99, 111]]], ["K ON is the oxygen to nitrogen ratio. k a and q a T-20 denote the reaeration rate at 20\u00b0C and the temperature coefficient for reaeration at the sea surface, respectively. k Nh4 and q nh4 T-20 are the ammonia oxidation rate at 20\u00b0C and the temperature coefficient.", [["sea surface", "ANATOMY", 144, 155], ["K", "CHEMICAL", 0, 1], ["oxygen", "CHEMICAL", 12, 18], ["nitrogen", "CHEMICAL", 22, 30], ["ammonia", "CHEMICAL", 200, 207], ["oxygen", "CHEMICAL", 12, 18], ["nitrogen", "CHEMICAL", 22, 30], ["ammonia", "CHEMICAL", 200, 207], ["oxygen", "SIMPLE_CHEMICAL", 12, 18], ["nitrogen", "SIMPLE_CHEMICAL", 22, 30], ["C", "GENE_OR_GENE_PRODUCT", 88, 89], ["Nh4", "GENE_OR_GENE_PRODUCT", 173, 176], ["q nh4 T-20", "GENE_OR_GENE_PRODUCT", 181, 191], ["ammonia", "SIMPLE_CHEMICAL", 200, 207], ["C", "GENE_OR_GENE_PRODUCT", 229, 230], ["Nh4", "PROTEIN", 173, 176], ["the oxygen", "TREATMENT", 8, 18], ["nitrogen ratio", "TEST", 22, 36], ["k", "TEST", 38, 39], ["a T", "TEST", 48, 51], ["the reaeration rate", "TEST", 62, 81], ["the temperature", "TEST", 94, 109], ["reaeration", "PROBLEM", 126, 136], ["Nh4", "TEST", 173, 176], ["T", "TEST", 187, 188], ["the ammonia oxidation rate", "TEST", 196, 222], ["the temperature coefficient", "TEST", 235, 262]]], ["K nit is the half saturation constant of ammonia oxidation. k RDOC and q rdoc T-20 are the RDOC mineralization rate at 20\u00b0C and the temperature coefficient for RDOC mineralization. k LDOC and q Ldoc T-20 mark the LDOC mineralization rate at 20\u00b0C and the temperature coefficient for LDOC mineralization.", [["K", "CHEMICAL", 0, 1], ["ammonia", "CHEMICAL", 41, 48], ["ammonia", "CHEMICAL", 41, 48], ["K nit", "GENE_OR_GENE_PRODUCT", 0, 5], ["ammonia", "SIMPLE_CHEMICAL", 41, 48], ["RDOC", "SIMPLE_CHEMICAL", 91, 95], ["C", "GENE_OR_GENE_PRODUCT", 122, 123], ["RDOC", "SIMPLE_CHEMICAL", 160, 164], ["LDOC", "SIMPLE_CHEMICAL", 213, 217], ["C", "GENE_OR_GENE_PRODUCT", 244, 245], ["LDOC", "SIMPLE_CHEMICAL", 282, 286], ["K nit", "TEST", 0, 5], ["ammonia oxidation", "PROBLEM", 41, 58], ["k RDOC", "TEST", 60, 66], ["rdoc T", "TEST", 73, 79], ["the RDOC mineralization rate", "TEST", 87, 115], ["the temperature", "TEST", 128, 143], ["RDOC mineralization", "PROBLEM", 160, 179], ["k", "TEST", 181, 182], ["LDOC", "TEST", 183, 187], ["Ldoc", "TEST", 194, 198], ["T", "TEST", 199, 200], ["the LDOC mineralization rate", "TEST", 209, 237], ["the temperature coefficient", "TEST", 250, 277], ["LDOC mineralization", "PROBLEM", 282, 301], ["ammonia oxidation", "OBSERVATION", 41, 58], ["RDOC mineralization", "OBSERVATION", 160, 179], ["mineralization", "OBSERVATION", 287, 301]]], ["K mLDOC is the half saturation constant for LDOC mineralization.", [["K", "CHEMICAL", 0, 1], ["LDOC", "CHEMICAL", 44, 48], ["LDOC", "SIMPLE_CHEMICAL", 44, 48], ["K mLDOC", "TEST", 0, 7], ["the half saturation", "TEST", 11, 30], ["LDOC mineralization", "PROBLEM", 44, 63], ["LDOC mineralization", "OBSERVATION", 44, 63]]], ["The concentration of DO saturation is proportional to temperature and salinity.", [["DO", "CHEMICAL", 21, 23], ["DO", "CHEMICAL", 21, 23], ["DO", "SIMPLE_CHEMICAL", 21, 23]]], ["Oxygen saturation value is calculated by using the following equation: where T is temperature and S is salinity.Applications of Models to Nutrients Budget QuantificationsTokyo Bay is located at the central part of the main island of Japan.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation value", "TEST", 0, 23], ["central", "ANATOMY_MODIFIER", 198, 205], ["main", "OBSERVATION_MODIFIER", 218, 222]]], ["The inner bay, the north of which is 50 km in length in its narrowest channel (Fig. 3.7 ) along the main axis of the bay, connects to the Pacific Ocean.", [["inner bay", "ANATOMY", 4, 13], ["Fig.", "TEST", 79, 83], ["inner", "OBSERVATION_MODIFIER", 4, 9], ["bay", "OBSERVATION_MODIFIER", 10, 13], ["north", "ANATOMY_MODIFIER", 19, 24], ["50 km", "OBSERVATION_MODIFIER", 37, 42], ["length", "OBSERVATION_MODIFIER", 46, 52], ["narrowest", "OBSERVATION_MODIFIER", 60, 69], ["main axis", "ANATOMY_MODIFIER", 100, 109], ["Pacific Ocean", "OBSERVATION", 138, 151]]], ["Its average depth and width are 18 m and 25 km, respectively.", [["width", "TEST", 22, 27], ["average", "OBSERVATION_MODIFIER", 4, 11], ["depth", "OBSERVATION_MODIFIER", 12, 17], ["width", "OBSERVATION_MODIFIER", 22, 27], ["18 m", "OBSERVATION_MODIFIER", 32, 36]]], ["Phytoplankton increase in the surface layer from late spring to early fall, and oxygen depletion and the formation of hydrogen sulfide occur on the sea bed.", [["surface layer", "ANATOMY", 30, 43], ["oxygen", "CHEMICAL", 80, 86], ["hydrogen sulfide", "CHEMICAL", 118, 134], ["oxygen", "CHEMICAL", 80, 86], ["hydrogen sulfide", "CHEMICAL", 118, 134], ["surface layer", "CELLULAR_COMPONENT", 30, 43], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["hydrogen sulfide", "SIMPLE_CHEMICAL", 118, 134], ["Phytoplankton increase", "PROBLEM", 0, 22], ["early fall", "PROBLEM", 64, 74], ["oxygen depletion", "TREATMENT", 80, 96], ["hydrogen sulfide", "TREATMENT", 118, 134], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["surface", "OBSERVATION_MODIFIER", 30, 37], ["layer", "OBSERVATION_MODIFIER", 38, 43], ["late spring", "OBSERVATION_MODIFIER", 49, 60], ["early", "OBSERVATION_MODIFIER", 64, 69], ["fall", "OBSERVATION", 70, 74], ["oxygen depletion", "OBSERVATION", 80, 96], ["hydrogen sulfide", "OBSERVATION", 118, 134]]], ["The sea-water color at the head of the bay sometimes becomes milky blue-green in late summer after a continuous north wind (Koibuchi et al. 2001 ) .", [["head", "ANATOMY", 27, 31], ["blue-green", "CHEMICAL", 67, 77], ["sea-water color", "MULTI-TISSUE_STRUCTURE", 4, 19], ["head", "ORGANISM_SUBDIVISION", 27, 31], ["milky blue", "PROBLEM", 61, 71], ["head", "ANATOMY", 27, 31], ["milky", "OBSERVATION_MODIFIER", 61, 66], ["blue", "OBSERVATION", 67, 71]]], ["This phenomenon is called a blue tide.", [["a blue tide", "PROBLEM", 26, 37]]], ["In the last decade, a variety of water quality observation equipment has been developed.", [["water quality observation equipment", "TREATMENT", 33, 68], ["variety", "OBSERVATION_MODIFIER", 22, 29]]], ["To quantify the nutrients budget, we applied our numerical model to Tokyo Bay.Applications of Models to Nutrients Budget QuantificationsThe computational domain was divided into 1km horizontal grids with 20 vertical layers.", [["The computational domain", "TREATMENT", 136, 160], ["vertical layers", "OBSERVATION_MODIFIER", 207, 222]]], ["Computation was carried out from April 1, 1999 to March 31, 2000, with time increments of 300s provided by the Japan Meteorological Agency giving hourly meteorological data that included surface wind stress, precipitation, and solar radiation.", [["surface", "ANATOMY", 187, 194], ["surface wind stress", "PROBLEM", 187, 206], ["solar radiation", "TREATMENT", 227, 242], ["solar radiation", "OBSERVATION", 227, 242]]], ["At the open boundary, an observed tide level was obtained which can be downloaded from the Japan Oceanographic Data Center (JODC) of the Japan Coastal Guard.", [["Coastal Guard", "OBSERVATION", 143, 156]]], ["DON and DOP was obtained at 30% of TN, TP based on the observation results of Suzumura and Ogawa (2001) at the open boundary.", [["DON", "CHEMICAL", 0, 3], ["DOP", "CHEMICAL", 8, 11], ["DON", "CHEMICAL", 0, 3], ["DOP", "CHEMICAL", 8, 11], ["DON", "SIMPLE_CHEMICAL", 0, 3], ["DOP", "SIMPLE_CHEMICAL", 8, 11], ["TN", "PROTEIN", 35, 37], ["DOP", "TEST", 8, 11], ["TN", "TREATMENT", 35, 37], ["TP", "TEST", 39, 41], ["the observation", "TEST", 51, 66], ["Suzumura", "TREATMENT", 78, 86]]], ["Fig. 3-8 shows a temporal variation of the computed density at S2.", [["S2", "PROTEIN", 63, 65], ["the computed density at S2", "PROBLEM", 39, 65], ["temporal", "OBSERVATION_MODIFIER", 17, 25], ["variation", "OBSERVATION_MODIFIER", 26, 35], ["density", "OBSERVATION", 52, 59], ["S2", "ANATOMY", 63, 65]]], ["The simulation of water column density over the whole period (April 1999-October 1999) agreed well with measured density.", [["The simulation of water column density", "TREATMENT", 0, 38], ["water column density", "OBSERVATION_MODIFIER", 18, 38], ["density", "OBSERVATION", 113, 120]]], ["Time variation of density effectively reproduced observed results, including shortterm wind-induced variation, formation of stratification during summer, and mixing after continuous strong wind in the middle of October.", [["density", "OBSERVATION", 18, 25], ["middle", "ANATOMY_MODIFIER", 201, 207]]], ["Calculation results also reproduced an upwelling event during the summer season.Applications of Models to Nutrients Budget QuantificationsTotal chlorophyll-a concentrations in the surface water were reproduced relatively well by model simulations.", [["surface", "ANATOMY", 180, 187], ["chlorophyll-a", "CHEMICAL", 144, 157], ["chlorophyll-a", "CHEMICAL", 144, 157], ["chlorophyll-a", "SIMPLE_CHEMICAL", 144, 157], ["Total chlorophyll", "TREATMENT", 138, 155], ["a concentrations in the surface water", "TREATMENT", 156, 193]]], ["The model captured the temporal increase in chlorophyll-a that were seen in the observation results, as denoted by arrows in Fig. 3-9 .", [["chlorophyll-a", "CHEMICAL", 44, 57], ["chlorophyll", "SIMPLE_CHEMICAL", 44, 55], ["temporal", "OBSERVATION_MODIFIER", 23, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["During these periods, phytoplankton increased more than 50 m g/l.", [["phytoplankton", "OBSERVATION_MODIFIER", 22, 35], ["increased", "OBSERVATION_MODIFIER", 36, 45]]], ["In Tokyo Bay, a red tide is defined as a chlorophyll a concentration of greater than 50 m g/l.", [["chlorophyll a", "CHEMICAL", 41, 54], ["chlorophyll", "SIMPLE_CHEMICAL", 41, 52], ["a chlorophyll a concentration", "TREATMENT", 39, 68]]], ["Four different types of plankton assemblages DO showed high variability compared with field measurements at the bottom, and was relatively higher than the field data from late September through October.", [["plankton assemblages", "TEST", 24, 44], ["high variability", "PROBLEM", 55, 71], ["field measurements", "TEST", 86, 104], ["plankton assemblages", "OBSERVATION", 24, 44], ["high variability", "OBSERVATION", 55, 71], ["bottom", "ANATOMY_MODIFIER", 112, 118], ["higher", "OBSERVATION_MODIFIER", 139, 145]]], ["Oxygen-depleted water was made on the seabed, representing a basic trend for DO variations (Fig. 3-10 ) .Applications of Models to Nutrients Budget QuantificationsThe simulation of phosphate captured not only the observed increase in the surface layer during the summer season, but also inter-annual variability observed over the study period (Fig. 3-11 ) .", [["surface layer", "ANATOMY", 238, 251], ["Oxygen", "CHEMICAL", 0, 6], ["phosphate", "CHEMICAL", 181, 190], ["Oxygen", "CHEMICAL", 0, 6], ["phosphate", "CHEMICAL", 181, 190], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["phosphate", "SIMPLE_CHEMICAL", 181, 190], ["Oxygen-depleted water", "TREATMENT", 0, 21], ["The simulation of phosphate", "TREATMENT", 163, 190], ["inter-annual variability", "PROBLEM", 287, 311], ["the study", "TEST", 326, 335], ["depleted", "OBSERVATION", 7, 15], ["increase", "OBSERVATION_MODIFIER", 222, 230], ["surface", "OBSERVATION_MODIFIER", 238, 245], ["layer", "OBSERVATION_MODIFIER", 246, 251], ["inter-annual", "OBSERVATION_MODIFIER", 287, 299], ["variability", "OBSERVATION_MODIFIER", 300, 311]]], ["For example, phosphate concentrations increased from June to July due to phosphate release from sediment.", [["phosphate", "CHEMICAL", 13, 22], ["phosphate", "CHEMICAL", 73, 82], ["phosphate", "CHEMICAL", 13, 22], ["phosphate", "CHEMICAL", 73, 82], ["phosphate", "SIMPLE_CHEMICAL", 13, 22], ["phosphate", "SIMPLE_CHEMICAL", 73, 82], ["phosphate concentrations", "PROBLEM", 13, 37], ["phosphate release", "PROBLEM", 73, 90], ["sediment", "OBSERVATION", 96, 104]]], ["Simulation results represented this kind of trend based on the oxygen-depleted water.", [["oxygen", "CHEMICAL", 63, 69], ["oxygen", "CHEMICAL", 63, 69], ["oxygen", "SIMPLE_CHEMICAL", 63, 69], ["the oxygen", "TREATMENT", 59, 69]]], ["Fig. 3-12 shows nitrate concentration.", [["nitrate", "CHEMICAL", 16, 23], ["nitrate", "CHEMICAL", 16, 23], ["nitrate", "SIMPLE_CHEMICAL", 16, 23], ["nitrate concentration", "TREATMENT", 16, 37]]], ["Nitrate concentration in the surface layer fluctuated considerably during this period.", [["surface layer", "ANATOMY", 29, 42], ["Nitrate", "CHEMICAL", 0, 7], ["Nitrate", "CHEMICAL", 0, 7], ["Nitrate", "SIMPLE_CHEMICAL", 0, 7], ["Nitrate concentration", "TREATMENT", 0, 21], ["concentration", "OBSERVATION_MODIFIER", 8, 21], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["layer", "OBSERVATION_MODIFIER", 37, 42], ["fluctuated", "OBSERVATION_MODIFIER", 43, 53], ["considerably", "OBSERVATION_MODIFIER", 54, 66]]], ["Nitrate levels doubled or tripled occasionally at the surface.", [["surface", "ANATOMY", 54, 61], ["Nitrate", "CHEMICAL", 0, 7], ["Nitrate", "CHEMICAL", 0, 7], ["Nitrate", "SIMPLE_CHEMICAL", 0, 7], ["surface", "CELLULAR_COMPONENT", 54, 61], ["Nitrate levels", "TEST", 0, 14]]], ["The timing of the high nitrate concentrations and the low density in the surface layer coincided with increases in the river discharge.", [["surface layer", "ANATOMY", 73, 86], ["nitrate", "CHEMICAL", 23, 30], ["nitrate", "CHEMICAL", 23, 30], ["nitrate", "SIMPLE_CHEMICAL", 23, 30], ["the high nitrate concentrations", "TREATMENT", 14, 45], ["the low density in the surface layer", "PROBLEM", 50, 86], ["low", "OBSERVATION_MODIFIER", 54, 57], ["density", "OBSERVATION", 58, 65], ["surface", "OBSERVATION_MODIFIER", 73, 80], ["layer", "OBSERVATION_MODIFIER", 81, 86], ["increases", "OBSERVATION_MODIFIER", 102, 111], ["river discharge", "OBSERVATION", 119, 134]]], ["Concentrations of nitrate were underestimated in bottom waters during summer.", [["nitrate", "CHEMICAL", 18, 25], ["nitrate", "CHEMICAL", 18, 25], ["nitrate", "SIMPLE_CHEMICAL", 18, 25], ["Concentrations of nitrate", "TREATMENT", 0, 25]]], ["Further study is needed to simulate denitrification processes in the sediment layer.", [["sediment layer", "ANATOMY", 69, 83], ["Further study", "TEST", 0, 13], ["denitrification processes", "PROBLEM", 36, 61], ["sediment", "OBSERVATION", 69, 77], ["layer", "OBSERVATION_MODIFIER", 78, 83]]], ["Fig. 3-13 shows the calculation results of an annual budget of nitrogen and phosphorus in Tokyo Bay.", [["nitrogen", "CHEMICAL", 63, 71], ["phosphorus", "CHEMICAL", 76, 86], ["nitrogen", "CHEMICAL", 63, 71], ["phosphorus", "CHEMICAL", 76, 86], ["nitrogen", "SIMPLE_CHEMICAL", 63, 71], ["phosphorus", "SIMPLE_CHEMICAL", 76, 86], ["nitrogen", "TREATMENT", 63, 71], ["phosphorus", "TREATMENT", 76, 86]]], ["The annual budget is useful in understanding nutrient cycles.", [["nutrient cycles", "OBSERVATION", 45, 60]]], ["Nitrogen is supplied to a considerable degree from rivers, since atmospheric nitrogen input is significant around urban areas.", [["Nitrogen", "CHEMICAL", 0, 8], ["nitrogen", "CHEMICAL", 77, 85], ["Nitrogen", "CHEMICAL", 0, 8], ["nitrogen", "CHEMICAL", 77, 85], ["Nitrogen", "SIMPLE_CHEMICAL", 0, 8], ["Nitrogen", "TREATMENT", 0, 8], ["atmospheric nitrogen input", "TREATMENT", 65, 91], ["nitrogen input", "OBSERVATION", 77, 91], ["significant", "OBSERVATION_MODIFIER", 95, 106]]], ["Phytoplankton uptake the nitrogen and sink to bottom waters, where they are decomposed by heterotrophic processes which consume oxygen.", [["Phytoplankton", "CHEMICAL", 0, 13], ["nitrogen", "CHEMICAL", 25, 33], ["oxygen", "CHEMICAL", 128, 134], ["nitrogen", "CHEMICAL", 25, 33], ["oxygen", "CHEMICAL", 128, 134], ["Phytoplankton", "SIMPLE_CHEMICAL", 0, 13], ["nitrogen", "SIMPLE_CHEMICAL", 25, 33], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["the nitrogen", "TREATMENT", 21, 33], ["oxygen", "TREATMENT", 128, 134], ["heterotrophic processes", "OBSERVATION", 90, 113], ["oxygen", "OBSERVATION_MODIFIER", 128, 134]]], ["At the head of the bay (between the line 1 and line 2 in Fig. 3-7 ) , about 40% of nitrogen is sunk as detritus and 20% of it is lost into the atmosphere by denitrification.", [["head", "ANATOMY", 7, 11], ["nitrogen", "CHEMICAL", 83, 91], ["nitrogen", "CHEMICAL", 83, 91], ["head", "ORGANISM_SUBDIVISION", 7, 11], ["nitrogen", "SIMPLE_CHEMICAL", 83, 91], ["the line", "TREATMENT", 32, 40], ["nitrogen", "TREATMENT", 83, 91], ["head", "ANATOMY", 7, 11], ["denitrification", "OBSERVATION", 157, 172]]], ["Ammonia released from sediment reaches 20%.", [["Ammonia", "CHEMICAL", 0, 7], ["Ammonia", "CHEMICAL", 0, 7], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["sediment", "ORGANISM_SUBSTANCE", 22, 30], ["Ammonia", "TEST", 0, 7], ["sediment", "OBSERVATION", 22, 30]]], ["About 60% of the nitrogen load flows out from the bay.", [["nitrogen", "CHEMICAL", 17, 25], ["nitrogen", "CHEMICAL", 17, 25], ["nitrogen", "SIMPLE_CHEMICAL", 17, 25], ["the nitrogen load flows", "TEST", 13, 36], ["nitrogen load", "OBSERVATION", 17, 30]]], ["In contrast, atmospheric phosphorus input to the bay is negligible compared to the contribution of phosphorus from other sources.Applications of Models to Nutrients Budget QuantificationsPhosphate is released from sediment in the same amount as that discharged from the rivers, and it is transported to the head of the bay by estuarine circulation.", [["head", "ANATOMY", 307, 311], ["phosphorus", "CHEMICAL", 25, 35], ["phosphorus", "CHEMICAL", 99, 109], ["Phosphate", "CHEMICAL", 187, 196], ["phosphorus", "CHEMICAL", 25, 35], ["phosphorus", "CHEMICAL", 99, 109], ["Phosphate", "CHEMICAL", 187, 196], ["phosphorus", "SIMPLE_CHEMICAL", 25, 35], ["phosphorus", "SIMPLE_CHEMICAL", 99, 109], ["Phosphate", "SIMPLE_CHEMICAL", 187, 196], ["head", "ORGANISM_SUBDIVISION", 307, 311], ["atmospheric phosphorus input", "TEST", 13, 41], ["Phosphate", "TREATMENT", 187, 196], ["negligible", "OBSERVATION", 56, 66], ["sediment", "OBSERVATION", 214, 222]]], ["As a result, the amount of phosphate in the inner bay remains high.", [["inner bay", "ANATOMY", 44, 53], ["phosphate", "CHEMICAL", 27, 36], ["phosphate", "CHEMICAL", 27, 36], ["phosphate", "SIMPLE_CHEMICAL", 27, 36], ["phosphate", "TREATMENT", 27, 36], ["high", "OBSERVATION", 62, 66]]], ["In contrast, nitrogen is mainly supplied from the river mouth and transported quickly out of the bay.", [["mouth", "ANATOMY", 56, 61], ["nitrogen", "CHEMICAL", 13, 21], ["nitrogen", "CHEMICAL", 13, 21], ["nitrogen", "SIMPLE_CHEMICAL", 13, 21], ["mouth", "ORGANISM_SUBDIVISION", 56, 61], ["nitrogen", "TREATMENT", 13, 21], ["river mouth", "ANATOMY", 50, 61]]], ["In conclusion, nitrogen and phosphorus showed important differences in the mechanisms by which they cycle in Fig. 3-13 .", [["nitrogen", "CHEMICAL", 15, 23], ["phosphorus", "CHEMICAL", 28, 38], ["nitrogen", "CHEMICAL", 15, 23], ["phosphorus", "CHEMICAL", 28, 38], ["nitrogen", "SIMPLE_CHEMICAL", 15, 23], ["phosphorus", "SIMPLE_CHEMICAL", 28, 38], ["nitrogen and phosphorus", "TEST", 15, 38]]], ["The regeneration of nutrients and their release from the sediment is an important source for phytoplankton growth and is equal to the contributions from the rivers.", [["the sediment", "PROBLEM", 53, 65], ["phytoplankton growth", "PROBLEM", 93, 113], ["regeneration", "OBSERVATION_MODIFIER", 4, 16]]], ["Phosphorus in particular is largely retained within the system through recycling between sediment and water.", [["Phosphorus", "CHEMICAL", 0, 10], ["Phosphorus", "CHEMICAL", 0, 10], ["Phosphorus", "SIMPLE_CHEMICAL", 0, 10], ["water", "SIMPLE_CHEMICAL", 102, 107], ["Phosphorus", "TEST", 0, 10], ["largely", "OBSERVATION_MODIFIER", 28, 35], ["retained", "OBSERVATION", 36, 44], ["sediment", "OBSERVATION", 89, 97]]], ["These results denote the difficulty of improving the eutrophication of bays through the construction of sewage treatment plants alone.IntroductionBig cities have long been developed near waterfronts.", [["sewage treatment plants", "TREATMENT", 104, 127]]], ["Today, many of the world's largest cities are located on coastal zones, and therefore vast quantities of human waste are discharged into near-shore zones (Walker 1990) .", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["largest", "OBSERVATION_MODIFIER", 27, 34], ["coastal", "ANATOMY_MODIFIER", 57, 64], ["zones", "ANATOMY_MODIFIER", 65, 70]]], ["Many people visit urban coastal zones for recreation and leisure, and we also consume seafood harvested from this area.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["As a result, effluents released into the water pose a risk of pathogen contamination and human disease.", [["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["pathogen contamination", "PROBLEM", 62, 84], ["human disease", "PROBLEM", 89, 102], ["effluents", "OBSERVATION", 13, 22], ["pathogen contamination", "OBSERVATION", 62, 84]]], ["This risk is particularly heightened for waters that receive combined sewer overflows (CSOs) from urban cities where both sanitary and storm waters are conveyed in the same sewer system.IntroductionTo decrease the risk from introduced pathogens, monitoring that is both well designed and routine is essential.", [["introduced pathogens", "PROBLEM", 224, 244]]], ["However, even though a surprising number of pathogens have been reported in the sea, measuring these pathogens is difficult and time consuming -not least because such pathogens typically exist in a \"viable but non-culturable\" (VBNC) state.IntroductionIn addition, the physical environments of urban coastal zones vary widely depending on time and location.", [["pathogens", "PROBLEM", 44, 53], ["such pathogens", "PROBLEM", 162, 176], ["urban coastal zones", "TREATMENT", 293, 312], ["pathogens", "OBSERVATION", 44, 53], ["pathogens", "OBSERVATION", 101, 110]]], ["Their complicated geographical features border both inland and outer oceans, and so both inland and outer oceans affect them.", [["outer", "OBSERVATION_MODIFIER", 63, 68], ["oceans", "OBSERVATION", 69, 75], ["outer", "OBSERVATION_MODIFIER", 100, 105], ["oceans", "OBSERVATION", 106, 112]]], ["For example, tidal currents, which are a dominant phenomenon in this area, oscillate according to diurnal periods.", [["a dominant phenomenon in this area", "PROBLEM", 39, 73], ["tidal currents", "OBSERVATION", 13, 27], ["dominant", "OBSERVATION_MODIFIER", 41, 49], ["phenomenon", "OBSERVATION", 50, 60]]], ["Even if the emitted levels of pathogens were constant and we could monitor the levels of pathogen indicator organisms at the same place, they would fluctuate according to tidal periods.", [["pathogens", "PROBLEM", 30, 39], ["pathogen indicator organisms", "PROBLEM", 89, 117]]], ["Density stratification also changes with the tides.IntroductionConsequently, the frequent measurement of pathogens is needed to discuss the risk pathogens pose in urban coastal zones.", [["Density stratification", "PROBLEM", 0, 22], ["pathogens", "PROBLEM", 105, 114], ["the risk pathogens", "PROBLEM", 136, 154], ["tides", "OBSERVATION_MODIFIER", 45, 50]]], ["However, this kind of frequent monitoring appears to be impossible.", [["frequent monitoring", "TEST", 22, 41]]], ["To solve this conundrum and achieve an assessment of pathogen risk, we developed a set of numerical models that expand upon the models developed in Sect.", [["an assessment", "TEST", 36, 49], ["pathogen risk", "PROBLEM", 53, 66]]], ["Section 3.2.2 deals with the distributions of pathogens in urban coastal zones.", [["pathogens", "PROBLEM", 46, 55], ["pathogens", "OBSERVATION", 46, 55], ["urban", "ANATOMY_MODIFIER", 59, 64], ["coastal", "ANATOMY_MODIFIER", 65, 72], ["zones", "ANATOMY_MODIFIER", 73, 78]]], ["The pathogens model is explained in greater detail in Sect.", [["The pathogens model", "TEST", 0, 19]]], ["Section 3.2.4 deals with numerical experiments that help to understand the effects of appropriate countermeasures.", [["numerical experiments", "TREATMENT", 25, 46], ["appropriate countermeasures", "TREATMENT", 86, 113]]], ["Figure 3 -14 shows some typical density distributions patterns in urban coastal zones.", [["Figure", "TEST", 0, 6], ["typical", "OBSERVATION_MODIFIER", 24, 31], ["density", "OBSERVATION", 32, 39], ["distributions", "OBSERVATION_MODIFIER", 40, 53], ["patterns", "OBSERVATION_MODIFIER", 54, 62], ["urban", "ANATOMY_MODIFIER", 66, 71], ["coastal", "ANATOMY_MODIFIER", 72, 79], ["zones", "ANATOMY_MODIFIER", 80, 85]]], ["As tidal currents increase, the production of turbulent kinetic energy grows and can become the largest source of mixing in the shallow coastal waters.", [["turbulent kinetic energy", "PROBLEM", 46, 70], ["turbulent", "OBSERVATION_MODIFIER", 46, 55], ["kinetic energy", "OBSERVATION", 56, 70], ["largest", "OBSERVATION_MODIFIER", 96, 103], ["mixing", "OBSERVATION", 114, 120], ["shallow", "OBSERVATION_MODIFIER", 128, 135], ["coastal waters", "OBSERVATION", 136, 150]]], ["On the other hand, river-discharged water has a low density, creating a density difference between sea water and land-input water.Distributions of Pathogens in Urban Coastal ZonesIn salt-wedge estuaries ( Fig. 3-14 , top) , river water is discharged into a small tidal-range sea.", [["a low density", "PROBLEM", 46, 59], ["Pathogens", "PROBLEM", 147, 156], ["wedge estuaries", "TREATMENT", 187, 202], ["low density", "OBSERVATION_MODIFIER", 48, 59], ["density", "OBSERVATION", 72, 79], ["Pathogens", "OBSERVATION_MODIFIER", 147, 156], ["wedge estuaries", "OBSERVATION", 187, 202], ["small", "OBSERVATION_MODIFIER", 257, 262], ["range sea", "OBSERVATION", 269, 278]]], ["The strength of the tidal currents decreases relative to the river flow.", [["strength", "OBSERVATION_MODIFIER", 4, 12], ["tidal", "ANATOMY_MODIFIER", 20, 25], ["river flow", "OBSERVATION", 61, 71]]], ["This creates a vertical stratification of density.", [["a vertical stratification of density", "PROBLEM", 13, 49], ["vertical", "OBSERVATION_MODIFIER", 15, 23], ["stratification", "OBSERVATION_MODIFIER", 24, 38], ["density", "OBSERVATION", 42, 49]]], ["As a result, river water distributes like a veil over the sea's surface and moves seaward.", [["surface", "ANATOMY", 64, 71], ["surface", "CELLULAR_COMPONENT", 64, 71], ["veil", "OBSERVATION", 44, 48]]], ["Cross-sectional view of the mixing patterns in urban coastal zones In contrast, bottom water moves to the river mouth and mixes with the river water.", [["mouth", "ANATOMY", 112, 117], ["mouth", "ORGANISM_SUBDIVISION", 112, 117], ["urban", "ANATOMY_MODIFIER", 47, 52], ["coastal", "ANATOMY_MODIFIER", 53, 60], ["zones", "ANATOMY_MODIFIER", 61, 66], ["river mouth", "ANATOMY", 106, 117]]], ["Under such conditions, pathogens move on the surface of the sea, and further mixing with low-density fresh water is restricted by stratification.Distributions of Pathogens in Urban Coastal ZonesIn partially mixed estuaries ( Fig. 3-14 , middle) , the tidal force becomes a more effective mixing mechanism.", [["surface", "ANATOMY", 45, 52], ["surface", "CELLULAR_COMPONENT", 45, 52], ["pathogens", "PROBLEM", 23, 32], ["low-density fresh water", "TREATMENT", 89, 112], ["Pathogens", "PROBLEM", 162, 171], ["the tidal force", "TREATMENT", 247, 262], ["sea", "ANATOMY", 60, 63], ["Pathogens", "OBSERVATION_MODIFIER", 162, 171], ["mixed estuaries", "OBSERVATION", 207, 222], ["tidal force", "OBSERVATION", 251, 262], ["more effective", "OBSERVATION_MODIFIER", 273, 287]]], ["Fresh water and sea water are mixed by turbulent energy.", [["turbulent energy", "OBSERVATION", 39, 55]]], ["As a result, pathogens that are emitted from sewer treatment plants are more mixed than those in the static salt-wedge estuaries.Distributions of Pathogens in Urban Coastal ZonesIn well-mixed estuaries ( Fig. 3-14 , bottom) , the mixing of salt and river waters becomes more complete due to the increased strength of tidal currents relative to river flow.", [["salt", "CHEMICAL", 240, 244], ["pathogens", "PROBLEM", 13, 22], ["sewer treatment plants", "TREATMENT", 45, 67], ["Pathogens", "PROBLEM", 146, 155], ["the mixing of salt and river waters", "TREATMENT", 226, 261], ["the increased strength of tidal currents", "PROBLEM", 291, 331], ["wedge estuaries", "OBSERVATION", 113, 128], ["Pathogens", "OBSERVATION_MODIFIER", 146, 155], ["river flow", "OBSERVATION", 344, 354]]], ["Here, the density difference is developed in a horizontal direction.", [["the density difference", "PROBLEM", 6, 28], ["density", "OBSERVATION_MODIFIER", 10, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28]]], ["As a result, pathogens are mixed in the water column and settle down on the sea bed, in turn contaminating estuarine waters during the spring tide or contaminating rainfall through re-suspension (Pommepuy et al. 1992) .", [["pathogens", "PROBLEM", 13, 22], ["the water column", "TREATMENT", 36, 52], ["mixed", "OBSERVATION_MODIFIER", 27, 32], ["water column", "OBSERVATION_MODIFIER", 40, 52]]], ["Figure 3 -15 shows distributions of pathogens under coastal environments.", [["Figure", "TEST", 0, 6], ["pathogens", "PROBLEM", 36, 45], ["pathogens", "OBSERVATION", 36, 45], ["coastal environments", "OBSERVATION", 52, 72]]], ["These pathogens encounter a wide range of stresses including UV rays (Sinton et al. 2002) , temperature differences (Matsumoto and Omura 1980) , pH (Soli\u0107 and Krstulovi\u0107 1992) , salinity (Omura et al. 1982) , and lack of nutrients.", [["These pathogens", "PROBLEM", 0, 15], ["UV rays", "TEST", 61, 68], ["temperature differences", "PROBLEM", 92, 115], ["pH", "TEST", 145, 147], ["wide", "OBSERVATION_MODIFIER", 28, 32]]], ["The pathogens are transported by currents and continue to become part of sedimentation and to be re-suspended in urban coastal zones (Pommepuy et al. 1992 ) .Modeling of Escherichia coliformThe modeling of major pathogens of concern (including Adenovirus, Enterovirus, Rotavirus, Norovirus, and Coronavirus) is not usually conducted owing to the difficulty of modeling and the lack of observational data in coastal environments.", [["Adenovirus, Enterovirus, Rotavirus, Norovirus", "DISEASE", 244, 289], ["Escherichia coliform", "GENE_OR_GENE_PRODUCT", 170, 190], ["Adenovirus", "ORGANISM", 244, 254], ["Escherichia coliform", "SPECIES", 170, 190], ["Adenovirus", "SPECIES", 244, 254], ["The pathogens", "PROBLEM", 0, 13], ["sedimentation", "PROBLEM", 73, 86], ["Escherichia coliform", "PROBLEM", 170, 190], ["Adenovirus", "PROBLEM", 244, 254], ["Enterovirus", "PROBLEM", 256, 267], ["Rotavirus", "PROBLEM", 269, 278], ["Norovirus", "PROBLEM", 280, 289], ["Coronavirus", "PROBLEM", 295, 306], ["pathogens", "OBSERVATION", 4, 13], ["sedimentation", "OBSERVATION", 73, 86], ["Escherichia coliform", "OBSERVATION", 170, 190], ["major", "OBSERVATION_MODIFIER", 206, 211], ["pathogens", "OBSERVATION", 212, 221]]], ["We modeled Escherichia coliform (E. coli) by using experimental data in coastal sea water.Modeling of Escherichia coliformThis model consists of a three-dimensional hydrodynamic model and an E. coli model (Onozawa et al. 2005) .", [["Escherichia coliform", "ORGANISM", 11, 31], ["E. coli", "ORGANISM", 33, 40], ["Escherichia coliform", "GENE_OR_GENE_PRODUCT", 102, 122], ["E. coli", "ORGANISM", 191, 198], ["E. coli", "SPECIES", 33, 40], ["E. coli", "SPECIES", 191, 198], ["E. coli", "SPECIES", 33, 40], ["Escherichia coliform", "SPECIES", 102, 122], ["E. coli", "SPECIES", 191, 198], ["modeled Escherichia coliform (E. coli", "PROBLEM", 3, 40], ["Escherichia coliform", "PROBLEM", 102, 122], ["an E. coli model", "TEST", 188, 204], ["Escherichia coliform", "OBSERVATION", 11, 31], ["E. coli", "OBSERVATION_MODIFIER", 33, 40], ["Escherichia coliform", "OBSERVATION", 102, 122], ["E. coli model", "OBSERVATION", 191, 204]]], ["The mathematical framework employed in the E. coli model takes the same approach that was explained in Sect.", [["E. coli", "ORGANISM", 43, 50], ["E. coli", "SPECIES", 43, 50], ["E. coli", "SPECIES", 43, 50], ["The mathematical framework", "TREATMENT", 0, 26], ["the E. coli model", "TREATMENT", 39, 56], ["coli model", "OBSERVATION", 46, 56]]], ["The mass balance of E. coli is expressed as follows: 3.33) where Coli denotes concentrations of E. coli (CFU/100 ml), and t is time.", [["E. coli", "ORGANISM", 20, 27], ["Coli", "ORGANISM", 65, 69], ["E. coli", "ORGANISM", 96, 103], ["E. coli", "SPECIES", 20, 27], ["E. coli", "SPECIES", 96, 103], ["E. coli", "SPECIES", 20, 27], ["E. coli", "SPECIES", 96, 103], ["E. coli", "PROBLEM", 20, 27], ["Coli", "PROBLEM", 65, 69], ["E. coli", "PROBLEM", 96, 103], ["mass", "OBSERVATION", 4, 8], ["E. coli", "OBSERVATION_MODIFIER", 20, 27], ["E. coli", "OBSERVATION", 96, 103]]], ["Sink represents the sinking speed of E. coli . u i denotes flow speed for the calculation of the advection term. e i denotes the diffusion coefficients. sal denotes the salinity-dependent die-off rate ( ppt/day).", [["E. coli", "SPECIES", 37, 44], ["E. coli", "SPECIES", 37, 44], ["the diffusion coefficients", "TEST", 125, 151], ["dependent die", "PROBLEM", 178, 191], ["sinking", "OBSERVATION_MODIFIER", 20, 27], ["E. coli", "OBSERVATION", 37, 44], ["advection term", "OBSERVATION", 97, 111]]], ["Sunlight is generally recognized to be one source by which bacteria are inactivated, due to UV damage to the bacterial cell (Sinton et al. 2002) .", [["cell", "ANATOMY", 119, 123], ["bacterial cell", "CELL", 109, 123], ["UV damage", "PROBLEM", 92, 101], ["the bacterial cell", "PROBLEM", 105, 123], ["bacterial cell", "OBSERVATION", 109, 123]]], ["However, this particular target area has high turbidity that rapidly absorbs UV rays at the sea's surface.", [["surface", "ANATOMY", 98, 105], ["surface", "CELLULAR_COMPONENT", 98, 105], ["high turbidity", "PROBLEM", 41, 55], ["high turbidity", "OBSERVATION", 41, 55], ["rapidly", "OBSERVATION_MODIFIER", 61, 68], ["absorbs", "OBSERVATION_MODIFIER", 69, 76], ["UV rays", "OBSERVATION", 77, 84]]], ["As a result, this process has been ignored in this model.Modeling of Escherichia coliformIn this model, we can see the numerical simulations performed with two nested domains to fit the complex geography feature around the Odaiba area .", [["Escherichia coliformIn", "ORGANISM", 69, 91], ["Escherichia coliformIn", "SPECIES", 69, 91], ["the numerical simulations", "TEST", 115, 140], ["Escherichia coliformIn", "OBSERVATION", 69, 91]]], ["These nested grids make possible a representation of the stratification effect.", [["These nested grids", "PROBLEM", 0, 18]]], ["The two computational domains cover the whole Fig. 3 -16 ) that includes both the salinity simulation and observation results.", [["the salinity simulation", "TREATMENT", 78, 101]]], ["The simulation results show stratification, mixing, and an upwelling phenomenon, and include levels and timing.", [["an upwelling phenomenon", "PROBLEM", 56, 79], ["upwelling phenomenon", "OBSERVATION", 59, 79]]], ["Fig. 3-19 shows a comparison between observation results and a calculation for temperature and salinity in a fine grid scale (domain 2 in Fig. 3-16 ) .", [["a calculation", "TEST", 61, 74], ["a fine grid scale (domain", "TREATMENT", 107, 132]]], ["The timing and periods of upwelling events were captured accurately.", [["upwelling events", "PROBLEM", 26, 42]]], ["After rain fall, river discharge was increased remarkably.", [["rain fall", "PROBLEM", 6, 15]]], ["Model results adequately represent precipitation variation events and their effects.", [["precipitation variation events", "PROBLEM", 35, 65], ["precipitation variation", "OBSERVATION", 35, 58]]], ["Figure 3 -20 shows a comparison between modeled and measured E. coli at Stn.1.", [["E. coli", "ORGANISM", 61, 68], ["Stn.1", "GENE_OR_GENE_PRODUCT", 72, 77], ["E. coli", "SPECIES", 61, 68], ["E. coli", "SPECIES", 61, 68], ["Figure", "TEST", 0, 6], ["coli", "OBSERVATION", 64, 68]]], ["The current standard for acceptably safe beaches for swimming set by of the Ministry of the Environment of Japan is a fecal coliform rate of 1000 coliforms unit per 100 mL (CFU/100 mL).", [["a fecal coliform rate", "TREATMENT", 116, 137]]], ["This index of fecal coliform includes not only E. coli but also others.", [["fecal coliform", "ANATOMY", 14, 28], ["fecal", "ORGANISM_SUBSTANCE", 14, 19], ["E. coli", "ORGANISM", 47, 54], ["E. coli", "SPECIES", 47, 54], ["E. coli", "SPECIES", 47, 54], ["This index", "TEST", 0, 10], ["fecal coliform", "PROBLEM", 14, 28], ["E. coli", "PROBLEM", 47, 54], ["fecal coliform", "OBSERVATION", 14, 28], ["E. coli", "OBSERVATION", 47, 54]]], ["However, it is well known that the majority of the fecal coliform in this area comes from E. coli .", [["fecal coliform", "ANATOMY", 51, 65], ["E. coli", "ORGANISM", 90, 97], ["E. coli", "SPECIES", 90, 97], ["E. coli", "SPECIES", 90, 97], ["the fecal coliform", "PROBLEM", 47, 65], ["E. coli", "PROBLEM", 90, 97], ["majority", "OBSERVATION_MODIFIER", 35, 43], ["fecal", "ANATOMY", 51, 56], ["coliform", "OBSERVATION", 57, 65], ["E. coli", "OBSERVATION", 90, 97]]], ["Therefore, we use a value of 1000 CFU/100 ml E. coli as the standard for the safety of swimming in the sea.", [["E. coli", "ORGANISM", 45, 52], ["E. coli", "SPECIES", 45, 52], ["E. coli", "SPECIES", 45, 52], ["E. coli", "TREATMENT", 45, 52]]], ["This result also denotes that the increasing rates of E. coli do not agree with levels of precipitation.", [["E. coli", "ORGANISM", 54, 61], ["E. coli", "SPECIES", 54, 61], ["E. coli", "SPECIES", 54, 61], ["E. coli", "PROBLEM", 54, 61], ["precipitation", "PROBLEM", 90, 103], ["increasing", "OBSERVATION_MODIFIER", 34, 44]]], ["Even in small precipitations, E. coli significantly increased.Model ValidationUnderstanding the effects of physical factors is important to understanding the fate and distributions of pathogens.", [["E. coli", "ORGANISM", 30, 37], ["E. coli", "SPECIES", 30, 37], ["E. coli", "SPECIES", 30, 37], ["small precipitations", "PROBLEM", 8, 28], ["E. coli", "PROBLEM", 30, 37], ["physical factors", "TREATMENT", 107, 123], ["pathogens", "PROBLEM", 184, 193], ["small", "OBSERVATION_MODIFIER", 8, 13], ["precipitations", "OBSERVATION", 14, 28], ["E. coli", "OBSERVATION_MODIFIER", 30, 37], ["significantly", "OBSERVATION_MODIFIER", 38, 51], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["pathogens", "OBSERVATION", 184, 193]]], ["Such an understanding is in turnNumerical ExperimentsVariations in levels of E. coli are directly correlated with the discharge from pumping stations, tidal currents, river discharges, and density distributions, as explained in Sect.", [["E. coli", "ORGANISM", 77, 84], ["E. coli", "SPECIES", 77, 84], ["E. coli", "SPECIES", 77, 84], ["E. coli", "PROBLEM", 77, 84], ["E. coli", "OBSERVATION", 77, 84], ["density distributions", "OBSERVATION", 189, 210]]], ["We performed numerical experiments in order to evaluate the contributions of these different discharges and phenomena to CSO distributions.", [["numerical experiments", "TEST", 13, 34], ["these different discharges", "PROBLEM", 77, 103], ["different discharges", "OBSERVATION", 83, 103]]], ["The first numerical experiment was a nowcast simulation that calculated E. coli distributions under realistic conditions.", [["E. coli", "ORGANISM", 72, 79], ["E. coli", "SPECIES", 72, 79], ["E. coli", "SPECIES", 72, 79], ["coli distributions", "OBSERVATION", 75, 93]]], ["The second experiment was a numerical experiment to estimate the effects of a waste-reservoir that was being constructed near the Shibaura area.", [["a waste-reservoir", "TREATMENT", 76, 93], ["Shibaura", "ANATOMY", 130, 138], ["area", "ANATOMY_MODIFIER", 139, 143]]], ["Numerical experiments were also applied Odaiba area, which is used as a bathing area.", [["Numerical experiments", "TREATMENT", 0, 21], ["a bathing area", "TREATMENT", 70, 84]]], ["Figure 3 -21 shows temporal variations of precipitation and river discharges (top), as well as tide levels and E. coli concentrations discharged from three different areas.", [["E. coli", "ORGANISM", 111, 118], ["E. coli", "SPECIES", 111, 118], ["E. coli", "SPECIES", 111, 118], ["Figure", "TEST", 0, 6], ["temporal variations of precipitation", "PROBLEM", 19, 55], ["river discharges", "PROBLEM", 60, 76], ["tide levels", "TEST", 95, 106], ["E. coli concentrations", "PROBLEM", 111, 133], ["precipitation", "OBSERVATION_MODIFIER", 42, 55], ["coli concentrations", "OBSERVATION", 114, 133]]], ["Shibaura and Sunamachi area are located at the upper bay location from the Odaiba area.", [["Sunamachi area", "ANATOMY", 13, 27], ["Shibaura", "TREATMENT", 0, 8], ["Sunamachi area", "TREATMENT", 13, 27], ["Sunamachi", "ANATOMY", 13, 22], ["upper bay", "ANATOMY_MODIFIER", 47, 56]]], ["Morigasaki has the largest area, but is located in the lower bay location from the Odaiba area (see Fig. 3 In this spring tide period, tidal ranges can reach 2 m.", [["Morigasaki", "CHEMICAL", 0, 10], ["largest", "OBSERVATION_MODIFIER", 19, 26], ["area", "OBSERVATION_MODIFIER", 27, 31], ["lower bay", "ANATOMY_MODIFIER", 55, 64]]], ["Small precipitations were measured from August 29th to 30th.", [["Small precipitations", "PROBLEM", 0, 20], ["precipitations", "OBSERVATION", 6, 20]]], ["The levels of E. coli increased rapidly after the rainfall event, due mainly to discharges from the Sunamachi and Chibaura areas.", [["E. coli", "ORGANISM", 14, 21], ["E. coli", "SPECIES", 14, 21], ["E. coli", "SPECIES", 14, 21], ["E. coli", "PROBLEM", 14, 21], ["the rainfall event", "PROBLEM", 46, 64], ["E. coli", "OBSERVATION", 14, 21], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["rapidly", "OBSERVATION_MODIFIER", 32, 39], ["Sunamachi", "ANATOMY", 100, 109], ["Chibaura", "ANATOMY", 114, 122], ["areas", "ANATOMY_MODIFIER", 123, 128]]], ["Near the end of this period of increase, effluent from Morigasaki also reached the Odaiba area.", [["end", "OBSERVATION_MODIFIER", 9, 12], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["effluent", "OBSERVATION_MODIFIER", 41, 49]]], ["Fig. 3-22 shows the spatial distributions of E. coli from three different times.", [["E. coli", "ORGANISM", 45, 52], ["E. coli", "SPECIES", 45, 52], ["E. coli", "SPECIES", 45, 52], ["Fig.", "TEST", 0, 4], ["E. coli", "PROBLEM", 45, 52], ["E. coli", "OBSERVATION", 45, 52]]], ["From this Fig., the E. coli emitted from the Morigasaki area can be seen to have been transported from the lower region of the bay to the Odaiba area.", [["E. coli", "ORGANISM", 20, 27], ["E. coli", "SPECIES", 20, 27], ["E. coli", "SPECIES", 20, 27], ["the E. coli", "PROBLEM", 16, 27], ["the Morigasaki area", "PROBLEM", 41, 60], ["coli emitted", "OBSERVATION", 23, 35], ["lower", "ANATOMY_MODIFIER", 107, 112], ["region", "ANATOMY_MODIFIER", 113, 119], ["Odaiba", "ANATOMY", 138, 144], ["area", "ANATOMY_MODIFIER", 145, 149]]], ["This is because the small amount of river discharge resulted in a thin layer of low-density, highly concentrated E. coli on the surface of the sea, and tended to isolate the E. coli by preventing it from mixing with the water column.", [["surface", "ANATOMY", 128, 135], ["E. coli", "ORGANISM", 113, 120], ["E. coli", "ORGANISM", 174, 181], ["E. coli", "SPECIES", 113, 120], ["E. coli", "SPECIES", 174, 181], ["E. coli", "SPECIES", 113, 120], ["E. coli", "SPECIES", 174, 181], ["a thin layer of low-density", "PROBLEM", 64, 91], ["highly concentrated E. coli", "PROBLEM", 93, 120], ["the E. coli", "PROBLEM", 170, 181], ["the water column", "TREATMENT", 216, 232], ["small", "OBSERVATION_MODIFIER", 20, 25], ["amount", "OBSERVATION_MODIFIER", 26, 32], ["river discharge", "OBSERVATION", 36, 51], ["thin", "OBSERVATION_MODIFIER", 66, 70], ["layer", "OBSERVATION_MODIFIER", 71, 76], ["low-density", "OBSERVATION_MODIFIER", 80, 91], ["highly", "OBSERVATION_MODIFIER", 93, 99], ["concentrated", "OBSERVATION_MODIFIER", 100, 112], ["E. coli", "OBSERVATION", 113, 120], ["sea", "ANATOMY", 143, 146], ["E. coli", "OBSERVATION", 174, 181], ["water column", "OBSERVATION", 220, 232]]], ["In contrast, Fig. 3-23 shows a large precipitation case under the neap tide period.", [["Fig.", "TEST", 13, 17], ["large", "OBSERVATION_MODIFIER", 31, 36], ["precipitation", "OBSERVATION", 37, 50]]], ["Large amounts of precipitation produced a large river discharge that reached 500 m 3 /s.", [["amounts", "OBSERVATION_MODIFIER", 6, 13], ["precipitation", "OBSERVATION_MODIFIER", 17, 30], ["large", "OBSERVATION_MODIFIER", 42, 47]]], ["In this period, only the upper bay's CSOs arrived at the Odaiba area.", [["upper", "ANATOMY_MODIFIER", 25, 30]]], ["No contributions from the Morigasaki area took place.Nowcast Simulations of E. coli DistributionsIn conclusion, the concentrations of E. coli vary widely according to space and time.", [["E. coli", "ORGANISM", 76, 83], ["E. coli", "ORGANISM", 134, 141], ["E. coli", "SPECIES", 76, 83], ["E. coli", "SPECIES", 134, 141], ["E. coli", "SPECIES", 76, 83], ["E. coli", "SPECIES", 134, 141], ["the Morigasaki area", "PROBLEM", 22, 41], ["E. coli Distributions", "PROBLEM", 76, 97], ["E. coli", "PROBLEM", 134, 141], ["E. coli Distributions", "OBSERVATION", 76, 97], ["E. coli", "OBSERVATION", 134, 141]]], ["The density distributions produced by the balance of Fig. 3-22 .", [["Fig.", "TEST", 53, 57], ["density", "OBSERVATION", 4, 11], ["distributions", "OBSERVATION_MODIFIER", 12, 25], ["balance", "OBSERVATION_MODIFIER", 42, 49]]], ["Spatial distributions of E. coli at Odaiba area tides and river discharges have very complex effects.", [["E. coli", "ORGANISM", 25, 32], ["E. coli", "SPECIES", 25, 32], ["E. coli", "SPECIES", 25, 32], ["E. coli at Odaiba area tides", "PROBLEM", 25, 53], ["river discharges", "PROBLEM", 58, 74], ["E. coli", "OBSERVATION", 25, 32], ["river discharges", "OBSERVATION", 58, 74]]], ["E. coli concentrations reached maximum levels after small precipitation events, but did not increase so much under large precipitation events due to mixing.", [["E. coli", "ORGANISM", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli concentrations", "PROBLEM", 0, 22], ["maximum levels", "TEST", 31, 45], ["small precipitation events", "PROBLEM", 52, 78], ["large precipitation events", "PROBLEM", 115, 141], ["coli concentrations", "OBSERVATION", 3, 22], ["small", "OBSERVATION_MODIFIER", 52, 57], ["precipitation", "OBSERVATION", 58, 71]]], ["The model successfully captured complex distributions of E. coli and helped our understanding of pathogens contaminations.Improvement of CSO Systems Through the Construction of Storage TanksTo mitigate CSO pollutions, the construction of storage tanks at three sites in Tokyo has been planned by the Tokyo Metropolitan Government.", [["E. coli", "ORGANISM", 57, 64], ["E. coli", "SPECIES", 57, 64], ["E. coli", "SPECIES", 57, 64], ["E. coli", "PROBLEM", 57, 64], ["pathogens contaminations", "PROBLEM", 97, 121], ["Storage Tanks", "TREATMENT", 177, 190], ["CSO pollutions", "TREATMENT", 202, 216], ["complex", "OBSERVATION_MODIFIER", 32, 39], ["distributions", "OBSERVATION_MODIFIER", 40, 53], ["E. coli", "OBSERVATION", 57, 64]]], ["Shibaura is the target area of this plan around the Odaiba area.", [["Shibaura", "CHEMICAL", 0, 8], ["Shibaura", "TREATMENT", 0, 8], ["target", "OBSERVATION_MODIFIER", 16, 22], ["area", "OBSERVATION_MODIFIER", 23, 27]]], ["Numerical Numerical simulation was performed with and without the proposed storage tank, which has a capacity of 30,000 m 3 .", [["Numerical Numerical simulation", "TEST", 0, 30]]], ["To include the effect of continuous rain, we assumed that the CSOs stored in the tank could be purified within 1 day.", [["CSOs", "SIMPLE_CHEMICAL", 62, 66]]], ["Table 3 .3 shows the calculation results for the mitigation effect of the storage tank.", [["the storage tank", "TREATMENT", 70, 86]]], ["From this table, Stn.3 shows the largest decrease in CSOs among these five stations.", [["CSOs", "DISEASE", 53, 57], ["Stn.3", "DNA", 17, 22], ["largest", "OBSERVATION_MODIFIER", 33, 40], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["CSOs", "OBSERVATION", 53, 57]]], ["This is because Stn.3 is located closest to the pumping stations, and therefore would be most sensitive to the CSOs.", [["CSOs", "DISEASE", 111, 115], ["Stn.3", "GENE_OR_GENE_PRODUCT", 16, 21], ["Stn.3", "DNA", 16, 21]]], ["Before the construction of the CSO storage tank, minimum bathing standards for CSO levels were exceeded on 15 days.", [["CSO", "SIMPLE_CHEMICAL", 79, 82], ["the CSO storage tank", "TREATMENT", 27, 47], ["minimum bathing standards", "TREATMENT", 49, 74], ["CSO levels", "TEST", 79, 89]]], ["After the construction of the storage tank, the duration of CSO levels that exceeded safety standards decreased to 11 days.", [["CSO", "CHEMICAL", 60, 63], ["the storage tank", "TREATMENT", 26, 42], ["CSO levels", "TEST", 60, 70]]], ["There was an improvement of 4 days.", [["improvement", "OBSERVATION_MODIFIER", 13, 24]]], ["Such differences could not be observed, especially in those stations that are located inside the Odaiba area due to the enclosed feature of bathymetry.Improvement of CSO Systems Through the Construction of Storage TanksFor example, over 10,000 storage tanks have been built in Germany alone, and another 10,000 were planned during the 1980s in Germany.", [["bathymetry", "PROBLEM", 140, 150], ["could not be observed", "UNCERTAINTY", 17, 38], ["bathymetry", "OBSERVATION", 140, 150], ["CSO", "OBSERVATION_MODIFIER", 166, 169]]], ["Our plans for dealing with CSOs are not enough to mitigate the effects of CSOs completely.", [["CSOs", "DISEASE", 27, 31], ["CSOs", "DISEASE", 74, 78], ["CSOs", "SIMPLE_CHEMICAL", 74, 78]]], ["At the same time, these results show us the complexity of pathogens distributions and the importance of numerical modeling for this problem.SummaryNumerical simulation is one of the most important tools for the management of water quality and ecosystems in urban coastal zones.", [["pathogens distributions", "PROBLEM", 58, 81], ["numerical modeling", "TREATMENT", 104, 122], ["this problem", "PROBLEM", 127, 139], ["pathogens", "OBSERVATION", 58, 67], ["zones", "ANATOMY_MODIFIER", 271, 276]]], ["We have developed a water quality model to simulate both nutrient cycles and pathogens distributions, and coupled it with a three-dimensional hydrodynamic model of urban coastal areas.", [["a water quality model", "PROBLEM", 18, 39], ["pathogens distributions", "PROBLEM", 77, 100], ["water quality", "OBSERVATION_MODIFIER", 20, 33], ["nutrient cycles", "OBSERVATION", 57, 72], ["pathogens distributions", "OBSERVATION", 77, 100]]], ["To quantify the nutrients budget, a numerical model should include material cycles with phytoplankton, zooplankton, carbons, nutrients, and oxygen.", [["oxygen", "CHEMICAL", 140, 146], ["carbons", "CHEMICAL", 116, 123], ["oxygen", "CHEMICAL", 140, 146], ["phytoplankton", "SIMPLE_CHEMICAL", 88, 101], ["zooplankton", "SIMPLE_CHEMICAL", 103, 114], ["carbons", "SIMPLE_CHEMICAL", 116, 123], ["oxygen", "SIMPLE_CHEMICAL", 140, 146], ["a numerical model", "TREATMENT", 34, 51], ["material cycles", "TREATMENT", 67, 82], ["phytoplankton", "TREATMENT", 88, 101], ["zooplankton", "TREATMENT", 103, 114], ["carbons", "TREATMENT", 116, 123], ["nutrients", "TREATMENT", 125, 134], ["oxygen", "TREATMENT", 140, 146]]], ["We applied this model to the Tokyo Bay and simulated water column temperatures, salinity, and nutrient concentrations that were closely linked with field observations.", [["simulated water column temperatures", "TREATMENT", 43, 78], ["salinity", "TREATMENT", 80, 88], ["nutrient concentrations", "TREATMENT", 94, 117]]], ["This model successfully captured periods of timing, stratification events, and subsequent changes in bottom water oxygen and nutrients.", [["oxygen", "CHEMICAL", 114, 120], ["oxygen", "CHEMICAL", 114, 120], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["stratification events", "PROBLEM", 52, 73], ["bottom water oxygen", "TREATMENT", 101, 120], ["bottom", "OBSERVATION_MODIFIER", 101, 107], ["water oxygen", "OBSERVATION", 108, 120]]], ["Our model results also indicated that there were clear differences between the material cycles of nitrogen and phosphorus inside the bay.", [["nitrogen", "CHEMICAL", 98, 106], ["phosphorus", "CHEMICAL", 111, 121], ["nitrogen", "CHEMICAL", 98, 106], ["phosphorus", "CHEMICAL", 111, 121], ["nitrogen", "SIMPLE_CHEMICAL", 98, 106], ["phosphorus", "SIMPLE_CHEMICAL", 111, 121], ["nitrogen", "TREATMENT", 98, 106], ["phosphorus", "TREATMENT", 111, 121], ["clear", "OBSERVATION", 49, 54]]], ["The regeneration of nutrients and its release from sediment was found to be a source of phytoplankton growth on the same order of importance as contributions from rivers.", [["phytoplankton growth", "PROBLEM", 88, 108], ["regeneration", "OBSERVATION_MODIFIER", 4, 16], ["phytoplankton growth", "OBSERVATION", 88, 108]]], ["In particular, phosphorus was found to have been largely retained within the system through recycling between sediment and water.", [["phosphorus", "CHEMICAL", 15, 25], ["phosphorus", "CHEMICAL", 15, 25], ["phosphorus", "SIMPLE_CHEMICAL", 15, 25], ["water", "SIMPLE_CHEMICAL", 123, 128], ["phosphorus", "TEST", 15, 25], ["largely", "OBSERVATION_MODIFIER", 49, 56], ["retained", "OBSERVATION", 57, 65], ["sediment", "OBSERVATION", 110, 118]]], ["We also developed a pathogen model that includes E. coli and is applied to the simulation of CSO influences in urban coastal zones.", [["E. coli", "ORGANISM", 49, 56], ["E. coli", "SPECIES", 49, 56], ["E. coli", "SPECIES", 49, 56], ["a pathogen model", "PROBLEM", 18, 34], ["E. coli", "PROBLEM", 49, 56], ["pathogen model", "OBSERVATION", 20, 34], ["E. coli", "OBSERVATION", 49, 56], ["coastal", "ANATOMY_MODIFIER", 117, 124], ["zones", "ANATOMY_MODIFIER", 125, 130]]], ["These results indicate that, because of stratification, concentrations of E. coli significantly increase after even small precipitation events.", [["E. coli", "ORGANISM", 74, 81], ["E. coli", "SPECIES", 74, 81], ["E. coli", "SPECIES", 74, 81], ["E. coli", "PROBLEM", 74, 81], ["small precipitation events", "PROBLEM", 116, 142], ["E. coli", "OBSERVATION_MODIFIER", 74, 81], ["significantly", "OBSERVATION_MODIFIER", 82, 95], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["small", "OBSERVATION_MODIFIER", 116, 121], ["precipitation", "OBSERVATION_MODIFIER", 122, 135]]], ["From this study, the balance between tidal mixing and river waters can be seen to be significant.", [["this study", "TEST", 5, 15], ["tidal mixing and river waters", "TREATMENT", 37, 66], ["significant", "OBSERVATION_MODIFIER", 85, 96]]], ["However, these are only two case studies; it remains necessary to simulate the structure and characteristics of CSO distributions and their impact on urban coastal zone pollution.", [["two case studies", "TEST", 24, 40], ["CSO distributions", "OBSERVATION", 112, 129], ["zone pollution", "OBSERVATION", 164, 178]]]], "cc507d29ec1836af0c8d383a7d4edee22c80b79b": [["INTRODUCTIONT o eliminate pathogens of viral or bacterial origin the adaptive immune system utilizes major histocompatibility complex class I (MHC-I) molecules to bind and present epitopes from intracellular and extracellular antigens to CD8 + cytotoxic T lymphocytes (CTLs).", [["intracellular", "ANATOMY", 194, 207], ["extracellular", "ANATOMY", 212, 225], ["CD8 + cytotoxic T lymphocytes", "ANATOMY", 238, 267], ["CTLs", "ANATOMY", 269, 273], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 194, 207], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["CD8", "GENE_OR_GENE_PRODUCT", 238, 241], ["major histocompatibility complex class I (MHC-I) molecules", "PROTEIN", 101, 159], ["epitopes", "PROTEIN", 180, 188], ["intracellular and extracellular antigens", "PROTEIN", 194, 234], ["CD8", "PROTEIN", 238, 241], ["cytotoxic T lymphocytes", "CELL_TYPE", 244, 267], ["CTLs", "CELL_TYPE", 269, 273], ["pathogens", "PROBLEM", 26, 35], ["viral or bacterial origin", "PROBLEM", 39, 64], ["intracellular and extracellular antigens", "TEST", 194, 234], ["CD8", "TEST", 238, 241], ["cytotoxic T lymphocytes", "PROBLEM", 244, 267], ["bacterial origin", "OBSERVATION_MODIFIER", 48, 64]]], ["These effector T cells scan the surface of virus-infected cells to detect MHC-I bound peptides (pMHC-I) and destroy the cells by either direct lysis or through secretion of cytokines and chemokines.", [["effector T cells", "ANATOMY", 6, 22], ["surface", "ANATOMY", 32, 39], ["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 120, 125], ["effector T cells", "CELL", 6, 22], ["surface", "CELLULAR_COMPONENT", 32, 39], ["cells", "CELL", 58, 63], ["MHC-I", "GENE_OR_GENE_PRODUCT", 74, 79], ["pMHC-I", "GENE_OR_GENE_PRODUCT", 96, 102], ["cells", "CELL", 120, 125], ["effector T cells", "CELL_TYPE", 6, 22], ["virus-infected cells", "CELL_TYPE", 43, 63], ["MHC", "PROTEIN", 74, 77], ["pMHC", "PROTEIN", 96, 100], ["cytokines", "PROTEIN", 173, 182], ["chemokines", "PROTEIN", 187, 197], ["These effector T cells scan", "TEST", 0, 27], ["virus", "PROBLEM", 43, 48], ["infected cells", "PROBLEM", 49, 63], ["MHC", "TEST", 74, 77], ["direct lysis", "TREATMENT", 136, 148], ["secretion of cytokines", "TREATMENT", 160, 182], ["chemokines", "TREATMENT", 187, 197]]], ["1, 2 The highly polymorphic nature of the MHC-I molecules Volume 6, March/April 2015 allows them to present a large repertoire of peptides representing the concealed intracellular antigens of infected or transformed cells.", [["intracellular", "ANATOMY", 166, 179], ["cells", "ANATOMY", 216, 221], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 166, 179], ["cells", "CELL", 216, 221], ["MHC", "PROTEIN", 42, 45], ["I molecules", "PROTEIN", 46, 57], ["intracellular antigens", "PROTEIN", 166, 188], ["infected or transformed cells", "CELL_TYPE", 192, 221], ["a large repertoire of peptides", "PROBLEM", 108, 138], ["infected or transformed cells", "PROBLEM", 192, 221], ["large", "OBSERVATION_MODIFIER", 110, 115], ["infected", "OBSERVATION", 192, 200], ["transformed cells", "OBSERVATION", 204, 221]]], ["Generating and loading these peptides into cognate MHC-1 binding grooves for antigen presentation defines the various steps of the MHC-1 antigen presentation pathway.", [["MHC-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["MHC-1", "GENE_OR_GENE_PRODUCT", 131, 136], ["MHC", "PROTEIN", 51, 54], ["MHC", "PROTEIN", 131, 134]]], ["To counter this process, viruses have evolved various strategies to circumvent what is usually a highly effective immune surveillance system in order to limit the endogenous processing and presentation of viral peptides.", [["viruses", "PROBLEM", 25, 32], ["the endogenous processing", "PROBLEM", 159, 184], ["viral peptides", "PROBLEM", 205, 219], ["viruses", "OBSERVATION", 25, 32], ["viral peptides", "OBSERVATION", 205, 219]]], ["[3] [4] [5] Indeed, members of several viral families including Herpesviridae and Retroviridae, use sophisticated mechanisms to interfere at key steps of the MHC-I antigen presentation pathway in order to evade immune recognition and as a result establish lifelong persistence in their host.", [["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 64, 77], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 158, 171], ["MHC", "PROTEIN", 158, 161], ["Herpesviridae", "TREATMENT", 64, 77], ["Retroviridae", "TREATMENT", 82, 94]]], ["6 An alternative mechanism utilized by viruses to limit the supply of viral peptides for T cell recognition is the downregulation of viral protein synthesis.", [["T cell", "ANATOMY", 89, 95], ["T cell", "CELL", 89, 95], ["viral protein", "PROTEIN", 133, 146], ["viruses", "PROBLEM", 39, 46], ["viral peptides", "PROBLEM", 70, 84], ["T cell recognition", "PROBLEM", 89, 107], ["viral protein synthesis", "PROBLEM", 133, 156], ["viral protein synthesis", "OBSERVATION", 133, 156]]], ["[7] [8] [9] [10] [11] Viruses that downregulate their protein synthesis at levels below the threshold required to initiate an immune response by host virus-specific T cells may escape immune detection.", [["T cells", "ANATOMY", 165, 172], ["[7] [8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 20], ["host virus", "ORGANISM", 145, 155], ["T cells", "CELL", 165, 172], ["T cells", "CELL_TYPE", 165, 172], ["Viruses", "PROBLEM", 22, 29], ["their protein synthesis", "TEST", 48, 71], ["host virus", "TEST", 145, 155], ["immune detection", "TEST", 184, 200]]], ["While there has been steady progress over recent years in characterizing the successive steps underlying the antigen processing and presentation pathway, and in unraveling specialized functions of the components of the MHC-1 presentation pathway, 2,12 our knowledge of the impact of translational regulatory mechanisms on MHC-1 mediated antigen presentation remains limited.INTRODUCTIONIn this review, we focus on translational regulatory mechanisms and their impact on antigen presentation, a critical step in the T cell-mediated control of intracellular pathogens.", [["T cell", "ANATOMY", 515, 521], ["intracellular", "ANATOMY", 542, 555], ["MHC-1", "GENE_OR_GENE_PRODUCT", 219, 224], ["MHC-1", "GENE_OR_GENE_PRODUCT", 322, 327], ["T cell", "CELL", 515, 521], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 542, 555], ["MHC", "PROTEIN", 219, 222], ["MHC", "PROTEIN", 322, 325], ["intracellular pathogens", "PROBLEM", 542, 565], ["steady", "OBSERVATION_MODIFIER", 21, 27], ["intracellular pathogens", "OBSERVATION", 542, 565]]], ["While there have been numerous studies demonstrating an impact of messenger RNA (mRNA) structure on translation, we are only now gaining insights into how some viruses exploit mRNA structure to regulate the supply of viral antigens into the MHC-I antigen presentation pathway.", [["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 241, 254], ["messenger RNA", "RNA", 66, 79], ["mRNA", "RNA", 81, 85], ["viral antigens", "PROTEIN", 217, 231], ["MHC", "PROTEIN", 241, 244], ["numerous studies", "TEST", 22, 38], ["messenger RNA (mRNA) structure", "PROBLEM", 66, 96], ["messenger RNA", "OBSERVATION", 66, 79]]], ["In parallel we discuss alternative translational mechanisms that are used by viruses to alter the nature of antigenic peptides.", [["alternative translational mechanisms", "TREATMENT", 23, 59], ["antigenic peptides", "TREATMENT", 108, 126]]], ["Characterization of the mechanisms by which viruses modulate their protein synthesis will not only help us in treating virus-induced pathology, but also enable the design of safer and more immunogenic viral vectors such as vaccines or gene delivery systems.", [["viruses modulate their protein synthesis", "PROBLEM", 44, 84], ["virus", "PROBLEM", 119, 124], ["immunogenic viral vectors", "TREATMENT", 189, 214], ["vaccines", "TREATMENT", 223, 231], ["gene delivery systems", "TREATMENT", 235, 256]]], ["Furthermore, these insights will stimulate development of novel therapeutics based on antisense strategies or small molecules that target viral mRNA structure for overriding evasion mechanisms of immune detection.MODULATION OF MHC-I ANTIGEN PRESENTATION BY HUMAN VIRUSESViral replication and therefore its persistence rely on the host's protein synthesis machinery to generate numerous viral and cellular proteins within the infected cell.", [["cellular", "ANATOMY", 396, 404], ["cell", "ANATOMY", 434, 438], ["cellular", "CELL", 396, 404], ["cell", "CELL", 434, 438], ["viral mRNA", "RNA", 138, 148], ["MHC", "PROTEIN", 227, 230], ["viral and cellular proteins", "PROTEIN", 386, 413], ["infected cell", "CELL_TYPE", 425, 438], ["novel therapeutics", "TREATMENT", 58, 76], ["antisense strategies", "TREATMENT", 86, 106], ["small molecules", "PROBLEM", 110, 125], ["target viral mRNA structure", "PROBLEM", 131, 158], ["immune detection", "PROBLEM", 196, 212], ["HUMAN VIRUSESViral replication", "TREATMENT", 257, 287], ["the host's protein synthesis machinery", "TREATMENT", 326, 364], ["numerous viral and cellular proteins within the infected cell", "PROBLEM", 377, 438], ["numerous", "OBSERVATION_MODIFIER", 377, 385], ["viral", "OBSERVATION", 386, 391], ["cellular proteins", "OBSERVATION", 396, 413], ["infected cell", "OBSERVATION", 425, 438]]], ["A high proportion of these viral cytosolic proteins are degraded by the proteasome to generate antigenic peptides for presentation to CTLs by MHC-1 molecules (Figure 1 ).", [["cytosolic", "ANATOMY", 33, 42], ["CTLs", "CELL", 134, 138], ["MHC-1", "GENE_OR_GENE_PRODUCT", 142, 147], ["viral cytosolic proteins", "PROTEIN", 27, 51], ["proteasome", "PROTEIN", 72, 82], ["CTLs", "CELL_TYPE", 134, 138], ["MHC-1 molecules", "PROTEIN", 142, 157], ["these viral cytosolic proteins", "TEST", 21, 51], ["CTLs", "TEST", 134, 138], ["high", "OBSERVATION_MODIFIER", 2, 6], ["viral cytosolic proteins", "OBSERVATION", 27, 51]]], ["The 20S/26S proteasome is the main cytoplasmic processing complex responsible for generating peptides for the MHC-I antigen presentation pathway.", [["cytoplasmic", "ANATOMY", 35, 46], ["20S", "GENE_OR_GENE_PRODUCT", 4, 7], ["26S", "GENE_OR_GENE_PRODUCT", 8, 11], ["cytoplasmic", "ORGANISM_SUBSTANCE", 35, 46], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 110, 123], ["20S", "PROTEIN", 4, 7], ["26S proteasome", "PROTEIN", 8, 22], ["cytoplasmic processing complex", "PROTEIN", 35, 65], ["MHC", "PROTEIN", 110, 113], ["The 20S/26S proteasome", "TREATMENT", 0, 22], ["26S proteasome", "OBSERVATION", 8, 22]]], ["13 Proteolysis is regulated in an ATP-dependent manner by a catalytic 20S core particle that is capped at both ends by 19S regulatory particles.", [["ATP", "CHEMICAL", 34, 37], ["ATP", "CHEMICAL", 34, 37], ["ATP", "SIMPLE_CHEMICAL", 34, 37], ["catalytic 20S core particle", "PROTEIN", 60, 87], ["19S regulatory particles", "PROTEIN", 119, 143], ["a catalytic 20S core particle", "TREATMENT", 58, 87], ["19S regulatory particles", "OBSERVATION", 119, 143]]], ["14 This proteolytic chamber recognizes and unfolds ubiquitylated proteins for degradation.", [["ubiquitylated proteins", "PROTEIN", 51, 73]]], ["A designated transporter, referred to as the transporter associated with antigen processing (TAP), translocates the degraded peptides into the endoplasmic reticulum (ER) where resident chaperones facilitate their binding to newly synthesized MHC-I molecules for vesicular migration through the golgi to the cell surface 2 (Figure 1 ).", [["endoplasmic reticulum", "ANATOMY", 143, 164], ["ER", "ANATOMY", 166, 168], ["vesicular", "ANATOMY", 262, 271], ["golgi", "ANATOMY", 294, 299], ["cell surface", "ANATOMY", 307, 319], ["antigen", "GENE_OR_GENE_PRODUCT", 73, 80], ["TAP", "GENE_OR_GENE_PRODUCT", 93, 96], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 143, 164], ["ER", "GENE_OR_GENE_PRODUCT", 166, 168], ["MHC-I", "GENE_OR_GENE_PRODUCT", 242, 247], ["vesicular", "MULTI-TISSUE_STRUCTURE", 262, 271], ["golgi", "GENE_OR_GENE_PRODUCT", 294, 299], ["cell", "CELL", 307, 311], ["TAP", "PROTEIN", 93, 96], ["ER", "PROTEIN", 166, 168], ["resident chaperones", "PROTEIN", 176, 195], ["MHC-I molecules", "PROTEIN", 242, 257], ["golgi", "PROTEIN", 294, 299], ["antigen processing (TAP", "TREATMENT", 73, 96], ["vesicular migration", "PROBLEM", 262, 281], ["endoplasmic reticulum", "ANATOMY", 143, 164], ["vesicular migration", "OBSERVATION", 262, 281]]], ["Since the MHC-I antigen presentation pathway plays a critical role in exposing virally infected cells to CD8 + T cells, it is not surprising that viruses have evolved immunomodulatory proteins to interfere with key steps of the presentation pathway.", [["cells", "ANATOMY", 96, 101], ["CD8 + T cells", "ANATOMY", 105, 118], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 10, 23], ["cells", "CELL", 96, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 105, 108], ["MHC", "PROTEIN", 10, 13], ["virally infected cells", "CELL_TYPE", 79, 101], ["CD8 + T cells", "CELL_TYPE", 105, 118], ["immunomodulatory proteins", "PROTEIN", 167, 192], ["virally infected cells", "PROBLEM", 79, 101], ["T cells", "PROBLEM", 111, 118], ["viruses", "PROBLEM", 146, 153], ["immunomodulatory proteins", "TREATMENT", 167, 192]]], ["These evasive mechanisms include inhibiting peptide transport into the ER 3 or inhibiting proteasomal degradation 15 (Table 1) .", [["proteasomal", "ANATOMY", 90, 101], ["ER 3", "GENE_OR_GENE_PRODUCT", 71, 75], ["ER 3", "PROTEIN", 71, 75], ["inhibiting proteasomal degradation", "PROBLEM", 79, 113]]], ["For example, herpes viruses including human cytomegalovirus (HCMV) and herpes simplex virus (HVS) have developed specific strategies to restrict antigen presentation through MHC-I molecules by binding specific viral proteins to TAP, blocking peptide translocation into the ER.", [["ER", "ANATOMY", 273, 275], ["herpes viruses", "DISEASE", 13, 27], ["human cytomegalovirus (HCMV) and herpes simplex virus", "DISEASE", 38, 91], ["herpes viruses", "ORGANISM", 13, 27], ["human cytomegalovirus", "ORGANISM", 38, 59], ["HCMV", "ORGANISM", 61, 65], ["herpes simplex virus", "ORGANISM", 71, 91], ["HVS", "ORGANISM", 93, 96], ["MHC-I", "GENE_OR_GENE_PRODUCT", 174, 179], ["TAP", "GENE_OR_GENE_PRODUCT", 228, 231], ["ER", "GENE_OR_GENE_PRODUCT", 273, 275], ["MHC-I molecules", "PROTEIN", 174, 189], ["viral proteins", "PROTEIN", 210, 224], ["TAP", "PROTEIN", 228, 231], ["ER", "PROTEIN", 273, 275], ["human", "SPECIES", 38, 43], ["cytomegalovirus", "SPECIES", 44, 59], ["herpes simplex virus", "SPECIES", 71, 91], ["human cytomegalovirus", "SPECIES", 38, 59], ["HCMV", "SPECIES", 61, 65], ["herpes simplex virus", "SPECIES", 71, 91], ["HVS", "SPECIES", 93, 96], ["herpes viruses", "PROBLEM", 13, 27], ["human cytomegalovirus (HCMV", "PROBLEM", 38, 65], ["herpes simplex virus", "PROBLEM", 71, 91], ["TAP", "TREATMENT", 228, 231], ["herpes viruses", "OBSERVATION", 13, 27], ["cytomegalovirus", "OBSERVATION", 44, 59]]], ["6,30 HCMV protein US6 blocks ATP binding to prevent peptide transport through the TAP pore 24, 25 while HVS protein ICP47 blocks peptide binding to TAP.", [["ATP", "CHEMICAL", 29, 32], ["ATP", "CHEMICAL", 29, 32], ["HCMV", "ORGANISM", 5, 9], ["US6", "GENE_OR_GENE_PRODUCT", 18, 21], ["ATP", "SIMPLE_CHEMICAL", 29, 32], ["ICP47", "GENE_OR_GENE_PRODUCT", 116, 121], ["TAP", "GENE_OR_GENE_PRODUCT", 148, 151], ["6,30 HCMV protein US6", "PROTEIN", 0, 21], ["TAP pore 24, 25", "PROTEIN", 82, 97], ["HVS protein", "PROTEIN", 104, 115], ["ICP47", "PROTEIN", 116, 121], ["TAP", "PROTEIN", 148, 151], ["HCMV", "SPECIES", 5, 9], ["HCMV protein US6 blocks", "TREATMENT", 5, 28], ["ATP binding", "PROBLEM", 29, 40], ["peptide transport", "TREATMENT", 52, 69], ["the TAP pore", "TREATMENT", 78, 90], ["HVS protein ICP47 blocks peptide", "TREATMENT", 104, 136], ["TAP", "TREATMENT", 148, 151]]], ["22, 23 The adenoviral protein E3-19K 18, 19 and the HCMV protein US3 16, 17 both act to retain MHC-I molecules in the ER, in addition to their inhibitory effects on the TAP-associated glycoprotein, tapasin.", [["ER", "ANATOMY", 118, 120], ["adenoviral", "ORGANISM", 11, 21], ["E3-19K 18", "GENE_OR_GENE_PRODUCT", 30, 39], ["HCMV", "ORGANISM", 52, 56], ["MHC-I", "GENE_OR_GENE_PRODUCT", 95, 100], ["ER", "GENE_OR_GENE_PRODUCT", 118, 120], ["TAP", "GENE_OR_GENE_PRODUCT", 169, 172], ["tapasin", "GENE_OR_GENE_PRODUCT", 198, 205], ["adenoviral protein E3-19K 18, 19", "PROTEIN", 11, 43], ["HCMV protein US3 16, 17", "PROTEIN", 52, 75], ["MHC-I molecules", "PROTEIN", 95, 110], ["ER", "PROTEIN", 118, 120], ["TAP", "PROTEIN", 169, 172], ["glycoprotein", "PROTEIN", 184, 196], ["tapasin", "PROTEIN", 198, 205], ["HCMV", "SPECIES", 52, 56], ["The adenoviral protein E3", "TEST", 7, 32], ["K", "TEST", 35, 36], ["the HCMV protein US3", "TEST", 48, 68], ["the TAP", "TREATMENT", 165, 172], ["glycoprotein, tapasin", "TREATMENT", 184, 205]]], ["19, 29, 28 It has also been shown that two HCMV proteins, US11 and US2, induce ER-associated degradation of MHC-1 molecules when bound to the ER binding immunoglobulin protein (BiP) chaperone (Table 1) .", [["HCMV", "ORGANISM", 43, 47], ["US11", "GENE_OR_GENE_PRODUCT", 58, 62], ["US2", "GENE_OR_GENE_PRODUCT", 67, 70], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["MHC-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["ER binding immunoglobulin protein", "GENE_OR_GENE_PRODUCT", 142, 175], ["BiP", "GENE_OR_GENE_PRODUCT", 177, 180], ["HCMV proteins", "PROTEIN", 43, 56], ["US11", "PROTEIN", 58, 62], ["US2", "PROTEIN", 67, 70], ["ER", "PROTEIN", 79, 81], ["MHC-1 molecules", "PROTEIN", 108, 123], ["ER binding immunoglobulin protein (BiP) chaperone", "PROTEIN", 142, 191], ["Table 1", "PROTEIN", 193, 200], ["HCMV", "SPECIES", 43, 47], ["two HCMV proteins", "TEST", 39, 56], ["US2", "TEST", 67, 70], ["immunoglobulin protein (BiP) chaperone", "TREATMENT", 153, 191]]], ["20 The MHC-I antigen presentation pathway presented in Figure 1 highlights the importance of translation as the initial step in a long cascade of biological processes that ultimately result in the presentation of antigenic peptides.", [["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 7, 20], ["MHC", "PROTEIN", 7, 10], ["antigenic peptides", "TREATMENT", 213, 231]]], ["Consequently, viruses that have developed mechanisms to self-regulate their protein synthesis at levels below the threshold required to initiate an immune response by host virus-specific T cells may escape immune recognition.RNA G-quadruplexes in the EBV-Nuclear Antigen 1 open Reading Frame Impact on Antigen PresentationThe double-stranded DNA Epstein-Barr virus (EBV), which infects over 90% of the world's population, is associated with a number of human malignancies including Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's lymphoma.", [["T cells", "ANATOMY", 187, 194], ["malignancies", "ANATOMY", 459, 471], ["Burkitt's lymphoma", "ANATOMY", 482, 500], ["nasopharyngeal carcinoma", "ANATOMY", 502, 526], ["Hodgkin's lymphoma", "ANATOMY", 532, 550], ["malignancies", "DISEASE", 459, 471], ["Burkitt's lymphoma", "DISEASE", 482, 500], ["nasopharyngeal carcinoma", "DISEASE", 502, 526], ["Hodgkin's lymphoma", "DISEASE", 532, 550], ["host virus", "ORGANISM", 167, 177], ["T cells", "CELL", 187, 194], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 229, 243], ["EBV", "ORGANISM", 251, 254], ["DNA", "CELLULAR_COMPONENT", 342, 345], ["Epstein-Barr virus", "ORGANISM", 346, 364], ["EBV", "ORGANISM", 366, 369], ["human", "ORGANISM", 453, 458], ["malignancies", "CANCER", 459, 471], ["Burkitt's lymphoma", "CANCER", 482, 500], ["nasopharyngeal carcinoma", "CANCER", 502, 526], ["Hodgkin's lymphoma", "CANCER", 532, 550], ["T cells", "CELL_TYPE", 187, 194], ["Epstein-Barr virus", "SPECIES", 346, 364], ["human", "SPECIES", 453, 458], ["Epstein-Barr virus", "SPECIES", 346, 364], ["EBV", "SPECIES", 366, 369], ["human", "SPECIES", 453, 458], ["viruses", "PROBLEM", 14, 21], ["host virus", "PROBLEM", 167, 177], ["RNA G", "TEST", 225, 230], ["quadruplexes", "TEST", 231, 243], ["the EBV", "TEST", 247, 254], ["Nuclear Antigen", "TEST", 255, 270], ["Antigen", "TEST", 302, 309], ["Barr virus (EBV", "PROBLEM", 354, 369], ["human malignancies", "PROBLEM", 453, 471], ["Burkitt's lymphoma", "PROBLEM", 482, 500], ["nasopharyngeal carcinoma", "PROBLEM", 502, 526], ["Hodgkin's lymphoma", "PROBLEM", 532, 550], ["viruses", "OBSERVATION", 14, 21], ["EBV", "ANATOMY", 251, 254], ["Barr virus", "OBSERVATION", 354, 364], ["malignancies", "OBSERVATION", 459, 471], ["Burkitt's lymphoma", "OBSERVATION", 482, 500], ["nasopharyngeal", "ANATOMY", 502, 516], ["carcinoma", "OBSERVATION", 517, 526], ["Hodgkin's lymphoma", "OBSERVATION", 532, 550]]], ["While the majority of EBV latent proteins elicit robust immune responses, EBV-encoded nuclear antigen 1 (EBNA1) a genome maintenance protein (GMP) expressed in all EBV-associated malignancies, self-regulates its synthesis at levels sufficient to maintain viral infection but below the level required to initiate an immune response by host virus-specific T cells.", [["malignancies", "ANATOMY", 179, 191], ["T cells", "ANATOMY", 354, 361], ["malignancies", "DISEASE", 179, 191], ["viral infection", "DISEASE", 255, 270], ["EBV", "ORGANISM", 22, 25], ["EBV-encoded nuclear antigen 1", "GENE_OR_GENE_PRODUCT", 74, 103], ["EBNA1", "GENE_OR_GENE_PRODUCT", 105, 110], ["GMP", "GENE_OR_GENE_PRODUCT", 142, 145], ["EBV", "ORGANISM", 164, 167], ["malignancies", "CANCER", 179, 191], ["host virus", "ORGANISM", 334, 344], ["T cells", "CELL", 354, 361], ["EBV latent proteins", "PROTEIN", 22, 41], ["EBV-encoded nuclear antigen 1", "PROTEIN", 74, 103], ["EBNA1", "PROTEIN", 105, 110], ["genome maintenance protein", "PROTEIN", 114, 140], ["GMP", "PROTEIN", 142, 145], ["T cells", "CELL_TYPE", 354, 361], ["EBV", "SPECIES", 22, 25], ["EBV latent proteins", "TEST", 22, 41], ["EBV", "TEST", 74, 77], ["nuclear antigen", "TEST", 86, 101], ["EBNA1", "TEST", 105, 110], ["GMP", "TEST", 142, 145], ["all EBV", "PROBLEM", 160, 167], ["associated malignancies", "PROBLEM", 168, 191], ["viral infection", "PROBLEM", 255, 270], ["host virus", "TEST", 334, 344], ["malignancies", "OBSERVATION", 179, 191], ["viral", "OBSERVATION_MODIFIER", 255, 260], ["infection", "OBSERVATION", 261, 270]]], ["8, 11, 31 The glycine-alanine repeat domain (GAr) of EBNA1 was initially thought to be responsible for limiting MHC-I-restricted presentation of EBNA1 epitopes to CTLs due to the GAr inhibiting its own proteasomal degradation and therefore presentation of EBNA1 peptides.", [["glycine", "CHEMICAL", 14, 21], ["alanine", "CHEMICAL", 22, 29], ["glycine", "CHEMICAL", 14, 21], ["alanine", "CHEMICAL", 22, 29], ["glycine", "AMINO_ACID", 14, 21], ["alanine", "AMINO_ACID", 22, 29], ["GAr", "GENE_OR_GENE_PRODUCT", 45, 48], ["EBNA1", "GENE_OR_GENE_PRODUCT", 53, 58], ["MHC-I-", "GENE_OR_GENE_PRODUCT", 112, 118], ["EBNA1", "GENE_OR_GENE_PRODUCT", 145, 150], ["CTLs", "CELL", 163, 167], ["GAr", "GENE_OR_GENE_PRODUCT", 179, 182], ["EBNA1", "GENE_OR_GENE_PRODUCT", 256, 261], ["glycine-alanine repeat domain", "PROTEIN", 14, 43], ["GAr", "PROTEIN", 45, 48], ["EBNA1", "PROTEIN", 53, 58], ["MHC", "PROTEIN", 112, 115], ["EBNA1 epitopes", "PROTEIN", 145, 159], ["CTLs", "CELL_TYPE", 163, 167], ["EBNA1", "PROTEIN", 256, 261], ["The glycine-alanine repeat domain", "TREATMENT", 10, 43], ["EBNA1", "TEST", 53, 58], ["EBNA1 epitopes", "PROBLEM", 145, 159], ["CTLs", "TEST", 163, 167], ["the GAr", "PROBLEM", 175, 182], ["proteasomal degradation", "PROBLEM", 202, 225], ["EBNA1 peptides", "TREATMENT", 256, 270]]], ["15, 32 Indeed, deleting the GAr was shown to alleviate the inhibitory constraint on antigen presentation.", [["GAr", "GENE_OR_GENE_PRODUCT", 28, 31], ["GAr", "DNA", 28, 31], ["the inhibitory constraint", "PROBLEM", 55, 80]]], ["31, 33 More recent investigations have demonstrated that reduced EBNA1 MHC-I peptide presentation is due to downregulated EBNA1 synthesis 9,11,31 and questioned whether the GAr has an impact on EBNA1 turnover.", [["EBNA1 MHC-I", "GENE_OR_GENE_PRODUCT", 65, 76], ["EBNA1", "GENE_OR_GENE_PRODUCT", 122, 127], ["GAr", "GENE_OR_GENE_PRODUCT", 173, 176], ["EBNA1", "GENE_OR_GENE_PRODUCT", 194, 199], ["EBNA1", "PROTEIN", 65, 70], ["MHC", "PROTEIN", 71, 74], ["EBNA1", "PROTEIN", 122, 127], ["GAr", "DNA", 173, 176], ["EBNA1", "PROTEIN", 194, 199], ["reduced EBNA1 MHC", "PROBLEM", 57, 74], ["downregulated EBNA1 synthesis", "PROBLEM", 108, 137], ["the GAr", "PROBLEM", 169, 176], ["EBNA1 MHC", "OBSERVATION", 65, 74], ["EBNA1 turnover", "OBSERVATION", 194, 208]]], ["34 Moreover, studies by several groups have demonstrated that EBNA1-specific epitopes are derived from newly synthesized protein and have shown both in vitro and in vivo, that the GAr inhibits mRNA translation of EBNA1 in cis.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 62, 67], ["GAr", "GENE_OR_GENE_PRODUCT", 180, 183], ["EBNA1", "GENE_OR_GENE_PRODUCT", 213, 218], ["EBNA1", "PROTEIN", 62, 67], ["epitopes", "PROTEIN", 77, 85], ["GAr", "PROTEIN", 180, 183], ["EBNA1", "PROTEIN", 213, 218], ["EBNA1", "TEST", 62, 67], ["the GAr", "PROBLEM", 176, 183], ["EBNA1", "OBSERVATION", 62, 67]]], ["31 These results support Yewdell's defective ribosomal products (DRiPs) hypothesis 35 where DRiPs, a subset of rapidly degraded polypeptides (RDPs), supply peptides for MHC-I molecules, thereby linking viral immune surveillance to translational control mechanisms and ensuring the immune Viral proteins exploiting different mechanisms that impact on immune evasion target the MHC-I antigen presentation pathway.RNA G-quadruplexes in the EBV-Nuclear Antigen 1 open Reading Frame Impact on Antigen Presentationsystem rapidly detects and eliminates virally infected cells.", [["ribosomal", "ANATOMY", 45, 54], ["cells", "ANATOMY", 563, 568], ["Yewdell", "SIMPLE_CHEMICAL", 25, 32], ["DRiPs", "GENE_OR_GENE_PRODUCT", 92, 97], ["RDPs", "GENE_OR_GENE_PRODUCT", 142, 146], ["MHC-I", "GENE_OR_GENE_PRODUCT", 169, 174], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 376, 389], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 415, 429], ["EBV", "ORGANISM", 437, 440], ["cells", "CELL", 563, 568], ["Yewdell's defective ribosomal products", "PROTEIN", 25, 63], ["DRiPs", "PROTEIN", 65, 70], ["DRiPs", "PROTEIN", 92, 97], ["RDPs", "PROTEIN", 142, 146], ["MHC-I molecules", "PROTEIN", 169, 184], ["Viral proteins", "PROTEIN", 288, 302], ["MHC", "PROTEIN", 376, 379], ["virally infected cells", "CELL_TYPE", 546, 568], ["Yewdell's defective ribosomal products (DRiPs", "TREATMENT", 25, 70], ["DRiPs", "TREATMENT", 92, 97], ["rapidly degraded polypeptides", "PROBLEM", 111, 140], ["viral immune surveillance", "TREATMENT", 202, 227], ["translational control mechanisms", "TREATMENT", 231, 263], ["the immune Viral proteins", "PROBLEM", 277, 302], ["immune evasion", "TREATMENT", 350, 364], ["RNA G", "TEST", 411, 416], ["the EBV", "TEST", 433, 440], ["Nuclear Antigen", "TEST", 441, 456], ["virally infected cells", "PROBLEM", 546, 568], ["EBV", "ANATOMY", 437, 440], ["virally", "OBSERVATION_MODIFIER", 546, 553], ["infected cells", "OBSERVATION", 554, 568]]], ["While the pendulum now seems to be swinging back in favor of mature functional proteins rather than DRiPs as the predominant source of MHC class I presented peptides, 36,37 recent investigations from the Khanna and Shastri group's demonstrated that EBNA1 peptide presentation is dependent on the proportion of generated DRiPs.", [["DRiPs", "GENE_OR_GENE_PRODUCT", 100, 105], ["MHC class I", "GENE_OR_GENE_PRODUCT", 135, 146], ["EBNA1", "GENE_OR_GENE_PRODUCT", 249, 254], ["DRiPs", "GENE_OR_GENE_PRODUCT", 320, 325], ["mature functional proteins", "PROTEIN", 61, 87], ["DRiPs", "PROTEIN", 100, 105], ["MHC class I", "PROTEIN", 135, 146], ["EBNA1", "PROTEIN", 249, 254], ["DRiPs", "PROTEIN", 320, 325], ["mature functional proteins", "PROBLEM", 61, 87], ["DRiPs", "TREATMENT", 100, 105], ["recent investigations", "TEST", 173, 194], ["the Khanna", "TEST", 200, 210], ["Shastri group's", "TEST", 215, 230], ["EBNA1 peptide presentation", "PROBLEM", 249, 275], ["generated DRiPs", "TREATMENT", 310, 325], ["EBNA1 peptide", "OBSERVATION", 249, 262]]], ["8, 38 Interestingly, it was demonstrated that the inhibition of EBNA1 self-synthesis and resultant decrease in antigen presentation is attributed to purine loading of the EBNA1 mRNA.", [["purine", "CHEMICAL", 149, 155], ["purine", "CHEMICAL", 149, 155], ["EBNA1", "GENE_OR_GENE_PRODUCT", 64, 69], ["antigen", "GENE_OR_GENE_PRODUCT", 111, 118], ["purine", "SIMPLE_CHEMICAL", 149, 155], ["EBNA1", "GENE_OR_GENE_PRODUCT", 171, 176], ["EBNA1", "PROTEIN", 64, 69], ["EBNA1 mRNA", "RNA", 171, 181], ["EBNA1 self-synthesis", "PROBLEM", 64, 84], ["resultant decrease in antigen presentation", "PROBLEM", 89, 131], ["purine loading of the EBNA1 mRNA", "PROBLEM", 149, 181], ["resultant", "OBSERVATION_MODIFIER", 89, 98], ["decrease", "OBSERVATION_MODIFIER", 99, 107], ["purine loading", "OBSERVATION", 149, 163], ["EBNA1 mRNA", "OBSERVATION", 171, 181]]], ["9 Studies by Cristillo et al. 39 who analyzed viral genome base compositions, suggested that many viruses purine-load their RNAs to resemble host RNAs thereby avoiding triggering of the host cell's double-stranded RNA (dsRNA) surveillance mechanism.", [["cell", "ANATOMY", 191, 195], ["purine", "CHEMICAL", 106, 112], ["purine", "CHEMICAL", 106, 112], ["purine", "SIMPLE_CHEMICAL", 106, 112], ["cell", "CELL", 191, 195], ["RNAs", "RNA", 124, 128], ["host RNAs", "RNA", 141, 150], ["viral genome base compositions", "TREATMENT", 46, 76], ["many viruses purine-load their RNAs", "PROBLEM", 93, 128], ["the host cell", "TREATMENT", 182, 195], ["double-stranded RNA (dsRNA", "TREATMENT", 198, 224], ["host cell", "OBSERVATION", 186, 195], ["stranded RNA", "OBSERVATION_MODIFIER", 205, 217]]], ["They observed a similar 'stealth' strategy is exploited by EBNA1, which is uniquely expressed in the most basic form of EBV latency (latency I).", [["EBNA1", "GENE_OR_GENE_PRODUCT", 59, 64], ["EBV", "ORGANISM", 120, 123], ["EBNA1", "PROTEIN", 59, 64], ["EBV latency", "PROBLEM", 120, 131], ["EBV latency", "OBSERVATION", 120, 131]]], ["40 It was proposed that the rightward transcribed (BKRF1) gene encoding EBNA1 has been under evolutionary pressure to accept mutations that increase the purine content of the top (mRNA-synonymous) strand 41 so that during latent infection EBNA1 evades recognition by CTLs by virtue of its purine-biased GAr mRNA preventing interactions with host RNAs.", [["purine", "CHEMICAL", 153, 159], ["infection", "DISEASE", 229, 238], ["purine", "CHEMICAL", 289, 295], ["purine", "CHEMICAL", 153, 159], ["purine", "CHEMICAL", 289, 295], ["BKRF1", "GENE_OR_GENE_PRODUCT", 51, 56], ["EBNA1", "GENE_OR_GENE_PRODUCT", 72, 77], ["purine", "SIMPLE_CHEMICAL", 153, 159], ["EBNA1", "GENE_OR_GENE_PRODUCT", 239, 244], ["CTLs", "GENE_OR_GENE_PRODUCT", 267, 271], ["purine", "SIMPLE_CHEMICAL", 289, 295], ["GAr", "GENE_OR_GENE_PRODUCT", 303, 306], ["rightward transcribed (BKRF1) gene", "DNA", 28, 62], ["EBNA1", "PROTEIN", 72, 77], ["top (mRNA-synonymous) strand 41", "DNA", 175, 206], ["EBNA1", "PROTEIN", 239, 244], ["CTLs", "CELL_TYPE", 267, 271], ["GAr mRNA", "RNA", 303, 311], ["host RNAs", "RNA", 341, 350], ["the rightward transcribed (BKRF1) gene encoding EBNA1", "PROBLEM", 24, 77], ["mutations", "PROBLEM", 125, 134], ["latent infection EBNA1", "PROBLEM", 222, 244], ["purine content", "OBSERVATION", 153, 167], ["infection", "OBSERVATION", 229, 238]]], ["Reduction of this purine-bias within the GAr mRNA through codon-modification dramatically reversed the inhibitory effect on EBNA1 self-synthesis and antigen presentation.", [["purine", "CHEMICAL", 18, 24], ["purine", "CHEMICAL", 18, 24], ["purine", "SIMPLE_CHEMICAL", 18, 24], ["GAr", "GENE_OR_GENE_PRODUCT", 41, 44], ["EBNA1", "GENE_OR_GENE_PRODUCT", 124, 129], ["GAr mRNA", "RNA", 41, 49], ["EBNA1", "PROTEIN", 124, 129], ["this purine-bias", "PROBLEM", 13, 29], ["codon-modification", "TREATMENT", 58, 76], ["the inhibitory effect", "PROBLEM", 99, 120], ["GAr mRNA", "OBSERVATION", 41, 49]]], ["9 In addition, altering the peptide sequence of the native EBNA1 GAr using alternative reading frames did not alleviate the inhibition of both EBNA1 synthesis and epitope presentation, 10 suggesting that regulatory structural elements within the EBNA1 GAr mRNA itself may regulate mRNA translation and antigen presentation.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 59, 64], ["EBNA1", "GENE_OR_GENE_PRODUCT", 143, 148], ["EBNA1", "GENE_OR_GENE_PRODUCT", 246, 251], ["GAr", "GENE_OR_GENE_PRODUCT", 252, 255], ["native EBNA1 GAr", "PROTEIN", 52, 68], ["alternative reading frames", "DNA", 75, 101], ["EBNA1", "PROTEIN", 143, 148], ["regulatory structural elements", "DNA", 204, 234], ["EBNA1 GAr mRNA", "RNA", 246, 260], ["altering the peptide sequence", "PROBLEM", 15, 44], ["both EBNA1 synthesis", "PROBLEM", 138, 158], ["epitope presentation", "TEST", 163, 183], ["regulatory structural elements", "PROBLEM", 204, 234], ["EBNA1 synthesis", "OBSERVATION", 143, 158], ["structural elements", "OBSERVATION", 215, 234]]], ["A subsequent analysis of the EBNA1 GAr encoding mRNA revealed that clustering of unusual RNA secondary structures, G-quadruplexes, within the EBNA1 GAr encoding mRNA are involved in the cis-acting translational regulation of the EBNA1 mRNA.", [["EBNA1 GAr", "GENE_OR_GENE_PRODUCT", 29, 38], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 115, 129], ["EBNA1", "GENE_OR_GENE_PRODUCT", 142, 147], ["GAr", "GENE_OR_GENE_PRODUCT", 148, 151], ["EBNA1", "GENE_OR_GENE_PRODUCT", 229, 234], ["EBNA1 GAr encoding mRNA", "RNA", 29, 52], ["EBNA1 GAr encoding mRNA", "RNA", 142, 165], ["EBNA1 mRNA", "RNA", 229, 239], ["A subsequent analysis", "TEST", 0, 21], ["the EBNA1 GAr encoding mRNA", "TEST", 25, 52], ["unusual RNA secondary structures", "PROBLEM", 81, 113], ["G-quadruplexes", "TREATMENT", 115, 129], ["unusual RNA", "OBSERVATION", 81, 92], ["secondary structures", "OBSERVATION", 93, 113], ["EBNA1 GAr", "OBSERVATION", 142, 151], ["cis-acting translational regulation", "OBSERVATION", 186, 221], ["EBNA1 mRNA", "OBSERVATION", 229, 239]]], ["7 G-quadruplexes are noncanonical structures of nucleic acids formed within G-rich DNA or RNA sequences.", [["nucleic acids", "CHEMICAL", 48, 61], ["G-quadruplexes", "SIMPLE_CHEMICAL", 2, 16], ["nucleic acids", "SIMPLE_CHEMICAL", 48, 61], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["G-rich DNA or RNA sequences", "DNA", 76, 103], ["nucleic acids", "TEST", 48, 61], ["RNA sequences", "TEST", 90, 103]]], ["These structures are stabilized by the stacking of guanine-tetrads that are formed by the coplanar arrangement of four G-bases interacting by Hoogsteen hydrogen-bonding 42 (Figure 2(a) ).", [["guanine", "CHEMICAL", 51, 58], ["Hoogsteen hydrogen", "CHEMICAL", 142, 160], ["guanine", "CHEMICAL", 51, 58], ["hydrogen", "CHEMICAL", 152, 160], ["guanine", "SIMPLE_CHEMICAL", 51, 58], ["guanine-tetrads", "TREATMENT", 51, 66], ["stabilized", "OBSERVATION", 21, 31], ["coplanar", "OBSERVATION_MODIFIER", 90, 98]]], ["G-quadruplex motifs, which can act as transcriptional and translational repressors have previously been identified in telomeres, promoters, and gene bodies where they perform important regulatory roles in diverse biological processes including replication and gene expression.", [["telomeres", "ANATOMY", 118, 127], ["telomeres", "CELLULAR_COMPONENT", 118, 127], ["G-quadruplex motifs", "DNA", 0, 19], ["telomeres", "DNA", 118, 127], ["promoters", "DNA", 129, 138], ["translational repressors", "TREATMENT", 58, 82]]], ["[43] [44] [45] Using a combination of biophysical and immunological techniques in order to assess the role played by the EBNA1 GAr in reducing EBNA1 synthesis and limiting EBNA1-restricted antigenic peptides, it was recently demonstrated that: (1) potassium-dependent G-quadruplexes are the major structural components of the native purine-rich EBNA1 GAr mRNA; (2) the presence of G-quadruplex motifs within the open reading frame (ORF) of EBNA1 act as 'steric blocks' to impede ribosome transit by inducing ribosome stalling and/or dissociation, and (3) destabilization of G-quadruplex structures following codon-modification of the EBNA1 mRNA encoding the GAr, to introduce stem-loop structures, results in enhanced translation and recognition by antigen-specific T cells.", [["ribosome", "ANATOMY", 479, 487], ["ribosome", "ANATOMY", 508, 516], ["stem-loop structures", "ANATOMY", 676, 696], ["T cells", "ANATOMY", 766, 773], ["potassium", "CHEMICAL", 248, 257], ["purine", "CHEMICAL", 333, 339], ["potassium", "CHEMICAL", 248, 257], ["purine", "CHEMICAL", 333, 339], ["EBNA1", "GENE_OR_GENE_PRODUCT", 121, 126], ["GAr", "GENE_OR_GENE_PRODUCT", 127, 130], ["EBNA1", "GENE_OR_GENE_PRODUCT", 143, 148], ["EBNA1", "GENE_OR_GENE_PRODUCT", 172, 177], ["potassium", "SIMPLE_CHEMICAL", 248, 257], ["G-quadruplexes", "SIMPLE_CHEMICAL", 268, 282], ["purine", "SIMPLE_CHEMICAL", 333, 339], ["EBNA1", "GENE_OR_GENE_PRODUCT", 345, 350], ["EBNA1", "GENE_OR_GENE_PRODUCT", 440, 445], ["ribosome", "CELLULAR_COMPONENT", 508, 516], ["EBNA1", "GENE_OR_GENE_PRODUCT", 634, 639], ["GAr", "GENE_OR_GENE_PRODUCT", 658, 661], ["antigen", "GENE_OR_GENE_PRODUCT", 749, 756], ["T cells", "CELL", 766, 773], ["EBNA1 GAr", "PROTEIN", 121, 130], ["EBNA1", "PROTEIN", 143, 148], ["EBNA1", "PROTEIN", 172, 177], ["native purine-rich EBNA1 GAr mRNA", "RNA", 326, 359], ["G-quadruplex motifs", "DNA", 381, 400], ["open reading frame", "DNA", 412, 430], ["ORF", "DNA", 432, 435], ["EBNA1", "PROTEIN", 440, 445], ["EBNA1 mRNA", "RNA", 634, 644], ["GAr", "PROTEIN", 658, 661], ["antigen-specific T cells", "CELL_TYPE", 749, 773], ["biophysical and immunological techniques", "TREATMENT", 38, 78], ["reducing EBNA1 synthesis", "PROBLEM", 134, 158], ["potassium", "TEST", 248, 257], ["G-quadruplex motifs", "TREATMENT", 381, 400], ["'steric blocks'", "TREATMENT", 453, 468], ["ribosome transit", "PROBLEM", 479, 495], ["ribosome stalling", "PROBLEM", 508, 525], ["dissociation", "PROBLEM", 533, 545], ["G-quadruplex structures", "TREATMENT", 574, 597], ["codon-modification", "TREATMENT", 608, 626], ["the EBNA1 mRNA", "PROBLEM", 630, 644], ["ribosome transit", "OBSERVATION", 479, 495], ["ribosome stalling", "OBSERVATION", 508, 525]]], ["7 Overall the study demonstrated that EBV-infected cells harboring G-quadruplexes within the EBNA1 GAr mRNA are less efficiently recognized by virus-specific T cells compared to EBV-infected cells synthesizing a codon-modified EBNA1 GAr mRNA which forms dsRNA structures due to altered base pairing following purine reduction.", [["cells", "ANATOMY", 51, 56], ["T cells", "ANATOMY", 158, 165], ["cells", "ANATOMY", 191, 196], ["purine", "CHEMICAL", 309, 315], ["purine", "CHEMICAL", 309, 315], ["EBV", "ORGANISM", 38, 41], ["cells", "CELL", 51, 56], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 67, 81], ["EBNA1", "GENE_OR_GENE_PRODUCT", 93, 98], ["GAr", "GENE_OR_GENE_PRODUCT", 99, 102], ["T cells", "CELL", 158, 165], ["EBV", "ORGANISM", 178, 181], ["cells", "CELL", 191, 196], ["EBNA1", "ORGANISM", 227, 232], ["GAr", "GENE_OR_GENE_PRODUCT", 233, 236], ["purine", "SIMPLE_CHEMICAL", 309, 315], ["EBNA1 GAr mRNA", "RNA", 93, 107], ["T cells", "CELL_TYPE", 158, 165], ["EBV-infected cells", "CELL_TYPE", 178, 196], ["EBNA1 GAr mRNA", "RNA", 227, 241], ["Overall the study", "TEST", 2, 19], ["EBV", "TEST", 38, 41], ["infected cells", "PROBLEM", 42, 56], ["the EBNA1 GAr mRNA", "TEST", 89, 107], ["virus", "TEST", 143, 148], ["specific T cells", "PROBLEM", 149, 165], ["EBV", "TEST", 178, 181], ["infected cells", "PROBLEM", 182, 196], ["a codon", "PROBLEM", 210, 217], ["modified EBNA1 GAr mRNA", "PROBLEM", 218, 241], ["dsRNA structures", "PROBLEM", 254, 270], ["altered base pairing", "PROBLEM", 278, 298], ["purine reduction", "TREATMENT", 309, 325], ["infected cells", "OBSERVATION", 42, 56], ["EBNA1 GAr mRNA", "OBSERVATION", 93, 107], ["EBNA1 GAr mRNA", "OBSERVATION", 227, 241], ["base", "ANATOMY_MODIFIER", 286, 290], ["purine reduction", "OBSERVATION", 309, 325]]], ["These results highlight the importance of G-quadruplexes Eight gammaherpes viral maintenance proteins, involved in immune evasion, are encoded by mRNAs possessing guanine-rich repeats that possess the ability to form G-quadruplex motifs.", [["guanine", "CHEMICAL", 163, 170], ["guanine", "CHEMICAL", 163, 170], ["gammaherpes viral", "ORGANISM", 63, 80], ["gammaherpes viral maintenance proteins", "PROTEIN", 63, 101], ["mRNAs", "RNA", 146, 151], ["guanine-rich repeats", "PROTEIN", 163, 183], ["G-quadruplex motifs", "DNA", 217, 236], ["G-quadruplexes Eight gammaherpes viral maintenance proteins", "TREATMENT", 42, 101], ["immune evasion", "TREATMENT", 115, 129], ["G-quadruplex motifs", "TREATMENT", 217, 236]]], ["The bolded guanines highlight the Gs most likely to be involved in the formation of guanine tetrads.RNA G-quadruplexes in the EBV-Nuclear Antigen 1 open Reading Frame Impact on Antigen Presentationwithin virally encoded transcripts as unique regulatory signals for translational control and immune evasion.", [["guanine", "CHEMICAL", 84, 91], ["guanines", "CHEMICAL", 11, 19], ["guanine", "CHEMICAL", 84, 91], ["guanines", "SIMPLE_CHEMICAL", 11, 19], ["Gs", "GENE_OR_GENE_PRODUCT", 34, 36], ["guanine tetrads", "SIMPLE_CHEMICAL", 84, 99], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 104, 118], ["EBV", "ORGANISM", 126, 129], ["Gs", "PROTEIN", 34, 36], ["Antigen Presentationwithin virally encoded transcripts", "PROTEIN", 177, 231], ["The bolded guanines", "TREATMENT", 0, 19], ["the Gs", "PROBLEM", 30, 36], ["guanine tetrads", "TREATMENT", 84, 99], ["RNA G", "TEST", 100, 105], ["the EBV", "TEST", 122, 129], ["Nuclear Antigen", "TEST", 130, 145], ["translational control", "TREATMENT", 265, 286], ["immune evasion", "TREATMENT", 291, 305], ["most likely", "UNCERTAINTY", 37, 48], ["guanine tetrads", "OBSERVATION", 84, 99], ["EBV", "ANATOMY", 126, 129]]], ["7Identification of G-quadruplex Motifs in Other Viral Maintenance Gene mRNAsIntriguingly, in several other members of the gammaherpesviral family, similar purine-biases are observed in the repetitive sequence-encoding regions within genes, some of which have been demonstrated to be latency-associated and known to regulate their self-synthesis (Table 2 ).", [["purine", "CHEMICAL", 155, 161], ["purine", "CHEMICAL", 155, 161], ["purine", "SIMPLE_CHEMICAL", 155, 161], ["repetitive sequence", "DNA", 189, 208], ["G-quadruplex Motifs", "TREATMENT", 19, 38]]], ["These include the ORF encoding latency-associated nuclear antigen (LANA1), the GMP of human herpesvirus 8 (HHV8) 46 and the ORF 73 of Ateline herpesvirus 3.", [["GMP", "CHEMICAL", 79, 82], ["ORF encoding latency-associated nuclear antigen", "GENE_OR_GENE_PRODUCT", 18, 65], ["LANA1", "GENE_OR_GENE_PRODUCT", 67, 72], ["human herpesvirus 8", "ORGANISM", 86, 105], ["HHV8) 46", "ORGANISM", 107, 115], ["Ateline herpesvirus 3", "GENE_OR_GENE_PRODUCT", 134, 155], ["ORF", "DNA", 18, 21], ["latency-associated nuclear antigen", "PROTEIN", 31, 65], ["LANA1", "PROTEIN", 67, 72], ["ORF 73", "DNA", 124, 130], ["human", "SPECIES", 86, 91], ["human herpesvirus", "SPECIES", 86, 103], ["Ateline herpesvirus", "SPECIES", 134, 153], ["the ORF encoding latency", "PROBLEM", 14, 38], ["the GMP of human herpesvirus", "TEST", 75, 103], ["the ORF", "TEST", 120, 127], ["Ateline herpesvirus", "PROBLEM", 134, 153]]], ["10 Similar to EBNA1, clusters of putative G-quadruplex motifs (PQSs) identified within the conserved purine-rich sequences of these other gammaherpesviral maintenance gene mRNAs were analyzed by CD and 1 H NMR spectroscopy and demonstrated to exhibit spectral signatures consistent with parallel G-quadruplex formation.", [["purine", "CHEMICAL", 101, 107], ["purine", "CHEMICAL", 101, 107], ["1 H", "CHEMICAL", 202, 205], ["EBNA1", "GENE_OR_GENE_PRODUCT", 14, 19], ["G-quadruplex", "GENE_OR_GENE_PRODUCT", 42, 54], ["G-quadruplex", "SIMPLE_CHEMICAL", 296, 308], ["EBNA1", "PROTEIN", 14, 19], ["G-quadruplex motifs", "DNA", 42, 61], ["PQSs", "DNA", 63, 67], ["conserved purine-rich sequences", "DNA", 91, 122], ["gammaherpesviral maintenance gene mRNAs", "RNA", 138, 177], ["putative G-quadruplex motifs", "TREATMENT", 33, 61], ["1 H NMR spectroscopy", "TEST", 202, 222], ["spectral signatures", "PROBLEM", 251, 270], ["parallel G-quadruplex formation", "PROBLEM", 287, 318], ["EBNA1", "ANATOMY", 14, 19], ["consistent with", "UNCERTAINTY", 271, 286], ["quadruplex formation", "OBSERVATION", 298, 318]]], ["7 Several of the examined GMPs have been implicated in immune evasion, suggesting gammaherpesviruses exploit RNA G-quadruplexes as structural regulatory elements impacting on antigen presentation.", [["GMPs", "GENE_OR_GENE_PRODUCT", 26, 30], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 113, 127], ["GMPs", "PROTEIN", 26, 30], ["gammaherpesviruses", "PROTEIN", 82, 100], ["structural regulatory elements", "DNA", 131, 161], ["immune evasion", "TREATMENT", 55, 69], ["gammaherpesviruses", "PROBLEM", 82, 100], ["immune evasion", "OBSERVATION", 55, 69], ["suggesting", "UNCERTAINTY", 71, 81], ["gammaherpesviruses", "OBSERVATION", 82, 100], ["regulatory elements", "OBSERVATION", 142, 161]]], ["Furthermore, the effect of RNA G-quadruplexes on viral mRNA translation and antigen presentation may have broader implications following the identification of G-quadruplex motifs in the highly pyrimidine-loaded retrovirus, Human T-cell Leukemia (Lymphotropic) Virus-1 (HTLV-1) (unpublished data).", [["pyrimidine", "CHEMICAL", 193, 203], ["pyrimidine", "CHEMICAL", 193, 203], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 31, 45], ["pyrimidine", "SIMPLE_CHEMICAL", 193, 203], ["retrovirus", "ORGANISM", 211, 221], ["Human T-cell Leukemia (Lymphotropic) Virus-1", "ORGANISM", 223, 267], ["HTLV-1", "ORGANISM", 269, 275], ["viral mRNA", "RNA", 49, 59], ["G-quadruplex motifs", "DNA", 159, 178], ["Human", "SPECIES", 223, 228], ["Virus-1", "SPECIES", 260, 267], ["HTLV-1", "SPECIES", 269, 275], ["RNA G", "TREATMENT", 27, 32], ["viral mRNA translation", "PROBLEM", 49, 71], ["G-quadruplex motifs", "TREATMENT", 159, 178], ["the highly pyrimidine-loaded retrovirus", "PROBLEM", 182, 221], ["Human T-cell Leukemia (Lymphotropic) Virus", "PROBLEM", 223, 265], ["loaded retrovirus", "OBSERVATION", 204, 221], ["cell Leukemia", "OBSERVATION", 231, 244]]], ["Like EBV, HTLV-1 is a latent, GC-rich virus, which is able to persist in its human host asymptomatically.", [["EBV", "ORGANISM", 5, 8], ["HTLV-1", "ORGANISM", 10, 16], ["GC-rich virus", "ORGANISM", 30, 43], ["human", "ORGANISM", 77, 82], ["HTLV-1", "SPECIES", 10, 16], ["human", "SPECIES", 77, 82], ["HTLV-1", "SPECIES", 10, 16], ["human", "SPECIES", 77, 82], ["EBV", "PROBLEM", 5, 8], ["HTLV", "TEST", 10, 14], ["a latent, GC-rich virus", "PROBLEM", 20, 43], ["EBV", "OBSERVATION", 5, 8], ["HTLV", "OBSERVATION", 10, 14], ["rich virus", "OBSERVATION", 33, 43]]], ["Larocca and colleagues reported an antisense transcript that like EBNA1 is heavily R-loaded (purine-loaded).", [["purine", "CHEMICAL", 93, 99], ["purine", "CHEMICAL", 93, 99], ["EBNA1", "GENE_OR_GENE_PRODUCT", 66, 71], ["purine", "SIMPLE_CHEMICAL", 93, 99], ["antisense transcript", "RNA", 35, 55], ["EBNA1", "PROTEIN", 66, 71], ["an antisense transcript", "TREATMENT", 32, 55]]], ["39, 47 The HTLV-1 antisense transcript translates into a basic leucine zipper protein (HBZ) that is poorly immunogenic.", [["leucine", "CHEMICAL", 63, 70], ["HTLV-1", "ORGANISM", 11, 17], ["HBZ", "GENE_OR_GENE_PRODUCT", 87, 90], ["HTLV-1 antisense transcript", "RNA", 11, 38], ["basic leucine zipper protein", "PROTEIN", 57, 85], ["HBZ", "PROTEIN", 87, 90], ["HTLV-1", "SPECIES", 11, 17], ["The HTLV-1 antisense transcript", "TREATMENT", 7, 38], ["a basic leucine zipper protein", "TEST", 55, 85], ["poorly immunogenic", "OBSERVATION_MODIFIER", 100, 118]]], ["48 HBZ, a likely GMP for HTLV-1 is increasingly seen as playing a major role in evasion of host immunosurveillance.", [["GMP", "CHEMICAL", 17, 20], ["HBZ", "GENE_OR_GENE_PRODUCT", 3, 6], ["HTLV-1", "ORGANISM", 25, 31], ["HBZ", "PROTEIN", 3, 6], ["HTLV-1", "SPECIES", 25, 31], ["HTLV", "PROBLEM", 25, 29], ["host immunosurveillance", "TREATMENT", 91, 114]]], ["48RECOGNITION OF RNA STRUCTURES BY CELLULAR AND VIRAL PROTEINSRNA binding proteins contain various domains that recognize structures within mRNAs in order to transport and localize mRNA, and control key steps of translation such as initiation, splicing, and termination.", [["VIRAL PROTEINSRNA binding proteins", "PROTEIN", 48, 82], ["mRNAs", "RNA", 140, 145], ["mRNA", "RNA", 181, 185], ["VIRAL PROTEINSRNA binding proteins", "TREATMENT", 48, 82], ["various domains", "PROBLEM", 91, 106], ["mRNA", "TEST", 181, 185], ["RNA STRUCTURES", "OBSERVATION", 17, 31], ["VIRAL PROTEINSRNA", "OBSERVATION", 48, 65]]], ["Viruses have evolved to select specific RNA structures in order to recruit cellular and viral proteins needed to initiate or regulate the maintenance of their genomes.", [["cellular", "ANATOMY", 75, 83], ["cellular", "CELL", 75, 83], ["cellular and viral proteins", "PROTEIN", 75, 102], ["Viruses", "PROBLEM", 0, 7], ["viral proteins", "PROBLEM", 88, 102]]], ["It is noteworthy that EBNA1, whose synthesis is modulated through the formation of G-quadruplex motifs within the ORF of its mRNA (see previous section), binds to G-rich RNAs that are predicted to form G-quadruplex structures.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 22, 27], ["EBNA1", "PROTEIN", 22, 27], ["G-quadruplex motifs", "DNA", 83, 102], ["ORF", "DNA", 114, 117], ["mRNA", "RNA", 125, 129], ["G-rich RNAs", "RNA", 163, 174], ["EBNA1", "PROBLEM", 22, 27], ["G-quadruplex motifs", "TREATMENT", 83, 102], ["G-rich RNAs", "PROBLEM", 163, 174], ["EBNA1", "OBSERVATION", 22, 27]]], ["49 These observations suggest that EBNA1 may also control its synthesis through a feedback loop mechanism.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 35, 40], ["EBNA1", "PROTEIN", 35, 40], ["EBNA1", "PROBLEM", 35, 40], ["a feedback loop mechanism", "TREATMENT", 80, 105]]], ["Thus, EBV may regulate the pool of MHC-I epitopes during the latency step of chronic infection by exploiting the complexity associated with EBNA1 mRNA translation.RECOGNITION OF RNA STRUCTURES BY CELLULAR AND VIRAL PROTEINSIn RNA positive-stranded viruses, the genomic RNA serves as template for both translation and replication.", [["chronic infection", "DISEASE", 77, 94], ["EBV", "ORGANISM", 6, 9], ["MHC-I", "GENE_OR_GENE_PRODUCT", 35, 40], ["EBNA1", "GENE_OR_GENE_PRODUCT", 140, 145], ["MHC-I epitopes", "PROTEIN", 35, 49], ["EBNA1 mRNA", "RNA", 140, 150], ["genomic RNA", "RNA", 261, 272], ["EBV", "PROBLEM", 6, 9], ["chronic infection", "PROBLEM", 77, 94], ["EBNA1 mRNA translation", "PROBLEM", 140, 162], ["CELLULAR AND VIRAL PROTEINSIn RNA", "TEST", 196, 229], ["stranded viruses", "PROBLEM", 239, 255], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["infection", "OBSERVATION", 85, 94], ["EBNA1 mRNA", "OBSERVATION", 140, 150], ["RNA STRUCTURES", "OBSERVATION", 178, 192], ["VIRAL", "OBSERVATION_MODIFIER", 209, 214], ["stranded viruses", "OBSERVATION", 239, 255]]], ["The two pathways are exclusive and these viruses employ both viral and cellular factors to initiate one or the other.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["viral and cellular factors", "PROTEIN", 61, 87]]], ["Most viral cis-acting RNA elements are located in the 5 \u2032 -and 3 \u2032 -untranslated regions of their genomes.", [["viral cis-acting RNA elements", "DNA", 5, 34], ["5 \u2032 -and 3 \u2032 -untranslated regions", "DNA", 54, 88], ["Most viral cis-acting RNA elements", "PROBLEM", 0, 34], ["viral", "OBSERVATION", 5, 10], ["cis-acting RNA elements", "OBSERVATION", 11, 34], ["their genomes", "OBSERVATION", 92, 105]]], ["The 5 \u2032 -noncoding regions of Entoroviral genomes are highly structured and contain two functional domains, which are involved in translation and RNA replication.", [["5 \u2032 -noncoding regions", "DNA", 4, 26], ["Entoroviral genomes", "DNA", 30, 49], ["Entoroviral genomes", "PROBLEM", 30, 49], ["RNA replication", "TREATMENT", 146, 161], ["Entoroviral genomes", "OBSERVATION", 30, 49], ["two", "OBSERVATION_MODIFIER", 84, 87], ["functional domains", "OBSERVATION", 88, 106], ["RNA replication", "OBSERVATION", 146, 161]]], ["50 The first domain comprises a cloverleaf (CL) structure (Figure 2(b) ) that carries signals to control both translation and RNA replication.", [["CL", "MULTI-TISSUE_STRUCTURE", 44, 46], ["Figure 2(b)", "GENE_OR_GENE_PRODUCT", 59, 70], ["cloverleaf (CL) structure", "PROTEIN", 32, 57], ["a cloverleaf (CL) structure", "PROBLEM", 30, 57], ["RNA replication", "TREATMENT", 126, 141], ["cloverleaf", "OBSERVATION_MODIFIER", 32, 42]]], ["The poliovirus (PV) CL (88 nt) contains four stem-loops (Stem-loop A to D) that are involved in the formation of a ribonucleoprotein (RNP) complex.", [["poliovirus", "ORGANISM", 4, 14], ["Stem-loop A", "GENE_OR_GENE_PRODUCT", 57, 68], ["D", "GENE_OR_GENE_PRODUCT", 72, 73], ["RNP", "CELLULAR_COMPONENT", 134, 137], ["stem-loops", "PROTEIN", 45, 55], ["Stem-loop A to D", "PROTEIN", 57, 73], ["ribonucleoprotein (RNP) complex", "PROTEIN", 115, 146], ["PV", "SPECIES", 16, 18], ["The poliovirus (PV) CL", "TEST", 0, 22], ["a ribonucleoprotein (RNP) complex", "PROBLEM", 113, 146], ["poliovirus", "OBSERVATION", 4, 14], ["four stem", "OBSERVATION", 40, 49], ["loops", "ANATOMY_MODIFIER", 50, 55], ["ribonucleoprotein", "OBSERVATION", 115, 132]]], ["A second domain comprises an internal ribosomal entry site (IRES) that promotes translation.", [["ribosomal", "ANATOMY", 38, 47], ["ribosomal", "CELLULAR_COMPONENT", 38, 47], ["internal ribosomal entry site", "DNA", 29, 58], ["IRES", "DNA", 60, 64], ["A second domain", "PROBLEM", 0, 15], ["an internal ribosomal entry site", "TREATMENT", 26, 58], ["internal", "OBSERVATION_MODIFIER", 29, 37], ["ribosomal", "OBSERVATION_MODIFIER", 38, 47], ["entry site", "OBSERVATION", 48, 58]]], ["It has been shown that the formation of a RNP complex within the 5 \u2032 -UTR region of the PV genome, consisting of the CL structure, the cellular protein poly(rC)-binding protein (PCBP) and the uncleaved viral proteinase 3CD is required to initiate viral RNA replication and translation.", [["cellular", "ANATOMY", 135, 143], ["RNP", "CELLULAR_COMPONENT", 42, 45], ["PV genome", "CELLULAR_COMPONENT", 88, 97], ["cellular", "CELL", 135, 143], ["poly(rC)-binding protein", "GENE_OR_GENE_PRODUCT", 152, 176], ["PCBP", "GENE_OR_GENE_PRODUCT", 178, 182], ["3CD", "GENE_OR_GENE_PRODUCT", 219, 222], ["RNP complex", "PROTEIN", 42, 53], ["5 \u2032 -UTR region", "DNA", 65, 80], ["PV genome", "DNA", 88, 97], ["cellular protein poly(rC)-binding protein", "PROTEIN", 135, 176], ["PCBP", "PROTEIN", 178, 182], ["uncleaved viral proteinase 3CD", "PROTEIN", 192, 222], ["a RNP complex", "PROBLEM", 40, 53], ["the CL structure", "PROBLEM", 113, 129], ["the cellular protein poly", "TEST", 131, 156], ["binding protein", "TEST", 161, 176], ["PCBP", "TEST", 178, 182], ["the uncleaved viral proteinase", "PROBLEM", 188, 218], ["viral RNA replication", "TREATMENT", 247, 268], ["RNP", "OBSERVATION_MODIFIER", 42, 45], ["complex", "OBSERVATION_MODIFIER", 46, 53], ["PV genome", "OBSERVATION", 88, 97], ["CL structure", "OBSERVATION", 117, 129], ["cellular", "OBSERVATION_MODIFIER", 135, 143], ["protein poly", "OBSERVATION", 144, 156], ["viral proteinase", "OBSERVATION", 202, 218]]], ["51 The cellular factor PCBP was shown to bind to the CL stem-loop B domain while the viral protein 3CD interacts with the stem-loop-D domain.", [["cellular", "ANATOMY", 7, 15], ["cellular", "CELL", 7, 15], ["PCBP", "GENE_OR_GENE_PRODUCT", 23, 27], ["3CD", "GENE_OR_GENE_PRODUCT", 99, 102], ["cellular factor", "PROTEIN", 7, 22], ["PCBP", "PROTEIN", 23, 27], ["CL stem-loop B domain", "PROTEIN", 53, 74], ["viral protein 3CD", "PROTEIN", 85, 102], ["stem-loop-D domain", "PROTEIN", 122, 140], ["The cellular factor PCBP", "TEST", 3, 27], ["the viral protein", "TEST", 81, 98], ["CL stem", "ANATOMY", 53, 60], ["stem", "ANATOMY", 122, 126]]], ["Mutational analysis has shown that the interaction of the CL structure with the cellular factor PCBP upregulates viral translation, while the binding of the viral protein 3CD represses translation and promotes negative-strand RNA synthesis.", [["cellular", "ANATOMY", 80, 88], ["CL", "GENE_OR_GENE_PRODUCT", 58, 60], ["cellular", "CELL", 80, 88], ["PCBP", "GENE_OR_GENE_PRODUCT", 96, 100], ["3CD", "GENE_OR_GENE_PRODUCT", 171, 174], ["CL structure", "PROTEIN", 58, 70], ["cellular factor", "PROTEIN", 80, 95], ["PCBP", "PROTEIN", 96, 100], ["3CD", "PROTEIN", 171, 174], ["Mutational analysis", "TEST", 0, 19], ["the viral protein", "TEST", 153, 170], ["strand RNA synthesis", "PROBLEM", 219, 239], ["strand RNA synthesis", "OBSERVATION", 219, 239]]], ["52 Consequently, it has been proposed that the interaction of 3CD with the CL structure controls whether the genomic RNA is translated or replicated.RECOGNITION OF RNA STRUCTURES BY CELLULAR AND VIRAL PROTEINSThe RNP complex controlling the state of the virus is stabilized by other viral factors such as proteins 3AB for PV or 3C pro for rhinoviruses.", [["3CD", "GENE_OR_GENE_PRODUCT", 62, 65], ["3AB", "GENE_OR_GENE_PRODUCT", 314, 317], ["3CD", "PROTEIN", 62, 65], ["genomic RNA", "RNA", 109, 120], ["RNP complex", "PROTEIN", 213, 224], ["viral factors", "PROTEIN", 283, 296], ["3AB", "PROTEIN", 314, 317], ["PV", "PROTEIN", 322, 324], ["PV", "SPECIES", 322, 324], ["the CL structure controls", "TREATMENT", 71, 96], ["the genomic RNA", "PROBLEM", 105, 120], ["The RNP complex", "PROBLEM", 209, 224], ["the virus", "PROBLEM", 250, 259], ["other viral factors", "PROBLEM", 277, 296], ["proteins 3AB", "TREATMENT", 305, 317], ["PV", "PROBLEM", 322, 324], ["rhinoviruses", "PROBLEM", 339, 351], ["genomic RNA", "OBSERVATION", 109, 120], ["RNA STRUCTURES", "OBSERVATION", 164, 178], ["VIRAL PROTEINS", "OBSERVATION", 195, 209], ["RNP complex", "OBSERVATION_MODIFIER", 213, 224], ["virus", "OBSERVATION", 254, 259]]], ["50 It is noteworthy that both isolated PV 3A protein and PV infection can inhibit functional MHC-I dependent antigen presentation.", [["infection", "DISEASE", 60, 69], ["PV 3A", "GENE_OR_GENE_PRODUCT", 39, 44], ["MHC-I", "GENE_OR_GENE_PRODUCT", 93, 98], ["PV 3A protein", "PROTEIN", 39, 52], ["MHC", "PROTEIN", 93, 96], ["PV", "SPECIES", 39, 41], ["PV", "SPECIES", 57, 59], ["PV infection", "PROBLEM", 57, 69], ["PV 3A", "OBSERVATION", 39, 44], ["PV", "ANATOMY", 57, 59], ["infection", "OBSERVATION", 60, 69]]], ["53 The study of the effect of PV 3A protein expression on the presentation of hepatitis C virus antigens in cultured chimpanzee cells revealed that protein 3A slows the rate of MHC-I transport to the cell surface and protects cells from CTL-mediated lysis.", [["cells", "ANATOMY", 128, 133], ["cell surface", "ANATOMY", 200, 212], ["cells", "ANATOMY", 226, 231], ["hepatitis C", "DISEASE", 78, 89], ["PV 3A", "GENE_OR_GENE_PRODUCT", 30, 35], ["hepatitis C virus", "ORGANISM", 78, 95], ["chimpanzee", "ORGANISM", 117, 127], ["cells", "CELL", 128, 133], ["protein 3A", "GENE_OR_GENE_PRODUCT", 148, 158], ["MHC-I", "GENE_OR_GENE_PRODUCT", 177, 182], ["cell surface", "CELLULAR_COMPONENT", 200, 212], ["cells", "CELL", 226, 231], ["CTL", "CELL", 237, 240], ["PV 3A protein", "PROTEIN", 30, 43], ["hepatitis C virus antigens", "PROTEIN", 78, 104], ["cultured chimpanzee cells", "CELL_LINE", 108, 133], ["protein 3A", "PROTEIN", 148, 158], ["MHC", "PROTEIN", 177, 180], ["hepatitis C virus", "SPECIES", 78, 95], ["hepatitis C virus", "SPECIES", 78, 95], ["The study", "TEST", 3, 12], ["PV", "TEST", 30, 32], ["hepatitis C virus antigens", "PROBLEM", 78, 104], ["cultured chimpanzee cells", "TEST", 108, 133], ["protein 3A", "TEST", 148, 158], ["the cell surface", "TREATMENT", 196, 212], ["CTL-mediated lysis", "TREATMENT", 237, 255], ["lysis", "OBSERVATION", 250, 255]]], ["It has been suggested that protein 3C pro induces fragmentation of the golgi compartment and blocks intra-golgi transport, thereby reducing the expression of MHC-I antigens and slowing the secretion of proinflammatory cytokines.", [["golgi compartment", "ANATOMY", 71, 88], ["intra-golgi", "ANATOMY", 100, 111], ["protein 3C pro", "GENE_OR_GENE_PRODUCT", 27, 41], ["intra-golgi", "SIMPLE_CHEMICAL", 100, 111], ["MHC-I antigens", "GENE_OR_GENE_PRODUCT", 158, 172], ["protein 3C pro", "PROTEIN", 27, 41], ["MHC-I antigens", "PROTEIN", 158, 172], ["proinflammatory cytokines", "PROTEIN", 202, 227], ["protein 3C pro", "TREATMENT", 27, 41], ["proinflammatory cytokines", "PROBLEM", 202, 227], ["golgi compartment", "OBSERVATION", 71, 88], ["proinflammatory cytokines", "OBSERVATION", 202, 227]]], ["54 Thus translational activation through RNP complex formation controls the synthesis of proteins involved in immune evasion in enteroviruses.", [["enteroviruses", "DISEASE", 128, 141], ["RNP", "CELLULAR_COMPONENT", 41, 44], ["enteroviruses", "ORGANISM", 128, 141], ["RNP complex", "PROTEIN", 41, 52], ["the synthesis of proteins", "PROBLEM", 72, 97], ["immune evasion", "TREATMENT", 110, 124], ["enteroviruses", "PROBLEM", 128, 141], ["immune evasion", "OBSERVATION", 110, 124], ["enteroviruses", "OBSERVATION", 128, 141]]], ["Further research is necessary to determine how these RNA structures and/or viral/cellular protein interactions may modulate the supply of antigenic peptides for MHC-I molecules and the replication of RNA positive-stranded viruses.IMPACT OF CRYPTIC TRANSLATIONAL CONTROL MECHANISMS ON MHC-I MEDIATED ANTIGEN PRESENTATIONMHC-I restricted epitopes are widely accepted to be derived from viral proteins encoded by primary ORFs.", [["cellular", "ANATOMY", 81, 89], ["cellular", "CELL", 81, 89], ["MHC-I", "GENE_OR_GENE_PRODUCT", 161, 166], ["MHC-I molecules", "PROTEIN", 161, 176], ["MHC", "PROTEIN", 284, 287], ["epitopes", "PROTEIN", 336, 344], ["viral proteins", "PROTEIN", 384, 398], ["primary ORFs", "DNA", 410, 422], ["these RNA structures", "PROBLEM", 47, 67], ["viral/cellular protein interactions", "PROBLEM", 75, 110], ["antigenic peptides", "PROBLEM", 138, 156], ["RNA positive", "PROBLEM", 200, 212], ["stranded viruses", "PROBLEM", 213, 229], ["viral proteins", "PROBLEM", 384, 398], ["cellular protein", "OBSERVATION", 81, 97], ["stranded viruses", "OBSERVATION", 213, 229], ["CRYPTIC TRANSLATIONAL", "OBSERVATION", 240, 261]]], ["However, recent studies have demonstrated that viruses also exploit alternative reading frames in order to fully express their genomes.", [["recent studies", "TEST", 9, 23], ["viruses", "PROBLEM", 47, 54], ["viruses", "OBSERVATION", 47, 54]]], ["The importance of these alternatively synthesized smaller polypeptides resulting from 'cryptic' translational control events are starting to be recognized as a crucial source of antigenic peptides.", [["these alternatively synthesized smaller polypeptides", "TREATMENT", 18, 70], ["'cryptic' translational control events", "PROBLEM", 86, 124], ["antigenic peptides", "TREATMENT", 178, 196]]], ["55 We will discuss in this section the two main mechanisms, frameshifting and non-AUG translation initiation, that are used by viruses to exploit the genomic information present in alternative reading frames and the impact of nonconventional peptides presented by MHC-I molecules.IMPACT OF CRYPTIC TRANSLATIONAL CONTROL MECHANISMS ON MHC-I MEDIATED ANTIGEN PRESENTATIONProgrammed ribosomal frameshifting is one of the many translational recoding processes used by viruses in order to appropriately express their genomes.", [["MHC-I molecules", "GENE_OR_GENE_PRODUCT", 264, 279], ["alternative reading frames", "DNA", 181, 207], ["MHC-I molecules", "PROTEIN", 264, 279], ["MHC", "PROTEIN", 334, 337], ["frameshifting", "TREATMENT", 60, 73], ["non-AUG translation initiation", "TREATMENT", 78, 108], ["nonconventional peptides", "TREATMENT", 226, 250], ["ANTIGEN PRESENTATIONProgrammed ribosomal frameshifting", "TREATMENT", 349, 403], ["CRYPTIC TRANSLATIONAL", "OBSERVATION", 290, 311], ["ribosomal frameshifting", "OBSERVATION", 380, 403]]], ["Frameshifting results from a change or shift in the reading frame by one or two nucleotides during mRNA translation.", [["nucleotides", "CHEMICAL", 80, 91], ["reading frame", "DNA", 52, 65]]], ["Frameshifting is widely employed by RNA viruses, such as HIV-1, coronaviruses and also influenza viruses to increase the diversity of proteins expressed from their compact genomes.", [["influenza viruses", "DISEASE", 87, 104], ["HIV-1", "ORGANISM", 57, 62], ["coronaviruses", "ORGANISM", 64, 77], ["influenza viruses", "ORGANISM", 87, 104], ["HIV-1", "SPECIES", 57, 62], ["HIV-1", "SPECIES", 57, 62], ["Frameshifting", "PROBLEM", 0, 13], ["RNA viruses", "PROBLEM", 36, 47], ["HIV-1", "PROBLEM", 57, 62], ["coronaviruses", "PROBLEM", 64, 77], ["influenza viruses", "PROBLEM", 87, 104], ["RNA viruses", "OBSERVATION", 36, 47], ["influenza viruses", "OBSERVATION", 87, 104]]], ["This process is programmed by the mRNA nucleotide sequence and is often initiated as a consequence of mRNA Volume 6, March/April 2015 secondary and tertiary structures such as stem-loops and pseudoknots.", [["stem-loops", "ANATOMY", 176, 186], ["nucleotide", "CHEMICAL", 39, 49], ["nucleotide", "CHEMICAL", 39, 49], ["mRNA nucleotide sequence", "DNA", 34, 58], ["the mRNA nucleotide sequence", "TEST", 30, 58], ["mRNA Volume", "TEST", 102, 113], ["pseudoknots", "PROBLEM", 191, 202], ["stem", "ANATOMY_MODIFIER", 176, 180], ["loops", "ANATOMY_MODIFIER", 181, 186]]], ["An example is the HIV-1 programmed ribosomal frameshifting secondary structures, depicted in Figure 2 (c), which induce a \u22121 frameshift that insure the synthesis of pol and gag that are encoded by the same ORF.", [["ribosomal", "ANATOMY", 35, 44], ["HIV-1", "ORGANISM", 18, 23], ["pol", "GENE_OR_GENE_PRODUCT", 165, 168], ["gag", "GENE_OR_GENE_PRODUCT", 173, 176], ["\u22121 frameshift", "DNA", 122, 135], ["pol and gag", "DNA", 165, 176], ["ORF", "DNA", 206, 209], ["HIV-1", "SPECIES", 18, 23], ["HIV-1", "SPECIES", 18, 23], ["the HIV", "PROBLEM", 14, 21], ["1 programmed ribosomal frameshifting secondary structures", "PROBLEM", 22, 79], ["a \u22121 frameshift", "PROBLEM", 120, 135], ["ribosomal frameshifting", "OBSERVATION", 35, 58], ["secondary structures", "OBSERVATION", 59, 79]]], ["56 Several cryptic MHC-I peptides have now been reported and the mechanisms by which viruses generate such peptides are starting to be elucidated.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 19, 24], ["MHC", "PROTEIN", 19, 22], ["such peptides", "PROBLEM", 102, 115], ["cryptic MHC", "OBSERVATION", 11, 22]]], ["55 Mammalian ribosomes carefully select the correct initiation codon of ORFs for the synthesis of functional proteins but they have also been shown to sometimes use alternative start codons to translate from other regions of the mRNAs irrespective of the ORF location for MHC-I presentation.", [["ribosomes", "ANATOMY", 13, 22], ["MHC-I", "GENE_OR_GENE_PRODUCT", 272, 277], ["ORFs", "DNA", 72, 76], ["mRNAs", "RNA", 229, 234], ["MHC", "PROTEIN", 272, 275], ["Mammalian ribosomes", "TREATMENT", 3, 22], ["ORFs", "TREATMENT", 72, 76], ["the synthesis of functional proteins", "PROBLEM", 81, 117], ["alternative start codons", "TREATMENT", 165, 189]]], ["The synthesized cryptic peptides compete with other MHC-I peptides for cell surface presentation and T cell activation.", [["cell surface", "ANATOMY", 71, 83], ["T cell", "ANATOMY", 101, 107], ["MHC-I", "GENE_OR_GENE_PRODUCT", 52, 57], ["cell", "CELL", 71, 75], ["T cell", "CELL", 101, 107], ["MHC", "PROTEIN", 52, 55], ["The synthesized cryptic peptides", "PROBLEM", 0, 32], ["cell surface presentation", "PROBLEM", 71, 96], ["T cell activation", "PROBLEM", 101, 118], ["cryptic peptides", "OBSERVATION", 16, 32], ["cell activation", "OBSERVATION", 103, 118]]], ["One of the first examples of a cryptic antigenic peptide was described following a study investigating murine AIDS, revealing stimulated CTL responses toward a peptide encoded in an alternative reading frame of the LP-BM5 gag gene.", [["AIDS", "DISEASE", 110, 114], ["murine", "ORGANISM", 103, 109], ["CTL", "CELL", 137, 140], ["gag", "GENE_OR_GENE_PRODUCT", 222, 225], ["alternative reading frame", "DNA", 182, 207], ["LP-BM5 gag gene", "DNA", 215, 230], ["murine", "SPECIES", 103, 109], ["a cryptic antigenic peptide", "PROBLEM", 29, 56], ["a study", "TEST", 81, 88], ["murine AIDS", "TREATMENT", 103, 114], ["stimulated CTL responses", "PROBLEM", 126, 150], ["the LP", "TEST", 211, 217]]], ["57 In HIV-infected mice, CTLs target a HLA-B*07-restricted alternative reading frame epitope translated from the (+2) ORF within the gag gene.", [["HIV-infected", "DISEASE", 6, 18], ["HIV", "ORGANISM", 6, 9], ["mice", "ORGANISM", 19, 23], ["CTLs", "CELL", 25, 29], ["gag", "GENE_OR_GENE_PRODUCT", 133, 136], ["CTLs", "CELL_TYPE", 25, 29], ["alternative reading frame epitope", "DNA", 59, 92], ["ORF", "DNA", 118, 121], ["gag gene", "DNA", 133, 141], ["HIV", "SPECIES", 6, 9], ["mice", "SPECIES", 19, 23], ["HIV", "SPECIES", 6, 9], ["mice", "SPECIES", 19, 23], ["gag gene", "OBSERVATION", 133, 141]]], ["Similarly, simian immunodeficiency virus (SIV) infected rhesus macaques displayed a strong CTL response toward an epitope that was translated from the (+2) reading frame relative to the env ORF.", [["simian immunodeficiency virus (SIV) infected", "DISEASE", 11, 55], ["simian immunodeficiency virus", "ORGANISM", 11, 40], ["SIV", "ORGANISM", 42, 45], ["rhesus macaques", "ORGANISM", 56, 71], ["CTL", "CANCER", 91, 94], ["(+2) reading frame", "DNA", 151, 169], ["env ORF", "DNA", 186, 193], ["simian immunodeficiency virus", "SPECIES", 11, 40], ["rhesus macaques", "SPECIES", 56, 71], ["simian immunodeficiency virus", "SPECIES", 11, 40], ["SIV", "SPECIES", 42, 45], ["rhesus macaques", "SPECIES", 56, 71], ["simian immunodeficiency virus (SIV) infected rhesus macaques", "PROBLEM", 11, 71], ["an epitope", "PROBLEM", 111, 121], ["the env ORF", "PROBLEM", 182, 193], ["simian immunodeficiency", "OBSERVATION", 11, 34], ["env ORF", "OBSERVATION", 186, 193]]], ["58 Interestingly, it has been shown that nearly one-quarter of the anti-SIV CTL responses in SIV-infected rhesus macaques are directed toward cryptic epitopes generated from alternative reading frame translation.", [["SIV-infected", "DISEASE", 93, 105], ["anti-SIV", "ORGANISM", 67, 75], ["CTL", "GENE_OR_GENE_PRODUCT", 76, 79], ["SIV", "ORGANISM", 93, 96], ["rhesus", "ORGANISM", 106, 112], ["macaques", "ORGANISM", 113, 121], ["cryptic epitopes", "PROTEIN", 142, 158], ["rhesus macaques", "SPECIES", 106, 121], ["anti-SIV", "SPECIES", 67, 75], ["SIV", "SPECIES", 93, 96], ["rhesus macaques", "SPECIES", 106, 121], ["the anti-SIV CTL responses", "TREATMENT", 63, 89], ["infected rhesus macaques", "TREATMENT", 97, 121]]], ["59 In order to assess the impact of cryptic epitopes on immune surveillance, bioinformatic screening was performed to identify nonconventional antigens in HIV-infected individuals.", [["HIV-infected", "DISEASE", 155, 167], ["HIV", "ORGANISM", 155, 158], ["individuals", "ORGANISM", 168, 179], ["cryptic epitopes", "PROTEIN", 36, 52], ["nonconventional antigens", "PROTEIN", 127, 151], ["HIV", "SPECIES", 155, 158], ["HIV", "SPECIES", 155, 158], ["cryptic epitopes", "PROBLEM", 36, 52], ["immune surveillance", "TEST", 56, 75], ["bioinformatic screening", "TEST", 77, 100], ["infected individuals", "PROBLEM", 159, 179]]], ["60 This approach identified 64 HLA-associated viral polymorphisms translated in alternative reading frames of the HIV gag, pol and nef mRNAs.", [["HIV", "ORGANISM", 114, 117], ["gag", "GENE_OR_GENE_PRODUCT", 118, 121], ["pol", "GENE_OR_GENE_PRODUCT", 123, 126], ["nef", "GENE_OR_GENE_PRODUCT", 131, 134], ["viral polymorphisms", "DNA", 46, 65], ["alternative reading frames", "DNA", 80, 106], ["HIV gag, pol and nef mRNAs", "RNA", 114, 140], ["HIV", "SPECIES", 114, 117], ["HIV", "SPECIES", 114, 117], ["64 HLA-associated viral polymorphisms", "PROBLEM", 28, 65], ["viral polymorphisms", "OBSERVATION", 46, 65], ["nef mRNAs", "OBSERVATION", 131, 140]]], ["Surprisingly, no upstream in-frame AUG start codons were identified and a codon normally encoding for leucine (CUG) was proposed as a start site for cryptic translation.", [["leucine", "CHEMICAL", 102, 109], ["leucine", "CHEMICAL", 102, 109], ["leucine", "AMINO_ACID", 102, 109], ["CUG", "AMINO_ACID", 111, 114], ["upstream in-frame AUG start codons", "DNA", 17, 51], ["start site", "DNA", 134, 144], ["codons", "PROBLEM", 45, 51], ["leucine (CUG)", "TREATMENT", 102, 115], ["cryptic translation", "PROBLEM", 149, 168], ["no", "UNCERTAINTY", 14, 16]]], ["Biochemical analyses of ribosomal initiation complexes at CUG start codons revealed that infected cells use an elongator leucine-bound transfer RNA to initiate translation at cryptic start codons.", [["ribosomal", "ANATOMY", 24, 33], ["cells", "ANATOMY", 98, 103], ["leucine", "CHEMICAL", 121, 128], ["leucine", "CHEMICAL", 121, 128], ["ribosomal", "CELLULAR_COMPONENT", 24, 33], ["cells", "CELL", 98, 103], ["leucine", "AMINO_ACID", 121, 128], ["ribosomal initiation complexes", "PROTEIN", 24, 54], ["CUG start codons", "DNA", 58, 74], ["infected cells", "CELL_TYPE", 89, 103], ["elongator leucine-bound transfer RNA", "RNA", 111, 147], ["cryptic start codons", "DNA", 175, 195], ["Biochemical analyses", "TEST", 0, 20], ["ribosomal initiation complexes", "PROBLEM", 24, 54], ["infected cells", "PROBLEM", 89, 103], ["an elongator leucine", "TREATMENT", 108, 128], ["infected cells", "OBSERVATION", 89, 103]]], ["61 Translation initiation at CUG codons was found to be independent of the canonical AUG initiator tRNA pathway and instead relied on the expression of eukaryotic initiation factor 2A.", [["eukaryotic initiation factor 2A", "GENE_OR_GENE_PRODUCT", 152, 183], ["CUG codons", "DNA", 29, 39], ["eukaryotic initiation factor 2A", "PROTEIN", 152, 183]]], ["The synthesis of cryptic antigenic peptides may provide an escape mechanism from the overloading of conventional peptides on the surface of the infected cell.", [["surface", "ANATOMY", 129, 136], ["cell", "ANATOMY", 153, 157], ["surface", "CELLULAR_COMPONENT", 129, 136], ["cell", "CELL", 153, 157], ["infected cell", "CELL_TYPE", 144, 157], ["cryptic antigenic peptides", "TREATMENT", 17, 43], ["an escape mechanism", "PROBLEM", 56, 75], ["conventional peptides", "TREATMENT", 100, 121], ["cryptic antigenic peptides", "OBSERVATION", 17, 43], ["overloading", "OBSERVATION_MODIFIER", 85, 96], ["infected cell", "OBSERVATION", 144, 157]]], ["For example, it has been reported that the inclusion of nonconventional epitopes, including cryptic epitopes from HIV-1 in DNA vaccines can trigger a much stronger response in rhesus macaques.", [["HIV-1", "ORGANISM", 114, 119], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["rhesus", "ORGANISM", 176, 182], ["macaques", "ORGANISM", 183, 191], ["nonconventional epitopes", "PROTEIN", 56, 80], ["cryptic epitopes", "PROTEIN", 92, 108], ["HIV-1", "SPECIES", 114, 119], ["rhesus macaques", "SPECIES", 176, 191], ["HIV-1", "SPECIES", 114, 119], ["rhesus macaques", "SPECIES", 176, 191], ["nonconventional epitopes", "TREATMENT", 56, 80], ["cryptic epitopes", "PROBLEM", 92, 108], ["HIV", "PROBLEM", 114, 117], ["DNA vaccines", "TREATMENT", 123, 135], ["rhesus macaques", "OBSERVATION", 176, 191]]], ["62 Influenza A viruses (IAV) are negative-stranded RNA viruses that are responsible for the worldwide spread of human or avian influenza.", [["Influenza A viruses", "DISEASE", 3, 22], ["avian influenza", "DISEASE", 121, 136], ["62", "ORGANISM", 0, 2], ["Influenza A viruses", "ORGANISM", 3, 22], ["IAV", "ORGANISM", 24, 27], ["human", "ORGANISM", 112, 117], ["avian influenza", "ORGANISM", 121, 136], ["Influenza A viruses", "SPECIES", 3, 22], ["human", "SPECIES", 112, 117], ["avian influenza", "SPECIES", 121, 136], ["Influenza A viruses", "SPECIES", 3, 22], ["IAV", "SPECIES", 24, 27], ["human", "SPECIES", 112, 117], ["Influenza A viruses", "PROBLEM", 3, 22], ["stranded RNA viruses", "PROBLEM", 42, 62], ["influenza", "PROBLEM", 127, 136], ["stranded", "OBSERVATION_MODIFIER", 42, 50], ["RNA viruses", "OBSERVATION", 51, 62]]], ["IAVs expressing the alternative full-length protein, PB1-F2, were responsible for causing the human influenza pandemics of the 20th century.", [["influenza pandemics", "DISEASE", 100, 119], ["IAVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 53, 59], ["human", "ORGANISM", 94, 99], ["IAVs", "PROTEIN", 0, 4], ["alternative full-length protein", "PROTEIN", 20, 51], ["PB1", "PROTEIN", 53, 56], ["F2", "PROTEIN", 57, 59], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["the human influenza pandemics", "PROBLEM", 90, 119], ["influenza", "OBSERVATION", 100, 109]]], ["63 The PB1-F2 protein has been shown to control viral pathogenicity and mortality.", [["PB1-F2", "GENE_OR_GENE_PRODUCT", 7, 13], ["PB1-F2 protein", "PROTEIN", 7, 21], ["The PB1-F2 protein", "TEST", 3, 21], ["viral pathogenicity", "PROBLEM", 48, 67], ["viral pathogenicity", "OBSERVATION", 48, 67]]], ["In the absence of this protein, the virus replicates to similar levels in mouse lungs but shows decreased proliferation.", [["lungs", "ANATOMY", 80, 85], ["mouse", "ORGANISM", 74, 79], ["lungs", "ORGAN", 80, 85], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 74, 79], ["this protein", "PROBLEM", 18, 30], ["the virus", "PROBLEM", 32, 41], ["decreased proliferation", "PROBLEM", 96, 119], ["virus", "OBSERVATION", 36, 41], ["lungs", "ANATOMY", 80, 85], ["decreased", "OBSERVATION_MODIFIER", 96, 105], ["proliferation", "OBSERVATION", 106, 119]]], ["Its expression, on the other hand, results in delayed clearance of the virus by the host immune system.", [["immune system", "ANATOMICAL_SYSTEM", 89, 102], ["delayed clearance of the virus", "PROBLEM", 46, 76], ["expression", "OBSERVATION_MODIFIER", 4, 14]]], ["64 PB1-F2 was identified in the course of a systematic search for alternative reading-frame peptides encoded by the IAV that are recognized by CD8 + T cells.", [["CD8 + T cells", "ANATOMY", 143, 156], ["IAV", "ORGANISM", 116, 119], ["CD8", "GENE_OR_GENE_PRODUCT", 143, 146], ["PB1", "DNA", 3, 6], ["CD8 + T cells", "CELL_TYPE", 143, 156], ["frame peptides", "PROBLEM", 86, 100]]], ["63 A CTL peptide, (PB1-F2 [62] [63] [64] [65] [66] [67] [68] [69] [70] , not corresponding to any of the known standard viral open reading frames was found.", [["viral open reading frames", "DNA", 120, 145], ["A CTL peptide, (PB1-F2", "TEST", 3, 25]]], ["Further genomic analysis of the IAV genome revealed the PB1-F2 62-70 peptide was derived from the conserved 87-amino-acid-long PB1-F2 protein encoded by the (+1) reading frame within the PB1 gene.", [["amino-acid", "CHEMICAL", 111, 121], ["amino-acid", "CHEMICAL", 111, 121], ["IAV", "ORGANISM", 32, 35], ["PB1", "GENE_OR_GENE_PRODUCT", 187, 190], ["IAV genome", "DNA", 32, 42], ["PB1", "DNA", 56, 59], ["87-amino-acid-long PB1-F2 protein", "PROTEIN", 108, 141], ["(+1) reading frame", "DNA", 157, 175], ["PB1 gene", "DNA", 187, 195], ["IAV", "SPECIES", 32, 35], ["Further genomic analysis", "TEST", 0, 24], ["the IAV genome", "TEST", 28, 42], ["the PB1", "TEST", 52, 59], ["amino", "TEST", 111, 116], ["IAV genome", "OBSERVATION", 32, 42]]], ["PB1-F2 and some truncation products resulting from a premature stop codon in the PB1-F2 ORF can be detected in human, mouse, and avian cells infected by IAV.", [["cells", "ANATOMY", 135, 140], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 0, 6], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 81, 87], ["human", "ORGANISM", 111, 116], ["mouse", "ORGANISM", 118, 123], ["avian", "ORGANISM", 129, 134], ["cells", "CELL", 135, 140], ["IAV", "ORGANISM", 153, 156], ["PB1", "DNA", 0, 3], ["F2", "DNA", 4, 6], ["truncation products", "PROTEIN", 16, 35], ["premature stop codon", "DNA", 53, 73], ["PB1", "DNA", 81, 84], ["F2 ORF", "DNA", 85, 91], ["human, mouse, and avian cells", "CELL_TYPE", 111, 140], ["human", "SPECIES", 111, 116], ["mouse", "SPECIES", 118, 123], ["human", "SPECIES", 111, 116], ["mouse", "SPECIES", 118, 123], ["IAV", "SPECIES", 153, 156], ["PB1", "TEST", 0, 3], ["some truncation products", "PROBLEM", 11, 35], ["a premature stop codon", "PROBLEM", 51, 73], ["ORF", "PROBLEM", 88, 91]]], ["63 Studies involving Kozak and mutational analyses have shown that RNA structures within PB1 strongly favor translation at the (+1) reading frame's predicted PB1-F2 start codon and are likely to be initiated by ribosomal scanning as opposed to internal ribosomal entry or other mechanisms.", [["ribosomal", "ANATOMY", 211, 220], ["ribosomal", "ANATOMY", 253, 262], ["PB1", "GENE_OR_GENE_PRODUCT", 89, 92], ["ribosomal", "CELLULAR_COMPONENT", 211, 220], ["ribosomal", "CELLULAR_COMPONENT", 253, 262], ["Kozak", "DNA", 21, 26], ["PB1", "DNA", 89, 92], ["(+1) reading frame", "DNA", 127, 145], ["PB1", "DNA", 158, 161], ["F2 start codon", "DNA", 162, 176], ["Studies", "TEST", 3, 10], ["Kozak", "TEST", 21, 26], ["mutational analyses", "TEST", 31, 50], ["RNA structures", "PROBLEM", 67, 81], ["codon", "PROBLEM", 171, 176], ["ribosomal scanning", "TEST", 211, 229], ["internal ribosomal entry", "PROBLEM", 244, 268]]], ["63 RNA secondary structure predictions revealed a conserved structured region at the start of the internal PB1-F2 ORF for six influenza genomes comprising the human, avian and swine strains.", [["human", "ORGANISM", 159, 164], ["avian", "ORGANISM", 166, 171], ["swine strains", "ORGANISM", 176, 189], ["PB1", "DNA", 107, 110], ["F2 ORF", "DNA", 111, 117], ["human", "SPECIES", 159, 164], ["avian", "SPECIES", 166, 171], ["swine", "SPECIES", 176, 181], ["human", "SPECIES", 159, 164], ["swine", "SPECIES", 176, 181], ["RNA secondary structure predictions", "TEST", 3, 38], ["a conserved structured region", "PROBLEM", 48, 77], ["the internal PB1", "TREATMENT", 94, 110], ["six influenza genomes", "PROBLEM", 122, 143], ["internal PB1", "ANATOMY", 98, 110], ["influenza genomes", "OBSERVATION", 126, 143]]], ["65 This protein contributes to influenza viral pathogenicity through several mechanisms.", [["influenza viral", "ORGANISM", 31, 46], ["influenza viral pathogenicity", "PROBLEM", 31, 60], ["influenza viral pathogenicity", "OBSERVATION", 31, 60]]], ["One described mechanism is a pro-apoptotic function in which PB1-F2 was found to localize to Hela cell mitochondria.", [["Hela cell mitochondria", "ANATOMY", 93, 115], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 61, 67], ["Hela cell", "CELL", 93, 102], ["mitochondria", "CELLULAR_COMPONENT", 103, 115], ["PB1", "PROTEIN", 61, 64], ["Hela cell mitochondria", "PROBLEM", 93, 115], ["pro-apoptotic function", "OBSERVATION", 29, 51], ["Hela cell mitochondria", "OBSERVATION", 93, 115]]], ["PB1-F2 disturbs the mitochondrial membrane potential resulting in a fluctuation of cytochrome c into the cytoplasm triggering apoptosis in these cells.", [["mitochondrial membrane", "ANATOMY", 20, 42], ["cytoplasm", "ANATOMY", 105, 114], ["cells", "ANATOMY", 145, 150], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 0, 6], ["mitochondrial membrane", "CELLULAR_COMPONENT", 20, 42], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 83, 95], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["cells", "CELL", 145, 150], ["PB1", "DNA", 0, 3], ["cytochrome c", "PROTEIN", 83, 95], ["PB1", "TEST", 0, 3], ["a fluctuation of cytochrome c", "PROBLEM", 66, 95], ["the cytoplasm triggering apoptosis in these cells", "PROBLEM", 101, 150], ["mitochondrial membrane", "OBSERVATION", 20, 42], ["cytoplasm triggering apoptosis", "OBSERVATION", 105, 135]]], ["63 The induction of apoptosis by PB1-F2 is proposed to occur specifically in immune cells in a strain dependent manner suggesting that the protein has a modulatory role in the host response to IAV by hastening the death of immune cells.", [["immune cells", "ANATOMY", 77, 89], ["immune cells", "ANATOMY", 223, 235], ["death", "DISEASE", 214, 219], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 33, 39], ["immune cells", "CELL", 77, 89], ["IAV", "ORGANISM", 193, 196], ["immune cells", "CELL", 223, 235], ["PB1", "DNA", 33, 36], ["immune cells", "CELL_TYPE", 77, 89], ["immune cells", "CELL_TYPE", 223, 235], ["IAV", "SPECIES", 193, 196], ["apoptosis", "PROBLEM", 20, 29], ["immune cells", "PROBLEM", 77, 89], ["the protein", "PROBLEM", 135, 146], ["IAV", "PROBLEM", 193, 196], ["immune cells", "PROBLEM", 223, 235], ["immune cells", "OBSERVATION", 223, 235]]], ["63, 66 In addition to pro-apoptotic activity, it has been reported that PB1-F2 also has proinflammatory properties.", [["PB1-F2", "GENE_OR_GENE_PRODUCT", 72, 78], ["PB1", "PROTEIN", 72, 75], ["proinflammatory properties", "PROBLEM", 88, 114], ["pro-apoptotic activity", "OBSERVATION", 22, 44], ["proinflammatory properties", "OBSERVATION", 88, 114]]], ["It was observed that an asparagine (N) to serine (S) substitution at position 66 in the PB1-F2 protein dramatically increased immunopathology and mortality by the 1918 pandemic strain and highly pathogenic H5N1 viruses.", [["asparagine", "CHEMICAL", 24, 34], ["immunopathology", "DISEASE", 126, 141], ["H5N1 viruses", "DISEASE", 206, 218], ["asparagine", "CHEMICAL", 24, 34], ["N", "CHEMICAL", 36, 37], ["serine", "CHEMICAL", 42, 48], ["asparagine", "AMINO_ACID", 24, 34], ["serine", "AMINO_ACID", 42, 48], ["position 66", "AMINO_ACID", 69, 80], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 88, 94], ["H5N1 viruses", "ORGANISM", 206, 218], ["PB1", "PROTEIN", 88, 91], ["F2 protein", "PROTEIN", 92, 102], ["H5N1 viruses", "SPECIES", 206, 218], ["an asparagine (N) to serine (S) substitution at position", "TREATMENT", 21, 77], ["the PB1", "TEST", 84, 91], ["increased immunopathology", "PROBLEM", 116, 141], ["pandemic strain", "PROBLEM", 168, 183], ["highly pathogenic H5N1 viruses", "PROBLEM", 188, 218], ["dramatically", "OBSERVATION_MODIFIER", 103, 115], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["immunopathology", "OBSERVATION", 126, 141], ["pathogenic", "OBSERVATION_MODIFIER", 195, 205], ["H5N1 viruses", "OBSERVATION", 206, 218]]], ["67 Also, transcriptional profiling of mice infected with a PB1-F2 N66S-expressing virus revealed an early suppression of interferon-stimulated genes (ISGs) 68 and in vitro experiments demonstrated an anti-interferon activity of PB1-F2 in relation to the mitochondrial antiviral signaling (MAVS) adaptor protein.", [["mitochondrial", "ANATOMY", 254, 267], ["mice", "ORGANISM", 38, 42], ["PB1-F2 N66S", "ORGANISM", 59, 70], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 121, 148], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 228, 234], ["mitochondrial", "CELLULAR_COMPONENT", 254, 267], ["MAVS", "GENE_OR_GENE_PRODUCT", 289, 293], ["PB1", "DNA", 59, 62], ["interferon-stimulated genes", "DNA", 121, 148], ["ISGs", "DNA", 150, 154], ["PB1", "DNA", 228, 231], ["mitochondrial antiviral signaling (MAVS) adaptor protein", "PROTEIN", 254, 310], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["a PB1", "TEST", 57, 62], ["expressing virus", "PROBLEM", 71, 87], ["interferon-stimulated genes", "TREATMENT", 121, 148], ["PB1-F2", "TREATMENT", 228, 234], ["early", "OBSERVATION_MODIFIER", 100, 105], ["mitochondrial antiviral", "OBSERVATION", 254, 277]]], ["69 Of note, PB1-F2 N66S inhibited IFN induction more efficiently than wild-type PB1-F2.", [["PB1-F2 N66S", "GENE_OR_GENE_PRODUCT", 12, 23], ["IFN", "GENE_OR_GENE_PRODUCT", 34, 37], ["PB1-F2", "CELL", 80, 86], ["PB1", "DNA", 12, 15], ["IFN", "PROTEIN", 34, 37], ["PB1", "DNA", 80, 83], ["PB1", "TEST", 12, 15], ["IFN induction", "TREATMENT", 34, 47]]], ["69 The wild-type PB1-F2 protein was initially shown to be highly unstable and to undergo proteasomal dependent degradation, 63 however, more recent experiments performed in murine and duck cells demonstrate that protein levels of the N66S mutant but not the wild-type increase following exposure of the infected cells to the proteasome inhibitor, lactacystin.", [["cells", "ANATOMY", 189, 194], ["cells", "ANATOMY", 312, 317], ["lactacystin", "CHEMICAL", 347, 358], ["lactacystin", "CHEMICAL", 347, 358], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 17, 23], ["murine", "ORGANISM", 173, 179], ["duck cells", "CELL", 184, 194], ["N66S", "GENE_OR_GENE_PRODUCT", 234, 238], ["cells", "CELL", 312, 317], ["lactacystin", "SIMPLE_CHEMICAL", 347, 358], ["wild-type PB1-F2 protein", "PROTEIN", 7, 31], ["murine and duck cells", "CELL_TYPE", 173, 194], ["N66S mutant", "PROTEIN", 234, 245], ["infected cells", "CELL_TYPE", 303, 317], ["murine", "SPECIES", 173, 179], ["duck", "SPECIES", 184, 188], ["The wild-type PB1-F2 protein", "TEST", 3, 31], ["proteasomal dependent degradation", "PROBLEM", 89, 122], ["duck cells", "TEST", 184, 194], ["protein levels", "TEST", 212, 226], ["the N66S mutant", "PROBLEM", 230, 245], ["the infected cells", "PROBLEM", 299, 317], ["the proteasome inhibitor", "TREATMENT", 321, 345], ["lactacystin", "TREATMENT", 347, 358], ["infected cells", "OBSERVATION", 303, 317]]], ["70 These examples highlight the impact of cryptic translation and the generation of alternative antigenic peptides on MHC-I mediated immune responses.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 118, 123], ["MHC", "PROTEIN", 118, 121], ["cryptic translation", "TREATMENT", 42, 61], ["alternative antigenic peptides", "TREATMENT", 84, 114], ["cryptic translation", "OBSERVATION", 42, 61]]], ["Aberrant translational control mechanisms appear to be actively used by viruses in order to modulate pathogenicity ( Figure 3 ).", [["Aberrant translational control mechanisms", "PROBLEM", 0, 41], ["viruses", "PROBLEM", 72, 79], ["viruses", "OBSERVATION", 72, 79]]], ["With only a few examples of RNA structures that control both the translation of alternative ORFs and antigenic peptide presentation having been reported to date, further identification and characterization of such important RNA structural regulatory elements would facilitate our understanding of the mechanisms exploited by viruses seeking to establish chronic infection.TARGETING RNA STRUCTURES TO CONTROL MHC-I MEDIATED ANTIGEN PRESENTATIONWe have described in the previous sections how secondary structures of RNA can impact on the translation of critical mRNAs encoding viral proteins that are the source of MHC-I restricted epitopes.", [["sections", "ANATOMY", 477, 485], ["chronic infection", "DISEASE", 354, 371], ["MHC-I", "GENE_OR_GENE_PRODUCT", 613, 618], ["ORFs", "DNA", 92, 96], ["RNA structural regulatory elements", "DNA", 224, 258], ["MHC", "PROTEIN", 408, 411], ["mRNAs", "RNA", 560, 565], ["viral proteins", "PROTEIN", 575, 589], ["MHC-I restricted epitopes", "PROTEIN", 613, 638], ["RNA structures", "PROBLEM", 28, 42], ["alternative ORFs", "TREATMENT", 80, 96], ["antigenic peptide presentation", "PROBLEM", 101, 131], ["further identification", "TEST", 162, 184], ["such important RNA structural regulatory elements", "PROBLEM", 209, 258], ["chronic infection", "PROBLEM", 354, 371], ["secondary structures of RNA", "PROBLEM", 490, 517], ["critical mRNAs encoding viral proteins", "PROBLEM", 551, 589], ["chronic", "OBSERVATION_MODIFIER", 354, 361], ["infection", "OBSERVATION", 362, 371], ["viral proteins", "OBSERVATION", 575, 589]]], ["In this section we discuss novel opportunities of targeting viral RNA secondary structures and associated cis-regulatory sequences or proteins in order to modulate the pool of antigenic determinants.", [["cis-regulatory sequences", "DNA", 106, 130], ["antigenic determinants", "PROTEIN", 176, 198], ["targeting viral RNA secondary structures", "PROBLEM", 50, 90], ["associated cis-regulatory sequences", "PROBLEM", 95, 130]]], ["Viruses often rely on a balance that necessitates the expression of viral proteins at levels sufficient to maintain viral replication but low enough to avoid stimulation of the immune surveillance system.", [["viral proteins", "PROTEIN", 68, 82], ["Viruses", "PROBLEM", 0, 7], ["viral proteins", "PROBLEM", 68, 82], ["viral replication", "PROBLEM", 116, 133]]], ["By interfering with the translation of key mRNAs, one may anticipate to see dramatic changes in viral infectivity and survival particularly when stimulating or inhibiting the synthesis of both conventional and non-conventional antigenic peptides.TARGETING RNA STRUCTURES TO CONTROL MHC-I MEDIATED ANTIGEN PRESENTATIONAs described previously, gammaherpes viruses comprise G-quadruplex motifs within the ORF of the mRNAs encoding their GMPs.", [["gammaherpes viruses", "ORGANISM", 342, 361], ["GMPs", "GENE_OR_GENE_PRODUCT", 434, 438], ["mRNAs", "RNA", 43, 48], ["MHC", "PROTEIN", 282, 285], ["G-quadruplex motifs", "DNA", 371, 390], ["ORF", "DNA", 402, 405], ["mRNAs", "RNA", 413, 418], ["GMPs", "PROTEIN", 434, 438], ["dramatic changes in viral infectivity", "PROBLEM", 76, 113], ["non-conventional antigenic peptides", "TREATMENT", 210, 245], ["gammaherpes viruses", "TREATMENT", 342, 361], ["G-quadruplex motifs", "TREATMENT", 371, 390], ["viral infectivity", "OBSERVATION", 96, 113]]], ["Within certain members of this viral family, G-quadruplexes act as ribosomal roadblocks to prohibit a significant proportion of ribosomes from shuttling down the transcripts and in the process impede translation.", [["ribosomal", "ANATOMY", 67, 76], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 45, 59], ["ribosomal", "CELLULAR_COMPONENT", 67, 76], ["ribosomes", "CELLULAR_COMPONENT", 128, 137], ["ribosomal roadblocks", "TREATMENT", 67, 87]]], ["7 Due to this decrease in translation, it was hypothesized that destabilization or stabilization of G-quadruplex motifs may have a direct impact on the generation of antigen-specific peptides.", [["G-quadruplex motifs", "PROTEIN", 100, 119], ["this decrease in translation", "PROBLEM", 9, 37], ["G-quadruplex motifs", "TREATMENT", 100, 119], ["decrease", "OBSERVATION_MODIFIER", 14, 22]]], ["Reported observations that codon-modification of the EBNA1 GAr mRNA destabilized G-quadruplexes by inducing the formation of double-stranded structures within the EBNA1 mRNA, prompted an assessment of the effect of potential exogenous factors such as antisense oligonucleotides to destabilize G-quadruplex motifs.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 53, 58], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 81, 95], ["EBNA1", "GENE_OR_GENE_PRODUCT", 163, 168], ["EBNA1 GAr mRNA", "RNA", 53, 67], ["EBNA1 mRNA", "RNA", 163, 173], ["exogenous factors", "PROTEIN", 225, 242], ["G-quadruplex motifs", "DNA", 293, 312], ["the EBNA1 GAr mRNA", "TEST", 49, 67], ["double-stranded structures", "PROBLEM", 125, 151], ["an assessment", "TEST", 184, 197], ["potential exogenous factors", "PROBLEM", 215, 242], ["antisense oligonucleotides", "TREATMENT", 251, 277], ["G-quadruplex motifs", "TREATMENT", 293, 312], ["EBNA1 mRNA", "OBSERVATION", 163, 173]]], ["It was subsequently demonstrated that an antisense oligonucleotide complementary to the G-quadruplex motif and selected for its ability to unwind G-quadruplexes in vitro, was able to increase EBNA1 mRNA translation and enhance immune recognition by antigen-specific T cells in EBV-infected cells (Figure 4(a) ).", [["T cells", "ANATOMY", 266, 273], ["cells", "ANATOMY", 290, 295], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 146, 160], ["EBNA1", "GENE_OR_GENE_PRODUCT", 192, 197], ["antigen", "GENE_OR_GENE_PRODUCT", 249, 256], ["T cells", "CELL", 266, 273], ["EBV", "ORGANISM", 277, 280], ["cells", "CELL", 290, 295], ["G-quadruplex motif", "DNA", 88, 106], ["EBNA1 mRNA", "RNA", 192, 202], ["T cells", "CELL_TYPE", 266, 273], ["EBV-infected cells", "CELL_TYPE", 277, 295], ["an antisense oligonucleotide", "TREATMENT", 38, 66], ["the G-quadruplex motif", "TREATMENT", 84, 106], ["EBNA1 mRNA translation", "TREATMENT", 192, 214], ["immune recognition", "TEST", 227, 245], ["antigen", "TEST", 249, 256], ["EBV", "TEST", 277, 280], ["infected cells", "PROBLEM", 281, 295], ["infected cells", "OBSERVATION", 281, 295]]], ["7 This result highlighted the ability of ribosomes to process RNA double-stranded structure more efficiently than G-quadruplex structure.", [["ribosomes", "CELLULAR_COMPONENT", 41, 50], ["G-quadruplex", "SIMPLE_CHEMICAL", 114, 126], ["RNA double-stranded structure", "TREATMENT", 62, 91], ["stranded structure", "OBSERVATION_MODIFIER", 73, 91]]], ["In contrast, the addition of a G-quadruplex stabilizing ligand, pyridostatin (Figure 4(a) ), to EBNA1 in vitro translation assays and an in vivo transfection system showed the opposite effect: a more pronounced inhibition of EBNA1 mRNA translation and a resultant decrease in virus-specific T-cell recognition of EBV-infected cells treated with the small molecule.", [["T-cell", "ANATOMY", 291, 297], ["cells", "ANATOMY", 326, 331], ["pyridostatin", "CHEMICAL", 64, 76], ["pyridostatin", "CHEMICAL", 64, 76], ["G-quadruplex", "SIMPLE_CHEMICAL", 31, 43], ["pyridostatin", "SIMPLE_CHEMICAL", 64, 76], ["Figure 4(a)", "SIMPLE_CHEMICAL", 78, 89], ["EBNA1", "GENE_OR_GENE_PRODUCT", 96, 101], ["EBNA1", "GENE_OR_GENE_PRODUCT", 225, 230], ["T-cell", "CELL", 291, 297], ["EBV", "ORGANISM", 313, 316], ["cells", "CELL", 326, 331], ["EBNA1", "PROTEIN", 96, 101], ["EBNA1 mRNA", "RNA", 225, 235], ["EBV-infected cells", "CELL_TYPE", 313, 331], ["a G-quadruplex stabilizing ligand", "TREATMENT", 29, 62], ["pyridostatin (Figure", "TREATMENT", 64, 84], ["vitro translation assays", "TEST", 105, 129], ["an in vivo transfection system", "TEST", 134, 164], ["EBNA1 mRNA translation", "PROBLEM", 225, 247], ["a resultant decrease in virus", "PROBLEM", 252, 281], ["EBV", "PROBLEM", 313, 316], ["infected cells", "PROBLEM", 317, 331], ["the small molecule", "PROBLEM", 345, 363], ["EBNA1 mRNA", "OBSERVATION", 225, 235], ["resultant", "OBSERVATION_MODIFIER", 254, 263], ["decrease", "OBSERVATION_MODIFIER", 264, 272], ["infected cells", "OBSERVATION", 317, 331], ["small molecule", "OBSERVATION", 349, 363]]], ["G-quadruplex destabilization, using the antisense oligonucleotide, or stabilization, using the small molecule G-quadruplex ligand, led to a 25% increase or 40% decrease, respectively, in the activation of EBNA1-specific T-cells in treated EBV-expressing HEK293 cells.", [["T-cells", "ANATOMY", 220, 227], ["HEK293 cells", "ANATOMY", 254, 266], ["G-quadruplex", "SIMPLE_CHEMICAL", 0, 12], ["EBNA1", "GENE_OR_GENE_PRODUCT", 205, 210], ["T-cells", "CELL", 220, 227], ["EBV", "ORGANISM", 239, 242], ["HEK293 cells", "CELL", 254, 266], ["EBNA1", "PROTEIN", 205, 210], ["T-cells", "CELL_TYPE", 220, 227], ["treated EBV-expressing HEK293 cells", "CELL_LINE", 231, 266], ["quadruplex destabilization", "TREATMENT", 2, 28], ["the antisense oligonucleotide", "TREATMENT", 36, 65], ["stabilization", "TREATMENT", 70, 83], ["the small molecule G-quadruplex ligand", "TREATMENT", 91, 129], ["EBNA1", "TEST", 205, 210], ["EBV", "TEST", 239, 242], ["quadruplex destabilization", "OBSERVATION", 2, 28], ["EBNA1", "ANATOMY", 205, 210], ["HEK293 cells", "OBSERVATION", 254, 266]]], ["The multifunctional roles of EBNA1 in initiating EBV-genome replication and episomal maintenance, while also contributing to immune evasion, suggest that this protein is a promising target for immunotherapy.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 29, 34], ["EBV", "ORGANISM", 49, 52], ["EBNA1", "PROTEIN", 29, 34], ["EBNA1", "TREATMENT", 29, 34], ["EBV-genome replication", "TREATMENT", 49, 71], ["episomal maintenance", "TREATMENT", 76, 96], ["immune evasion", "PROBLEM", 125, 139], ["this protein", "PROBLEM", 154, 166], ["immunotherapy", "TREATMENT", 193, 206]]], ["Stimulation of the immune recognition of EBV-infected cells through G-quadruplex destabilization or inhibition of replication of the EBV genome through G-quadruplex stabilization may lead to potential elimination of viral latency.TARGETING RNA STRUCTURES TO CONTROL MHC-I MEDIATED ANTIGEN PRESENTATIONSimilarly, several groups have investigated the use of antisense oligonucleotides and derivatives to control programmed frameshifting events.", [["cells", "ANATOMY", 54, 59], ["EBV", "ORGANISM", 41, 44], ["cells", "CELL", 54, 59], ["G-quadruplex", "GENE_OR_GENE_PRODUCT", 68, 80], ["EBV", "ORGANISM", 133, 136], ["G-quadruplex", "GENE_OR_GENE_PRODUCT", 152, 164], ["EBV-infected cells", "CELL_TYPE", 41, 59], ["EBV genome", "DNA", 133, 143], ["MHC", "PROTEIN", 266, 269], ["EBV", "PROBLEM", 41, 44], ["infected cells", "PROBLEM", 45, 59], ["G-quadruplex destabilization", "TREATMENT", 68, 96], ["replication", "TREATMENT", 114, 125], ["the EBV genome", "TREATMENT", 129, 143], ["G-quadruplex stabilization", "TREATMENT", 152, 178], ["viral latency", "PROBLEM", 216, 229], ["antisense oligonucleotides", "TREATMENT", 356, 382], ["derivatives", "TREATMENT", 387, 398], ["programmed frameshifting events", "PROBLEM", 410, 441], ["infected cells", "OBSERVATION", 45, 59], ["EBV genome", "OBSERVATION", 133, 143], ["viral latency", "OBSERVATION", 216, 229]]], ["This approach relies on the hypothesis that the formation of an RNA secondary structure downstream of a slippery sequence that is known to induce frameshifting will shift ribosomes into a new frame (Figure 4(b) ).", [["ribosomes", "CELLULAR_COMPONENT", 171, 180], ["slippery sequence", "DNA", 104, 121], ["a slippery sequence", "TREATMENT", 102, 121]]], ["The efficiency of frameshifting using morphilino, 2 \u2032 -O-methyl phosphorothioate, locked nucleic acid (LNA) and RNA antisense oligonucleotides can be as high as 40% and depends on the stability of the secondary structure rather than the three-dimensional structure formed.", [["morphilino", "CHEMICAL", 38, 48], ["2 \u2032 -O-methyl phosphorothioate", "CHEMICAL", 50, 80], ["nucleic acid", "CHEMICAL", 89, 101], ["LNA", "CHEMICAL", 103, 106], ["morphilino", "CHEMICAL", 38, 48], ["2 \u2032 -O-methyl phosphorothioate", "CHEMICAL", 50, 80], ["morphilino", "SIMPLE_CHEMICAL", 38, 48], ["2 \u2032 -O-methyl phosphorothioate", "SIMPLE_CHEMICAL", 50, 80], ["locked nucleic acid", "SIMPLE_CHEMICAL", 82, 101], ["LNA", "SIMPLE_CHEMICAL", 103, 106], ["frameshifting", "PROBLEM", 18, 31], ["morphilino", "TREATMENT", 38, 48], ["methyl phosphorothioate", "TREATMENT", 57, 80], ["locked nucleic acid (LNA", "TREATMENT", 82, 106], ["RNA antisense oligonucleotides", "TREATMENT", 112, 142], ["frameshifting", "OBSERVATION", 18, 31], ["secondary structure", "OBSERVATION", 201, 220]]], ["[71] [72] [73] The targeted slippery sequences comprise the HIV gag-pol, UUUUUUA, MMTV gag-pro, AAAAAAC and RSV gag-pol, AAAUUA frameshift sites.", [["HIV", "ORGANISM", 60, 63], ["gag-pol", "GENE_OR_GENE_PRODUCT", 64, 71], ["MMTV", "ORGANISM", 82, 86], ["gag", "GENE_OR_GENE_PRODUCT", 87, 90], ["RSV", "ORGANISM", 108, 111], ["gag-pol", "GENE_OR_GENE_PRODUCT", 112, 119], ["targeted slippery sequences", "DNA", 19, 46], ["HIV gag-pol, UUUUUUA, MMTV gag-pro, AAAAAAC and RSV gag-pol, AAAUUA frameshift sites", "DNA", 60, 144], ["RSV", "SPECIES", 108, 111], ["The targeted slippery sequences", "TEST", 15, 46], ["the HIV gag", "TEST", 56, 67], ["UUUUUUA", "TEST", 73, 80], ["MMTV gag", "TEST", 82, 90], ["AAAAAAC", "TEST", 96, 103], ["AAAUUA frameshift sites", "PROBLEM", 121, 144], ["RSV gag", "ANATOMY", 108, 115]]], ["This in vitro research investigation highlights the potential of synthetic oligonucleotides to interfere with the translation of key mRNAs to insure infectivity and survival of RNA viruses.", [["mRNAs", "RNA", 133, 138], ["synthetic oligonucleotides", "TREATMENT", 65, 91], ["infectivity", "PROBLEM", 149, 160], ["RNA viruses", "PROBLEM", 177, 188], ["RNA viruses", "OBSERVATION", 177, 188]]], ["Unfortunately, at present no results for an effect on the in vivo synthesis of related MHC-I restricted epitopes using this approach exist, however, one would expect that interfering with translation would ultimately affect the pool of antigenic peptides.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 87, 92], ["MHC-I restricted epitopes", "PROTEIN", 87, 112], ["this approach", "TREATMENT", 119, 132], ["antigenic peptides", "TREATMENT", 236, 254]]], ["This approach may also be used to stimulate translation at non-AUG start codons by creating RNA secondary structures in close proximity of tRNA binding sites.", [["AUG start codons", "DNA", 63, 79], ["tRNA binding sites", "DNA", 139, 157], ["AUG start codons", "TREATMENT", 63, 79], ["creating RNA secondary structures", "PROBLEM", 83, 116], ["tRNA binding sites", "PROBLEM", 139, 157], ["tRNA binding sites", "OBSERVATION", 139, 157]]], ["The use of an antisense microwalk assay may allow the identification of sequences and structures controlling the synthesis of cryptic epitopes.TARGETING RNA STRUCTURES TO CONTROL MHC-I MEDIATED ANTIGEN PRESENTATIONThe main goal of identifying RNA structures that impact on MHC-I mediated antigen presentation is to define potential targets for modulating the pool of antigenic peptides.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 273, 278], ["cryptic epitopes", "PROTEIN", 126, 142], ["MHC", "PROTEIN", 273, 276], ["an antisense microwalk assay", "TREATMENT", 11, 39], ["cryptic epitopes", "PROBLEM", 126, 142], ["antigenic peptides", "TREATMENT", 367, 385], ["cryptic epitopes", "OBSERVATION", 126, 142], ["main", "OBSERVATION_MODIFIER", 218, 222], ["RNA structures", "OBSERVATION", 243, 257]]], ["The use of small molecules for this purpose represents an alternative way to design vaccines in order to control viral infectivity.", [["small molecules", "TREATMENT", 11, 26], ["design vaccines", "TREATMENT", 77, 92], ["viral infectivity", "PROBLEM", 113, 130], ["small molecules", "OBSERVATION", 11, 26], ["viral infectivity", "OBSERVATION", 113, 130]]], ["By targeting the EBNA1 repeat with a small molecule, a G-quadruplex stabilizing ligand, allowed regulation of EBNA1 synthesis and the subsequent modulation of EBNA1 specific antigenic peptides.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 17, 22], ["EBNA1", "GENE_OR_GENE_PRODUCT", 110, 115], ["EBNA1", "GENE_OR_GENE_PRODUCT", 159, 164], ["EBNA1 repeat", "DNA", 17, 29], ["EBNA1", "PROTEIN", 110, 115], ["EBNA1", "PROTEIN", 159, 164], ["the EBNA1 repeat", "TEST", 13, 29], ["a small molecule", "PROBLEM", 35, 51], ["a G-quadruplex stabilizing ligand", "TREATMENT", 53, 86], ["EBNA1 synthesis", "TREATMENT", 110, 125], ["EBNA1 specific antigenic peptides", "TREATMENT", 159, 192], ["EBNA1 synthesis", "OBSERVATION", 110, 125]]], ["On a similar note, high-throughput screening and combinatorial chemistry approaches have been successfully used in order to identify small molecules that interact with the HIV-1 RNA stem-loop (Figure 2(c) ) frameshift stimulatory structure.", [["HIV-1", "ORGANISM", 172, 177], ["HIV-1", "SPECIES", 172, 177], ["HIV-1", "SPECIES", 172, 177], ["throughput screening", "TEST", 24, 44], ["combinatorial chemistry approaches", "TREATMENT", 49, 83], ["small molecules", "PROBLEM", 133, 148], ["the HIV", "TEST", 168, 175], ["loop (Figure 2(c) ) frameshift stimulatory structure", "PROBLEM", 187, 239], ["small", "OBSERVATION_MODIFIER", 133, 138], ["molecules", "OBSERVATION", 139, 148]]], ["71 The compound depicted in Figure 4 (c) was shown to selectively bind this RNA, and enhanced frameshifting by greater than 50% in a dual-luciferase assay in HEK293 cells and also strongly inhibited the infectivity of pseudotyped HIV-1 virions.", [["HEK293 cells", "ANATOMY", 158, 170], ["luciferase", "GENE_OR_GENE_PRODUCT", 138, 148], ["HEK293 cells", "CELL", 158, 170], ["pseudotyped HIV-1 virions", "ORGANISM", 218, 243], ["luciferase", "PROTEIN", 138, 148], ["HEK293 cells", "CELL_LINE", 158, 170], ["HIV-1", "SPECIES", 230, 235], ["HIV-1", "SPECIES", 230, 235], ["enhanced frameshifting", "PROBLEM", 85, 107], ["a dual-luciferase assay", "TEST", 131, 154], ["pseudotyped HIV", "PROBLEM", 218, 233]]], ["74 These examples highlight the relevance of stabilizing or creating structures in the vicinity of cis-regulating sequences within viral mRNAs in order to control translation.", [["cis-regulating sequences", "DNA", 99, 123], ["viral mRNAs", "RNA", 131, 142], ["cis-regulating sequences", "TREATMENT", 99, 123], ["viral mRNAs", "TREATMENT", 131, 142], ["stabilizing", "OBSERVATION", 45, 56], ["viral mRNAs", "OBSERVATION", 131, 142]]], ["The limited amount of data available in the literature supports this approach to control the presentation of MHC-I restricted epitopes and the activation of virus-specific T-cells.", [["T-cells", "ANATOMY", 172, 179], ["MHC-I", "GENE_OR_GENE_PRODUCT", 109, 114], ["T-cells", "CELL", 172, 179], ["MHC-I restricted epitopes", "PROTEIN", 109, 134], ["virus-specific T-cells", "CELL_TYPE", 157, 179], ["this approach", "TREATMENT", 64, 77], ["virus", "PROBLEM", 157, 162]]], ["The identification and characterization of exogenous agents able to stabilize or induce relevant RNA Volume 6, March/April 2015 structures represents an opportunity to interfere with the MHC-I antigen presentation pathway, which will lead to a better understanding of how viruses escape the immune system.CONCLUSION AND PERSPECTIVESRecent insights into viral immune evasion mechanisms have provided an important awareness of how some viruses exploit mRNA structure to modulate viral protein synthesis and antigen presentation in order to escape immune detection and establish a successful latent infection.", [["immune system", "ANATOMY", 291, 304], ["infection", "DISEASE", 596, 605], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 187, 200], ["immune system", "ANATOMICAL_SYSTEM", 291, 304], ["MHC", "PROTEIN", 187, 190], ["The identification", "TEST", 0, 18], ["exogenous agents", "TREATMENT", 43, 59], ["viral immune evasion", "TREATMENT", 353, 373], ["some viruses", "PROBLEM", 429, 441], ["viral protein synthesis", "PROBLEM", 477, 500], ["immune detection", "TEST", 545, 561], ["a successful latent infection", "PROBLEM", 576, 605], ["latent", "OBSERVATION_MODIFIER", 589, 595], ["infection", "OBSERVATION", 596, 605]]], ["In this review, we have described several mechanisms that link recently identified structural elements within viral mRNAs to protein translation and MHC-I-restricted antigen presentation.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 149, 154], ["structural elements", "DNA", 83, 102], ["viral mRNAs", "RNA", 110, 121], ["MHC-I", "PROTEIN", 149, 154], ["MHC", "TEST", 149, 152], ["structural elements", "OBSERVATION", 83, 102], ["viral mRNAs", "OBSERVATION", 110, 121]]], ["In particular, we have highlighted a novel function of RNA G-quadruplexes within gammaherpesviral GMP transcripts through cis-acting modulation of their mRNA translation and MHC-I antigen presentation.", [["GMP", "CHEMICAL", 98, 101], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 59, 73], ["gammaherpesviral GMP", "GENE_OR_GENE_PRODUCT", 81, 101], ["MHC-I antigen", "GENE_OR_GENE_PRODUCT", 174, 187], ["RNA G-quadruplexes", "RNA", 55, 73], ["gammaherpesviral GMP transcripts", "RNA", 81, 113], ["MHC", "PROTEIN", 174, 177], ["RNA G", "TREATMENT", 55, 60], ["gammaherpesviral GMP transcripts", "TREATMENT", 81, 113]]], ["Altering the translational regulatory effects of the G-quadruplex motifs and their resultant impact on antigen presentation has the potential to enhance immune recognition of virally infected cells or inhibit replication of the viral genome, leading to elimination of viral latency.", [["cells", "ANATOMY", 192, 197], ["cells", "CELL", 192, 197], ["G-quadruplex motifs", "DNA", 53, 72], ["virally infected cells", "CELL_TYPE", 175, 197], ["viral genome", "DNA", 228, 240], ["the G-quadruplex motifs", "TREATMENT", 49, 72], ["virally infected cells", "PROBLEM", 175, 197], ["the viral genome", "PROBLEM", 224, 240], ["viral latency", "PROBLEM", 268, 281], ["viral genome", "OBSERVATION", 228, 240], ["viral latency", "OBSERVATION", 268, 281]]], ["With no available vaccines to prevent EBV and other gammaherpesviral-associated malignancies, the identification of new therapeutic targets based on RNA G-quadruplex structures within viral GMP mRNAs will promote the advancement of RNA-directed drug design to reduce the burden of associated viral malignancies.", [["malignancies", "ANATOMY", 80, 92], ["malignancies", "ANATOMY", 298, 310], ["malignancies", "DISEASE", 80, 92], ["GMP", "CHEMICAL", 190, 193], ["viral malignancies", "DISEASE", 292, 310], ["EBV", "ORGANISM", 38, 41], ["malignancies", "CANCER", 80, 92], ["malignancies", "CANCER", 298, 310], ["RNA G-quadruplex structures", "RNA", 149, 176], ["viral GMP mRNAs", "RNA", 184, 199], ["EBV", "SPECIES", 38, 41], ["available vaccines", "TREATMENT", 8, 26], ["EBV", "PROBLEM", 38, 41], ["other gammaherpesviral-associated malignancies", "PROBLEM", 46, 92], ["new therapeutic targets", "PROBLEM", 116, 139], ["RNA G-quadruplex structures", "TREATMENT", 149, 176], ["viral GMP mRNAs", "TREATMENT", 184, 199], ["RNA-directed drug design", "TREATMENT", 232, 256], ["associated viral malignancies", "PROBLEM", 281, 310], ["malignancies", "OBSERVATION", 80, 92], ["viral GMP mRNAs", "OBSERVATION", 184, 199], ["viral malignancies", "OBSERVATION", 292, 310]]], ["While recent demonstrations that an antisense oligonucleotide and a small molecule G-quadruplex binding ligand can selectively target EBNA1 G-quadruplexes to impact on EBNA1 synthesis, the next challenge will require rigorous assessment of the mechanistic impact and specificity of these exogenous agents in vivo.CONCLUSION AND PERSPECTIVESWe also described RNP complexes and cryptic translational regulatory mechanisms that potentially impact on the supply of antigenic peptides to MHC-I molecules.", [["EBNA1", "GENE_OR_GENE_PRODUCT", 134, 139], ["EBNA1", "GENE_OR_GENE_PRODUCT", 168, 173], ["MHC-I molecules", "GENE_OR_GENE_PRODUCT", 483, 498], ["EBNA1", "PROTEIN", 134, 139], ["EBNA1", "PROTEIN", 168, 173], ["RNP complexes", "PROTEIN", 358, 371], ["MHC-I molecules", "PROTEIN", 483, 498], ["an antisense oligonucleotide", "TREATMENT", 33, 61], ["a small molecule G-quadruplex binding ligand", "TREATMENT", 66, 110], ["EBNA1 G-quadruplexes", "TREATMENT", 134, 154], ["EBNA1 synthesis", "TREATMENT", 168, 183], ["rigorous assessment", "TEST", 217, 236], ["these exogenous agents", "TREATMENT", 282, 304], ["antigenic peptides", "TREATMENT", 461, 479], ["small", "OBSERVATION_MODIFIER", 68, 73], ["RNP complexes", "OBSERVATION", 358, 371]]], ["Although RNA structures within the 5 \u2032 -UTR of RNA viruses, that control the translation and replication of viral genomes, have been characterized, further effort is needed to fully appreciate their impact on antigen presentation.", [["5 \u2032 -UTR", "DNA", 35, 43], ["viral genomes", "DNA", 108, 121], ["RNA structures", "PROBLEM", 9, 23], ["RNA viruses", "PROBLEM", 47, 58], ["viral genomes", "PROBLEM", 108, 121], ["RNA viruses", "OBSERVATION", 47, 58], ["viral genomes", "OBSERVATION", 108, 121]]], ["Only limited data are available regarding the impact of these RNA structures on immune evasion.", [["immune evasion", "TREATMENT", 80, 94], ["immune evasion", "OBSERVATION", 80, 94]]], ["Chemical tools could be used to inhibit the formation of RNP complexes needed to initiate translation and to unravel the mechanisms used by RNA viruses to regulate the pool of antigenic determinants.", [["RNP complexes", "PROTEIN", 57, 70], ["antigenic determinants", "PROTEIN", 176, 198], ["RNP complexes", "PROBLEM", 57, 70], ["RNA viruses", "PROBLEM", 140, 151]]], ["Further research is also required to identify the relevant RNA structures controlling the generation of antigenic peptides resulting from frameshift events and non-AUG translation initiation.", [["antigenic peptides", "TREATMENT", 104, 122], ["frameshift events", "PROBLEM", 138, 155], ["non-AUG translation initiation", "TREATMENT", 160, 190]]], ["The characterization of such structures will allow deciphering of the mechanism of cryptic translation and open the way to new approaches to modulate CTL activation.", [["CTL", "GENE_OR_GENE_PRODUCT", 150, 153], ["such structures", "PROBLEM", 24, 39], ["cryptic translation", "PROBLEM", 83, 102]]]], "PMC7451050": [], "PMC7293524": [["Patient Retrieval Organization ::: DiscussionThe regional task force receives calls from the sending hospitals (SHs) and takes care of contacting the receiving hospital (RH) to check the availability of ICU beds.", [["Patient", "SPECIES", 0, 7], ["ICU beds", "TREATMENT", 203, 211]]], ["Once availability is confirmed based on the patient's characteristics and the receiving ICU's capabilities, the regional task force decides which patients to transfer and where to send them (Fig. 1), so the on-call team is activated and the retrieval mission is then organized.", [["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 146, 154], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 146, 154]]], ["Clinical information (Table 1) needs to be collected in order to check the feasibility and to plan the mission.Patient Retrieval Organization ::: DiscussionCOVID-19 patients are often highly complex ICU patients with more than 1 system failure; therefore, the choice of the patient to send and the vehicle adopted is fundamental.", [["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 203, 211], ["patient", "ORGANISM", 274, 281], ["Patient", "SPECIES", 111, 118], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 203, 211], ["patient", "SPECIES", 274, 281], ["1 system failure", "PROBLEM", 227, 243], ["failure", "OBSERVATION", 236, 243]]], ["Absolute and relative contraindications to transfer are summarized in Table 27, 8, 9, 10; it is important to note that stricter criteria were adopted for the use of HEMS transfer because of higher technical complexity of emergency interventions during flight.", [["HEMS transfer", "TREATMENT", 165, 178], ["emergency interventions", "TREATMENT", 221, 244]]], ["However, the final decision about the appropriateness of the transfer and the eventual measures to take before transfer were up to the physician responsible for the transfer.Retrieval Team ::: DiscussionThe composition of the retrieval team was related to the needs of the patients transported; however, for patients needing continuous positive airway pressure or noninvasive11 or invasive ventilation, the team had to include an anesthesiologist/intensivist,12 a critical care nurse, and a professional ambulance driver in order to grant adequate management in case of complications occurring during the transfer.Vehicles ::: DiscussionThe ambulances involved in these missions could belong to the EMS of the RH or the SH, and the transport personnel could be brought to the SH via ground or air.", [["airway", "ANATOMY", 345, 351], ["patients", "ORGANISM", 273, 281], ["patients", "ORGANISM", 308, 316], ["airway", "MULTI-TISSUE_STRUCTURE", 345, 351], ["patients", "SPECIES", 273, 281], ["patients", "SPECIES", 308, 316], ["continuous positive airway pressure", "TREATMENT", 325, 360], ["noninvasive11", "TREATMENT", 364, 377], ["invasive ventilation", "TREATMENT", 381, 401], ["complications", "PROBLEM", 570, 583], ["air", "OBSERVATION", 793, 796]]], ["Because of the complexity of these patients, there were difficulties in terms of movement while wearing personal protective equipment (PPE), and, in order to reduce the risk of contamination, the ambulances were functionally divided into a clean zone (the driver cabin) and a contaminated zone (the patient cabin) as shown in Figure 2.The latter was further divided into 2 areas, an area dedicated to airway management and breathing supervised by the attending doctor and an area dedicated to monitoring and infusions, which was functionally supervised by the attending nurse.Equipment ::: DiscussionThe personnel directly involved in the management of the infected patient (doctor and nurse) wore an FFP2 mask, gowns, gloves, and eye protection, whereas the driver not directly involved in patient management did not have to wear any protections as per World Health Organization recommendations.13 In addition to basic ambulance equipment involving a mechanical ventilator, monitor/defibrillator, infusion pumps (at least 2), a portable suction unit, and a backpack carrying basic and advanced airway management devices and emergency drugs, premade kits containing all the necessary PPEs and quick kits (Fig. 3) for the management of airway management and monitoring problems were added.", [["airway", "ANATOMY", 401, 407], ["eye", "ANATOMY", 731, 734], ["airway", "ANATOMY", 1095, 1101], ["airway", "ANATOMY", 1235, 1241], ["patients", "ORGANISM", 35, 43], ["patient", "ORGANISM", 299, 306], ["airway", "MULTI-TISSUE_STRUCTURE", 401, 407], ["patient", "ORGANISM", 666, 673], ["eye", "ORGAN", 731, 734], ["patient", "ORGANISM", 791, 798], ["airway", "MULTI-TISSUE_STRUCTURE", 1095, 1101], ["airway", "MULTI-TISSUE_STRUCTURE", 1235, 1241], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 299, 306], ["patient", "SPECIES", 666, 673], ["patient", "SPECIES", 791, 798], ["personal protective equipment", "TREATMENT", 104, 133], ["contamination", "PROBLEM", 177, 190], ["a contaminated zone", "PROBLEM", 274, 293], ["airway management", "TREATMENT", 401, 418], ["infusions", "TREATMENT", 508, 517], ["an FFP2 mask", "TREATMENT", 698, 710], ["gowns", "TREATMENT", 712, 717], ["gloves", "TREATMENT", 719, 725], ["eye protection", "TREATMENT", 731, 745], ["any protections", "TREATMENT", 831, 846], ["basic ambulance equipment", "TREATMENT", 914, 939], ["a mechanical ventilator", "TREATMENT", 950, 973], ["defibrillator", "TREATMENT", 983, 996], ["infusion pumps", "TREATMENT", 998, 1012], ["a portable suction unit", "TREATMENT", 1027, 1050], ["a backpack carrying basic", "TREATMENT", 1056, 1081], ["advanced airway management devices", "TREATMENT", 1086, 1120], ["emergency drugs", "TREATMENT", 1125, 1140], ["premade kits", "TREATMENT", 1142, 1154], ["the necessary PPEs", "TREATMENT", 1170, 1188], ["airway management", "TREATMENT", 1235, 1252], ["monitoring problems", "TREATMENT", 1257, 1276], ["airway", "ANATOMY", 401, 407], ["eye", "ANATOMY", 731, 734], ["airway", "ANATOMY", 1095, 1101], ["airway", "ANATOMY", 1235, 1241]]], ["The last 2 are inside a hard-shell box that grants rapid access to both airway devices and drugs most frequently used for emergencies without the need to open the standard backpack, allowing a reduction of material needing sanification at the end of the mission.Transport ::: DiscussionThe drivers must always stay more than 1 meter away from both the patient and other personnel, keep the front cabin closed, store any clean materials (eg, retrieval team sweatshirts and personal belongings), communicate with the dispatch center to confirm departure, and estimate the time of arrival at the RH.", [["airway", "ANATOMY", 72, 78], ["airway", "MULTI-TISSUE_STRUCTURE", 72, 78], ["patient", "ORGANISM", 352, 359], ["patient", "SPECIES", 352, 359], ["a hard-shell box", "TREATMENT", 22, 38], ["both airway devices", "TREATMENT", 67, 86], ["drugs", "TREATMENT", 91, 96], ["open the standard backpack", "TREATMENT", 154, 180], ["a reduction of material", "TREATMENT", 191, 214], ["sanification", "TREATMENT", 223, 235], ["shell box", "OBSERVATION", 29, 38], ["airway", "ANATOMY", 72, 78]]], ["Considering the difficulty of moving around in the sanitary compartment with protection, it is suggested to simplify the required equipment by minimizing the number of infusions, giving priority to sedative and vasoactive drugs, opiates, and muscle relaxants that can be administered by boluses.Transport ::: DiscussionAnother aspect to take into consideration is the high level of alertness with respect to airway management.", [["muscle", "ANATOMY", 242, 248], ["airway", "ANATOMY", 408, 414], ["opiates", "SIMPLE_CHEMICAL", 229, 236], ["muscle", "ORGAN", 242, 248], ["airway", "MULTI-TISSUE_STRUCTURE", 408, 414], ["infusions", "TREATMENT", 168, 177], ["sedative", "TREATMENT", 198, 206], ["vasoactive drugs", "TREATMENT", 211, 227], ["opiates", "TREATMENT", 229, 236], ["muscle relaxants", "TREATMENT", 242, 258], ["airway management", "TREATMENT", 408, 425], ["muscle", "ANATOMY", 242, 248], ["airway", "ANATOMY", 408, 414]]], ["It is advisable not to postpone intubation in case of suspicion and, in case of accidental extubation, to use a device for difficult airway management in the first instance.14 Patient records must be transported and delivered in a bag to keep them clean.", [["airway", "ANATOMY", 133, 139], ["airway", "MULTI-TISSUE_STRUCTURE", 133, 139], ["Patient", "SPECIES", 176, 183], ["intubation", "TREATMENT", 32, 42], ["accidental extubation", "TREATMENT", 80, 101], ["a device", "TREATMENT", 110, 118], ["difficult airway management", "TREATMENT", 123, 150], ["a bag", "TREATMENT", 229, 234], ["clean", "OBSERVATION", 248, 253]]], ["Once the patient has been delivered to the RH, all team material must be recovered by collecting all the cables in a bag.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["all team material", "TREATMENT", 47, 64], ["a bag", "TREATMENT", 115, 120]]], ["The retrieval team gets on the ambulance and goes to the decontamination area still wearing all the PPE.Transport of Multiple Patients With Noninvasive Ventilation ::: DiscussionIn this case, an experienced ICU doctor has assessed all patients according to their clinical condition (Table 3) and care needs and assigned each one an appropriate type of team and an RH.", [["Patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 235, 243], ["Patients", "SPECIES", 126, 134], ["patients", "SPECIES", 235, 243], ["the decontamination area", "TREATMENT", 53, 77], ["Noninvasive Ventilation", "TREATMENT", 140, 163]]], ["Because of the high risk of deterioration and need of emergency endotracheal intubation, we decided to keep ambulances with the same destination in line to take advantage of mutual support.", [["endotracheal", "ANATOMY", 64, 76], ["emergency endotracheal intubation", "TREATMENT", 54, 87], ["mutual support", "TREATMENT", 174, 188], ["deterioration", "OBSERVATION", 28, 41]]], ["A dedicated radio channel was used to communicate in the ambulance group.Decontamination Plan ::: DiscussionSince COVID-19 inter- and intrahospital transport started, a decontamination area was instituted at the ambulance home base.", [["A dedicated radio channel", "TREATMENT", 0, 25], ["intrahospital transport", "TREATMENT", 134, 157], ["a decontamination area", "TREATMENT", 167, 189]]], ["Afterward, because of the increase in transport demand and the concomitant start of the COVID-19 HEMS retrieval program, it was necessary to establish a larger and more equipped decontamination area close to the hospital.Decontamination Plan ::: DiscussionThe vehicle (ambulance or helicopter) is sanitized by dedicated personnel, all surfaces are thoroughly cleaned with alcohol-based products, and all medical devices are disinfected with chlorhexidine wipes or hydrogen peroxide and then put in a decontamination cell for ozonation.", [["cell", "ANATOMY", 516, 520], ["alcohol", "CHEMICAL", 372, 379], ["chlorhexidine wipes", "CHEMICAL", 441, 460], ["hydrogen peroxide", "CHEMICAL", 464, 481], ["alcohol", "CHEMICAL", 372, 379], ["chlorhexidine", "CHEMICAL", 441, 454], ["hydrogen peroxide", "CHEMICAL", 464, 481], ["alcohol", "SIMPLE_CHEMICAL", 372, 379], ["chlorhexidine", "SIMPLE_CHEMICAL", 441, 454], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 464, 481], ["cell", "CELL", 516, 520], ["the increase in transport demand", "PROBLEM", 22, 54], ["the COVID-19 HEMS retrieval program", "TREATMENT", 84, 119], ["all medical devices", "TREATMENT", 400, 419], ["chlorhexidine wipes", "TREATMENT", 441, 460], ["hydrogen peroxide", "TREATMENT", 464, 481], ["a decontamination cell", "TREATMENT", 498, 520], ["ozonation", "TREATMENT", 525, 534], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["larger", "OBSERVATION_MODIFIER", 153, 159]]], ["Showers and clean uniforms are available on site.", [["clean", "OBSERVATION", 12, 17]]], ["Every 15 days the aircraft can be sanitized with the ozone machine.", [["ozone", "CHEMICAL", 53, 58], ["ozone", "CHEMICAL", 53, 58], ["the ozone machine", "TREATMENT", 49, 66]]], ["The entire process should last less than 45 minutes for an ambulance and 1 hour for the helicopter.COVID-19 HEMS Retrieval Program ::: DiscussionIn agreement with the regional task force and emergency dispatch center, the retrieval may be performed entirely by HEMS.", [["the retrieval", "TREATMENT", 218, 231]]], ["Maggiore Hospital HEMS is on duty 24/7 as reported earlier, and, after the outbreak began, a panel barrier was installed inside the helicopter to separate the sanitary compartment from the cockpit to protect pilots.COVID-19 HEMS Retrieval Program ::: DiscussionIn view of the increased complexity due to air transport, the criteria for patient selection are necessarily stricter than for ground transport.", [["patient", "ORGANISM", 336, 343], ["patient", "SPECIES", 336, 343], ["a panel barrier", "TREATMENT", 91, 106], ["the increased complexity", "PROBLEM", 272, 296], ["sanitary compartment", "OBSERVATION", 159, 179]]], ["Patients with relative contraindications reported in Table 1 are not eligible for HEMS.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The retrieval team and equipment are the same as for ground transport.COVID-19 HEMS Retrieval Program ::: DiscussionIn case of landing on the roof helipad that can be reached directly from the ICU without the need for an ambulance, it is advisable to unload the patient from the helicopter directly onto the ICU bed in order to minimize movements and the consequent risk of disconnection of the respiratory circuit.", [["respiratory", "ANATOMY", 395, 406], ["patient", "ORGANISM", 262, 269], ["patient", "SPECIES", 262, 269], ["the respiratory circuit", "TREATMENT", 391, 414], ["disconnection", "OBSERVATION", 374, 387], ["respiratory circuit", "OBSERVATION", 395, 414]]], ["After patient discharge, HEMS take off, heading to the decontamination area where the aircraft is sanitized with a process analog to that used for ambulances.Activity Report ::: DiscussionFrom March 5, 2020, to April 21, 2020, 159 patients were transferred from the Piacenza area to other regional ICUs or medium care units; of these, 139 were ICU patients undergoing invasive ventilation, and 20 patients were undergoing noninvasive ventilation or continuous positive airway pressure.", [["airway", "ANATOMY", 469, 475], ["patient", "ORGANISM", 6, 13], ["patients", "ORGANISM", 231, 239], ["patients", "ORGANISM", 348, 356], ["patients", "ORGANISM", 397, 405], ["airway", "MULTI-TISSUE_STRUCTURE", 469, 475], ["patient", "SPECIES", 6, 13], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 348, 356], ["patients", "SPECIES", 397, 405], ["a process analog", "TREATMENT", 113, 129], ["invasive ventilation", "TREATMENT", 368, 388], ["noninvasive ventilation", "TREATMENT", 422, 445], ["continuous positive airway pressure", "TREATMENT", 449, 484], ["airway pressure", "OBSERVATION", 469, 484]]], ["In one third of the missions, the team was brought to the site by helicopter; this allowed a significant reduction in total mission time, from a median of 6 hours for transports totally managed with ambulances to 4 hours 30 minutes.", [["significant", "OBSERVATION_MODIFIER", 93, 104], ["reduction", "OBSERVATION_MODIFIER", 105, 114]]], ["During these transfers, we had 2 nonfatal events and no fatal events.", [["2 nonfatal events", "PROBLEM", 31, 48], ["fatal events", "PROBLEM", 56, 68], ["no", "UNCERTAINTY", 53, 55]]], ["One was due to ventilator failure and was managed with a quick switch to bag valve ventilation with transient desaturation, and the second one was a sudden worsening of hemodynamics caused by the onset of supraventricular tachycardia managed with drugs.Activity Report ::: DiscussionThe most frequent complication was transient desaturation.", [["valve", "ANATOMY", 77, 82], ["supraventricular", "ANATOMY", 205, 221], ["ventilator failure", "DISEASE", 15, 33], ["desaturation", "DISEASE", 110, 122], ["supraventricular tachycardia", "DISEASE", 205, 233], ["desaturation", "DISEASE", 328, 340], ["ventilator failure", "PROBLEM", 15, 33], ["bag valve ventilation", "TREATMENT", 73, 94], ["transient desaturation", "PROBLEM", 100, 122], ["a sudden worsening of hemodynamics", "PROBLEM", 147, 181], ["supraventricular tachycardia", "PROBLEM", 205, 233], ["drugs", "TREATMENT", 247, 252], ["The most frequent complication", "PROBLEM", 283, 313], ["transient desaturation", "PROBLEM", 318, 340], ["ventilator failure", "OBSERVATION", 15, 33], ["bag valve", "OBSERVATION", 73, 82], ["desaturation", "OBSERVATION_MODIFIER", 110, 122], ["supraventricular tachycardia", "OBSERVATION", 205, 233], ["transient", "OBSERVATION_MODIFIER", 318, 327], ["desaturation", "OBSERVATION", 328, 340]]], ["In nearly 25% of cases, oxygen saturation below 90% was not correctable during the transfer but did not lead to death.", [["oxygen", "CHEMICAL", 24, 30], ["death", "DISEASE", 112, 117], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["oxygen saturation", "TEST", 24, 41], ["death", "PROBLEM", 112, 117]]], ["One third of the patients needed noradrenaline infusion during transport; this is probably related to the fact that several patients were transported shortly after being intubated in the emergency room because of the unavailability of ICU beds.", [["noradrenaline", "CHEMICAL", 33, 46], ["noradrenaline", "CHEMICAL", 33, 46], ["patients", "ORGANISM", 17, 25], ["noradrenaline", "SIMPLE_CHEMICAL", 33, 46], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 124, 132], ["noradrenaline infusion", "TREATMENT", 33, 55], ["ICU beds", "TREATMENT", 235, 243], ["probably related to", "UNCERTAINTY", 82, 101]]], ["The rapid induction probably induced hypotension in these patients who showed fluidic depletion due to persistent fever in the previous days.", [["hypotension", "DISEASE", 37, 48], ["fever", "DISEASE", 114, 119], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["hypotension", "PROBLEM", 37, 48], ["fluidic depletion", "PROBLEM", 78, 95], ["persistent fever", "PROBLEM", 103, 119], ["hypotension", "OBSERVATION", 37, 48], ["fluidic depletion", "OBSERVATION", 78, 95], ["persistent", "OBSERVATION_MODIFIER", 103, 113], ["fever", "OBSERVATION", 114, 119]]], ["No critical events concerning the risk of contamination of personnel have been reported.ConclusionsWhen an epidemic outbreak puts in crisis the surge capacity of a hospital,15 the redistribution of critically ill patients is an accepted strategy16 to unload the ICUs and maintain a high quality of care.", [["critically ill", "DISEASE", 198, 212], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["critical events", "PROBLEM", 3, 18], ["an epidemic outbreak", "PROBLEM", 104, 124], ["epidemic", "OBSERVATION_MODIFIER", 107, 115], ["outbreak", "OBSERVATION_MODIFIER", 116, 124]]], ["In our case, the need to transport many patients in a short time required rapid standardization of procedures to minimize risks, and all the staff involved gave satisfactory feedback.ConclusionsAlthough further studies are needed to highlight any detrimental effects of transport among this type of patient, it must be considered that in many cases at the time of transport, it was not possible to offer adequate treatment to patients at the SH.", [["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 299, 306], ["patients", "ORGANISM", 426, 434], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 299, 306], ["patients", "SPECIES", 426, 434], ["rapid standardization of procedures", "TREATMENT", 74, 109], ["further studies", "TEST", 203, 218], ["adequate treatment", "TREATMENT", 404, 422]]], ["Major concerns are raised against the risk of spreading the infection17 and reducing available beds in case of a sudden increase in patients in the RH too.", [["infection17", "DISEASE", 60, 71], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["the infection17", "PROBLEM", 56, 71], ["a sudden increase in patients in the RH", "PROBLEM", 111, 150], ["increase", "OBSERVATION_MODIFIER", 120, 128]]], ["This possibility has been averted thanks to strict social and health prevention measures as well as the implementation of dedicated hospital pathways and the increase in ICU beds.", [["ICU beds", "TREATMENT", 170, 178]]], ["Interhospital transfers of infected patients, even the critically ill, during an epidemic outbreak are feasible and help to maintain a high level of care thanks to a fairer distribution of resources.", [["critically ill", "DISEASE", 55, 69], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["infected", "OBSERVATION", 27, 35]]]], "9417b014e5c0ae0cd27c40e01177145606eadcac": [["T he coronavirus disease pandemic caused by the severe acute respiratory syndrome coronavirus 2 1\u22123 (SARS-CoV-2) has so far affected >8 million people worldwide, with a mortality rate over 5%.", [["coronavirus disease pandemic", "DISEASE", 5, 33], ["acute respiratory syndrome coronavirus", "DISEASE", 55, 93], ["T he coronavirus", "ORGANISM", 0, 16], ["SARS-CoV-2", "ORGANISM", 101, 111], ["people", "ORGANISM", 144, 150], ["T he coronavirus", "SPECIES", 0, 16], ["people", "SPECIES", 144, 150], ["T he coronavirus", "SPECIES", 0, 16], ["severe acute respiratory syndrome coronavirus", "SPECIES", 48, 93], ["SARS-CoV-2", "SPECIES", 101, 111], ["he coronavirus disease pandemic", "PROBLEM", 2, 33], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 44, 93], ["a mortality rate", "TEST", 167, 183], ["coronavirus disease", "OBSERVATION", 5, 24], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory syndrome", "OBSERVATION", 61, 81]]], ["Main protease (M pro or 3CLpro) is one of the most extensively studied targets of coronaviruses.", [["M pro", "GENE_OR_GENE_PRODUCT", 15, 20], ["3CLpro", "GENE_OR_GENE_PRODUCT", 24, 30], ["coronaviruses", "ORGANISM", 82, 95], ["protease", "PROTEIN", 5, 13], ["3CLpro", "PROTEIN", 24, 30], ["Main protease (M pro or 3CLpro)", "TREATMENT", 0, 31], ["coronaviruses", "PROBLEM", 82, 95], ["coronaviruses", "OBSERVATION", 82, 95]]], ["4 M pro plays an essential role in the cleavage of viral RNA-translated virus polypeptide 5 and recognizes at least 11 cleavage sites in replicase polyprotein 1ab, e.g., LQ\u2193SAG (\u2193 denotes the cleavage site).", [["viral RNA", "RNA", 51, 60], ["viral RNA", "TREATMENT", 51, 60], ["translated virus polypeptide", "TREATMENT", 61, 89], ["replicase polyprotein", "TREATMENT", 137, 158]]], ["Covalent inhibitors against the SARS-CoV-2 M pro have recently demonstrated potency toward inhibiting viral replication in cellular assays; 6, 7 this further underpins the druggability of M pro .", [["cellular", "ANATOMY", 123, 131], ["cellular", "CELL", 123, 131], ["M pro", "GENE_OR_GENE_PRODUCT", 188, 193], ["SARS-CoV-2 M pro", "PROTEIN", 32, 48], ["Covalent inhibitors", "TREATMENT", 0, 19], ["the SARS", "PROBLEM", 28, 36], ["inhibiting viral replication in cellular assays", "PROBLEM", 91, 138], ["viral replication", "OBSERVATION", 102, 119]]], ["However, these compounds remain in the early stages of preclinical studies, and the development of new drugs usually takes years.", [["preclinical studies", "TEST", 55, 74], ["compounds", "OBSERVATION_MODIFIER", 15, 24], ["early stages", "OBSERVATION_MODIFIER", 39, 51], ["new", "OBSERVATION_MODIFIER", 99, 102], ["drugs", "OBSERVATION", 103, 108]]], ["The lack of drugs targeting SARS-CoV-2 currently poses a threat to numerous COVID-19 patients.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "ORGANISM", 28, 38], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 28, 36], ["drugs", "TREATMENT", 12, 17]]]], "PMC3808714": [], "PMC7382508": [["IntroductionProtein\u2013ligand binding interaction is fundamental to a large variety of cellular functions, including enzymatic reactions, catalysis, signal transduction, and regulation.", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["enzymatic reactions", "PROBLEM", 114, 133], ["signal transduction", "TEST", 146, 165], ["large", "OBSERVATION_MODIFIER", 67, 72], ["variety", "OBSERVATION_MODIFIER", 73, 80], ["cellular functions", "OBSERVATION", 84, 102]]], ["The importance of protein\u2013ligand interactions explains the ongoing interest to redesign these interactions, conferring novel functions or finding suitable drugs and molecular targets1.", [["suitable drugs", "TREATMENT", 146, 160]]], ["A typical binding pocket consisting of 10 residues gives rise to 2010 possible mutations; together with an estimated amount of 1060 potential drug-like compounds, this composes a vast chemical space.", [["A typical binding pocket", "PROBLEM", 0, 24], ["10 residues", "PROBLEM", 39, 50], ["mutations", "PROBLEM", 79, 88], ["potential drug-like compounds", "PROBLEM", 132, 161], ["binding pocket", "OBSERVATION", 10, 24], ["chemical space", "OBSERVATION", 184, 198]]], ["To harness this potential, a lot of progress has been made in the development of high-throughput experimental screening techniques together with computational methods2\u20135.", [["computational methods2\u20135", "TREATMENT", 145, 169]]], ["In this process, a significant increase of the drug design success rate arises out of the development of novel computational strategies.IntroductionCurrent approaches typically rely on docking assays to either predict or optimize the ligand-binding mode6\u20138.", [["ligand-binding mode6\u20138", "PROTEIN", 234, 256], ["the drug design success rate", "TREATMENT", 43, 71], ["IntroductionCurrent approaches", "TREATMENT", 136, 166], ["docking assays", "TEST", 185, 199], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["Although docking-based methods allow for high-throughput screening of large compound and/or protein mutant libraries, the accuracy of the predictions is limited.", [["large compound and/or protein mutant libraries", "PROBLEM", 70, 116]]], ["The main sources of limitation are the use of simplified energy (\u201cscoring\u201d) functions as well as the limited treatment of protein and ligand flexibility and solvation models.", [["protein and ligand flexibility and solvation models", "TREATMENT", 122, 173], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In the case of protein engineering studies, only local mutations around the binding/catalytic site can benefit of docking-based methods.", [["catalytic site", "PROTEIN", 84, 98], ["protein engineering studies", "TEST", 15, 42], ["local mutations", "PROBLEM", 49, 64], ["the binding/catalytic site", "PROBLEM", 72, 98], ["docking-based methods", "TREATMENT", 114, 135]]], ["A variety of enhanced sampling methods, such as replica exchange, funnel-metadynamics, or adaptive sampling, exist to improve the sampling and to study the binding kinetics and pathways14\u201317.", [["enhanced sampling methods", "TREATMENT", 13, 38], ["funnel-metadynamics", "TREATMENT", 66, 85], ["adaptive sampling", "TREATMENT", 90, 107], ["the sampling", "TEST", 126, 138], ["the binding kinetics", "TEST", 152, 172], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["Fully atomistic MD simulations, however, are computationally too expensive to allow for high-throughput applications.IntroductionA potential solution is the use of coarse-grained (CG) force fields, which reduce the computational cost by uniting groups of atoms into effective interaction sites resulting in a substantial computational speed-up24,25.", [["IntroductionA potential solution", "TREATMENT", 117, 149], ["coarse-grained (CG) force fields", "TREATMENT", 164, 196]]], ["The Martini model26 is among the most popular CG force fields, and has been applied to study a wide range of biomolecular processes including successful prediction of protein\u2013lipid binding modes27.", [["The Martini model26", "TREATMENT", 0, 19], ["protein\u2013lipid binding modes", "TREATMENT", 167, 194], ["Martini model26", "OBSERVATION", 4, 19]]], ["In some cases, binding of lipids to sites deeply buried inside the proteins were recovered by brute force MD28,29.", [["lipids", "SIMPLE_CHEMICAL", 26, 32], ["lipids", "TREATMENT", 26, 32]]], ["The question remains, therefore, whether such CG models can be applied to capture protein\u2013ligand binding in general, including small organic compounds, such as enzyme substrates, receptor ligands, drugs, or pesticides.IntroductionHere we show that the recently re-parameterized Martini model33 can perform this task with high accuracy, based on unbiased sampling.", [["Martini model33", "DNA", 278, 293], ["such CG models", "PROBLEM", 41, 55], ["small organic compounds", "PROBLEM", 127, 150], ["enzyme substrates", "TREATMENT", 160, 177], ["receptor ligands", "TREATMENT", 179, 195], ["drugs", "TREATMENT", 197, 202], ["unbiased sampling", "TEST", 345, 362], ["small", "OBSERVATION_MODIFIER", 127, 132], ["organic compounds", "OBSERVATION", 133, 150]]], ["For all the simulations presented here, the ligands (depicted together with the CG mapping in Supplementary Fig. 1) were initially positioned randomly in the solvent.", [["the CG mapping", "TEST", 76, 90]]], ["We use three different classes of examples to illustrate the potential power of this approach.", [["this approach", "TREATMENT", 80, 93]]], ["First, we show millisecond long sampling of the reversible binding of seven different ligands (binders as well as non-binders) to mutants of T4 lysozyme, a well-studied protein for which ample experimental and all-atom MD simulation data are available for comparison.", [["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 141, 152], ["T4 lysozyme", "PROTEIN", 141, 152], ["the reversible binding", "PROBLEM", 44, 66], ["seven different ligands (binders", "TREATMENT", 70, 102], ["mutants of T4 lysozyme", "PROBLEM", 130, 152], ["atom MD simulation data", "TEST", 214, 237], ["reversible binding", "OBSERVATION", 48, 66]]], ["Second, we show spontaneous binding and unbinding of both agonist and antagonist ligands to the adenosine A2A receptor (A2AR) and adrenergic \u03b22 receptor (\u03b22AR), two different members of the membrane-embedded protein family of G protein-coupled receptors (GPCRs), as well as to the nuclear receptor farnesoid X receptor (FXR), all representing prominent pharmacological targets.", [["membrane", "ANATOMY", 190, 198], ["nuclear", "ANATOMY", 281, 288], ["adenosine", "CHEMICAL", 96, 105], ["adenosine", "CHEMICAL", 96, 105], ["adenosine A2A receptor", "GENE_OR_GENE_PRODUCT", 96, 118], ["A2AR", "GENE_OR_GENE_PRODUCT", 120, 124], ["adrenergic \u03b22 receptor", "GENE_OR_GENE_PRODUCT", 130, 152], ["\u03b22AR", "GENE_OR_GENE_PRODUCT", 154, 158], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 226, 253], ["farnesoid X receptor", "GENE_OR_GENE_PRODUCT", 298, 318], ["FXR", "GENE_OR_GENE_PRODUCT", 320, 323], ["adenosine A2A receptor", "PROTEIN", 96, 118], ["A2AR", "PROTEIN", 120, 124], ["adrenergic \u03b22 receptor", "PROTEIN", 130, 152], ["\u03b22AR", "PROTEIN", 154, 158], ["membrane-embedded protein family", "PROTEIN", 190, 222], ["G protein-coupled receptors", "PROTEIN", 226, 253], ["GPCRs", "PROTEIN", 255, 260], ["nuclear receptor farnesoid X receptor", "PROTEIN", 281, 318], ["FXR", "PROTEIN", 320, 323], ["spontaneous binding", "PROBLEM", 16, 35], ["antagonist ligands", "TREATMENT", 70, 88], ["the adenosine A2A receptor", "TREATMENT", 92, 118], ["adrenergic \u03b22 receptor", "TEST", 130, 152], ["G protein", "TEST", 226, 235], ["spontaneous binding", "OBSERVATION", 16, 35], ["FXR", "ANATOMY", 320, 323], ["prominent", "OBSERVATION_MODIFIER", 343, 352], ["pharmacological targets", "OBSERVATION", 353, 376]]], ["Third, we demonstrate the versatility of our approach by simulating ligand binding to different enzymes, namely binding of a substrate to a complex catalytic site of an aminotransferase, which is an important representative of biocatalytic applications and binding of drugs to two members of the kinase family, proto-oncogene tyrosine-protein kinase (c-Src) and the AP2-associated protein kinase 1 (AAK1) involved in virus endocytosis and a potential target for COVID-19 treatment34.Binding of ligands to T4 lysozyme ::: ResultsT4 lysozyme serves as a benchmark system to investigate ligand binding18.", [["tyrosine", "CHEMICAL", 326, 334], ["tyrosine", "CHEMICAL", 326, 334], ["COVID-19", "CHEMICAL", 462, 470], ["aminotransferase", "SIMPLE_CHEMICAL", 169, 185], ["proto-oncogene tyrosine-protein kinase", "GENE_OR_GENE_PRODUCT", 311, 349], ["c-Src", "GENE_OR_GENE_PRODUCT", 351, 356], ["AP2-associated protein kinase 1", "GENE_OR_GENE_PRODUCT", 366, 397], ["AAK1", "GENE_OR_GENE_PRODUCT", 399, 403], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 505, 516], ["ResultsT4 lysozyme", "GENE_OR_GENE_PRODUCT", 521, 539], ["enzymes", "PROTEIN", 96, 103], ["complex catalytic site", "PROTEIN", 140, 162], ["aminotransferase", "PROTEIN", 169, 185], ["kinase family", "PROTEIN", 296, 309], ["proto-oncogene tyrosine-protein kinase", "PROTEIN", 311, 349], ["c", "PROTEIN", 351, 352], ["Src", "PROTEIN", 353, 356], ["AP2-associated protein kinase 1", "PROTEIN", 366, 397], ["AAK1", "PROTEIN", 399, 403], ["T4 lysozyme", "PROTEIN", 505, 516], ["ResultsT4 lysozyme", "PROTEIN", 521, 539], ["ligand binding18", "PROTEIN", 584, 600], ["different enzymes", "TEST", 86, 103], ["an aminotransferase", "TEST", 166, 185], ["biocatalytic applications", "TREATMENT", 227, 252], ["drugs", "TREATMENT", 268, 273], ["proto-oncogene tyrosine", "TEST", 311, 334], ["protein kinase", "TEST", 335, 349], ["the AP2", "TEST", 362, 369], ["protein kinase", "TEST", 381, 395], ["AAK1", "TEST", 399, 403], ["virus endocytosis", "PROBLEM", 417, 434], ["COVID", "TEST", 462, 467], ["treatment", "TREATMENT", 471, 480]]], ["Notably, the L99A mutant is known to bind hydrophobic ligands into a well-defined cavity in the core of the C-terminal domain35.", [["C", "CHEMICAL", 108, 109], ["L99A", "GENE_OR_GENE_PRODUCT", 13, 17], ["cavity", "PATHOLOGICAL_FORMATION", 82, 88], ["L99A mutant", "PROTEIN", 13, 24], ["C-terminal domain35", "PROTEIN", 108, 127], ["well-defined", "OBSERVATION_MODIFIER", 69, 81], ["cavity", "OBSERVATION", 82, 88], ["core", "ANATOMY_MODIFIER", 96, 100], ["terminal domain35", "ANATOMY_MODIFIER", 110, 127]]], ["To investigate the ligand binding to the L99A mutant of T4 lysozyme, the protein is embedded in a cubic box with 10 nm edge length containing ~8850 CG water beads (corresponding to 35,400 water molecules) and one ligand molecule, as shown in Fig. 1a.", [["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 56, 67], ["L99A mutant", "PROTEIN", 41, 52], ["T4 lysozyme", "PROTEIN", 56, 67], ["T4 lysozyme", "TREATMENT", 56, 67], ["a cubic box", "TREATMENT", 96, 107], ["~8850 CG water beads", "TREATMENT", 142, 162]]], ["Thus, the ligand concentration is around 1.6 mM.", [["the ligand concentration", "TEST", 6, 30], ["concentration", "OBSERVATION_MODIFIER", 17, 30], ["1.6 mM", "OBSERVATION_MODIFIER", 41, 47]]], ["Figure 1b\u2013e summarizes the results obtained for the seven examined ligands benzene, phenol, indole, thieno-pyridine, toluene, ethylbenzene, and n-propylbenzene with a sampling time of 0.9 ms each (30 independent trajectories of 30 \u00b5s per ligand).", [["benzene", "CHEMICAL", 75, 82], ["phenol", "CHEMICAL", 84, 90], ["indole", "CHEMICAL", 92, 98], ["thieno-pyridine, toluene, ethylbenzene", "CHEMICAL", 100, 138], ["n-propylbenzene", "CHEMICAL", 144, 159], ["benzene", "CHEMICAL", 75, 82], ["phenol", "CHEMICAL", 84, 90], ["indole", "CHEMICAL", 92, 98], ["thieno-pyridine", "CHEMICAL", 100, 115], ["toluene", "CHEMICAL", 117, 124], ["ethylbenzene", "CHEMICAL", 126, 138], ["n-propylbenzene", "CHEMICAL", 144, 159], ["benzene", "SIMPLE_CHEMICAL", 75, 82], ["phenol", "SIMPLE_CHEMICAL", 84, 90], ["indole", "SIMPLE_CHEMICAL", 92, 98], ["thieno-pyridine", "SIMPLE_CHEMICAL", 100, 115], ["toluene", "SIMPLE_CHEMICAL", 117, 124], ["ethylbenzene", "SIMPLE_CHEMICAL", 126, 138], ["n-propylbenzene", "SIMPLE_CHEMICAL", 144, 159], ["phenol", "TREATMENT", 84, 90], ["thieno-pyridine", "TREATMENT", 100, 115], ["toluene", "TREATMENT", 117, 124], ["ethylbenzene", "TREATMENT", 126, 138], ["n-propylbenzene", "TREATMENT", 144, 159]]], ["In addition, the binding of benzene and toluene to the L99A/M102Q double mutant of T4 lysozyme was studied.", [["benzene", "CHEMICAL", 28, 35], ["toluene", "CHEMICAL", 40, 47], ["benzene", "CHEMICAL", 28, 35], ["toluene", "CHEMICAL", 40, 47], ["benzene", "SIMPLE_CHEMICAL", 28, 35], ["toluene", "SIMPLE_CHEMICAL", 40, 47], ["L99A", "GENE_OR_GENE_PRODUCT", 55, 59], ["M102Q", "GENE_OR_GENE_PRODUCT", 60, 65], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 83, 94], ["L99A", "PROTEIN", 55, 59], ["M102Q double mutant", "PROTEIN", 60, 79], ["T4 lysozyme", "PROTEIN", 83, 94], ["the L99A", "TEST", 51, 59], ["T4 lysozyme", "TREATMENT", 83, 94], ["T4 lysozyme", "OBSERVATION_MODIFIER", 83, 94]]], ["The additional M102Q mutation reduces the hydrophobic character of the binding pocket36 which is expected to reduce the affinity to benzene and toluene.Binding of ligands to T4 lysozyme ::: ResultsIn case of benzene and the L99A T4 lysozyme, each individual simulation of 30 \u00b5s shows between 2\u20139 binding and unbinding events.", [["benzene", "CHEMICAL", 132, 139], ["toluene", "CHEMICAL", 144, 151], ["benzene", "CHEMICAL", 208, 215], ["benzene", "CHEMICAL", 132, 139], ["toluene", "CHEMICAL", 144, 151], ["benzene", "CHEMICAL", 208, 215], ["M102Q", "GENE_OR_GENE_PRODUCT", 15, 20], ["pocket36", "GENE_OR_GENE_PRODUCT", 79, 87], ["benzene", "SIMPLE_CHEMICAL", 132, 139], ["toluene", "SIMPLE_CHEMICAL", 144, 151], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 174, 185], ["benzene", "SIMPLE_CHEMICAL", 208, 215], ["binding pocket36", "PROTEIN", 71, 87], ["T4 lysozyme", "PROTEIN", 174, 185], ["L99A T4 lysozyme", "PROTEIN", 224, 240], ["The additional M102Q mutation", "TREATMENT", 0, 29], ["benzene", "TEST", 208, 215], ["the L99A T4 lysozyme", "TEST", 220, 240], ["each individual simulation", "TEST", 242, 268], ["unbinding events", "PROBLEM", 308, 324], ["hydrophobic character", "OBSERVATION_MODIFIER", 42, 63]]], ["The crystal structure of L99A T4 lysozyme including a bound benzene molecule (green) is depicted in Fig. 1b.", [["benzene", "CHEMICAL", 60, 67], ["benzene", "CHEMICAL", 60, 67], ["L99A T4 lysozyme", "GENE_OR_GENE_PRODUCT", 25, 41], ["benzene molecule", "SIMPLE_CHEMICAL", 60, 76], ["L99A T4 lysozyme", "PROTEIN", 25, 41], ["benzene molecule", "PROTEIN", 60, 76], ["a bound benzene molecule", "PROBLEM", 52, 76], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["T4 lysozyme", "OBSERVATION", 30, 41], ["benzene molecule", "OBSERVATION", 60, 76]]], ["In addition, the figure contains several CG snapshots of benzene taken from our binding simulations (red) and the benzene density in the binding pocket (transparent red isosurface).", [["benzene", "CHEMICAL", 57, 64], ["benzene", "CHEMICAL", 114, 121], ["benzene", "CHEMICAL", 57, 64], ["benzene", "CHEMICAL", 114, 121], ["benzene", "SIMPLE_CHEMICAL", 57, 64], ["benzene", "SIMPLE_CHEMICAL", 114, 121], ["binding pocket", "PROTEIN", 137, 151], ["the benzene density in the binding pocket", "PROBLEM", 110, 151], ["several", "OBSERVATION_MODIFIER", 33, 40], ["CG", "OBSERVATION_MODIFIER", 41, 43], ["benzene density", "OBSERVATION", 114, 129], ["binding pocket", "OBSERVATION", 137, 151]]], ["A comparison of the benzene position in the crystal structure with the CG snapshots as well as the averaged benzene density clearly shows that the CG force field Martini properly locates the buried hydrophobic binding pocket.", [["benzene", "CHEMICAL", 20, 27], ["benzene", "CHEMICAL", 108, 115], ["benzene", "CHEMICAL", 20, 27], ["benzene", "CHEMICAL", 108, 115], ["benzene", "SIMPLE_CHEMICAL", 20, 27], ["benzene", "SIMPLE_CHEMICAL", 108, 115], ["buried hydrophobic binding pocket", "PROTEIN", 191, 224], ["the CG snapshots", "TEST", 67, 83], ["the averaged benzene density", "PROBLEM", 95, 123], ["the CG force field Martini", "TREATMENT", 143, 169], ["the buried hydrophobic binding pocket", "PROBLEM", 187, 224], ["benzene position", "OBSERVATION", 20, 36], ["benzene density", "OBSERVATION", 108, 123], ["buried", "OBSERVATION_MODIFIER", 191, 197], ["hydrophobic binding pocket", "OBSERVATION", 198, 224]]], ["The experimentally observed binding pose of the ligand in the binding pocket is excellently reproduced with a root mean square deviation (RMSD) of 1.4 \u00b1 0.2 \u00c5, which is similar to the one from atomistic studies37.", [["RMSD", "TEST", 138, 142], ["atomistic studies", "TEST", 193, 210], ["binding pocket", "OBSERVATION", 62, 76], ["root", "OBSERVATION_MODIFIER", 110, 114]]], ["Fig. 1c visualizes the benzene density around L99A T4 lysozyme.", [["benzene", "CHEMICAL", 23, 30], ["benzene", "CHEMICAL", 23, 30], ["benzene", "SIMPLE_CHEMICAL", 23, 30], ["L99A T4 lysozyme", "GENE_OR_GENE_PRODUCT", 46, 62], ["L99A T4 lysozyme", "PROTEIN", 46, 62], ["the benzene density", "TEST", 19, 38], ["T4 lysozyme", "TREATMENT", 51, 62], ["benzene density", "OBSERVATION", 23, 38]]], ["The blue, cyan, red, and violet isosurfaces represent occupancies which are 10, 100, 1000, and 10,000 fold higher than in water.", [["violet isosurfaces", "SIMPLE_CHEMICAL", 25, 43], ["The blue, cyan, red, and violet isosurfaces represent occupancies", "PROBLEM", 0, 65], ["blue", "OBSERVATION_MODIFIER", 4, 8], ["violet isosurfaces", "OBSERVATION", 25, 43], ["occupancies", "OBSERVATION_MODIFIER", 54, 65]]], ["A binding channel indicated by the blue isosurface leads from the surface of the protein toward the buried binding pocket.", [["surface", "CELLULAR_COMPONENT", 66, 73], ["blue isosurface", "PROTEIN", 35, 50], ["buried binding pocket", "PROTEIN", 100, 121], ["A binding channel", "PROBLEM", 0, 17], ["the buried binding pocket", "PROBLEM", 96, 121], ["binding pocket", "OBSERVATION", 107, 121]]], ["The density inside the binding pocket (red isosurface) is about 1000 fold higher compared to the bulk.Binding of ligands to T4 lysozyme ::: ResultsFigure 1d unravels the existence of more than just one binding/unbinding path which could be already easily spotted by eye based on the overall ligand densities shown in Fig. 1c.", [["eye", "ANATOMY", 266, 269], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 124, 135], ["eye", "ORGAN", 266, 269], ["binding pocket", "PROTEIN", 23, 37], ["red isosurface", "PROTEIN", 39, 53], ["T4 lysozyme", "PROTEIN", 124, 135], ["The density inside the binding pocket", "PROBLEM", 0, 37], ["red isosurface", "TEST", 39, 53], ["density", "OBSERVATION", 4, 11], ["binding", "OBSERVATION_MODIFIER", 23, 30], ["pocket", "OBSERVATION_MODIFIER", 31, 37], ["1000 fold", "OBSERVATION_MODIFIER", 64, 73], ["higher", "OBSERVATION_MODIFIER", 74, 80], ["bulk", "OBSERVATION_MODIFIER", 97, 101]]], ["The benzene density in the vicinity of the binding pocket as well as snapshots of the benzene molecules show four binding/unbinding paths in total.", [["benzene", "CHEMICAL", 4, 11], ["benzene", "CHEMICAL", 86, 93], ["benzene", "CHEMICAL", 4, 11], ["benzene", "CHEMICAL", 86, 93], ["benzene", "SIMPLE_CHEMICAL", 4, 11], ["benzene molecules", "SIMPLE_CHEMICAL", 86, 103], ["benzene molecules", "PROTEIN", 86, 103], ["The benzene density", "PROBLEM", 0, 19], ["the binding pocket", "PROBLEM", 39, 57], ["benzene density", "OBSERVATION", 4, 19], ["binding pocket", "OBSERVATION", 43, 57]]], ["The high density channel from Fig. 1c corresponds to path 1 which also has been found to be the dominant dissociation path in a weighted ensemble approach38 and the second dominant dissociation pathway in a biased MD study39, both at atomistic resolution.", [["The high density channel from Fig", "PROBLEM", 0, 33], ["high density", "OBSERVATION_MODIFIER", 4, 16], ["channel", "OBSERVATION_MODIFIER", 17, 24], ["dominant", "OBSERVATION_MODIFIER", 96, 104], ["dissociation", "OBSERVATION", 105, 117]]], ["An example of a binding event is provided in Supplementary Movie 1.Binding of ligands to T4 lysozyme ::: ResultsThe ligand densities for the other ligands as well as the L99A/M102Q double mutant are depicted in Supplementary Fig. 2.", [["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 89, 100], ["L99A", "GENE_OR_GENE_PRODUCT", 170, 174], ["M102Q", "GENE_OR_GENE_PRODUCT", 175, 180], ["T4 lysozyme", "PROTEIN", 89, 100], ["L99A", "PROTEIN", 170, 174], ["M102Q", "PROTEIN", 175, 180], ["a binding event", "PROBLEM", 14, 29], ["the L99A/M102Q double mutant", "TREATMENT", 166, 194], ["ligand densities", "OBSERVATION", 116, 132]]], ["Also in these eight cases, the hydrophobic binding pocket shows the highest occupancy, in agreement with the crystal structures of T4 lysozyme with the respective ligands43\u201345.", [["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 131, 142], ["hydrophobic binding pocket", "PROTEIN", 31, 57], ["T4 lysozyme", "PROTEIN", 131, 142], ["the hydrophobic binding pocket", "PROBLEM", 27, 57], ["T4 lysozyme", "TREATMENT", 131, 142], ["hydrophobic", "OBSERVATION", 31, 42], ["binding pocket", "OBSERVATION", 43, 57], ["highest occupancy", "OBSERVATION", 68, 85], ["T4 lysozyme", "OBSERVATION", 131, 142]]], ["The binding channel density representing path 1 is very similar to the one of benzene for all ligands except phenol, for which this region is less populated.", [["benzene", "CHEMICAL", 78, 85], ["phenol", "CHEMICAL", 109, 115], ["benzene", "CHEMICAL", 78, 85], ["phenol", "CHEMICAL", 109, 115], ["benzene", "SIMPLE_CHEMICAL", 78, 85], ["phenol", "SIMPLE_CHEMICAL", 109, 115], ["phenol", "TREATMENT", 109, 115], ["binding channel", "OBSERVATION_MODIFIER", 4, 19], ["density", "OBSERVATION", 20, 27], ["less", "OBSERVATION_MODIFIER", 142, 146], ["populated", "OBSERVATION", 147, 156]]], ["In the case of thieno-pyridine, indole, toluene, ethylbenzene, and n-propylbenzene, the RMSD distributions show two binding modes (Supplementary Fig. 3).Binding of ligands to T4 lysozyme ::: ResultsFigure 1e compares the binding free energies obtained from our simulations", [["thieno-pyridine", "CHEMICAL", 15, 30], ["indole", "CHEMICAL", 32, 38], ["toluene", "CHEMICAL", 40, 47], ["ethylbenzene", "CHEMICAL", 49, 61], ["n-propylbenzene", "CHEMICAL", 67, 82], ["thieno-pyridine", "CHEMICAL", 15, 30], ["indole", "CHEMICAL", 32, 38], ["toluene", "CHEMICAL", 40, 47], ["ethylbenzene", "CHEMICAL", 49, 61], ["n-propylbenzene", "CHEMICAL", 67, 82], ["thieno-pyridine", "SIMPLE_CHEMICAL", 15, 30], ["indole", "SIMPLE_CHEMICAL", 32, 38], ["toluene", "SIMPLE_CHEMICAL", 40, 47], ["ethylbenzene", "SIMPLE_CHEMICAL", 49, 61], ["n-propylbenzene", "SIMPLE_CHEMICAL", 67, 82], ["T4 lysozyme", "GENE_OR_GENE_PRODUCT", 175, 186], ["T4 lysozyme", "PROTEIN", 175, 186], ["thieno-pyridine", "TREATMENT", 15, 30], ["ethylbenzene", "TREATMENT", 49, 61], ["n-propylbenzene", "TREATMENT", 67, 82]]]]}